NZ725814B2 - Biaryl kinase inhibitors - Google Patents
Biaryl kinase inhibitors Download PDFInfo
- Publication number
- NZ725814B2 NZ725814B2 NZ725814A NZ72581415A NZ725814B2 NZ 725814 B2 NZ725814 B2 NZ 725814B2 NZ 725814 A NZ725814 A NZ 725814A NZ 72581415 A NZ72581415 A NZ 72581415A NZ 725814 B2 NZ725814 B2 NZ 725814B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- oxy
- dimethylpentanamine
- methyl
- difluoromethyl
- bipyridin
- Prior art date
Links
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 5
- 125000005841 biaryl group Chemical group 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 170
- 150000001875 compounds Chemical class 0.000 claims abstract description 87
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 24
- 101700070337 AAK1 Proteins 0.000 claims abstract description 11
- 102100011475 AAK1 Human genes 0.000 claims abstract description 11
- -1 methoxy, methyl Chemical group 0.000 claims description 1172
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 110
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 83
- 150000001412 amines Chemical class 0.000 claims description 66
- 239000011780 sodium chloride Substances 0.000 claims description 60
- 150000003839 salts Chemical class 0.000 claims description 59
- 229910052757 nitrogen Inorganic materials 0.000 claims description 58
- 201000010099 disease Diseases 0.000 claims description 46
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 37
- JFDZBHWFFUWGJE-UHFFFAOYSA-N Benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 34
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 23
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 22
- 125000005843 halogen group Chemical group 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 15
- 208000002193 Pain Diseases 0.000 claims description 13
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 239000001301 oxygen Chemical group 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 10
- 201000000980 schizophrenia Diseases 0.000 claims description 9
- 208000004296 Neuralgia Diseases 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- QWEXPXGCXPEXGZ-UHFFFAOYSA-N NC(COC1=CC=C(C=N1)C1=CC(=NC=C1)NC(OC)=O)(CC(C)C)C Chemical compound NC(COC1=CC=C(C=N1)C1=CC(=NC=C1)NC(OC)=O)(CC(C)C)C QWEXPXGCXPEXGZ-UHFFFAOYSA-N 0.000 claims description 7
- 230000001404 mediated Effects 0.000 claims description 7
- VSOSXKMEQPYESP-UHFFFAOYSA-N 1,6-naphthyridine Chemical compound C1=CN=CC2=CC=CN=C21 VSOSXKMEQPYESP-UHFFFAOYSA-N 0.000 claims description 6
- LFYHQHOSMHERPO-UHFFFAOYSA-N NC(COC1=C(C(=C(C=C1)C1=CC(=NC=C1)NC(OC)=O)C)C)(CC(C)C)C Chemical compound NC(COC1=C(C(=C(C=C1)C1=CC(=NC=C1)NC(OC)=O)C)C)(CC(C)C)C LFYHQHOSMHERPO-UHFFFAOYSA-N 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 6
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 claims description 5
- 206010061536 Parkinson's disease Diseases 0.000 claims description 5
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 5
- WMCGGHPSLQFUDV-UHFFFAOYSA-N 3-(fluoromethyl)pyridine Chemical compound FCC1=CC=CN=C1 WMCGGHPSLQFUDV-UHFFFAOYSA-N 0.000 claims description 4
- 206010001897 Alzheimer's disease Diseases 0.000 claims description 4
- 206010004938 Bipolar disease Diseases 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000005842 heteroatoms Chemical group 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 229910052717 sulfur Chemical group 0.000 claims description 4
- 239000011593 sulfur Chemical group 0.000 claims description 4
- KUHSAAHTEMAJTF-UHFFFAOYSA-N 2-(difluoromethyl)pyridine Chemical compound FC(F)C1=CC=CC=N1 KUHSAAHTEMAJTF-UHFFFAOYSA-N 0.000 claims description 3
- 208000001640 Fibromyalgia Diseases 0.000 claims description 3
- IQVJIKOTUBXEIL-UHFFFAOYSA-N NC(COC=1C=NC(=NC=1)C1=CC=NC=C1)(CC(C)C)C Chemical compound NC(COC=1C=NC(=NC=1)C1=CC=NC=C1)(CC(C)C)C IQVJIKOTUBXEIL-UHFFFAOYSA-N 0.000 claims description 3
- QUAPBONUOLGMAD-NRFANRHFSA-N N[C@](COC=1C(=CC(=NC1C)C1=CC(=NC=C1)NC(OC)=O)C)(CC(C)C)C Chemical compound N[C@](COC=1C(=CC(=NC1C)C1=CC(=NC=C1)NC(OC)=O)C)(CC(C)C)C QUAPBONUOLGMAD-NRFANRHFSA-N 0.000 claims description 3
- 208000001293 Peripheral Nervous System Disease Diseases 0.000 claims description 3
- 206010034606 Peripheral neuropathy Diseases 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical compound C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 claims description 2
- ATRQECRSCHYSNP-UHFFFAOYSA-N 2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=CC=N1 ATRQECRSCHYSNP-UHFFFAOYSA-N 0.000 claims description 2
- IRTWLWBEQPMVNM-UHFFFAOYSA-N 5,7-difluoroquinoline Chemical compound C1=CC=NC2=CC(F)=CC(F)=C21 IRTWLWBEQPMVNM-UHFFFAOYSA-N 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- QHZRZIWCGRXBRY-UHFFFAOYSA-N 2-methylhexan-2-amine Chemical compound CCCCC(C)(C)N QHZRZIWCGRXBRY-UHFFFAOYSA-N 0.000 claims 20
- DPBLXKKOBLCELK-UHFFFAOYSA-N Pentylamine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 claims 4
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-Methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 claims 1
- MTAODLNXWYIKSO-UHFFFAOYSA-N 2-fluoropyridine Chemical compound FC1=CC=CC=N1 MTAODLNXWYIKSO-UHFFFAOYSA-N 0.000 claims 1
- KRIMXCDMVRMCTC-UHFFFAOYSA-N 2-methylhexan-2-ol Chemical compound CCCCC(C)(C)O KRIMXCDMVRMCTC-UHFFFAOYSA-N 0.000 claims 1
- HNTZKNJGAFJMHQ-UHFFFAOYSA-N 2-methylpyridine-3-carboxylic acid Chemical compound CC1=NC=CC=C1C(O)=O HNTZKNJGAFJMHQ-UHFFFAOYSA-N 0.000 claims 1
- KDYVCOSVYOSHOL-UHFFFAOYSA-N 7-methylquinoline Chemical compound C1=CC=NC2=CC(C)=CC=C21 KDYVCOSVYOSHOL-UHFFFAOYSA-N 0.000 claims 1
- AXLOCHLTNQDFFS-BESJYZOMSA-N Azastene Chemical compound C([C@H]1[C@@H]2CC[C@@]([C@]2(CC[C@@H]1[C@@]1(C)C2)C)(O)C)C=C1C(C)(C)C1=C2C=NO1 AXLOCHLTNQDFFS-BESJYZOMSA-N 0.000 claims 1
- YFCHGWJOKRATOE-UHFFFAOYSA-N CC1=NC=CC(=C1)C1=NC=CC=C1C(F)(F)F Chemical compound CC1=NC=CC(=C1)C1=NC=CC=C1C(F)(F)F YFCHGWJOKRATOE-UHFFFAOYSA-N 0.000 claims 1
- WGBBUURBHXLGFM-UHFFFAOYSA-N hexan-2-amine Chemical compound CCCCC(C)N WGBBUURBHXLGFM-UHFFFAOYSA-N 0.000 claims 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 874
- 230000014759 maintenance of location Effects 0.000 description 430
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 362
- 239000007787 solid Substances 0.000 description 155
- 235000019439 ethyl acetate Nutrition 0.000 description 138
- HEDRZPFGACZZDS-MICDWDOJSA-N cdcl3 Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 125
- 239000000243 solution Substances 0.000 description 117
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 102
- 238000006243 chemical reaction Methods 0.000 description 98
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 98
- 230000002829 reduced Effects 0.000 description 87
- 239000010410 layer Substances 0.000 description 74
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 74
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 70
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 70
- 239000011734 sodium Substances 0.000 description 64
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 56
- 235000020127 ayran Nutrition 0.000 description 47
- 238000006069 Suzuki reaction reaction Methods 0.000 description 44
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 44
- 239000011541 reaction mixture Substances 0.000 description 44
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 42
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 238000010898 silica gel chromatography Methods 0.000 description 39
- 239000000543 intermediate Substances 0.000 description 37
- 239000000725 suspension Substances 0.000 description 35
- 239000012267 brine Substances 0.000 description 34
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 32
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 32
- 239000000463 material Substances 0.000 description 31
- 238000000746 purification Methods 0.000 description 30
- 239000003921 oil Substances 0.000 description 29
- 235000019198 oils Nutrition 0.000 description 28
- 239000005695 Ammonium acetate Substances 0.000 description 27
- USFZMSVCRYTOJT-UHFFFAOYSA-N ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 27
- 235000019257 ammonium acetate Nutrition 0.000 description 27
- 229940043376 ammonium acetate Drugs 0.000 description 27
- 239000008079 hexane Substances 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 26
- 239000012071 phase Substances 0.000 description 26
- 239000012044 organic layer Substances 0.000 description 23
- 229910020313 ClF Inorganic materials 0.000 description 22
- 230000037283 Clf Effects 0.000 description 22
- 238000010511 deprotection reaction Methods 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 22
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 21
- 125000003277 amino group Chemical group 0.000 description 21
- 239000007858 starting material Substances 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 238000007792 addition Methods 0.000 description 17
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 17
- 239000012230 colorless oil Substances 0.000 description 17
- 238000002953 preparative HPLC Methods 0.000 description 17
- 239000001187 sodium carbonate Substances 0.000 description 16
- 229910000029 sodium carbonate Inorganic materials 0.000 description 16
- 238000004007 reversed phase HPLC Methods 0.000 description 15
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 229910014264 BrF Inorganic materials 0.000 description 13
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 13
- 235000011056 potassium acetate Nutrition 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 101710043771 PDCL Proteins 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- NMMPMZWIIQCZBA-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane;2-phenylethanamine Chemical compound [Pd+]Cl.NCCC1=CC=CC=[C-]1.CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 NMMPMZWIIQCZBA-UHFFFAOYSA-M 0.000 description 12
- JCWIWBWXCVGEAN-UHFFFAOYSA-L cyclopentyl(diphenyl)phosphane;dichloropalladium;iron Chemical compound [Fe].Cl[Pd]Cl.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1 JCWIWBWXCVGEAN-UHFFFAOYSA-L 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cells Anatomy 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- CSJLBAMHHLJAAS-UHFFFAOYSA-N Diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 239000000969 carrier Substances 0.000 description 9
- 239000006260 foam Substances 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 230000001225 therapeutic Effects 0.000 description 9
- IPWKHHSGDUIRAH-UHFFFAOYSA-N Bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- OKKJLVBELUTLKV-VMNATFBRSA-N deuteriooxymethane Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 239000003039 volatile agent Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 150000001642 boronic acid derivatives Chemical class 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate tribasic Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 7
- 235000019798 tripotassium phosphate Nutrition 0.000 description 7
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- QMZGHZOFPCTDQS-LBPRGKRZSA-N CC(C)C[C@@]1(C)COS(=O)(=O)N1C(=O)OC(C)(C)C Chemical compound CC(C)C[C@@]1(C)COS(=O)(=O)N1C(=O)OC(C)(C)C QMZGHZOFPCTDQS-LBPRGKRZSA-N 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000007872 degassing Methods 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (NE)-N-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- GPAYUJZHTULNBE-UHFFFAOYSA-N Diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 5
- XEBLYMQXQWZRAQ-UHFFFAOYSA-N NC(COC=1C=CC(=NC1)C1=CC(=NC=C1)NC(OC)=O)(CC(C)C)C Chemical compound NC(COC=1C=CC(=NC1)C1=CC(=NC=C1)NC(OC)=O)(CC(C)C)C XEBLYMQXQWZRAQ-UHFFFAOYSA-N 0.000 description 5
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 5
- 230000005587 bubbling Effects 0.000 description 5
- NHYCGSASNAIGLD-UHFFFAOYSA-N chlorine monoxide Inorganic materials Cl[O] NHYCGSASNAIGLD-UHFFFAOYSA-N 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- SKOWZLGOFVSKLB-UHFFFAOYSA-N hypodiboric acid Chemical compound OB(O)B(O)O SKOWZLGOFVSKLB-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Substances [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- LXUDFEOAGBMKQF-UHFFFAOYSA-N (2-chloro-4-fluoropyridin-3-yl)boronic acid Chemical compound OB(O)C1=C(F)C=CN=C1Cl LXUDFEOAGBMKQF-UHFFFAOYSA-N 0.000 description 4
- FSSPGSAQUIYDCN-UHFFFAOYSA-N 1,3-Propane sultone Chemical compound O=S1(=O)CCCO1 FSSPGSAQUIYDCN-UHFFFAOYSA-N 0.000 description 4
- IINNRDCVXQBJBL-NCWAPJAISA-N BrC1=CC(=C(O[C@@H](C(CC(C)C)C)N)C=C1)C(F)(F)F Chemical compound BrC1=CC(=C(O[C@@H](C(CC(C)C)C)N)C=C1)C(F)(F)F IINNRDCVXQBJBL-NCWAPJAISA-N 0.000 description 4
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 4
- LXSZMGQQXZXQKX-UHFFFAOYSA-N N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]acetamide Chemical compound C1=NC(NC(=O)C)=CC(B2OC(C)(C)C(C)(C)O2)=C1 LXSZMGQQXZXQKX-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Substances BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 102400000058 Neuregulin-1 Human genes 0.000 description 4
- 108090000556 Neuregulin-1 Proteins 0.000 description 4
- IUBQJLUDMLPAGT-UHFFFAOYSA-N Potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N Xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000001154 acute Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- LKYXEULZVGJVTG-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH] LKYXEULZVGJVTG-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 239000001184 potassium carbonate Substances 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000004808 supercritical fluid chromatography Methods 0.000 description 4
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
- 238000004293 19F NMR spectroscopy Methods 0.000 description 3
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 3
- QGLVHVGCUXYOAN-UHFFFAOYSA-N 4-bromo-2-chloroquinoline Chemical compound C1=CC=CC2=NC(Cl)=CC(Br)=C21 QGLVHVGCUXYOAN-UHFFFAOYSA-N 0.000 description 3
- IDCPJMXIWPFVIX-UHFFFAOYSA-N 4-bromo-5,7-difluoroquinoline Chemical compound BrC1=CC=NC2=CC(F)=CC(F)=C21 IDCPJMXIWPFVIX-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- INUFZHHAKHUNOO-UHFFFAOYSA-N 4-methyl-5H-oxathiazole 2,2-dioxide Chemical compound CC1=NS(=O)(=O)OC1 INUFZHHAKHUNOO-UHFFFAOYSA-N 0.000 description 3
- OPLCXLXORZDTMX-UHFFFAOYSA-N 5-bromo-3-(trifluoromethyl)-1H-pyridin-2-one Chemical compound OC1=NC=C(Br)C=C1C(F)(F)F OPLCXLXORZDTMX-UHFFFAOYSA-N 0.000 description 3
- OVBUBBZWODRDRD-UHFFFAOYSA-N 6-chloro-3-fluoro-1H-pyridin-2-one Chemical compound OC1=NC(Cl)=CC=C1F OVBUBBZWODRDRD-UHFFFAOYSA-N 0.000 description 3
- LQHUFVIPEYGKCO-JTQLQIEISA-N BrC1=CC(=C(OC[C@H](CC(C)C)C)C=C1)C(F)(F)F Chemical compound BrC1=CC(=C(OC[C@H](CC(C)C)C)C=C1)C(F)(F)F LQHUFVIPEYGKCO-JTQLQIEISA-N 0.000 description 3
- BMPXRHMVKOFTSU-UHFFFAOYSA-N BrC=1C=C(C(=NC1)F)C(F)F Chemical compound BrC=1C=C(C(=NC1)F)C(F)F BMPXRHMVKOFTSU-UHFFFAOYSA-N 0.000 description 3
- 210000004556 Brain Anatomy 0.000 description 3
- OVFLVFMXODBADI-UHFFFAOYSA-N C(C(C)C)C1(CN(C1)C(=O)OC(C)(C)C)C(=O)OC Chemical compound C(C(C)C)C1(CN(C1)C(=O)OC(C)(C)C)C(=O)OC OVFLVFMXODBADI-UHFFFAOYSA-N 0.000 description 3
- FBBMOAAEBAIJSL-UHFFFAOYSA-N CC(C)CC(C)COc1ccc(Br)cc1C#N Chemical compound CC(C)CC(C)COc1ccc(Br)cc1C#N FBBMOAAEBAIJSL-UHFFFAOYSA-N 0.000 description 3
- WVDZBDZXQWXZRA-ZETCQYMHSA-N CC(C)C[C@](C)(O)CO Chemical compound CC(C)C[C@](C)(O)CO WVDZBDZXQWXZRA-ZETCQYMHSA-N 0.000 description 3
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 3
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N Glibenclamide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 229920002459 Intron Polymers 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
- LFMGMKPLBDZJLP-UHFFFAOYSA-N N-(4-bromopyridin-2-yl)acetamide Chemical compound CC(=O)NC1=CC(Br)=CC=N1 LFMGMKPLBDZJLP-UHFFFAOYSA-N 0.000 description 3
- CLGVAROYAZLCMG-UHFFFAOYSA-N NC(COC1=CC=C(C2=CC=CC=C12)C1=CC=NC=C1)(CC(C)C)C Chemical compound NC(COC1=CC=C(C2=CC=CC=C12)C1=CC=NC=C1)(CC(C)C)C CLGVAROYAZLCMG-UHFFFAOYSA-N 0.000 description 3
- LIXLLCOPWGLFSZ-FQEVSTJZSA-N N[C@](COC1=CC(=C(C=C1)C1=CC(=NC=C1)NC(C)=O)OC(F)(F)F)(CC(C)C)C Chemical compound N[C@](COC1=CC(=C(C=C1)C1=CC(=NC=C1)NC(C)=O)OC(F)(F)F)(CC(C)C)C LIXLLCOPWGLFSZ-FQEVSTJZSA-N 0.000 description 3
- UARYFSPHUOXJGP-UHFFFAOYSA-N OB(O)c1cccnc1C(F)F Chemical compound OB(O)c1cccnc1C(F)F UARYFSPHUOXJGP-UHFFFAOYSA-N 0.000 description 3
- 108091000081 Phosphotransferases Proteins 0.000 description 3
- 102000001253 Protein Kinases Human genes 0.000 description 3
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N XPhos Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000001861 immunosuppresant Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- XEVGBKYKRAHUNV-UHFFFAOYSA-N methyl N-pyridin-2-ylcarbamate Chemical compound COC(=O)NC1=CC=CC=N1 XEVGBKYKRAHUNV-UHFFFAOYSA-N 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000000865 phosphorylative Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000011369 resultant mixture Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000001256 tonic Effects 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- ZPFCRVKPKDEXID-UHFFFAOYSA-N (2-chloro-1H-pyridin-2-yl)boronic acid Chemical compound OB(O)C1(Cl)NC=CC=C1 ZPFCRVKPKDEXID-UHFFFAOYSA-N 0.000 description 2
- XHYBEDDNBACEEH-UHFFFAOYSA-N (2-ethylpyridin-3-yl)boronic acid Chemical compound CCC1=NC=CC=C1B(O)O XHYBEDDNBACEEH-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N 1-Hexanol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 2
- GYOVBMLJVOOBQA-UHFFFAOYSA-N 2,4-dimethyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC(C)CC(C)(C(O)=O)NC(=O)OC(C)(C)C GYOVBMLJVOOBQA-UHFFFAOYSA-N 0.000 description 2
- OSBHDMWFFSTJRJ-UHFFFAOYSA-N 2-bromo-6-(fluoromethyl)pyridine Chemical compound FCC1=CC=CC(Br)=N1 OSBHDMWFFSTJRJ-UHFFFAOYSA-N 0.000 description 2
- SVAZIMBLBHOVIR-UHFFFAOYSA-N 2-chloro-3-fluoropyridine Chemical compound FC1=CC=CN=C1Cl SVAZIMBLBHOVIR-UHFFFAOYSA-N 0.000 description 2
- MGESYKOZCHKVPD-UHFFFAOYSA-N 2-methylpropyl azetidine-1-carboxylate Chemical compound CC(C)COC(=O)N1CCC1 MGESYKOZCHKVPD-UHFFFAOYSA-N 0.000 description 2
- OKLBYPMDIRXALH-UHFFFAOYSA-N 4-(bromomethyl)pyrimidine Chemical compound BrCC1=CC=NC=N1 OKLBYPMDIRXALH-UHFFFAOYSA-N 0.000 description 2
- MLPBCCFSVCUOME-UHFFFAOYSA-N 4-chloro-2-(difluoromethyl)pyridine;hydrochloride Chemical compound Cl.FC(F)C1=CC(Cl)=CC=N1 MLPBCCFSVCUOME-UHFFFAOYSA-N 0.000 description 2
- WGXXKIPCZQQLGO-UHFFFAOYSA-N 4-chloro-2-fluoroquinoline Chemical compound C1=CC=CC2=NC(F)=CC(Cl)=C21 WGXXKIPCZQQLGO-UHFFFAOYSA-N 0.000 description 2
- ZLUANTAMHPVYLL-UHFFFAOYSA-N 5-bromo-1,3-difluoro-2-hexoxybenzene Chemical compound CCCCCCOC1=C(F)C=C(Br)C=C1F ZLUANTAMHPVYLL-UHFFFAOYSA-N 0.000 description 2
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- ZRBKEVRKFBDXOJ-UHFFFAOYSA-N BrC1=CC(=C(OCC(CC(C)C)C)C=C1)C1CC1 Chemical compound BrC1=CC(=C(OCC(CC(C)C)C)C=C1)C1CC1 ZRBKEVRKFBDXOJ-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- NARKEYDRMQSHAO-UHFFFAOYSA-N CC(C)CC1(C)COS(=O)(=O)N1C(=O)OCC1=CC=CC=C1 Chemical compound CC(C)CC1(C)COS(=O)(=O)N1C(=O)OCC1=CC=CC=C1 NARKEYDRMQSHAO-UHFFFAOYSA-N 0.000 description 2
- HVOLVGXBUGAQJF-UHFFFAOYSA-M CC1N(S(OC1)(=O)=O)C(=O)[O-] Chemical compound CC1N(S(OC1)(=O)=O)C(=O)[O-] HVOLVGXBUGAQJF-UHFFFAOYSA-M 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N Codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 101700062901 DPP Proteins 0.000 description 2
- 102100012353 DPP4 Human genes 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 210000001671 Embryonic Stem Cells Anatomy 0.000 description 2
- 229920000665 Exon Polymers 0.000 description 2
- 210000002683 Foot Anatomy 0.000 description 2
- 102100003818 GCG Human genes 0.000 description 2
- 101710042131 GCG Proteins 0.000 description 2
- 229960004580 GLIBENCLAMIDE Drugs 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229940065521 Glucocorticoid inhalants for obstructive airway disease Drugs 0.000 description 2
- 229940014653 Glyburide Drugs 0.000 description 2
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- 210000004185 Liver Anatomy 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 108020004999 Messenger RNA Proteins 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N Methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- GWMITJAOCAXXCT-DEOSSOPVSA-N N[C@](COC1=CC=C(C2=CC=CC=C12)C1=CC(=NC=C1)NC(OC)=O)(CC(C)C)C Chemical compound N[C@](COC1=CC=C(C2=CC=CC=C12)C1=CC(=NC=C1)NC(OC)=O)(CC(C)C)C GWMITJAOCAXXCT-DEOSSOPVSA-N 0.000 description 2
- 108010028924 PPAR alpha Proteins 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L Palladium(II) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 230000025458 RNA interference Effects 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229940037128 Systemic Glucocorticoids Drugs 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- ZBCRZEJNAADYKG-UHFFFAOYSA-N [4-methoxy-2-(trifluoromethyl)phenyl]boronic acid Chemical compound COC1=CC=C(B(O)O)C(C(F)(F)F)=C1 ZBCRZEJNAADYKG-UHFFFAOYSA-N 0.000 description 2
- WOOPKNHVVMARBE-UHFFFAOYSA-M [O-]C(=O)C1=CC=CB1 Chemical compound [O-]C(=O)C1=CC=CB1 WOOPKNHVVMARBE-UHFFFAOYSA-M 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000000172 allergic Effects 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 108090001123 antibodies Proteins 0.000 description 2
- 102000004965 antibodies Human genes 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 125000004429 atoms Chemical group 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atoms Chemical group C* 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000002939 deleterious Effects 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- NZTNZPDOBQDOSO-UHFFFAOYSA-N lithium;boron(1-) Chemical compound [Li+].[B-] NZTNZPDOBQDOSO-UHFFFAOYSA-N 0.000 description 2
- 239000010807 litter Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229920002106 messenger RNA Polymers 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- 230000003040 nociceptive Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002987 rna-interference Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 238000009491 slugging Methods 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 229940001607 sodium bisulfite Drugs 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium;triacetyloxyboron(1-) Chemical compound [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- QAHVHSLSRLSVGS-UHFFFAOYSA-N sulfamoyl chloride Chemical compound NS(Cl)(=O)=O QAHVHSLSRLSVGS-UHFFFAOYSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- ZXGCWGYBIXCFMP-UHFFFAOYSA-N (2-chloro-3-fluoropyridin-4-yl)boronic acid Chemical compound OB(O)C1=CC=NC(Cl)=C1F ZXGCWGYBIXCFMP-UHFFFAOYSA-N 0.000 description 1
- VRDAOVQZVXYRNH-UHFFFAOYSA-N (2-chloropyridin-3-yl)boronic acid Chemical compound OB(O)C1=CC=CN=C1Cl VRDAOVQZVXYRNH-UHFFFAOYSA-N 0.000 description 1
- TWKMYNQPIICYNV-UHFFFAOYSA-N (2-methylpyridin-3-yl)boronic acid Chemical compound CC1=NC=CC=C1B(O)O TWKMYNQPIICYNV-UHFFFAOYSA-N 0.000 description 1
- YKXCWZVUWWQSAV-BTVCFUMJSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O YKXCWZVUWWQSAV-BTVCFUMJSA-N 0.000 description 1
- XUFXOAAUWZOOIT-WVJZLWNXSA-N (2S,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-WVJZLWNXSA-N 0.000 description 1
- UOYUUFBFEICSRZ-UHFFFAOYSA-N (3-fluoro-2-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(F)=C1O UOYUUFBFEICSRZ-UHFFFAOYSA-N 0.000 description 1
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3E)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N (3S)-3-(aminomethyl)-5-methylhexanoic acid Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- BFCUWOVHOAODGT-UHFFFAOYSA-N (4,6-dichloropyridin-2-yl)methanol Chemical compound OCC1=CC(Cl)=CC(Cl)=N1 BFCUWOVHOAODGT-UHFFFAOYSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- SECFRXGVLMVUPD-UHFFFAOYSA-N 1-O-tert-butyl 3-O-methyl azetidine-1,3-dicarboxylate Chemical compound COC(=O)C1CN(C(=O)OC(C)(C)C)C1 SECFRXGVLMVUPD-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-Deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
- LXFQSRIDYRFTJW-UHFFFAOYSA-M 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-M 0.000 description 1
- LXQPBCHJNIOMQU-UHFFFAOYSA-N 2,4-dimethylpent-1-ene Chemical compound CC(C)CC(C)=C LXQPBCHJNIOMQU-UHFFFAOYSA-N 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- ZOQOPXVJANRGJZ-UHFFFAOYSA-N 2-(trifluoromethyl)phenol Chemical compound OC1=CC=CC=C1C(F)(F)F ZOQOPXVJANRGJZ-UHFFFAOYSA-N 0.000 description 1
- WXWCXVNMFZTDCP-UHFFFAOYSA-N 2-bromo-3-fluoropyridine-4-carbaldehyde Chemical compound FC1=C(Br)N=CC=C1C=O WXWCXVNMFZTDCP-UHFFFAOYSA-N 0.000 description 1
- CBCSCFDVRNETAU-UHFFFAOYSA-M 2-carboxyphenolate;2-hydroxyethyl(trimethyl)azanium;magnesium Chemical compound [Mg].C[N+](C)(C)CCO.OC(=O)C1=CC=CC=C1[O-] CBCSCFDVRNETAU-UHFFFAOYSA-M 0.000 description 1
- PKSPCHZIAYGSDB-UHFFFAOYSA-N 2-chloro-4-fluoro-3-iodopyridine Chemical compound FC1=CC=NC(Cl)=C1I PKSPCHZIAYGSDB-UHFFFAOYSA-N 0.000 description 1
- VKTBILBRBSALKI-UHFFFAOYSA-N 2-cyclopropylphenol Chemical compound OC1=CC=CC=C1C1CC1 VKTBILBRBSALKI-UHFFFAOYSA-N 0.000 description 1
- IWTFOFMTUOBLHG-UHFFFAOYSA-N 2-methoxypyridine Chemical compound COC1=CC=CC=N1 IWTFOFMTUOBLHG-UHFFFAOYSA-N 0.000 description 1
- LIYGDLOJVBHOBO-UHFFFAOYSA-N 2-methyl-1H-pyridin-2-ol Chemical compound CC1(O)NC=CC=C1 LIYGDLOJVBHOBO-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- JHDCDEHVUADNKQ-UHFFFAOYSA-N 3-(trifluoromethyl)-1H-pyridin-2-one Chemical compound OC1=NC=CC=C1C(F)(F)F JHDCDEHVUADNKQ-UHFFFAOYSA-N 0.000 description 1
- HXEWMTXDBOQQKO-UHFFFAOYSA-N 4,7-dichloroquinoline Chemical compound ClC1=CC=NC2=CC(Cl)=CC=C21 HXEWMTXDBOQQKO-UHFFFAOYSA-N 0.000 description 1
- PSFSCKGJFKEHQJ-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)quinoline Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC(C(F)(F)F)=NC2=CC=CC=C12 PSFSCKGJFKEHQJ-UHFFFAOYSA-N 0.000 description 1
- MKNQNPYGAQGARI-UHFFFAOYSA-N 4-(bromomethyl)phenol Chemical compound OC1=CC=C(CBr)C=C1 MKNQNPYGAQGARI-UHFFFAOYSA-N 0.000 description 1
- OLSKQWRLRYMCAO-UHFFFAOYSA-N 4-(chloromethyl)quinoline Chemical compound C1=CC=C2C(CCl)=CC=NC2=C1 OLSKQWRLRYMCAO-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- VIBJPUXLAKVICD-UHFFFAOYSA-N 4-bromo-2-chlorophenol Chemical compound OC1=CC=C(Br)C=C1Cl VIBJPUXLAKVICD-UHFFFAOYSA-N 0.000 description 1
- OEPBVXQEVBURGC-UHFFFAOYSA-N 4-bromo-2-fluoro-1-(trifluoromethyl)benzene Chemical compound FC1=CC(Br)=CC=C1C(F)(F)F OEPBVXQEVBURGC-UHFFFAOYSA-N 0.000 description 1
- PURVFIJFYPESBD-UHFFFAOYSA-N 4-bromo-2-fluoro-1-hexoxybenzene Chemical compound CCCCCCOC1=CC=C(Br)C=C1F PURVFIJFYPESBD-UHFFFAOYSA-N 0.000 description 1
- ISSNNKYYINPTHS-UHFFFAOYSA-N 4-bromo-2-fluoro-1-methylsulfonylbenzene Chemical compound CS(=O)(=O)C1=CC=C(Br)C=C1F ISSNNKYYINPTHS-UHFFFAOYSA-N 0.000 description 1
- RYVOZMPTISNBDB-UHFFFAOYSA-N 4-bromo-2-fluorophenol Chemical compound OC1=CC=C(Br)C=C1F RYVOZMPTISNBDB-UHFFFAOYSA-N 0.000 description 1
- OJPQVYZLQGRFSO-UHFFFAOYSA-N 4-bromo-2-methylpyrimidine Chemical compound CC1=NC=CC(Br)=N1 OJPQVYZLQGRFSO-UHFFFAOYSA-N 0.000 description 1
- ODQMSVUYWCRULD-UHFFFAOYSA-N 4-bromo-3-chloro-2-fluorophenol Chemical compound OC1=CC=C(Br)C(Cl)=C1F ODQMSVUYWCRULD-UHFFFAOYSA-N 0.000 description 1
- DMAYBPBPEUFIHJ-UHFFFAOYSA-N 4-bromobut-1-ene Chemical compound BrCCC=C DMAYBPBPEUFIHJ-UHFFFAOYSA-N 0.000 description 1
- BAQKUNMKVAPWGU-UHFFFAOYSA-N 4-bromopyridin-2-amine Chemical compound NC1=CC(Br)=CC=N1 BAQKUNMKVAPWGU-UHFFFAOYSA-N 0.000 description 1
- GKEOOUFCVWEWHA-UHFFFAOYSA-N 4-chloro-1,6-naphthyridine Chemical compound C1=NC=C2C(Cl)=CC=NC2=C1 GKEOOUFCVWEWHA-UHFFFAOYSA-N 0.000 description 1
- ONNDFDQMHCNEGF-UHFFFAOYSA-N 4-chloro-2-(trifluoromethyl)quinoline Chemical compound C1=CC=CC2=NC(C(F)(F)F)=CC(Cl)=C21 ONNDFDQMHCNEGF-UHFFFAOYSA-N 0.000 description 1
- ZJTFMBZVSQOTPA-UHFFFAOYSA-N 4-chloro-5,7-difluoroquinoline Chemical compound ClC1=CC=NC2=CC(F)=CC(F)=C21 ZJTFMBZVSQOTPA-UHFFFAOYSA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N 4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- PVMNPAUTCMBOMO-UHFFFAOYSA-N 4-chloropyridine Chemical compound ClC1=CC=NC=C1 PVMNPAUTCMBOMO-UHFFFAOYSA-N 0.000 description 1
- XPGIBDJXEVAVTO-UHFFFAOYSA-N 5-bromo-2-chloropyrimidine Chemical compound ClC1=NC=C(Br)C=N1 XPGIBDJXEVAVTO-UHFFFAOYSA-N 0.000 description 1
- MUYVOGAJRCBWCY-UHFFFAOYSA-N 5-bromo-2-fluoropyridine-3-carbaldehyde Chemical compound FC1=NC=C(Br)C=C1C=O MUYVOGAJRCBWCY-UHFFFAOYSA-N 0.000 description 1
- CBWNYRRNUIMSBQ-UHFFFAOYSA-N 5-bromo-2-hexoxybenzonitrile Chemical compound CCCCCCOC1=CC=C(Br)C=C1C#N CBWNYRRNUIMSBQ-UHFFFAOYSA-N 0.000 description 1
- MKKSTJKBKNCMRV-UHFFFAOYSA-N 5-bromo-2-hydroxybenzaldehyde Chemical compound OC1=CC=C(Br)C=C1C=O MKKSTJKBKNCMRV-UHFFFAOYSA-N 0.000 description 1
- SWTLLSLCDHXNIU-UHFFFAOYSA-N 5-bromo-2-oxo-1H-pyridine-3-carbonitrile Chemical compound BrC1=CNC(=O)C(C#N)=C1 SWTLLSLCDHXNIU-UHFFFAOYSA-N 0.000 description 1
- SZFUWUOHDRMCKD-UHFFFAOYSA-N 5-chloro-1H-pyridin-2-one Chemical compound OC1=CC=C(Cl)C=N1 SZFUWUOHDRMCKD-UHFFFAOYSA-N 0.000 description 1
- BFBRCFKSFRYJGE-UHFFFAOYSA-N 6-bromo-3-fluoropyridine-2-carbaldehyde Chemical compound FC1=CC=C(Br)N=C1C=O BFBRCFKSFRYJGE-UHFFFAOYSA-N 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 101700007619 AURKA Proteins 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N AZAPROPAZONE Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 108010061171 Abatacept Proteins 0.000 description 1
- 229960004892 Acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N Acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N Acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 108010007562 Adalimumab Proteins 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229960003896 Aminopterin Drugs 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229960002170 Azathioprine Drugs 0.000 description 1
- FEJKLNWAOXSSNR-UHFFFAOYSA-N Benorilate Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1OC(C)=O FEJKLNWAOXSSNR-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N Benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940050390 Benzoate Drugs 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N Benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N Betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- 210000002459 Blastocyst Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- LJWUMLKSPLBOFI-ZDUSSCGKSA-N BrC1=CC(=C(OC[C@](CC(C)C)(N)C)C=C1)OC(F)(F)F Chemical compound BrC1=CC(=C(OC[C@](CC(C)C)(N)C)C=C1)OC(F)(F)F LJWUMLKSPLBOFI-ZDUSSCGKSA-N 0.000 description 1
- RQPMGZHKGGZUMV-SFHVURJKSA-N BrC=1C=C(C(=NC1)OC[C@@](CC(C)C)(C)NC(OC(C)(C)C)=O)C#N Chemical compound BrC=1C=C(C(=NC1)OC[C@@](CC(C)C)(C)NC(OC(C)(C)C)=O)C#N RQPMGZHKGGZUMV-SFHVURJKSA-N 0.000 description 1
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N Bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 1
- KMGBZBJJOKUPIA-UHFFFAOYSA-N Butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 1
- BTBPZGLEDPKZBT-SFHVURJKSA-N CC(C)C[C@](C)(N)COC1=C(C=C(C=C1)C1=C(F)C(F)=NC=C1)C(F)(F)F Chemical compound CC(C)C[C@](C)(N)COC1=C(C=C(C=C1)C1=C(F)C(F)=NC=C1)C(F)(F)F BTBPZGLEDPKZBT-SFHVURJKSA-N 0.000 description 1
- UBGBKYMFKRUGAM-UHFFFAOYSA-N CC1=CC=C(N=N1)B(O)O Chemical compound CC1=CC=C(N=N1)B(O)O UBGBKYMFKRUGAM-UHFFFAOYSA-N 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- YKPUWZUDDOIDPM-SOFGYWHQSA-N Capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N Carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229940105329 Carboxymethylcellulose Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N Carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- RTGDFNSFWBGLEC-UHFFFAOYSA-N CellCept Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1CC=C(C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-UHFFFAOYSA-N 0.000 description 1
- 229940107810 Cellcept Drugs 0.000 description 1
- 108010070202 Certolizumab Pegol Proteins 0.000 description 1
- WRJWRGBVPUUDLA-UHFFFAOYSA-N Chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
- 229960001761 Chlorpropamide Drugs 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- 229940001468 Citrate Drugs 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- 241001529297 Coregonus peled Species 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- 229940119740 Deoxycorticosterone Drugs 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 208000001636 Diabetic Neuropathy Diseases 0.000 description 1
- 206010012680 Diabetic neuropathy Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N Diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N Dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N Duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- 101710043593 ENSANGG00000000822 Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 229940079360 Enema for Constipation Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 210000002615 Epidermis Anatomy 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- HEZNVIYQEUHLNI-UHFFFAOYSA-N Ethiofencarb Chemical compound CCSCC1=CC=CC=C1OC(=O)NC HEZNVIYQEUHLNI-UHFFFAOYSA-N 0.000 description 1
- 229960005293 Etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N Etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N Etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N Fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001419 Fenoprofen Drugs 0.000 description 1
- RDJGLLICXDHJDY-UHFFFAOYSA-N Fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 101710023322 GOT2 Proteins 0.000 description 1
- 102100006245 GOT2 Human genes 0.000 description 1
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapen Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 229960000346 Gliclazide Drugs 0.000 description 1
- BOVGTQGAOIONJV-UHFFFAOYSA-N Gliclazide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CC2CCCC2C1 BOVGTQGAOIONJV-UHFFFAOYSA-N 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N Glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960001381 Glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N Glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 229940112611 Glucovance Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N Glycerol 3-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- 208000005721 HIV Infections Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000007514 Herpes Zoster Diseases 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N Hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 Hydroxychloroquine Drugs 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Ilacox Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 229960000905 Indomethacin Drugs 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 108010053490 Infliximab Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108020004391 Introns Proteins 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N Ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 101710009221 LD Proteins 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N Leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N Lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 101700064507 MARK2 Proteins 0.000 description 1
- 102100000541 MARK2 Human genes 0.000 description 1
- 102100000165 MS4A1 Human genes 0.000 description 1
- 101710010909 MS4A1 Proteins 0.000 description 1
- 229940072082 Magnesium Salicylate Drugs 0.000 description 1
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 210000002264 Mammary Glands, Animal Anatomy 0.000 description 1
- 210000004293 Mammary Glands, Human Anatomy 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N Mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229960003105 Metformin Drugs 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N Methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N Minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960004023 Minocycline Drugs 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 1
- 229960000951 Mycophenolic Acid Drugs 0.000 description 1
- 229940083410 Myfortic Drugs 0.000 description 1
- UQEIFYRRSNJVDO-UHFFFAOYSA-N N,N-dibenzyl-2-phenylethanamine Chemical compound C=1C=CC=CC=1CN(CC=1C=CC=CC=1)CCC1=CC=CC=C1 UQEIFYRRSNJVDO-UHFFFAOYSA-N 0.000 description 1
- OKDQKPLMQBXTNH-UHFFFAOYSA-N N,N-dimethyl-2H-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N N-benzyl-1-phenylmethanamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- WIQBGBWFHCHFPV-UHFFFAOYSA-N NC(COC1=C(C(=C(C=C1)C1=CC=NC=C1)C)C)(CC(C)C)C Chemical compound NC(COC1=C(C(=C(C=C1)C1=CC=NC=C1)C)C)(CC(C)C)C WIQBGBWFHCHFPV-UHFFFAOYSA-N 0.000 description 1
- KPYMRFGAAXFXIK-UHFFFAOYSA-N NC(COC1=C(C=C(C=C1)C1=CC(=NC=C1)NC(OC)=O)Cl)(CC(C)C)C Chemical compound NC(COC1=C(C=C(C=C1)C1=CC(=NC=C1)NC(OC)=O)Cl)(CC(C)C)C KPYMRFGAAXFXIK-UHFFFAOYSA-N 0.000 description 1
- SHMBDCWCMCTJGG-SSDOTTSWSA-N N[C@](C(=O)O)(CC(C)C)CF Chemical compound N[C@](C(=O)O)(CC(C)C)CF SHMBDCWCMCTJGG-SSDOTTSWSA-N 0.000 description 1
- DMQUKGCEMCHERU-SFHVURJKSA-N N[C@](COC=1C=NC(=NC1)C1=CC(=NC=C1)NC(OC)=O)(CC(C)C)C Chemical compound N[C@](COC=1C=NC(=NC1)C1=CC(=NC=C1)NC(OC)=O)(CC(C)C)C DMQUKGCEMCHERU-SFHVURJKSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229940100662 Nasal Drops Drugs 0.000 description 1
- 229940097496 Nasal Spray Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N Nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 210000001331 Nose Anatomy 0.000 description 1
- XYEOALKITRFCJJ-UHFFFAOYSA-N O-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 1
- XYWXXQIMRRMQRO-UHFFFAOYSA-N OC1=CC=C(Br)C=C1C1=NOC=C1 Chemical compound OC1=CC=C(Br)C=C1C1=NOC=C1 XYWXXQIMRRMQRO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 229940046781 Other immunosuppressants in ATC Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N Oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycontin Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 229940105606 Oxycontin Drugs 0.000 description 1
- 101700025050 PKN1 Proteins 0.000 description 1
- 101710040024 POLE Proteins 0.000 description 1
- 102000024367 PPAR alpha Human genes 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 102100003647 PPARA Human genes 0.000 description 1
- 102100000077 PPARG Human genes 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N Penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 229960003243 Phenformin Drugs 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N Phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229960002895 Phenylbutazone Drugs 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Chemical compound C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 229960005095 Pioglitazone Drugs 0.000 description 1
- HYAFETHFCAUJAY-UHFFFAOYSA-N Pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229950010765 Pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N Propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 108010001645 Rituximab Proteins 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N Rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 1
- 101700033344 SCP2 Proteins 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- 229940076279 Serotonin Drugs 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 210000000278 Spinal Cord Anatomy 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 229960001940 Sulfasalazine Drugs 0.000 description 1
- 229940090121 Sulfonylureas for blood glucose lowering Drugs 0.000 description 1
- 229960000894 Sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N Sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960004492 Suprofen Drugs 0.000 description 1
- MDKGKXOCJGEUJW-UHFFFAOYSA-N Suprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-UHFFFAOYSA-N 0.000 description 1
- 102000003673 Symporters Human genes 0.000 description 1
- 108090000088 Symporters Proteins 0.000 description 1
- 210000002504 Synaptic Vesicles Anatomy 0.000 description 1
- 229960001967 Tacrolimus Drugs 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N Tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N Tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 210000001541 Thymus Gland Anatomy 0.000 description 1
- GUHPRPJDBZHYCJ-UHFFFAOYSA-N Tiaprofenic acid Chemical compound S1C(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-UHFFFAOYSA-N 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N Tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N Triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N Tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 229940066528 Trichloroacetate Drugs 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N Trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N Troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 210000002845 Virion Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 101710024331 YTA7 Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N Zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- GCUVBACNBHGZRS-UHFFFAOYSA-N [Fe++].c1cc[cH-]c1.c1cc[c-](c1)P(c1ccccc1)c1ccccc1 Chemical compound [Fe++].c1cc[cH-]c1.c1cc[c-](c1)P(c1ccccc1)c1ccccc1 GCUVBACNBHGZRS-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229920002892 amber Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940111133 antiinflammatory and antirheumatic drugs Oxicams Drugs 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960004495 beclometasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 230000003542 behavioural Effects 0.000 description 1
- 229960004277 benorilate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- 150000005347 biaryls Chemical class 0.000 description 1
- 229940058933 biguanide antimalarials Drugs 0.000 description 1
- 229940090145 biguanide blood glucose lower drugs Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229940090129 blood glucose lowering drugs Thiazolidinediones Drugs 0.000 description 1
- 125000005621 boronate group Chemical group 0.000 description 1
- 229960003655 bromfenac Drugs 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-M camphorsulfonate anion Chemical compound C1CC2(CS([O-])(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-M 0.000 description 1
- 229960001713 canagliflozin Drugs 0.000 description 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 229930003833 capsaicin Natural products 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 230000001149 cognitive Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 210000004748 cultured cells Anatomy 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 229960003654 desoxycortone Drugs 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N diguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical class O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002121 endocytic Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002343 gold Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLSMFKSTNGKWQX-UHFFFAOYSA-N hydroxyacetone Chemical compound CC(=O)CO XLSMFKSTNGKWQX-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229960005085 indometacin Drugs 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000002348 inosinate dehydrogenase inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 229960000994 lumiracoxib Drugs 0.000 description 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229950000257 metamizole Drugs 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 125000005394 methallyl group Chemical group 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- PZXIEBDIPWIRGB-UHFFFAOYSA-N methyl 2-pyridin-3-ylacetate Chemical compound COC(=O)CC1=CC=CN=C1 PZXIEBDIPWIRGB-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- UAVOCTDYPKOULU-UHFFFAOYSA-N methylchloranuidyl formate Chemical compound C[Cl-]OC=O UAVOCTDYPKOULU-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229930014694 morphine Natural products 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000003505 mutagenic Effects 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- DOZYTHNHLLSNIK-JOKMOOFLSA-M mycophenolate sodium Chemical compound [Na+].OC1=C(C\C=C(/C)CCC([O-])=O)C(OC)=C(C)C2=C1C(=O)OC2 DOZYTHNHLLSNIK-JOKMOOFLSA-M 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N nabumeton Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 210000004789 organ systems Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000003218 pyrazolidines Chemical class 0.000 description 1
- UMLDUMMLRZFROX-UHFFFAOYSA-N pyridin-2-ylboronic acid Chemical compound OB(O)C1=CC=CC=N1 UMLDUMMLRZFROX-UHFFFAOYSA-N 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000000580 secretagogue Effects 0.000 description 1
- 231100000489 sensitizer Toxicity 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- YEXRRCHQJDSEJI-UHFFFAOYSA-M sodium;3-fluoro-2-oxopropanoate Chemical compound [Na+].[O-]C(=O)C(=O)CF YEXRRCHQJDSEJI-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical class CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N stearylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- KCKPPJXOWKJHDP-VIFPVBQESA-N tert-butyl N-[(2S)-1-hydroxyhexan-2-yl]carbamate Chemical compound CCCC[C@@H](CO)NC(=O)OC(C)(C)C KCKPPJXOWKJHDP-VIFPVBQESA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960001312 tiaprofenic acid Drugs 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-M trichloroacetate Chemical compound [O-]C(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-M 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
- C07D213/34—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/18—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member containing only hydrogen and carbon atoms in addition to the ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/20—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hydrogen atoms and substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D309/22—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
The present disclosure is generally directed to compounds of formula (I) which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
Description
BIARYL KINASE INHIBITORS
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority to Provisional Patent Application USSN
62/061,591 filed October 8, 2014 and Provisional Patent Application USSN
61/973,942 filed April 2, 2014, hereby incorporated by reference in their entireties.
The present disclosure is generally directed to compounds which can inhibit
adaptor associated kinase 1 (AAK1), compositions comprising such compounds, and
methods for inhibiting AAK1.
Adaptor associated kinase 1 (AAK1) is a member of the Ark1/Prk1 family of
serine/threonine kinases. AAK1 mRNA exists in two splice forms termed short and
long. The long form predominates and is highly expressed in brain and heart
(Henderson and Conner, Mol. Biol. Cell. 2007, 18, 2698-2706). AAK1 is enriched
in synaptosomal preparations and is co-localized with endocytic structures in cultured
cells. AAK1 modulates clatherin coated endocytosis, a process that is important in
synaptic vesicle recycling and receptor-mediated endocytosis. AAK1 associates with
the AP2 complex, a hetero-tetramer which links receptor cargo to the clatherin coat.
The binding of clatherin to AAK1 stimulates AAK1 kinase activity (Conner et. al.,
Traffic 2003, 4, 885-890; Jackson et. al., J. Cell. Biol. 2003, 163, 231-236). AAK1
phosphorylates the mu-2 subunit of AP-2, which promotes the binding of mu-2 to
tyrosine containing sorting motifs on cargo receptors (Ricotta et. al., J. Cell Bio.
2002, 156, 791-795; Conner and Schmid, J. Cell Bio. 2002, 156, 921-929). Mu2
phosphorylation is not required for receptor uptake, but phosphorylation enhances the
efficiency of internalization (Motely et. al., Mol. Biol. Cell. 2006, 17, 5298-5308).
AAK1 has been identified as an inhibitor of Neuregulin-1/ErbB4 signaling in
PC12 cells. Loss of AAK1 expression through RNA interference mediated gene
silencing or treatment with the kinase inhibitor K252a (which inhibits AAK1 kinase
activity) results in the potentiation of Neuregulin-1 induced neurite outgrowth. These
treatments result in increased expression of ErbB4 and accumulation of ErbB4 in or
near the plasma membrane (Kuai et. al., Chemistry and Biology 2011, 18, 891-906).
NRG1 and ErbB4 are putative schizophrenia susceptibility genes (Buonanno, Brain
Res. Bull. 2010, 83, 122-131). SNPs in both genes have been associated with
multiple schizophrenia endophenotypes (Greenwood et. al., Am. J. Psychiatry
2011, 168, 930-946). Neuregulin 1 and ErbB4 KO mouse models have shown
schizophrenia relevant morphological changes and behavioral phenotypes (Jaaro-
Peled et. al., Schizophrenia Bulletin 2010, 36, 301-313; Wen et. al., Proc. Natl.
Acad. Sci. USA. 2010, 107, 1211-1216). In addition, a single nucleotide
polymorphism in an intron of the AAK1 gene has been associated with the age of
onset of Parkinson’s disease (Latourelle et. al., BMC Med. Genet. 2009, 10, 98).
These results suggest that inhibition of AAK1 activity may have utility in the
treatment of schizophrenia, cognitive deficits in schizophrenia, Parkinson’s disease,
neuropathic pain, bipolar disorder, and Alzheimer’s disease.
In addition, studies using Huh-7.5 cells indicate a potential utility for AAK1
kinase inhibitors in the treatment of hepatitis C (HCV) infection. Reduction of AAK1
protein using RNA interference mediated gene silencing, treatment with the kinase
inhibitor sunitinib (a potent AAK1 inhibitor), and overexpression of Mu2 (AAK1
substrate) phosphorylation site mutant all result in reduced HCV virion assembly.
Furthermore the same treatments were shown to inhibit HCV entry, suggesting
AAK1 inhibitors can disrupt two host dependent stages of the virus life cycle (Neveu
et. al., PLoS Pathog. 2012, 8, 1-16; Neveu et. al., J. Virol. 2015, posted online 4
February). AAK1 inhibitors may also be useful against HIV and HBV (see, for
example, Boge et al., J. Biol. Chem. 1998, 273, 15773-15778).
In its first aspect the present disclosure provides a compound of formula (I)
A compound of formula (I)
(I),
or a pharmaceutically acceptable salt thereof, wherein:
A is selected from
, , , , ,
, and ; wherein “ ” denotes the point of attachment to B;
B is selected from
, , , , , and ;
wherein “*” indicates the point of attachment to R5 and “**” indicates the point of
attachment to ring A;
R is selected from hydrogen, amino, -CO H, difluoromethyl, ethyl, halo,
hydroxymethyl, methoxy, methyl, –NHC(O)CH3, -NHCO2CH3, trifluoromethoxy,
and trifluoromethyl;
R is selected from hydrogen, cyano, -CH OH, halo, and methyl;
R is selected from hydrogen, cyano, cyclopropyl, difluoromethyl, halo,
hydroxymethyl, methoxy, methyl, methylsulfonyl, trifluoromethoxy, trifluoromethyl,
-CH N(CH ) , and a five-membered aromatic ring containing one, two, or three
2 3 2
heteroatoms selected from nitrogen, oxygen, and sulfur;
R is selected from hydrogen, halo, and methyl;
R is selected from
, , and ;
R is selected from hydrogen, ethyl, fluoromethyl, difluoromethyl, methyl,
and trifluoromethyl; and
R is methyl.
In a first embodiment of the first aspect the present disclosure provides a
compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein A is
selected from
, , and .
In a second embodiment of the first aspect the present disclosure provides a
compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein B is
selected from
and .
In a third embodiment, B is .
In a fourth embodiment of the first aspect the present disclosure provides a
compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R is
.
In a second aspect the present disclosure provides a compound of formula (II)
(II),
or a pharmaceutically acceptable salt thereof, wherein:
A is selected from
, , , , , and ;
wherein “ ” denotes the point of attachment to B;
B is selected from phenyl and pyridinyl;
R is selected from hydrogen, difluoromethyl, halo, methoxy, methyl, –
NHC(O)CH ,
-NHCO CH , and trifluoromethyl;
R is selected from hydrogen, -CH OH, and halo;
R is selected from hydrogen, cyano, cyclopropyl, difluoromethyl, halo,
hydroxymethyl, methoxy, methyl, trifluoromethoxy, trifluoromethyl, and a five-
membered aromatic ring containing one, two, or three heteroatoms selected from
nitrogen, oxygen, and sulfur;
R is selected from hydrogen, halo, and methyl; and
R is selected from hydrogen, ethyl, fluoromethyl, difluoromethyl, methyl,
and trifluoromethyl.
In a first embodiment of the second aspect the present disclosure provides a
compound of formula (II), or a pharmaceutically acceptable salt thereof, wherein A is
selected from
, , and .
In a second embodiment of the second aspect the present disclosure provides
a compound of formula (II), or a pharmaceutically acceptable salt thereof, wherein B
is pyridinyl. In a third embodiment B is .
wherein “ ” denotes the point of attachment to A and “ ” denotes the point
of attachment to the oxygen atom.
In a fourth embodiment of the second aspect the present disclosure provides a
compound of formula (II), or a pharmaceutically acceptable salt thereof, wherein
wherein
A is selected from
, , and and
B is
In a third aspect the present disclosure provides a composition comprising a
pharmaceutically acceptable amount of a compound of formula (I), or a
pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
In another aspect the present invention provides a use of a compound of the
first apect, or a pharmaceutically acceptable salt thereof in the manufacture of a
medicament for inhibiting adaptor associated kinase 1 (AAK1) activity.
In another aspect the present invention provides a use of a compound of the
first claimed aspect, or a pharmaceutically acceptable salt thereof in the manufacture
of a medicament for treating or managing a disease or a disorder mediated by AAK1
activity.
In another aspect the present invention provides a composition comprising a
pharmaceutically acceptable amount of (S)((2',6-bis(difluoromethyl)-[2,4'-
bipyridin]yl)oxy)-2,4-dimethylpentanamine, or a pharmaceutically acceptable
salt thereof, and a pharmaceutically acceptable carrier.
In another aspect the present invention provides a use of (S)((2',6-
bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine, or a
pharmaceutically acceptable salt thereof in the manufacture of a medicament for
inhibiting adaptor associated kinase 1 (AAK1) activity.
In another aspect, the present invention provides a use of (S)((2',6-
bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine, or a
pharmaceutically acceptable salt thereof in the manufacture of a medicament for for
treating or managing a disease or a disorder mediated by AAK1 activity.
Described herein is a method of inhibiting adaptor associated kinase 1
(AAK1) activity, comprising contacting AAK1 with a compound of formula (I),or a
pharmaceutically acceptable salt thereof.
Described herein is a method for treating or managing a disease or a disorder
mediated by AAK1activity, the method comprising administering to a patient in need
thereof a therapeutically effective amount of a compound of formula (I), or a
pharmaceutically acceptable salt thereof. In a first embodiment of said method the
disease or disorder is selected from Alzheimer’s disease, bipolar disorder, pain,
Parkinson’s disease, and schizophrenia. In a second embodiment the pain is
neuropathic pain. In a third embodiment the neuropathic pain is fibromyalgia or
peripheral neuropathy.
Other aspects of the present disclosure may include suitable combinations of
embodiments disclosed herein.
Yet other aspects and embodiments may be found in the description provided
herein.
In the description in this specification reference may be made to subject
matter that is not within the scope of the claims of the current application. That
subject matter should be readily identifiable by a person skilled in the art and may
assist in putting into practice the invention as defined in the claims of this
application.
BRIEF DESCRIPTION OF THE FIGURES
Aspects of the disclosure are illustrated in Figure 1, which shows results
obtained from a formalin pain model using AAK1 homozygous (-/-) knockout mice
and their wild-type (+/+) littermates. The AAK1 homozygous (-/-) knockout mice
show a clear reduction in both acute and tonic pain response as compared to their
wild-type (+/+) littermates.
This disclosure is based, in part, on the discovery that AAK1 knockout mice
exhibit a high resistance to pain. That discovery prompted research that ultimately
led to the discovery of AAK1 inhibitors, compositions comprising them, and methods
of their use.
The description of the present disclosure herein should be construed in
congruity with the laws and principals of chemical bonding. In some instances it
may be necessary to remove a hydrogen atom in order to accommodate a substituent
at any given location.
It should be understood that the compounds encompassed by the present
disclosure are those that are suitably stable for use as pharmaceutical agent.
As used in the present specification, the following terms have the meanings
indicated:
All patents, patent applications, and literature references cited in the
specification are herein incorporated by reference in their entirety. In the case of
inconsistencies, the present disclosure, including definitions, will prevail.
As used herein, the singular forms “a”, “an”, and “the” include plural
reference unless the context clearly dictates otherwise.
In some instances, the number of carbon atoms in any particular group is
denoted before the recitation of the group. For example, the term “C alkyl”
denotes an alkyl group containing one to six carbon atoms. Where these designations
exist they supercede all other definitions contained herein.
The term “halo,” as used herein, refers to Br, Cl, F, and/or I.
Asymmetric centers may exist in the compounds of the present disclosure. It
should be understood that the disclosure encompasses all stereochemical isomeric
forms, or mixtures thereof, which possess the ability to inhibit AAK1. Individual
stereoisomers of compounds can be prepared synthetically from commercially
available starting materials which contain chiral centers or by preparation of mixtures
of enantiomeric products followed by separation such as conversion to a mixture of
diastereomers followed by separation or recrystallization, chromatographic
techniques, or direct separation of enantiomers on chiral chromatographic columns.
Starting compounds of particular stereochemistry are either commercially available
or can be made and resolved by techniques known in the art.
Certain compounds of the present disclosure may also exist in different stable
conformational forms which may be separable. Torsional asymmetry due to
restricted rotation about an asymmetric single bond, for example because of steric
hindrance or ring strain, may permit separation of different conformers. The present
disclosure includes each conformational isomer of these compounds and mixtures
thereof.
The term "compounds of the present disclosure", and equivalent expressions,
are meant to embrace compounds of formula (I), and pharmaceutically acceptable
enantiomers, diastereomers, and salts thereof. Similarly, references to intermediates
are meant to embrace their salts where the context so permits.
The present disclosure is intended to include all isotopes of atoms occurring
in the present compounds. Isotopes include those atoms having the same atomic
number but different mass numbers. By way of general example and without
limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon
13 14
include C and C. Isotopically-labeled compounds of the disclosure can generally
be prepared by conventional techniques known to those skilled in the art or by
processes analogous to those described herein, using an appropriate isotopically-
labeled reagent in place of the non-labeled reagent otherwise employed. Such
compounds may have a variety of potential uses, for example as standards and
reagents in determining biological activity. In the case of stable isotopes, such
compounds may have the potential to favorably modify biological, pharmacological,
or pharmacokinetic properties.
The compounds of the present disclosure can exist as pharmaceutically
acceptable salts. The term “pharmaceutically acceptable salt,” as used herein,
represents salts or zwitterionic forms of the compounds of the present disclosure
which are water or oil-soluble or dispersible, which are, within the scope of sound
medical judgment, suitable for use in contact with the tissues of patients without
excessive toxicity, irritation, allergic response, or other problem or complication
commensurate with a reasonable benefit/risk ratio, and are effective for their intended
use. The salts can be prepared during the final isolation and purification of the
compounds or separately by reacting a suitable nitrogen atom with a suitable acid.
Representative acid addition salts include acetate, adipate, alginate, citrate, aspartate,
benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate;
digluconate, dihydrobromide, diydrochloride, dihydroiodide, glycerophosphate,
hemisulfate, heptanoate, hexanoate, formate, fumarate, hydrochloride, hydrobromide,
hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, mesitylenesulfonate,
methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate,
palmoate, pectinate, persulfate, 3-phenylproprionate, picrate, pivalate, propionate,
succinate, tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate,
bicarbonate, para-toluenesulfonate, and undecanoate. Examples of acids which can
be employed to form pharmaceutically acceptable addition salts include inorganic
acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids
such as oxalic, maleic, succinic, and citric.
Basic addition salts can be prepared during the final isolation and purification
of the compounds by reacting a carboxy group with a suitable base such as the
hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic
primary, secondary, or tertiary amine. The cations of pharmaceutically acceptable
salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as
well as nontoxic quaternary amine cations such as ammonium,
tetramethylammonium, tetraethylammonium, methylamine, dimethylamine,
trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine,
N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine,
procaine, dibenzylamine, N,N-dibenzylphenethylamine, and N,N’-
dibenzylethylenediamine. Other representative organic amines useful for the
formation of base addition salts include ethylenediamine, ethanolamine,
diethanolamine, piperidine, and piperazine.
One embodiment of this disclosure encompasses methods of inhibiting adaptor
associated kinase 1 (AAK1), both in vitro and in vivo, which comprise contacting
AAK1 with a compound of formula I or a pharmaceutically acceptable salt thereof.
When it is possible that, for use in therapy, therapeutically effective amounts
of a compound of formula (I), as well as pharmaceutically acceptable salts thereof,
may be administered as the raw chemical, it is possible to present the active
ingredient as a pharmaceutical composition. Accordingly, the disclosure further
provides pharmaceutical compositions, which include therapeutically effective
amounts of compounds of formula (I) or pharmaceutically acceptable salts thereof,
and one or more pharmaceutically acceptable carriers, diluents, or excipients.
Unless otherwise indicated, a “therapeutically effective amount” of a compound is an
amount sufficient to provide a therapeutic benefit in the treatment or management of
a disease or condition, or to delay or minimize one or more symptoms associated
with the disease or condition. The term “therapeutically effective amount” can
encompass an amount that improves overall therapy, reduces or avoids symptoms or
causes of a disease or condition, or enhances the therapeutic efficacy of another
therapeutic agent.
The term “therapeutically effective amount,” as used herein, refers to an
amount of a compound or compounds sufficient to provide a therapeutic benefit in
the treatment or management of a disease or condition, or to delay or minimize one
or more symptoms associated with the disease or condition. A “therapeutically
effective amount” of a compound means an amount of therapeutic agent, alone or in
combination with other therapies, that provides a therapeutic benefit in the treatment
or management of the disease or condition. The term “therapeutically effective
amount” can encompass an amount that improves overall therapy, reduces or avoids
symptoms or causes of a disease or condition, or enhances the therapeutic efficacy of
another therapeutic agent. When applied to an individual active ingredient,
administered alone, the term refers to that ingredient alone. When applied to a
combination, the term refers to combined amounts of the active ingredients that result
in the therapeutic effect, whether administered in combination, serially, or
simultaneously. The compounds of formula (I) and pharmaceutically acceptable salts
thereof, are as described above. The carrier(s), diluent(s), or excipient(s) must be
acceptable in the sense of being compatible with the other ingredients of the
formulation and not deleterious to the recipient thereof. Described herein is a process
for the preparation of a pharmaceutical formulation including admixing a compound
of formula (I), or a pharmaceutically acceptable salt thereof, with one or more
pharmaceutically acceptable carriers, diluents, or excipients. The term
“pharmaceutically acceptable,” as used herein, refers to those compounds, materials,
compositions, and/or dosage forms which are, within the scope of sound medical
judgment, suitable for use in contact with the tissues of patients without excessive
toxicity, irritation, allergic response, or other problem or complication commensurate
with a reasonable benefit/risk ratio, and are effective for their intended use.
Pharmaceutical formulations may be presented in unit dose forms containing
a predetermined amount of active ingredient per unit dose. Dosage levels of between
about 0.01 and about 250 milligram per kilogram ("mg/kg") body weight per day,
preferably between about 0.05 and about 100 mg/kg body weight per day of the
compounds of the present disclosure are typical in a monotherapy for the prevention
and treatment of disease. Typically, the pharmaceutical compositions of this
disclosure will be administered from about 1 to about 5 times per day or alternatively,
as a continuous infusion. Such administration can be used as a chronic or acute
therapy. The amount of active ingredient that may be combined with the carrier
materials to produce a single dosage form will vary depending on the condition being
treated, the severity of the condition, the time of administration, the route of
administration, the rate of excretion of the compound employed, the duration of
treatment, and the age, gender, weight, and condition of the patient. Preferred unit
dosage formulations are those containing a daily dose or sub-dose, as herein above
recited, or an appropriate fraction thereof, of an active ingredient. Treatment may be
initiated with small dosages substantially less than the optimum dose of the
compound. Thereafter, the dosage is increased by small increments until the
optimum effect under the circumstances is reached. In general, the compound is
most desirably administered at a concentration level that will generally afford
effective results without causing any harmful or deleterious side effects.
When the compositions of this disclosure comprise a combination of a
compound of the present disclosure and one or more additional therapeutic or
prophylactic agent, both the compound and the additional agent are usually present at
dosage levels of between about 10 to 150%, and more preferably between about 10
and 80% of the dosage normally administered in a monotherapy regimen.
Compounds of the disclosure may be administered in combination with one or
more additional therapeutic or prophylactic agents. For example, when used for the
treatment of pain, possible additional agents include immunosuppressive agents, anti-
inflammatory agents, and/or other agents used in the treatment of pain.
Immunosuppressants suitable for use in the methods and compositions of this
disclosure include those known in the art. Examples include aminopterin,
azathioprine, cyclosporin A, D-penicillamine, gold salts, hydroxychloroquine,
leflunomide, methotrexate, minocycline, rapamycin, sulfasalazine, tacrolimus
(FK506), and pharmaceutically acceptable salts thereof. A particular
immunosuppressant is methotrexate.
Additional examples of immunosuppressants include anti-TNF antibodies,
such as adalimumab, certolizumab pegol, etanercept, and infliximab. Others include
interleukin-1 blockers, such as anakinra. Others include anti-B cell (CD20)
antibodies, such as rituximab. Others include T cell activation blockers, such as
abatacept.
Other immunosuppressants include inosine monophosphate dehydrogenase
inhibitors, such as mycophenolate mofetil (CellCept®) and mycophenolic acid
(Myfortic®).
Anti-inflammatory drugs suitable for use in the methods and compositions of
this disclosure include those known in the art. Examples include glucocorticoids and
NSAIDs. Examples of glucocorticoids include aldosterone, beclometasone,
betamethasone, cortisone, deoxycorticosterone, dexamethasone, fludrocortisones,
hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone, and
pharmaceutically acceptable salts thereof.
Examples of NSAID include salicylates (e.g., aspirin, amoxiprin, benorilate,
choline magnesium salicylate, diflunisal, faislamine, methyl salicylate, magnesium
salicylate, salicyl salicylate, and pharmaceutically acceptable salts thereof),
arylalkanoic acids (e.g., diclofenac, aceclofenac, acemetacin, bromfenac, etodolac,
indometacin, nabumetone, sulindac, tolmetin, and pharmaceutically acceptable salts
thereof), arylpropionic acids (e.g., ibuprofen, carprofen, fenbufen, fenoprofen,
flurbiprofen, ketoprofen, ketorolac, loxoprofen, naproxen, oxaprozin, tiaprofenic
acid, suprofen, and pharmaceutically acceptable salts thereof), arylanthranilic acids
(e.g., meclofenamic acid, mefenamic acid, and pharmaceutically acceptable salts
thereof), pyrazolidine derivatives (e.g., azapropazone, metamizole, oxyphenbutazone,
phenylbutazone, sulfinprazone, and pharmaceutically acceptable salts thereof),
oxicams (e.g., lornoxicam, meloxicam, piroxicam, tenoxicam, and pharmaceutically
acceptable salts thereof), COX-2 inhibitors (e.g., celecoxib, etoricoxib, lumiracoxib,
parecoxib, rofecoxib, valdecoxib, and pharmaceutically acceptable salts thereof), and
sulphonanilides (e.g., nimesulide and pharmaceutically acceptable salts thereof).
Other agents used in the treatment of pain (including but not limited to
neuropathic and inflammatory pain) include, but are not limited to, agents such as
pregabalin, lidocaine, duloxetine, gabapentin, carbamazepine, capsaicin, and other
serotonin/norepinephrine/dopamine reuptake inhibitors, and opiates (such as
oxycontin, morphine, and codeine).
In the treatment of pain caused by a known disease or condition, such as
diabetes, infection (e.g., herpes zoster or HIV infection), or cancer, compounds of the
disclosure may be administered in combination with one or more additional
therapeutic or prophylactic agents directed at the underlying disease or condition.
For example, when used to treat diabetic neuropathy, compounds of the disclosure
may be administered in combination with one or more anti-diabetic agents, anti-
hyperglycemic agents, hypolipidemic/lipid lowering agents, anti-obesity agents, anti-
hypertensive agents and appetite suppressants. Examples of anti-diabetic agents
include biguanides (e.g., metformin, phenformin), glucosidase inhibitors (e.g.,
acarbose, miglitol), insulins (including insulin secretagogues and insulin sensitizers),
meglitinides (e.g., repaglinide), sulfonylureas (e.g., glimepiride, glyburide, gliclazide,
chlorpropamide, and glipizide), biguanide/glyburide combinations (e.g.,
Glucovance), thiazolidinediones (e.g., troglitazone, rosiglitazone, and pioglitazone),
PPAR-alpha agonists, PPAR-gamma agonists, PPAR alpha/gamma dual agonists,
glycogen phosphorylase inhibitors, inhibitors of fatty acid binding protein (aP2),
glucagon-like peptide-1 (GLP-1) or other agonists of the GLP-1 receptor, dipeptidyl
peptidase IV (DPP4) inhibitors, and sodium-glucose co-transporter 2 (SGLT2)
inhibitors (e.g., dapagliflozin, canagliflozin, and LX-4211).
Pharmaceutical formulations may be adapted for administration by any
appropriate route, for example by the oral (including buccal or sublingual), rectal,
nasal, topical (including buccal, sublingual, or transdermal), vaginal, or parenteral
(including subcutaneous, intracutaneous, intramuscular, intra-articular, intrasynovial,
intrasternal, intrathecal, intralesional, intravenous, or intradermal injections or
infusions) route. Such formulations may be prepared by any method known in the art
of pharmacy, for example by bringing into association the active ingredient with the
carrier(s) or excipient(s). Oral administration or administration by injection are
preferred.
Pharmaceutical formulations adapted for oral administration may be
presented as discrete units such as capsules or tablets; powders or granules; solutions
or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-
water liquid emulsions or water-in-oil emulsions.
For instance, for oral administration in the form of a tablet or capsule, the
active drug component can be combined with an oral, non-toxic pharmaceutically
acceptable inert carrier such as ethanol, glycerol, water, and the like. Powders are
prepared by comminuting the compound to a suitable fine size and mixing with a
similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for
example, starch or mannitol. Flavoring, preservative, dispersing, and coloring agent
can also be present.
Capsules are made by preparing a powder mixture, as described above, and
filling formed gelatin sheaths. Glidants and lubricants such as colloidal silica, talc,
magnesium stearate, calcium stearate, or solid polyethylene glycol can be added to
the powder mixture before the filling operation. A disintegrating or solubilizing
agent such as agar-agar, calcium carbonate, or sodium carbonate can also be added to
improve the availability of the medicament when the capsule is ingested.
Moreover, when desired or necessary, suitable binders, lubricants,
disintegrating agents, and coloring agents can also be incorporated into the mixture.
Suitable binders include starch, gelatin, natural sugars such as glucose or beta-
lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or
sodium alginate, carboxymethylcellulose, polyethylene glycol, and the like.
Lubricants used in these dosage forms include sodium oleate, sodium chloride, and
the like. Disintegrators include, without limitation, starch, methyl cellulose, agar,
betonite, xanthan gum, and the like. Tablets are formulated, for example, by
preparing a powder mixture, granulating or slugging, adding a lubricant and
disintegrant, and pressing into tablets. A powder mixture is prepared by mixing the
compound, suitable comminuted, with a diluent or base as described above, and
optionally, with a binder such as carboxymethylcellulose, an aliginate, gelating, or
polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator
such as a quaternary salt and/or and absorption agent such as betonite, kaolin, or
dicalcium phosphate. The powder mixture can be granulated by wetting with a
binder such as syrup, starch paste, acadia mucilage, or solutions of cellulosic or
polymeric materials and forcing through a screen. As an alternative to granulating,
the powder mixture can be run through the tablet machine and the result is
imperfectly formed slugs broken into granules. The granules can be lubricated to
prevent sticking to the tablet forming dies by means of the addition of stearic acid, a
stearate salt, talc, or mineral oil. The lubricated mixture is then compressed into
tablets. The compounds of the present disclosure can also be combined with a free
flowing inert carrier and compressed into tablets directly without going through the
granulating or slugging steps. A clear or opaque protective coating consisting of a
sealing coat of shellac, a coating of sugar or polymeric material, and a polish coating
of wax can be provided. Dyestuffs can be added to these coatings to distinguish
different unit dosages.
Oral fluids such as solution, syrups, and elixirs can be prepared in dosage unit
form so that a given quantity contains a predetermined amount of the compound.
Syrups can be prepared by dissolving the compound in a suitably flavored aqueous
solution, while elixirs are prepared through the use of a non-toxic vehicle.
Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and
polyoxyethylene sorbitol ethers, preservatives, flavor additive such as peppermint oil
or natural sweeteners, or saccharin or other artificial sweeteners, and the like can also
be added.
Where appropriate, dosage unit formulations for oral administration can be
microencapsulated. The formulation can also be prepared to prolong or sustain the
release as for example by coating or embedding particulate material in polymers,
wax, or the like.
The compounds of formula (I), and pharmaceutically acceptable salts thereof,
can also be administered in the form of liposome delivery systems, such as small
unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
Liposomes can be formed from a variety of phopholipids, such as cholesterol,
stearylamine, or phophatidylcholines.
The compounds of formula (I) and pharmaceutically acceptable salts thereof
may also be delivered by the use of monoclonal antibodies as individual carriers to
which the compound molecules are coupled. The compounds may also be coupled
with soluble polymers as targetable drug carriers. Such polymers can include
polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol,
polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine substituted
with palitoyl residues. Furthermore, the compounds may be coupled to a class of
biodegradable polymers useful in achieving controlled release of a drug, for example,
polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters,
polyacetals, polydihydropyrans, polycyanoacrylates, and cross-linked or amphipathic
block copolymers of hydrogels.
Pharmaceutical formulations adapted for transdermal administration may be
presented as discrete patches intended to remain in intimate contact with the
epidermis of the recipient for a prolonged period of time. For example, the active
ingredient may be delivered from the patch by iontophoresis as generally described in
Pharmaceutical Research 1986, 3(6), 318.
Pharmaceutical formulations adapted for topical administration may be
formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes,
gels, sprays, aerosols, or oils.
Pharmaceutical formulations adapted for rectal administration may be
presented as suppositories or as enemas.
Pharmaceutical formulations adapted for nasal administration wherein the
carrier is a solid include a course powder having a particle size for example in the
range 20 to 500 microns which is administered in the manner in which snuff is taken,
i.e., by rapid inhalation through the nasal passage from a container of the powder
held close up to the nose. Suitable formulations wherein the carrier is a liquid, for
administration as a nasal spray or nasal drops, include aqueous or oil solutions of the
active ingredient.
Pharmaceutical formulations adapted for administration by inhalation include
fine particle dusts or mists, which may be generated by means of various types of
metered, dose pressurized aerosols, nebulizers, or insufflators.
Pharmaceutical formulations adapted for vaginal administration may be
presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulations.
Pharmaceutical formulations adapted for parenteral administration include
aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants,
buffers, bacteriostats, and soutes which render the formulation isotonic with the
blood of the intended recipient; and aqueous and non-aqueous sterile suspensions
which may include suspending agents and thickening agents. The formulations may
be presented in unit-dose or multi-dose containers, for example sealed ampoules and
vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the
addition of the sterile liquid carrier, for example water for injections, immediately
prior to use. Extemporaneous injection solutions and suspensions may be prepared
from sterile powders, granules, and tablets.
It should be understood that in addition to the ingredients particularly
mentioned above, the formulations may include other agents conventional in the art
having regard to the type of formulation in question, for example those suitable for
oral administration may include flavoring agents.
The term "patient" includes both human and other mammals.
Unless otherwise indicated, the terms “manage,” “managing”, and “management”
encompass preventing the recurrence of the specified disease or disorder in a patient
who has already suffered from the disease or disorder, and/or lengthening the time
that a patient who has suffered from the disease or disorder remains in remission.
The terms encompass modulating the threshold, development and/or duration of the
disease or disorder, or changing the way that a patient responds to the disease or
disorder.
The term "treating" refers to: (i) preventing a disease, disorder or condition
from occurring in a patient that may be predisposed to the disease, disorder, and/or
condition but has not yet been diagnosed as having it; (ii) inhibiting the disease,
disorder, or condition, i.e., arresting its development; and (iii) relieving the disease,
disorder, or condition, i.e., causing regression of the disease, disorder, and/or
condition.
This disclosure is intended to encompass compounds having Formula (I)
when prepared by synthetic processes or by metabolic processes including those
occurring in the human or animal body (in vivo) or processes occurring in vitro.
The term “comprising” as used in this specification and claims means
“consisting at least in part of”. When interpreting statements in this specification,
and claims which include the term “comprising”, it is to be understood that other
features that are additional to the features prefaced by this term in each statement or
claim may also be present. Related terms such as “comprise” and “comprised” are to
be interpreted in similar manner.
In this specification where reference has been made to patent specifications,
other external documents, or other sources of information, this is generally for the
purpose of providing a context for discussing the features of the invention. Unless
specifically stated otherwise, reference to such external documents is not to be
construed as an admission that such documents, or such sources of information, in
any jurisdiction, are prior art, or form part of the common general knowledge in the
art.
EXAMPLES
The present disclosure will now be described in connection with certain
embodiments which are not intended to limit its scope. On the contrary, the present
disclosure covers all alternatives, modifications, and equivalents as can be included
within the scope of the claims. Thus, the following examples, which include specific
embodiments, will illustrate one practice of the present disclosure, it being
understood that the examples are for the purposes of illustration of certain
embodiments and are presented to provide what is believed to be the most useful and
readily understood description of its procedures and conceptual aspects.
The abbreviations used in the present application, including particularly in the
illustrative schemes and examples which follow, are well-known to those skilled in
the art. Some of the abbreviations used are as follows: MeOH for methanol; min for
minutes, EtOAc or ETOAC for ethyl acetate; h or hr or hrs for hours; Ph P for
triphenylphosphine, DIAD for diisopropyl azodicarboxylate; RT or rt or r.t. for room
temperature or retention time (context will dictate); t for retention time; EtOH for
ethanol; DMSO for dimethylsulfoxide; THF for tetrahydrofuran; dppf for
diphenylphosphinoferrocene; TFA for trifluoracetic acid; NMP for N-
methylpyrrolidine; CBz or Cbz for benzyloxycarbonyl; DCM for dichloromethane;
IPA for isopropyl alcohol; DMAP for N,N-dimethylaminopyridine; BOC or Boc for
tert-butoxycarbonyl; (BOC) O for di-tert-butyl dicarbonate/ DMF for N,N-
dimethylformamide; OAc for acetate; Cbz for carbobenzyloxy; TMS for
trimethylsilane; LDA for lithium diisopropylamide; MOM-Cl for chloromethyl
methyl ether; KHMDS for potassium hexamethyldisilazide; KOtBu for potassium
tert-butoxide; DAST for diethylaminosulfur trifloride; BuOH for n-butanol; n-BuLi
for n-butyllithium; and NBS for N-bromosuccinimide.
The compounds of the present disclosure may be prepared using the reactions
and techniques described in this section as well as other synthetic methods known to
those of ordinary skill in the art. The reactions are performed in solvents appropriate
to the reagents and materials employed and suitable for the transformation being
affected. Also, in the description of the synthetic methods described below, it is to be
understood that all proposed reaction conditions, including choice of solvents,
reaction temperature, duration of the experiment and workup procedures, are chosen
to be the conditions standard for that reaction, which should be readily recognized by
one skilled in the art. It is understood by one skilled in the art of organic synthesis
that the functionality present on various portions of the molecule must be compatible
with the reagents and reactions proposed. Such restrictions to the substituents which
are compatible with the reaction conditions will be readily apparent to one skilled in
the art and alternate methods must then be used.
Compounds of Formula Ia can be synthesized following General Scheme I.
The two key reactions, Suzuki coupling and ether formation, could alternate as
shown depending on the commercially available starting materials. The Suzuki
coupling substrates, boronic acids/boronates, were either commercially available or
prepared from corresponding halogen intermediates (Cl/Br/I) with various standard
literature conditions. The ether formation can be achieved by SN when a fluorine
intermediate (Formula IV) is available, by Mitsunobu reaction or alkylation with
suitable amino alcohol when an OH is available (Formula III/V), and by Buchwald’s
Pd-catalyzed ether formation reaction when a Cl intermediate (Formula III/V) is
available. In cases where R is bigger than H, an activated form of the amino alcohol
(Formula VII) was used as the OH-alkylating reagent. Sometimes NH and OH were
protected and deprotected during the reaction sequence.
General Scheme I:
In the following examples, proton NMR spectra were recorded on either a
Bruker 400 or 500 MHz NMR spectrometer. Chemical shifts are reported in δ values
relative to tetramethylsilane. Liquid chromatography (LC)/mass spectra were run on
a Shimadzu LC coupled to a Waters Micromass ZQ using at least one of the
following methods.
LC/MS Method A:
Column : Phenomenex LUNA C18, 30x2, 3μm; Solvent A = 5 % MeOH: 95%
Water:10mM Ammonium Acetate; Solvent B = 95% MeOH:5% Water:10mM
Ammonium Acetate; Flow rate: 1 ml/min; Starting B = 0%; Final B = 100%;
Gradient time = 2 min; Run time: 3 min.
LC/MS Method B:
Column : Phenomenex LUNA C18, 30x2, 3μm; Solvent A = 10 % MeOH: 90%
Water:0.1%TFA; Solvent B = 90% MeOH:10% Water:0.1%TFA; Flow rate: 1
ml/min; Starting B = 0%; Final B = 100%; Gradient time = 2 min; Run time: 3 min.
LC/MS Method C:
Column : Phenomenex LUNA C18, 30x2, 3μm; Solvent A = 5 % MeOH: 95%
Water:10mM Ammonium Acetate; Solvent B = 95% MeOH:5% Water:10mM
Ammonium Acetate; Flow rate: 0.8 ml/min; Starting B = 0%; Final B = 100%;
Gradient time = 4 min; Run time: 5 min.
Example 1
(S)-N-(4-(4-((2-aminomethylpentyl)oxy)fluorophenyl)pyridinyl)acetamide
Part A: N-(4-bromopyridinyl)acetamide
To a mixture of 4-bromopyridinamine (3.11 g, 17.98 mmol) in CH Cl (60
mL) at 0 °C was added acetyl chloride (1.406 mL, 19.77 mmol) and pyridine (1.745
mL, 21.57 mmol). The mixture was warmed to rt and stirred for 2 h. The reaction
was quenched with water and diluted with EtOAc. The layers were separated. The
organic layer was washed with water, brine, dried (Na SO ) and concentrated under
reduced pressure to obtain N-(4-bromopyridinyl)acetamide (3.82 g, 17.05 mmol,
95% yield) as a white solid. The material was carried on without further purification.
LCMS (ESI) m/e 215.0 [(M+H) , calcd C H Br N O , 215.0]; LC/MS retention time
7 8 1 2 1
(method A): t = 2.61 min.
Part B: N-(4-(3-fluorohydroxyphenyl)pyridinyl)acetamide
To a 15 mL vial was added N-(4-bromopyridinyl)acetamide (205.8 mg,
0.957 mmol), (3-fluorohydroxyphenyl)boronic acid (239 mg, 1.531 mmol), and
Na CO (1.435 mL, 2.87 mmol) in dioxane (3 mL) under nitrogen to give a colorless
solution. 1,1'-bis(diphenylphosphino)ferrocenepalladium(II) dichloride, toluene
(39.4 mg, 0.048 mmol) was added under nitrogen. The vial was sealed and heated at
130 °C (microwave) for 2 h. The mixture was partitioned between water and EtOAc.
The layers were separated. The organic layer was washed with brine, dried (Na SO )
and concentrated under reduced pressure to obtain N-(4-(3-fluoro
hydroxyphenyl)pyridinyl)acetamide (200 mg, 0.812 mmol, 85% yield) as a tan
solid. LCMS (ESI) m/e 247.0 [(M+H) , calcd C H F N O , 247.1]; LC/MS
13 12 1 2 2
retention time (method A): t = 1.51 min.
Part C: (S)(1-hydroxymethylpentanyl)isoindoline-1,3-dione
To a 250 mL round-bottomed flask was added (S)aminomethylhexan
ol (2.166 g, 16.51 mmol) and isobenzofuran-1,3-dione (2.445 g, 16.51 mmol) in
toluene (60 mL) to give a colorless suspension. The mixture was heated at 110 °C
for 16 h. The volatiles were removed under high vacuum to afford (S)(1-hydroxy-
4-methylpentanyl)isoindoline-1,3-dione (4.08 g, 16.51 mmol, quantitative yield)
as a light yellow dense oil. LCMS (ESI) m/e 246.2 [(M-H) , calcd C H N O ,
14 16 1 3
246.1]; LC/MS retention time (method A): t = 1.88 min.
Part D: (S)-N-(4-(4-((2-(1,3-dioxoisoindolinyl)methylpentyl)oxy)
fluorophenyl)pyridinyl)acetamide
To a 50 mL round-bottomed flask was added (S)(1-hydroxy
methylpentanyl)isoindoline-1,3-dione (93 mg, 0.375 mmol), Ph P (123 mg, 0.468
mmol), and (S)(1-hydroxymethylpentanyl)isoindoline-1,3-dione (93 mg,
0.375 mmol) in tetrahydrofuran (1 mL) to give a tan suspension. DIAD (0.091 mL,
0.468 mmol) was added dropwise at rt. The resultant clear tan solution was stirred at
rt for 19 h. The solution was concentrated under reduced pressure to give a tan oil
which was carried directly into the next reaction. LCMS (ESI) m/e 476.3 [(M+H) ,
calcd C H F N O , 476.2]; LC/MS retention time (method A): t = 2.21 min.
27 27 1 3 4 R
Part E: (S)-N-(4-(4-((2-aminomethylpentyl)oxy)fluorophenyl)pyridin
yl)acetamide
To a 50 mL round-bottomed flask was added (S)-N-(4-(4-((2-(1,3-
dioxoisoindolinyl)methylpentyl)oxy)fluorophenyl)pyridinyl)acetamide
(148 mg, 0.312 mmol) in EtOH (2 mL) to give a tan solution. Hydrazine (0.049 mL,
1.560 mmol) was added and the mixture was heated at 60 °C for 2 h. The solution
was cooled to rt and was concentrated under reduced pressure. The residue was
suspended in MeOH, filtered, and purified by prep-HPLC (24 mg, 0.069 mmol, 22%
yield for 3 steps): H NMR (500 MHz, DMSO-d ) δ 10.53 (s, 1H), 8.33 (d, J = 4.9
Hz, 2H), 7.61 (dd, J = 12.5, 2.2 Hz, 1H), 7.52 (dd, J = 8.5, 2.2 Hz, 1H), 7.43 - 7.37
(m, 1H), 7.32 (t, J = 8.7 Hz, 1H), 3.97 (dd, J = 9.5, 4.9 Hz, 1H), 3.90 (dd, J = 9.5,
6.5 Hz, 1H), 3.12 (dt, J = 11.9, 5.4 Hz, 1H), 2.12 (s, 3H), 1.81 (dq, J = 13.0, 6.5 Hz,
1H), 1.33 (ddd, J = 13.5, 8.5, 5.0 Hz, 1H), 1.26 (ddd, J = 13.5, 8.5, 5.5 Hz, 1H), 0.92
(d, J = 6.6 Hz, 3H), 0.88 (d, J = 6.5 Hz, 3H); LCMS (ESI) m/e 346.2 [(M+H) , calcd
C H F N O , 346.2]; LC/MS retention time (method A): t = 1.89 min.
19 25 1 3 2 R
Alternative Synthesis of Example 1
(S)-N-(4-(4-((2-aminomethylpentyl)oxy)fluorophenyl)pyridinyl)acetamide
Part 2A: (S)-tert-butyl (1-(4-bromofluorophenoxy)methylpentan
yl)carbamate
To a 15 mL vial was added (S)-tert-butyl (1-hydroxymethylpentan
yl)carbamate (172 mg, 0.792 mmol), Ph P (260 mg, 0.990 mmol), and 4-bromo
fluorophenol (126 mg, 0.660 mmol) in tetrahydrofuran (2mL) to give a tan solution.
DIAD (0.180 mL, 0.924 mmol) was added at rt. The resulted clear tan solution was
stirred at rt for 16 h. The solution was concentrated under reduced pressure to afford
a tan oil which was directly purified by silica gel column chromatography (up to 60%
EtOAc/hexane to afford (S)-tert-butyl (1-(4-bromofluorophenoxy)
methylpentanyl)carbamate (249 mg, 0.638 mmol, 97% yield) as a colorless oil: H
NMR (400 MHz, Chloroform-d) δ 7.24 (dd, J = 10.5, 2.4 Hz, 1H), 7.21 - 7.16 (m,
1H), 6.90 - 6.81 (m, 1H), 4.83 - 4.69 (m, 1H), 4.08 - 3.92 (m, 3H), 1.71 (dp, J = 13.2,
6.6 Hz, 1H), 1.59 - 1.49 (m, 2H), 1.47 (d, J = 3.8 Hz, 9H), 0.96 (dd, J = 6.6, 4.4 Hz,
6H); LCMS (ESI) m/e 412.1 [(M+Na) , calcd C H BrFNNaO , 412.1]; LC/MS
17 25 3
retention time (method B): t = 2.41 min.
Part 2B: (S)-tert-butyl (1-(4-(2-acetamidopyridinyl)fluorophenoxy)
methylpentanyl)carbamate
To a 15 mL vial was added N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan
yl)pyridinyl)acetamide (208 mg, 0.792 mmol), (S)-tert-butyl (1-(4-bromo
fluorophenoxy)methylpentanyl)carbamate (258 mg, 0.66 mmol), and Na CO
(0.990 mL, 1.980 mmol) in dioxane (2 mL) under nitrogen to give a colorless
suspension. 1,1'-Bis(diphenylphosphino)ferrocenepalladium(II) dichloride, toluene
(27.1 mg, 0.033 mmol) was added under nitrogen. The vial was sealed and heated at
130 °C (microwave) for 2 h. The mixture was diluted with water and EtOAc. The
layers were separated. The organic layer was washed with brine, dried (Na SO ) and
concentrated. The residue was purified by silica gel column chromatography (up to
70% EtOAc/hexane) to afford the desired product (200 mg, 0.449 mmol, 68% yield
for two steps) as a colorless oil: H NMR (400 MHz, Chloroform-d) δ 8.79 (s, 1H),
8.46 (s, 1H), 8.29 (d, J = 5.4 Hz, 1H), 7.50 - 7.38 (m, 2H), 7.21 (dd, J = 5.2, 1.7 Hz,
1H), 7.06 (t, J = 8.7 Hz, 1H), 4.81 (d, J = 9.2 Hz, 1H), 4.12 - 3.96 (m, 3H), 2.25 (s,
3H), 1.74 (dq, J = 13.5, 6.5, 6.1 Hz, 1H), 1.63 - 1.52 (m, 2H), 1.47 (s, 9H), 0.98 (dd,
J = 6.6, 3.3 Hz, 6H); LCMS (ESI) m/e 446.2 [(M+H) , calcd C H F N O , 446.2];
24 33 1 3 4
LC/MS retention time (method B): t = 2.11 min.
Part 2C: (S)-N-(4-(4-((2-aminomethylpentyl)oxy)fluorophenyl)pyridin
yl)acetamide
To a 50 mL round-bottomed flask was added (S)-tert-butyl (1-(4-(2-
acetamidopyridinyl)fluorophenoxy)methylpentanyl)carbamate (202 mg,
0.453 mmol) in dichloromethane (2 mL) to give a colorless solution. TFA (0.5 mL)
was added, and the resulted tan solution was stirred at rt for 1 h. The volatiles were
removed under reduced pressure. The residue was diluted with EtOAc and basified
with 1N NaOH. The layers were separated. The organic layer was washed with
brine, dried (Na SO ) and concentrated under reduced pressure to afford (S)-N-(4-(4-
((2-aminomethylpentyl)oxy)fluorophenyl)pyridinyl)acetamide (155 mg,
0.449 mmol, 99% yield) as a slightly tan oil: H NMR and LCMS matched that of the
previously prepared; F NMR (376 MHz, Chloroform-d) δ -133.47.
Example 2
(S)-N-(4-(4-((2-aminomethylpentyl)oxy)methoxyphenyl)pyridin
yl)acetamide
Prepared as described in Example 1.
Part A: N-(4-(3-methoxyhydroxyphenyl)pyridinyl)acetamide
LCMS (ESI) m/e 259.1 [(M+H) , calcd C H N O , 259.3]; LC/MS retention
14 15 2 3
time (method A): t = 1.51 min.
Part B: (S)-N-(4-(4-((2-(1,3-dioxoisoindolinyl)methylpentyl)oxy)
methoxyphenyl)pyridinyl)acetamide
LCMS (ESI) m/e 488.3 [(M+H) , calcd C H N O , 488.2]; LC/MS retention
28 30 3 5
time (method A): t = 2.17 min.
Part C: (S)-N-(4-(4-((2-aminomethylpentyl)oxy)methoxyphenyl)pyridin
yl)acetamide.
Obtained (S)-N-(4-(4-((2-aminomethylpentyl)oxy)
methoxyphenyl)pyridinyl)acetamide (14.9 mg, 0.042 mmol, 80% yield for final
step) as a slightly tan foam: H NMR (500 MHz, DMSO-d ) δ 10.50 (s, 1H), 8.35 (s,
1H), 8.32 (d, J = 5.2 Hz, 1H), 7.40 (dd, J = 5.2, 1.8 Hz, 1H), 7.32 - 7.22 (m, 2H),
7.12 (d, J = 8.2 Hz, 1H), 3.90 (dd, J = 9.3, 4.6 Hz, 1H), 3.87 (s, 3H), 3.78 (dd, J =
9.4, 6.9 Hz, 1H), 3.09 (p, J = 5.5, 5.1 Hz, 1H), 2.12 (s, 3H), 1.82 (dt, J = 13.4, 6.7
Hz, 1H), 1.32 (ddd, J = 13.5, 8.6, 5.0 Hz, 1H), 1.24 (ddd, J = 13.6, 8.7, 5.5 Hz, 1H),
0.92 (d, J = 6.6 Hz, 3H), 0.89 (d, J = 6.5 Hz, 3H); LCMS (ESI) m/e 358.2 [(M+H) ,
calcd C H N O , 358.2]; LC/MS retention time (method A): t = 1.70 min.
28 3 3 R
Example 3
(S)-N-(4-(4-((2-aminomethylpentyl)oxy)cyanophenyl)pyridinyl)acetamide
Prepared as described in Example 1.
Part A: (S)bromo((2-(1,3-dioxoisoindolinyl)
methylpentyl)oxy)benzonitrile.
H NMR (400 MHz, Chloroform-d) δ 7.86 (dd, J = 5.4, 3.0 Hz, 2H), 7.74 (dd,
J = 5.5, 3.1 Hz, 2H), 7.63 - 7.55 (m, 2H), 6.87 (d, J = 8.8 Hz, 1H), 4.85 (tdd, J = 9.8,
5.6, 3.9 Hz, 1H), 4.57 (t, J = 9.2 Hz, 1H), 4.32 (dd, J = 9.3, 5.7 Hz, 1H), 2.28 - 2.14
(m, 1H), 1.66 - 1.53 (m, 2H), 1.00 (d, J = 5.8 Hz, 3H), 0.96 (d, J = 6.0 Hz, 3H);
LCMS (ESI) m/e 427.1 [(M+H) , calcd C H Br N O , 427.1]; LC/MS retention
21 20 1 2 3
time (method B): t = 2.29 min.
Part B: (S)-N-(4-(3-cyano((2-(1,3-dioxoisoindolinyl)
methylpentyl)oxy)phenyl)pyridinyl)acetamide.
LCMS (ESI) m/e 483.3 [(M+H) , calcd C H N O , 483.2]; LC/MS
28 27 4 4
retention time (method B): t = 2.06 min.
Part C: (S)-N-(4-(4-((2-aminomethylpentyl)oxy)cyanophenyl)pyridin
yl)acetamide
Acetamide was partially hydrolyzed (see Example 4) and the two products
were separated and identified. Obtained (S)-N-(4-(4-((2-aminomethylpentyl)oxy)-
3-cyanophenyl)pyridinyl)acetamide (10.1 mg, 0.028 mmol, 23% yield) as a
colorless foam. H NMR (500 MHz, DMSO-d ) δ 10.58 (s, 1H), 8.39 - 8.32 (m, 2H),
8.12 (d, J = 2.5 Hz, 1H), 8.00 (dd, J = 8.8, 2.5 Hz, 1H), 7.44 (d, J = 5.4 Hz, 1H),
7.41 (d, J = 8.8 Hz, 1H), 4.05 (dd, J = 9.3, 5.0 Hz, 1H), 3.99 (t, J = 7.9 Hz, 1H), 3.12
(s, 1H), 2.13 (s, 3H), 1.84 (p, J = 6.6 Hz, 1H), 1.42 - 1.31 (m, 1H), 1.27 (dq, J =
14.0, 7.0, 6.2 Hz, 1H), 0.93 (d, J = 6.6 Hz, 3H), 0.89 (d, J = 6.4 Hz, 3H); LCMS
(ESI) m/e 353.2 [(M+H) , calcd C H N O , 353.2]; LC/MS retention time (method
25 4 2
B): t = 1.44 min.
Example 4
(S)((2-aminomethylpentyl)oxy)(2-aminopyridinyl)benzonitrile
The hydrolyzed material from Example 3 was identified as (S)((2-amino
methylpentyl)oxy)(2-aminopyridinyl)benzonitrile (10.1 mg, 0.030 mmol, 26%
yield) as a colorless foam. H NMR (500 MHz, DMSO-d ) δ 8.02 (d, J = 2.4 Hz,
1H), 7.97 (d, J = 5.3 Hz, 1H), 7.93 (dd, J = 8.8, 2.4 Hz, 1H), 7.36 (d, J = 8.9 Hz,
1H), 6.82 (dd, J = 5.3, 1.6 Hz, 1H), 6.70 (s, 1H), 5.97 (s, 2H), 4.03 (dd, J = 9.3, 5.1
Hz, 1H), 3.96 (t, J = 7.7 Hz, 1H), 3.10 (s, 1H), 1.84 (p, J = 6.4 Hz, 1H), 1.35 (q, J =
9.3, 6.6 Hz, 1H), 1.26 (dq, J = 13.7, 6.8, 6.1 Hz, 1H), 0.92 (d, J = 6.6 Hz, 3H), 0.89
(d, J = 6.5 Hz, 3H); LCMS (ESI) m/e 311.2 [(M+H) , calcd C H N O , 311.2];
18 23 4 1
LC/MS retention time (method B): t = 1.35 min.
Example 5
(S)-N-(4-(4-((2-aminomethylpentyl)oxy)(trifluoromethyl)phenyl)pyridin
yl)acetamide
Prepared as described in Example 1.
Part A: (S)-tert-butyl (1-(4-bromo(trifluoromethyl)phenoxy)methylpentan
yl)carbamate.
H NMR (400 MHz, Chloroform-d) δ 7.67 (d, J = 2.4 Hz, 1H), 7.57 (dd, J =
8.8, 2.5 Hz, 1H), 6.88 (d, J = 8.8 Hz, 1H), 4.71 (d, J = 8.3 Hz, 1H), 4.03 (p, J = 7.2
Hz, 3H), 1.68 (hept, J = 6.7 Hz, 1H), 1.55 - 1.48 (m, 2H), 1.44 (s, 9H), 0.95 (dd, J =
6.6, 4.2 Hz, 6H); LCMS (ESI) m/e 462.1 [(M+Na) , calcd C H Br F N Na O ,
18 25 1 3 1 1 3
462.1]; LC/MS retention time (method B): t = 2.45 min.
Part B: (S)-tert-butyl (1-(4-(2-acetamidopyridinyl)(trifluoromethyl)phenoxy)
methylpentanyl)carbamate.
H NMR (400 MHz, Chloroform-d) δ 9.50 (s, 1H), 8.48 (s, 1H), 8.29 (d, J =
.3 Hz, 1H), 7.86 (d, J = 2.4 Hz, 1H), 7.81 (dd, J = 8.5, 2.4 Hz, 1H), 7.21 (dd, J =
.3, 1.7 Hz, 1H), 7.08 (d, J = 8.6 Hz, 1H), 4.79 (d, J = 8.7 Hz, 1H), 4.13 - 4.04 (m,
3H), 2.25 (s, 3H), 1.70 (dt, J = 13.6, 6.9 Hz, 1H), 1.54 (t, J = 7.2 Hz, 2H), 1.44 (s,
9H), 0.96 (d, J = 2.8 Hz, 3H), 0.95 (d, J = 2.7 Hz, 3H); LCMS (ESI) m/e 496.2
[(M+H) , calcd C H F N O , 446.2]; LC/MS retention time (method A): t = 2.28
33 3 3 4 R
min.
Part C: (S)-N-(4-(4-((2-aminomethylpentyl)oxy)
(trifluoromethyl)phenyl)pyridinyl)acetamide
(221 mg, 0.531 mmol, quantitative yield for final step) as a white foam. H
NMR (400 MHz, Chloroform-d) δ 9.15 (s, 1H), 8.48 (s, 1H), 8.30 (d, J = 5.3 Hz,
1H), 7.88 (d, J = 2.2 Hz, 1H), 7.82 (dd, J = 8.7, 2.3 Hz, 1H), 7.23 (dd, J = 5.3, 1.7
Hz, 1H), 7.07 (d, J = 8.7 Hz, 1H), 4.08 (dd, J = 8.7, 3.6 Hz, 1H), 3.85 (dd, J = 8.7,
7.1 Hz, 1H), 3.32 (qd, J = 7.0, 3.6 Hz, 1H), 2.25 (s, 3H), 1.80 (dp, J = 13.5, 6.7 Hz,
1H), 1.57 (s, 2H), 1.38 (t, J = 7.0 Hz, 2H), 0.98 (d, J = 6.5 Hz, 3H), 0.96 (d, J = 6.6
Hz, 3H); F NMR (376 MHz, Chloroform-d) δ -62.40; LCMS (ESI) m/e 394.2 [(M-
H) , calcd C H F N O , 394.2]; LC/MS retention time (method A): t = 1.97 min.
23 3 3 2 R
Example 6
(S)-N-(4-(4-((2-aminomethylpentyl)oxy)(trifluoromethoxy)phenyl)pyridin
yl)acetamide
Prepared as described in Example 1.
Part A: (S)-tert-butyl (1-(4-bromo(trifluoromethoxy)phenoxy)methylpentan
yl)carbamate.
H NMR (400 MHz, Chloroform-d) δ 7.42 - 7.33 (m, 2H), 6.89 (d, J = 8.8
Hz, 1H), 4.78 - 4.61 (m, 1H), 4.09 - 3.90 (m, 3H), 1.68 (dq, J = 13.3, 6.7 Hz, 1H),
1.51 (t, J = 6.8 Hz, 2H), 1.45 (s, 9H), 0.95 (dd, J = 6.6, 5.4 Hz, 6H); LCMS (ESI)
m/e 478.1 [(M+Na) , calcd C H Br F N Na O , 478.0]; LC/MS retention time
18 25 1 3 1 1 4
(method B): t = 2.45 min.
Part B: (S)-tert-butyl (1-(4-(2-acetamidopyridinyl)(trifluoromethoxy)phenoxy)-
4-methylpentanyl)carbamate.
H NMR (400 MHz, Chloroform-d) δ 9.13 (s, 1H), 8.47 (s, 1H), 8.29 (d, J =
.3 Hz, 1H), 7.61 (dd, J = 8.5, 2.3 Hz, 1H), 7.56 (q, J = 1.3 Hz, 1H), 7.21 (dd, J =
.3, 1.7 Hz, 1H), 7.09 (d, J = 8.6 Hz, 1H), 4.77 (d, J = 8.3 Hz, 1H), 4.12 - 3.98 (m,
3H), 2.25 (s, 3H), 1.73 (dq, J = 13.7, 7.1, 6.4 Hz, 1H), 1.55 (t, J = 7.0 Hz, 2H), 1.46
(s, 9H), 0.97 (dd, J = 6.6, 4.1 Hz, 6H); LCMS (ESI) m/e 512.2 [(M+H) , calcd
C H F N O , 512.2]; LC/MS retention time (method A): t = 2.29 min.
33 3 3 5 R
Part C: (S)-N-(4-(4-((2-aminomethylpentyl)oxy)
(trifluoromethoxy)phenyl)pyridinyl)acetamide
(225 mg, 0.520 mmol, 95% yield for final step) as a white foam. H NMR
(400 MHz, Chloroform-d) δ 9.59 (s, 1H), 8.47 (s, 1H), 8.27 (d, J = 5.3 Hz, 1H), 7.58
(dd, J = 8.5, 2.3 Hz, 1H), 7.55 (d, J = 2.0 Hz, 1H), 7.19 (dd, J = 5.4, 1.7 Hz, 1H),
7.04 (d, J = 8.6 Hz, 1H), 4.00 (dd, J = 8.8, 3.7 Hz, 1H), 3.80 (dd, J = 8.8, 7.3 Hz,
1H), 3.31 (qd, J = 7.1, 3.7 Hz, 1H), 2.23 (s, 3H), 1.86 - 1.72 (m, J = 6.9 Hz, 1H),
1.63 (s, 2H), 1.35 (t, J = 7.0 Hz, 2H), 0.95 (dd, J = 9.1, 6.6 Hz, 6H); F NMR (376
MHz, Chloroform-d) δ -58.10; LCMS (ESI) m/e 412.1 [(M+H) , calcd
C H F N O , 412.2]; LC/MS retention time (method A): t = 1.99 min.
25 3 3 3 R
Example 7
(S)-N-(4-(4-((2-aminomethylpentyl)oxy)methylphenyl)pyridinyl)acetamide
Part A: (S)-tert-butyl (1-(4-bromomethylphenoxy)methylpentanyl)carbamate
DIAD (0.090 mL, 0.464 mmol) was added to a solution of
triphenylphosphine(0.097 g, 0.371 mmol), 4-bromomethylphenol (0.069 g, 0.371
mmol) and (S)-tert-butyl (1-hydroxymethylpentanyl)carbamate (0.0672 g,
0.309 mmol) in THF (1.5 mL) at rt under N . The reaction was stirred at room
temperature overnight. The solvent was removed under reduced pressure. The
residue was purified via silica gel chromatography (0 to 25% ethyl acetate in
hexanes). NMR and LCMS showed the product contained the starting material (4-
bromomethoxyphenol). This mixture was taken up in ethyl acetate and washed
with 1N NaOH (2X) and water (1X). The ethyl acetate layer was separated, dried
(Na2SO4), filtered and concentrated under reduced pressure to give (S)-tert-butyl (1-
(4-bromomethylphenoxy)methylpentanyl)carbamate (31.2 mg, 0.081 mmol,
26% yield) as a colorless wax. LCMS (ESI) m/e 408.1 [(M+Na) , calcd
C H BrNO Na, 408.1]; LC/MS retention time (method B): t = 2.44 min.
18 28 3 R
Part B: (S)-tert-butyl (1-(4-(2-acetamidopyridinyl)methylphenoxy)
methylpentanyl)carbamate
A mixture of sodium carbonate (0.061 mL, 0.121 mmol), N-(4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolanyl)pyridinyl)acetamide (0.028 g, 0.105 mmol),
(S)-tert-butyl (1-(4-bromomethylphenoxy)methylpentanyl)carbamate
(0.0312 g, 0.081 mmol) in dioxane (1 mL) was purged with nitrogen 5 times.
PdCl (dppf) (5.91 mg, 8.08 µmol) was added to the reaction mixture and the reaction
was heated at 80 °C overnight. The reaction was cooled to room temperature and
diluted with ethyl acetate. The organic layer was separated and washed with brine
(1X). The ethyl acetate layer was separated, dried (Na SO ), filtered and
concentrated under reduced pressure . The crude was used as it is at the next
reaction. LCMS (ESI) m/e 442.3 [(M+H) , calcd C H N O , 442.3]; LC/MS
36 3 4
retention time (method B): t = 2.13 min.
Part C: (S)-N-(4-(4-((2-aminomethylpentyl)oxy)methylphenyl)pyridin
yl)acetamide
A mixture of TFA (1 mL, 12.98 mmol) and (S)-tert-butyl (1-(4-(2-
acetamidopyridinyl)methylphenoxy)methylpentanyl)carbamate (35.8 mg,
0.081 mmol) in CH Cl (4 mL) was stirred at room temperature for 1 h. The solvent
was removed under reduced pressure and the residue was purified via reverse phase
HPLC (acetonitrile/water/10 mM ammonium acetate). To afford (S)-N-(4-(4-((2-
aminomethylpentyl)oxy)methylphenyl)pyridinyl)acetamide (9.7 mg, 0.028
mmol, 35% yield for two steps). H NMR (500MHz, DMSO-d ) δ 10.50 (s, 1H),
8.34 (br. s., 1H), 8.30 (d, J=5.2 Hz, 1H), 7.53 (br. s., 2H), 7.35 (d, J=4.6 Hz, 1H),
7.08 - 7.03 (m, J=9.2 Hz, 1H), 3.92 - 3.86 (m, 1H), 3.84 - 3.78 (m, 1H), 3.10 (br. s.,
1H), 2.26 (s, 3H), 2.12 (s, 3H), 1.87 - 1.79 (m, 1H), 1.40 - 1.31 (m, 1H), 1.27 (d,
J=6.4 Hz, 1H), 0.93 (d, J=6.7 Hz, 3H), 0.89 (d, J=6.4 Hz, 3H); LCMS (ESI) m/e
342.2 [(M+H) , calcd C H N O , 342.2]; LC/MS retention time (method B): t =
28 3 2 R
1.73 min.
Example 8
(S)-N-(4-(4-((2-aminomethylpentyl)oxy)chlorophenyl)pyridinyl)acetamide
Part A: (S)-tert-butyl (1-(4-bromochlorophenoxy)methylpentanyl)carbamate
Prepared as described in Example 1, Part 2A. H NMR (400MHz,
CHLOROFORM-d) δ 7.52 (d, J=2.5 Hz, 1H), 7.33 (dd, J=8.8, 2.5 Hz, 1H), 6.82 (d,
J=8.8 Hz, 1H), 4.08 - 3.95 (m, 3H), 1.77 - 1.66 (m, 1H), 1.57 (br. m, 2H), 1.47 (s,
9H), 0.98 (dd, J=6.5, 3.8 Hz, 6H). LCMS (ESI) m/e 428.0 [(M+Na) , calcd
C H BrClNO Na, 428.1]; LC/MS retention time (method B): t = 2.47 min.
17 25 3 R
Part B: (S)-tert-butyl (1-(4-(2-acetamidopyridinyl)chlorophenoxy)
methylpentanyl)carbamate
The mixture of sodium carbonate (0.113 mL, 0.226 mmol), N-(4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolanyl)pyridinyl)acetamide (0.051 g, 0.196 mmol),
(S)-tert-butyl (1-(4-bromochlorophenoxy)methylpentanyl)carbamate (0.0612
g, 0.150 mmol) in dioxane (1 mL) was evacuated and back-filled with N (5X).
PdCl (dppf) (0.011 g, 0.015 mmol) was added to the reaction mixture and the
reaction was heated at 80 °C overnight. The reaction was diluted with ethyl acetate
and washed with brine (1X). The ethyl acetate layer was separated, dried (Na SO ),
filtered and concentrated under reduced pressure . The crude was purified by silica
gel chromatography (50% ethyl acetate in hexanes) to afford. (S)-tert-butyl (1-(4-(2-
acetamidopyridinyl)chlorophenoxy)methylpentanyl)carbamate (51.7mg,
0.112 mmol, 74% yield). LCMS (ESI) m/e 462.2 [(M+H) , calcd C H ClN O ,
24 33 3 4
462.2]; LC/MS retention time (method B): t = 2.21 min.
Part C: (S)-N-(4-(4-((2-aminomethylpentyl)oxy)chlorophenyl)pyridin
yl)acetamide
A mixture of (S)-tert-butyl (1-(4-(2-acetamidopyridinyl)
chlorophenoxy)methylpentanyl)carbamate (51.7 mg, 0.112 mmol) and TFA (1
mL, 12.98 mmol) was stirred in CH Cl (3 mL) at room temperature for 2 h. The
solvent was removed under reduced pressure and the residue was purified via reverse
phase HPLC (acetonitrile/water/10 mM ammonium acetate). (42.7 mg, 0.111 mmol,
99% yield). H NMR (500MHz, DMSO-d ) δ 10.58 (br. s., 1H), 8.35 (d, J=4.6 Hz,
2H), 7.81 (s, 1H), 7.70 (d, J=8.9 Hz, 1H), 7.42 (d, J=5.2 Hz, 1H), 7.33 (d, J=8.5 Hz,
1H), 4.18 - 4.12 (m, 1H), 4.08 - 4.01 (m, 1H), 3.39 - 3.35 (m, 1H), 2.13 (s, 3H), 1.86
- 1.74 (m, 1H), 1.50 (d, J=6.1 Hz, 1H), 1.45 - 1.36 (m, 1H), 0.92 (dd, J=10.2, 6.6 Hz,
6H); LCMS (ESI) m/e 362.2 [(M+H) , calcd C H ClN O , 362.2]; LC/MS
19 25 3 3
retention time (method B): t = 1.69 min.
Example 9
(S)-N-(4-(4-((2-aminomethylpentyl)oxy)-3,5-difluorophenyl)pyridin
yl)acetamide
Prepared as described in Example 1.
Part A: (S)-tert-butyl (1-(4-bromo-2,6-difluorophenoxy)methylpentan
yl)carbamate.
H NMR (400 MHz, Chloroform-d) δ 7.42 - 7.33 (m, 2H), 6.89 (d, J = 8.8
Hz, 1H), 4.78 - 4.61 (m, 1H), 4.09 - 3.90 (m, 3H), 1.68 (dq, J = 13.3, 6.7 Hz, 1H),
1.51 (t, J = 6.8 Hz, 2H), 1.45 (s, 9H), 0.95 (dd, J = 6.6, 5.4 Hz, 6H); LCMS (ESI)
m/e 478.1 [(M+Na) , calcd C H Br F N Na O , 478.0]; LC/MS retention time
18 25 1 3 1 1 4
(method B): t = 2.45 min.
Part B: (S)-tert-butyl (1-(4-(2-acetamidopyridinyl)-2,6-difluorophenoxy)
methylpentanyl)carbamate.
H NMR (400 MHz, Chloroform-d) δ 9.01 (s, 1H), 8.42 (s, 1H), 8.28 (d, J =
5.3 Hz, 1H), 7.22 (d, J = 8.7 Hz, 2H), 7.15 (dd, J = 5.4, 1.7 Hz, 1H), 4.88 (d, J = 9.0
Hz, 1H), 4.24 - 4.13 (m, 2H), 3.94 (s, 1H), 2.24 (s, 3H), 1.74 (dt, J = 13.5, 6.7 Hz,
1H), 1.55 (t, J = 7.3 Hz, 2H), 1.24 (s, 9H), 0.97 (d, J = 6.5 Hz, 6H); F NMR (376
MHz, Chloroform-d) δ -126.89; LCMS (ESI) m/e 464.2 [(M+H) , calcd
C H F N O , 464.2]; LC/MS retention time (method A): t = 2.24 min.
24 32 2 3 4 R
Part C: (S)-N-(4-(4-((2-aminomethylpentyl)oxy)-3,5-difluorophenyl)pyridin
yl)acetamide.
Obtained (S)-N-(4-(4-((2-aminomethylpentyl)oxy)-3,5-
difluorophenyl)pyridinyl)acetamide (48.4 mg, 0.152 mmol, 99% yield for final
step) as an off-white foam. H NMR (500 MHz, DMSO-d ) δ 10.62 (s, 1H), 8.37 (d,
J = 5.3 Hz, 1H), 8.32 (s, 1H), 7.59 - 7.48 (m, 2H), 7.42 (dd, J = 5.2, 1.8 Hz, 1H),
4.16 (dd, J = 10.0, 4.5 Hz, 1H), 4.07 (dd, J = 9.9, 5.7 Hz, 1H), 3.24 (dq, J = 10.5, 5.8
Hz, 1H), 2.13 (s, 3H), 1.82 - 1.74 (m, 1H), 1.46 (ddd, J = 13.7, 8.1, 5.8 Hz, 1H), 1.35
(ddd, J = 13.9, 8.1, 6.3 Hz, 1H), 0.90 (dd, J = 9.0, 6.5 Hz, 6H); LCMS (ESI) m/e
364.1 [(M+H) , calcd C H F N O , 364.2]; LC/MS retention time (method A): t =
19 24 2 3 2 R
1.81 min.
Example 10
(S)-N-(4-(4-((2-aminomethylpentyl)oxy)chlorofluorophenyl)pyridin
yl)acetamide
Prepared as described in Example 1.
Part A: (S)-tert-butyl (1-(4-bromo-2,6-difluorophenoxy)methylpentan
yl)carbamate.
LCMS (ESI) m/e 424.2 [(M+H) , calcd C H Br Cl F N O , 424.1]; LC/MS
17 25 1 1 1 1 3
retention time (method A): t = 2.37 min.
Part B: (S)-tert-butyl (1-(4-(2-acetamidopyridinyl)chlorofluorophenoxy)
methylpentanyl)carbamate.
LCMS (ESI) m/e 480.2 [(M+H) , calcd C H F N O , 480.2]; LC/MS
24 32 2 3 4
retention time (method B): tR = 2.28 min.
Part C: (S)-N-(4-(4-((2-aminomethylpentyl)oxy)chlorofluorophenyl)pyridin-
2-yl)acetamide.
Obtained (S)-N-(4-(4-((2-aminomethylpentyl)oxy)chloro
fluorophenyl)pyridinyl)acetamide (26.5 mg, 0.066 mmol, 56% yield for final step)
as a colorless solid. H NMR (500 MHz, DMSO-d ) δ 10.60 (s, 1H), 8.37 (d, J = 5.2
Hz, 1H), 8.30 (s, 1H), 7.67 (d, J = 9.5 Hz, 2H), 7.43 (d, J = 5.1 Hz, 1H), 4.04 (dd, J
= 9.4, 4.7 Hz, 1H), 3.96 (dd, J = 9.5, 6.2 Hz, 1H), 3.11 (dq, J = 10.7, 5.1 Hz, 1H),
2.12 (s, 3H), 1.79 (dq, J = 13.6, 6.4 Hz, 1H), 1.41 (ddd, J = 13.6, 8.5, 5.2 Hz, 1H),
1.26 (ddd, J = 14.1, 8.6, 5.8 Hz, 1H), 0.91 (d, J = 6.5 Hz, 3H), 0.88 (d, J = 6.5 Hz,
3H); LCMS (ESI) m/e 380.2 [(M+H) , calcd C H Cl F N O , 380.2]; LC/MS
19 24 1 1 3 2
retention time (method B): t = 1.82 min.
Example 11
(S)-N-(4-(4-((2-aminomethylpentyl)oxy)fluoro
(trifluoromethyl)phenyl)pyridinyl)acetamide
Prepared as described in Example 1.
Part A: (S)-tert-butyl (1-(4-bromofluoro(trifluoromethyl)phenoxy)
methylpentanyl)carbamate.
H NMR (400 MHz, Chloroform-d) δ 7.52 (t, J = 1.9 Hz, 1H), 7.47 (dd, J =
.7, 2.4 Hz, 1H), 4.76 (d, J = 9.1 Hz, 1H), 4.19 (s, 2H), 3.96 (d, J = 7.7 Hz, 1H),
1.74 (dq, J = 13.5, 6.7 Hz, 1H), 1.54 (t, J = 7.1 Hz, 2H), 1.47 (s, 9H), 0.98 (d, J = 6.6
Hz, 6H); LCMS (ESI) m/e 480.0 [(M+Na) , calcd C H Br F N Na O , 480.1];
18 24 1 4 1 1 3
LC/MS retention time (method B): t = 2.50 min.
Part B: (S)-tert-butyl (1-(4-(2-acetamidopyridinyl)fluoro
(trifluoromethyl)phenoxy)methylpentanyl)carbamate.
LCMS (ESI) m/e 536.2 [(M+Na) , calcd C H F Na N O , 536.2]; LC/MS
31 4 1 3 4
retention time (method B): t = 2.34 min.
Part C: (S)-N-(4-(4-((2-aminomethylpentyl)oxy)fluoro
(trifluoromethyl)phenyl)pyridinyl)acetamide.
Obtained (S)-N-(4-(4-((2-aminomethylpentyl)oxy)fluoro
(trifluoromethyl)phenyl)pyridinyl)acetamide (49 mg, 0.116 mmol, 75% yield for
final step) as a colorless solid. H NMR (500 MHz, DMSO-d ) δ 10.63 (s, 1H), 8.39
(d, J = 5.3 Hz, 1H), 8.35 (s, 1H), 8.01 (dd, J = 12.9, 2.2 Hz, 1H), 7.74 (s, 1H), 7.48
(d, J = 5.4 Hz, 1H), 4.06 (p, J = 8.2 Hz, 2H), 3.12 - 3.03 (m, 1H), 2.13 (s, 3H), 1.82
(dt, J = 13.6, 7.2 Hz, 1H), 1.35 (ddd, J = 13.4, 8.9, 4.8 Hz, 1H), 1.22 (ddd, J = 13.8,
9.0, 5.5 Hz, 1H), 0.92 (d, J = 6.6 Hz, 3H), 0.88 (d, J = 6.6 Hz, 3H); LCMS (ESI) m/e
414.2 [(M+H) , calcd C H F N O , 414.2]; LC/MS retention time (method A): t =
24 4 3 2 R
2.01 min.
Example 12
(S)-N-(4-(4-((2-aminomethylpentyl)oxy)-2,5-difluorophenyl)pyridin
yl)acetamide
Prepared as described in Example 1.
Part A: (S)-tert-butyl (1-(4-bromo-2,5-difluorophenoxy)methylpentan
yl)carbamate.
H NMR (400 MHz, Chloroform-d) δ 7.29 (t, J = 9.5 Hz, 1H), 6.81 (dd, J =
9.5, 7.3 Hz, 1H), 4.68 (s, 1H), 4.09 - 3.91 (m, 3H), 1.71 (dt, J = 13.4, 7.0 Hz, 1H),
1.53 (dd, J = 15.3, 7.8 Hz, 2H), 1.47 (s, 9H), 0.97 (dd, J = 6.6, 4.5 Hz, 6H); LCMS
(ESI) m/e 408.0 [(M+H) , calcd C H Br F N O , 408.1]; LC/MS retention time
17 25 1 2 1 3
(method A): t = 2.40 min.
Part B: (S)-tert-butyl (1-(4-(2-acetamidopyridinyl)-2,5-difluorophenoxy)
methylpentanyl)carbamate.
LCMS (ESI) m/e 464.2 [(M+H) , calcd C H F N O , 464.3]; LC/MS
24 32 2 3 4
retention time (method A): t = 2.29 min.
Part C: (S)-N-(4-(4-((2-aminomethylpentyl)oxy)-2,5-difluorophenyl)pyridin
yl)acetamide.
Obtained (S)-N-(4-(4-((2-aminomethylpentyl)oxy)-2,5-
difluorophenyl)pyridinyl)acetamide (46.4 mg, 0.125 mmol, 77% yield for final
step) as a colorless solid. H NMR (500 MHz, DMSO-d ) δ 10.59 (s, 1H), 8.37 (d, J
= 5.2 Hz, 1H), 8.29 (s, 1H), 7.54 (dd, J = 11.8, 7.3 Hz, 1H), 7.34 (dd, J = 12.3, 7.2
Hz, 1H), 7.26 (d, J = 5.2 Hz, 1H), 4.08 (dd, J = 9.8, 4.5 Hz, 1H), 3.98 (dd, J = 10.0,
6.4 Hz, 1H), 3.24 (p, J = 6.0 Hz, 1H), 2.11 (s, 3H), 1.80 (dq, J = 15.3, 8.4, 7.6 Hz,
1H), 1.35 (qt, J = 13.7, 6.8 Hz, 2H), 0.91 (dd, J = 14.1, 6.6 Hz, 6H); LCMS (ESI)
m/e 364.2 [(M+H) , calcd C H F N O , 364.2]; LC/MS retention time (method A):
19 24 2 3 2
t = 1.82 min.
Example 13
(S)-methyl (4-(4-((2-aminomethylpentyl)oxy)fluorophenyl)pyridin
yl)carbamate
Prepared as described in Example 1.
Part A: (2-((methoxycarbonyl)amino)pyridinyl)boronic acid
The mixture of 2-(dicyclohexylphosphino)-2’,4’,6’-
triisopropylbiphenyl(0.079 g, 0.166 mmol), potassium acetate(2.446 g, 24.92 mmol),
2 generation Xphos precatalyst (0.065 g, 0.083 mmol), methyl (4-chloropyridin
yl)carbamate (1.55 g, 8.31 mmol) and hypodiboric acid (1.117 g, 12.46 mmol) in
ethanol (80 mL) was degassed three times via vacuum/N fill cycle. The reaction
mixture was heated at 80 °C for 3 h. The reaction mixture was cooled to rt and the
solvent was removed under reduced pressure and the solid was washed with acetone.
The remaining solid was suspended with mixture of methanol and CH Cl . The
suspension was filtered and the filtrate was concentrated under reduced pressure to
give the crude product as a solid. The solid was suspended in water and filtered. The
solid was washed with acetone to give (2-((methoxycarbonyl)amino)pyridin
yl)boronic acid (702mg, 3.58 mmol, 43% yield) as an off-white solid. LCMS (ESI)
m/e 197.2 [(M+H) , calcd C H BN O , 197.1]; LC/MS retention time (method B): t
7 10 2 4 R
= 0.46 min.
Part B: (S)-tert-butyl (1-(4-(2-aminopyridinyl)fluorophenoxy)methylpentan-
2-yl)carbamate.
H NMR (400 MHz, Chloroform-d) δ 9.86 (s, 1H), 8.35 (d, J = 5.4 Hz, 1H),
8.31 - 8.24 (m, 1H), 7.52 - 7.39 (m, 2H), 7.17 (dd, J = 5.4, 1.7 Hz, 1H), 7.06 (t, J =
8.6 Hz, 1H), 4.84 (d, J = 8.5 Hz, 1H), 4.15 - 3.99 (m, 3H), 3.87 (s, 3H), 1.80 - 1.67
(m, 1H), 1.56 (dt, J = 13.3, 7.8 Hz, 2H), 1.47 (s, 9H), 0.99 (d, J = 3.7 Hz, 3H), 0.97
(d, J = 3.6 Hz, 3H); F NMR (376 MHz, Chloroform-d) δ -133.39; LCMS (ESI) m/e
462.2 [(M+H) , calcd C H F N O , 462.2]; LC/MS retention time (method B): t =
24 33 1 3 5 R
2.20 min.
Part C: (S)-methyl (4-(4-((2-aminomethylpentyl)oxy)fluorophenyl)pyridin
yl)carbamate.
Obtained (S)-methyl (4-(4-((2-aminomethylpentyl)oxy)
fluorophenyl)pyridinyl)carbamate (33.2 mg, 0.091 mmol, 93% yield for the final
step) as an off-white solid. H NMR (500 MHz, DMSO-d ) δ 10.26 (s, 1H), 8.30 (d,
J = 5.3 Hz, 1H), 8.09 (s, 1H), 7.63 (dd, J = 12.7, 2.4 Hz, 1H), 7.55 - 7.49 (m, 1H),
7.37 (dd, J = 5.3, 1.9 Hz, 1H), 7.32 (t, J = 8.7 Hz, 1H), 3.97 (dd, J = 9.4, 5.0 Hz,
1H), 3.90 (dd, J = 9.4, 6.5 Hz, 1H), 3.71 (s, 3H), 3.12 (p, J = 5.6 Hz, 1H), 1.83 (dt, J
= 14.1, 6.7 Hz, 1H), 1.33 (ddd, J = 13.4, 8.5, 4.9 Hz, 1H), 1.26 (ddd, J = 13.9, 8.7,
.5 Hz, 1H), 0.92 (d, J = 6.6 Hz, 3H), 0.89 (d, J = 6.5 Hz, 3H); LCMS (ESI) m/e
362.1 [(M+H) , calcd C H F N O , 362.2]; LC/MS retention time (method A): t =
19 25 1 3 3 R
1.85 min.
Example 14
(S)-methyl (4-(4-((2-aminomethylpentyl)oxy)(isoxazolyl)phenyl)pyridin
yl)carbamate
Prepared as described in Example 1.
Part A: (S)-tert-butyl (1-(4-bromo(isoxazolyl)phenoxy)methylpentan
yl)carbamate.
H NMR (400 MHz, Chloroform-d) δ 8.31 (s, 1H), 8.09 (d, J = 2.4 Hz, 1H),
7.46 (dd, J = 9.1, 2.6 Hz, 1H), 6.88 (d, J = 9.0 Hz, 2H), 4.60 (d, J = 8.9 Hz, 1H),
4.19 (d, J = 7.0 Hz, 1H), 4.02 (qd, J = 9.2, 5.2 Hz, 2H), 1.75 (dq, J = 13.6, 6.7 Hz,
1H), 1.46 (d, J = 12.0 Hz, 11H), 0.98 (d, J = 6.6 Hz, 6H); LCMS (ESI) m/e 461.0
[(M+Na) , calcd C H Br N Na O , 461.1]; LC/MS retention time (method B): t =
27 1 2 1 4 R
2.41 min.
Part B: (S)-methyl (4-(4-((2-Boc-aminomethylpentyl)oxy)(isoxazol
yl)phenyl)pyridinyl)carbamate.
LCMS (ESI) m/e 511.4 [(M+H) , calcd C H N O , 511.2]; LC/MS retention
27 35 4 6
time (method A): t = 2.27 min.
Part C: (S)-methyl (4-(4-((2-aminomethylpentyl)oxy)(isoxazol
yl)phenyl)pyridinyl)carbamate.
Obtained (S)-methyl (4-(4-((2-aminomethylpentyl)oxy)(isoxazol
yl)phenyl)pyridinyl)carbamate (10.9 mg, 0.027 mmol, 34% yield for the final
step) as an off-white solid. H NMR (500 MHz, DMSO-d ) δ 8.74 (d, J = 1.7 Hz,
1H), 8.34 (d, J = 5.2 Hz, 1H), 8.19 (t, J = 2.4 Hz, 2H), 7.89 (dd, J = 8.7, 2.4 Hz, 1H),
7.44 (d, J = 5.3 Hz, 1H), 7.41 (d, J = 8.8 Hz, 1H), 7.05 (d, J = 1.9 Hz, 1H), 4.18 (dd,
J = 9.7, 4.5 Hz, 1H), 4.09 (dd, J = 9.6, 6.3 Hz, 1H), 3.72 (s, 3H), 3.36 (d, J = 4.3 Hz,
1H), 1.83 (dt, J = 13.7, 6.7 Hz, 1H), 1.44 (dt, J = 13.6, 7.0 Hz, 1H), 1.41 - 1.32 (m,
1H), 0.92 (dd, J = 9.4, 6.6 Hz, 6H); LCMS (ESI) m/e 411.1 [(M+H) , calcd
C H N O , 411.2]; LC/MS retention time (method B): t = 1.63 min.
22 27 4 4 R
Example 15
(S)((2-aminomethylpentyl)oxy)(2-methylpyridinyl)benzonitrile
Prepared as described in Example 1.
Part A: (S)-tert-butyl (1-(4-bromocyanophenoxy)methylpentanyl)carbamate.
H NMR (400 MHz, Chloroform-d) δ 7.68 (d, J = 2.5 Hz, 1H), 7.64 (dd, J =
8.9, 2.5 Hz, 1H), 6.91 (d, J = 8.9 Hz, 1H), 4.71 (s, 1H), 4.12 (t, J = 6.1 Hz, 1H), 4.10
- 3.98 (m, 2H), 1.79 - 1.67 (m, 1H), 1.59 (dd, J = 13.8, 6.9 Hz, 2H), 1.47 (s, 9H),
0.98 (dd, J = 6.5, 5.2 Hz, 6H); LCMS (ESI) m/e 397.1 [(M+H) , calcd
C H Br N O , 397.1]; LC/MS retention time (method A): t = 2.22 min.
18 26 1 2 3 R
Part B: (S)-tert-butyl (1-(2-cyano(2-methylpyridinyl)phenoxy)methylpentan-
2-yl)carbamate.
H NMR (400 MHz, Chloroform-d) δ 8.56 (d, J = 5.3 Hz, 1H), 7.84 (d, J =
2.3 Hz, 1H), 7.80 (dd, J = 8.8, 2.4 Hz, 1H), 7.31 (d, J = 1.7 Hz, 1H), 7.25 (dd, J =
.3, 1.8 Hz, 1H), 7.12 (d, J = 8.8 Hz, 1H), 4.81 (d, J = 8.6 Hz, 1H), 4.21 - 4.11 (m,
2H), 4.10 - 4.03 (m, 1H), 2.64 (s, 3H), 1.76 - 1.68 (m, 1H), 1.60 (tt, J = 15.6, 6.2 Hz,
2H), 1.46 (s, 9H), 0.98 (dd, J = 6.5, 5.0 Hz, 6H); LCMS (ESI) m/e 410.2 [(M+H) ,
calcd C H N O , 410.2]; LC/MS retention time (method A): t = 2.18 min.
24 32 3 3 R
Part C: (S)((2-aminomethylpentyl)oxy)(2-methylpyridinyl)benzonitrile.
Obtained (48.4 mg, 0.152 mmol, 99% yield for the final step) as an off-white
solid. H NMR (500 MHz, DMSO-d ) δ 8.49 (d, J = 5.3 Hz, 1H), 8.24 (d, J = 2.4
Hz, 1H), 8.11 (dd, J = 8.9, 2.4 Hz, 1H), 7.65 (s, 1H), 7.57 - 7.52 (m, 1H), 7.38 (d, J
= 8.9 Hz, 1H), 4.09 (dd, J = 9.5, 5.1 Hz, 1H), 4.01 (dd, J = 9.5, 6.2 Hz, 1H), 3.16
(dq, J = 10.8, 5.4 Hz, 1H), 2.53 (s, 3H), 2.51 (s, 2H), 1.83 (dq, J = 12.8, 6.5 Hz, 1H),
1.39 (ddd, J = 13.5, 8.4, 5.1 Hz, 1H), 1.30 (ddd, J = 13.8, 8.6, 5.9 Hz, 1H), 0.93 (d, J
= 6.6 Hz, 3H), 0.89 (d, J = 6.6 Hz, 3H); LCMS (ESI) m/e 310.1 [(M+H) , calcd
C H N O , 310.2]; LC/MS retention time (method A): t = 1.82 min.
19 24 3 1 R
Example 16
(S)((2-aminomethylpentyl)oxy)(2-methoxypyridinyl)benzonitrile
Prepared as described in Example 1.
Part A: (S)-tert-butyl (1-(2-cyano(2-methylpyridinyl)phenoxy)
methoxypentanyl)carbamate.
H NMR (500 MHz, Chloroform-d) δ 8.20 (dd, J = 5.4, 0.7 Hz, 1H), 7.79 (d,
J = 2.3 Hz, 1H), 7.76 (dd, J = 8.7, 2.4 Hz, 1H), 7.11 - 7.05 (m, 1H), 7.00 (dd, J =
.4, 1.6 Hz, 1H), 6.85 (dd, J = 1.6, 0.7 Hz, 1H), 4.84 (d, J = 8.7 Hz, 1H), 4.20 - 4.14
(m, 1H), 4.11 (ddd, J = 8.7, 4.6, 2.5 Hz, 1H), 4.07 - 4.03 (m, 1H), 3.97 (s, 3H), 1.76 -
1.66 (m, 1H), 1.64 - 1.52 (m, 2H), 1.44 (s, 9H), 0.96 (dd, J = 6.6, 5.7 Hz, 6H); LCMS
(ESI) m/e 426.2 [(M+H) , calcd C H N O , 426.2]; LC/MS retention time (method
24 32 3 4
A): t = 2.27 min.
Part B: (S)((2-aminomethylpentyl)oxy)(2-methoxypyridinyl)benzonitrile.
Obtained (S)((2-aminomethylpentyl)oxy)(2-methoxypyridin
yl)benzonitrile (28.6 mg, 0.088 mmol, 60% yield for the final step) as an off-white
solid. H NMR (500 MHz, DMSO-d ) δ 8.23 (dd, J = 6.7, 3.9 Hz, 2H), 8.10 (dd, J =
8.9, 2.4 Hz, 1H), 7.41 - 7.32 (m, 2H), 7.18 (s, 1H), 4.05 (dd, J = 9.3, 5.1 Hz, 1H),
3.98 (dd, J = 9.4, 6.3 Hz, 1H), 3.90 (s, 3H), 3.12 (dq, J = 10.4, 5.4 Hz, 1H), 1.83 (tt,
J = 13.3, 6.7 Hz, 1H), 1.36 (ddd, J = 13.4, 8.5, 4.9 Hz, 1H), 1.26 (ddd, J = 13.9, 8.8,
5.7 Hz, 1H), 0.92 (d, J = 6.6 Hz, 3H), 0.89 (d, J = 6.6 Hz, 3H); LCMS (ESI) m/e
326.1 [(M+H) , calcd C H N O , 326.2]; LC/MS retention time (method A): t =
19 24 3 2 R
1.88 min.
Example 17
(S)((2-aminomethylpentyl)oxy)(2-(trifluoromethyl)pyridinyl)benzonitrile
Prepared as described in Example 1.
Part A: (S)-tert-butyl (1-(2-cyano(2-(trifluoromethyl)pyridinyl)phenoxy)
methylpentanyl)carbamate.
H NMR (400 MHz, Chloroform-d) δ 8.80 (d, J = 5.1 Hz, 1H), 7.89 (d, J =
2.4 Hz, 1H), 7.86 (dd, J = 8.8, 2.5 Hz, 1H), 7.84 - 7.80 (m, 1H), 7.64 (dd, J = 5.1, 1.8
Hz, 1H), 7.19 (d, J = 8.8 Hz, 1H), 4.79 (d, J = 8.5 Hz, 1H), 4.26 - 4.14 (m, 2H), 4.11
- 4.04 (m, 1H), 1.73 (p, J = 6.5 Hz, 1H), 1.66 - 1.54 (m, 2H), 1.46 (s, 9H), 0.98 (t, J
= 6.3 Hz, 6H); F NMR (376 MHz, Chloroform-d) δ -68.06; LCMS (ESI) m/e 486.2
[(M+Na) , calcd C H F Na N O , 486.2]; LC/MS retention time (method B): t =
24 28 3 1 3 3 R
2.35 min.
Part B: (S)((2-aminomethylpentyl)oxy)(2-(trifluoromethyl)pyridin
yl)benzonitrile.
Obtained (S)((2-aminomethylpentyl)oxy)(2-(trifluoromethyl)pyridin-
4-yl)benzonitrile (34.3 mg, 0.093 mmol, 93% yield for the final step) as an off-white
solid.. H NMR (500 MHz, DMSO-d ) δ 8.81 (d, J = 5.2 Hz, 1H), 8.46 (d, J = 2.9
Hz, 1H), 8.34 - 8.21 (m, 2H), 8.11 (d, J = 5.1 Hz, 1H), 7.42 (d, J = 8.9 Hz, 1H), 4.08
(dd, J = 9.9, 5.2 Hz, 1H), 4.05 - 3.95 (m, 1H), 3.13 (d, J = 7.5 Hz, 1H), 1.85 (t, J =
7.0 Hz, 1H), 1.43 - 1.32 (m, 1H), 1.27 (q, J = 11.7, 9.8 Hz, 1H), 0.93 (d, J = 6.4 Hz,
3H), 0.89 (d, J = 6.4 Hz, 3H); LCMS (ESI) m/e 364.1 [(M+H) , calcd C H F N O ,
19 21 3 3 1
364.2]; LC/MS retention time (method B): t = 1.97 min.
Example 18
(S)(2-(isoxazolyl)(2-methylpyridinyl)phenoxy)methylpentanamine
Prepared as described in Example 1.
Part A: (S)-tert-butyl (1-(2-(isoxazolyl)(2-methylpyridinyl)phenoxy)
methylpentanyl)carbamate.
LCMS (ESI) m/e 452.1 [(M+H) , calcd C H N O , 452.2]; LC/MS retention
26 34 3 4
time (method B): t = 2.03 min.
Part B: (S)(2-(isoxazolyl)(2-methylpyridinyl)phenoxy)methylpentan
amine.
Obtained (S)(2-(isoxazolyl)(2-methylpyridinyl)phenoxy)
methylpentanamine (14.6 mg, 0.041 mmol, 49% yield for the final step) as an off-
white solid. H NMR (500 MHz, DMSO-d ) δ 8.72 (d, J = 1.9 Hz, 1H), 8.49 (d, J =
.3 Hz, 1H), 8.24 (d, J = 2.4 Hz, 1H), 7.93 (dd, J = 8.8, 2.4 Hz, 1H), 7.65 (s, 1H),
7.59 - 7.52 (m, 1H), 7.37 (d, J = 8.8 Hz, 1H), 7.03 (d, J = 1.9 Hz, 1H), 4.12 (dd, J =
9.6, 4.6 Hz, 1H), 4.04 (dd, J = 9.5, 6.3 Hz, 1H), 3.27 (dq, J = 10.3, 5.3 Hz, 1H), 2.51
(s, 3H), 1.83 (dt, J = 14.0, 6.7 Hz, 1H), 1.40 (ddd, J = 13.4, 8.4, 5.2 Hz, 1H), 1.32
(ddd, J = 13.7, 8.5, 5.7 Hz, 1H), 0.91 (dd, J = 10.5, 6.5 Hz, 6H); LCMS (ESI) m/e
352.1 [(M+H) , calcd C H N O , 352.2]; LC/MS retention time (method B): t =
21 26 3 2 R
1.50 min.
Example 19
(S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)(trifluoromethyl)phenyl)pyridin
yl)acetamide
Part A: (S)(4-bromo(trifluoromethyl)phenoxy)-2,4-dimethylpentanamine
To a 50 mL round-bottomed flask was added (S)amino-2,4-
dimethylpentanol (66.1 mg, 0.504 mmol) in tetrahydrofuran (1.5 mL) to give a
colorless solution. Potassium tert-butoxide (0.604 mL, 0.604 mmol) (1.0 M in THF)
was added dropwise under nitrogen. After 5 min, 4-bromofluoro
(trifluoromethyl)benzene (0.079 mL, 0.604 mmol) was added in one portion. The
mixture was stirred at rt for 2h. The reaction was quenched with water and extracted
with EtOAc. The organic layer was washed with brine, dried (Na SO ) and
concentrated under reduced pressure to obtain crude (S)(4-bromo
(trifluoromethyl)phenoxy)-2,4-dimethylpentanamine (146 mg, o.412 mmol, 82%
yield) as a tan oil which was used as is. H NMR (500 MHz, Chloroform-d) δ 7.70
(d, J = 2.5 Hz, 1H), 7.59 (dd, J = 8.8, 2.5 Hz, 1H), 6.86 (d, J = 8.8 Hz, 1H), 3.80 -
3.72 (m, 2H), 1.83 - 1.73 (m, 1H), 1.53 - 1.44 (m, 2H), 1.23 (s, 3H), 0.98 (dd, J =
12.2, 6.7 Hz, 6H); F NMR (470 MHz, Chloroform-d) δ -62.61.; LCMS (ESI) m/e
354.0 [(M+H) , calcd C H Br F N O , 354.1]; LC/MS retention time (method B):
14 20 1 3 1 1
t = 2.14 min.
Part B: (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)
(trifluoromethyl)phenyl)pyridinyl)acetamide
To a 2 mL vial was added (S)(4-bromo(trifluoromethyl)phenoxy)-2,4-
dimethylpentanamine (43.5 mg, 0.123 mmol), N-(4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolanyl)pyridinyl)acetamide (26.5 mg, 0.147 mmol) (prepared as
described in Example 1, Part A), and Na CO (0.184 mL, 0.368 mmol) in dioxane
(0.5 mL) under nitrogen to give a colorless suspension. 1,1'-
bis(diphenylphosphino)ferrocene palladium(II) dichloride, toluene (5.05 mg, 6.14
µmol) was added under nitrogen. The vial was sealed and heated at 130 °C
(microwave) for 2 h (100 °C oil heating for 2 h was fine and was used for all other
examples). The mixture was cooled to rt and diluted with EtOAc then passed
through a plug of Na SO . The organic solution was concentrated under reduced
pressure . The residue was purified by reverse phase HPLC (acetonitrile: water with
mM ammonium) to give (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)
(trifluoromethyl)phenyl)pyridinyl)acetamide (24 mg, 0.057 mmol, 47% yield) as
an off-white solid. H NMR (500 MHz, DMSO-d ) δ 10.58 (s, 1H), 8.36 (d, J = 5.2
Hz, 2H), 7.97 (t, J = 8.1 Hz, 1H), 7.89 (s, 1H), 7.44 (d, J = 5.4 Hz, 1H), 7.38 (d, J =
8.7 Hz, 1H), 3.86 (q, J = 8.8 Hz, 2H), 2.13 (s, 3H), 1.79 (dq, J = 10.2, 5.2, 4.0 Hz,
1H), 1.39 (d, J = 5.5 Hz, 2H), 1.12 (s, 3H), 0.91 (d, J = 6.6 Hz, 6H); LCMS (ESI)
m/e 410.2 [(M-H) , calcd C20H23F3N3O2, 410.2]; LC/MS retention time (method B):
t = 1.87 min.
Example 20
(S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)
(trifluoromethyl)phenyl)pyridinyl)carbamate
Prepared as described in Example 19 to obtain (S)-methyl (4-(4-((2-amino-
2,4-dimethylpentyl)oxy)(trifluoromethyl)phenyl)pyridinyl)carbamate (22.9 mg,
0.051 mmol, 38% yield) as an off-white solid. H NMR (500 MHz, DMSO-d ) δ
.29 (s, 1H), 8.32 (d, J = 5.3 Hz, 1H), 8.11 (s, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.90
(s, 1H), 7.39 (dd, J = 12.5, 7.0 Hz, 2H), 3.87 (q, J = 8.8 Hz, 2H), 3.71 (s, 3H), 1.79
(dq, J = 10.8, 5.6, 4.8 Hz, 1H), 1.40 (d, J = 5.6 Hz, 2H), 1.13 (s, 3H), 0.91 (d, J = 6.6
Hz, 6H); LCMS (ESI) m/e 426.3 [(M-H) , calcd C H F N O , 426.2]; LC/MS
21 27 3 3 3
retention time (method A): t = 2.23 min.
Example 21
(S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)cyanophenyl)pyridin
yl)acetamide
Prepared as described in Example 19
Part A: (S)((2-amino-2,4-dimethylpentyl)oxy)bromobenzonitrile.
H NMR (400 MHz, Chloroform-d) δ 7.68 (d, J = 2.5 Hz, 1H), 7.63 (dd, J =
8.9, 2.4 Hz, 1H), 6.86 (d, J = 9.0 Hz, 1H), 3.84 - 3.77 (m, 2H), 1.87 - 1.74 (m, 1H),
1.59 - 1.53 (m, 2H), 1.27 (s, 3H), 1.00 (dd, J = 8.3, 6.6 Hz, 6H); LCMS (ESI) m/e
311.1, 313.1 Br pattern [(M+H) , calcd C H BrN O, 311.1]; LC/MS retention time
14 20 2
(method A): t = 2.01 min.
Part B: (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)cyanophenyl)pyridin
yl)acetamide.
Obtained (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)
cyanophenyl)pyridinyl)acetamide (28.9 mg, 0.078 mmol, 70% yield) as an off-
white solid. H NMR (500 MHz, DMSO-d ) δ 10.58 (s, 1H), 8.44 - 8.29 (m, 2H), 8.12
(s, 1H), 8.00 (d, J = 8.9 Hz, 1H), 7.44 (d, J = 5.3 Hz, 1H), 7.39 (d, J = 8.8 Hz, 1H),
3.91 (t, J = 6.7 Hz, 2H), 2.13 (s, 3H), 1.82 (p, J = 6.2 Hz, 1H), 1.43 (t, J = 5.4 Hz,
2H), 1.15 (s, 3H), 0.93 (dd, J = 6.7, 3.7 Hz, 6H); LCMS (ESI) m/e 367.3 [(M+H) ,
calcd C H N O , 367.2]; LC/MS retention time (method A): t = 1.82 min.
21 27 4 2 R
Example 22
(S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)cyanophenyl)pyridin
yl)carbamate
Prepared as described in Example 19 to obtain (S)-methyl (4-(4-((2-amino-
2,4-dimethylpentyl)oxy)cyanophenyl)pyridinyl)carbamate (21.1 mg, 0.053
mmol, 47% yield) as an off-white solid. H NMR (500 MHz, DMSO-d ) δ 10.29 (s,
1H), 8.32 (d, J = 5.3 Hz, 1H), 8.13 (s, 1H), 8.10 (s, 1H), 8.01 (d, J = 9.1 Hz, 1H),
7.40 (dd, J = 11.9, 7.1 Hz, 2H), 3.91 (t, J = 6.5 Hz, 2H), 3.71 (s, 3H), 1.81 (dq, J =
12.5, 6.2 Hz, 1H), 1.42 (q, J = 8.2, 6.6 Hz, 2H), 1.15 (s, 3H), 0.93 (dd, J = 6.8, 3.8
Hz, 6H); LCMS (ESI) m/e 405.2 [(M+Na) , calcd C H N Na O , 405.2]; LC/MS
21 26 4 1 3
retention time (method B): t = 1.87 min.
Example 23
(S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)(difluoromethyl)phenyl)pyridin
yl)acetamide
Prepared as described in Example 19.
Part A: (S)(4-bromo(difluoromethyl)phenoxy)-2,4-dimethylpentanamine.
H NMR (400 MHz, Chloroform-d) δ 7.67 (dd, J = 2.4, 1.1 Hz, 1H), 7.53
(ddt, J = 8.8, 2.3, 1.1 Hz, 1H), 6.93 - 6.70 (m, 2H), 3.79 - 3.72 (m, 2H), 1.85 - 1.73
(m, 1H), 1.52 - 1.47 (m, 2H), 1.23 (s, 3H), 0.99 (dd, J = 7.6, 6.6 Hz, 6H); F NMR
(376 MHz, Chloroform-d) δ -116.21; LCMS (ESI) m/e 336.1 [(M+H) , calcd
C14H21Br1F2N1O1, 336.1]; LC/MS retention time (method A): tR = 2.18 min.
Part B: (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)
(difluoromethyl)phenyl)pyridinyl)acetamide.
Obtained (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)
(difluoromethyl)phenyl)pyridinyl)acetamide (13 mg, 0.033 mmol, 32% yield) as
an off-white solid. H NMR (500 MHz, DMSO-d ) δ 10.56 (s, 1H), 8.45 - 8.29 (m,
2H), 7.87 (d, J = 8.7 Hz, 1H), 7.82 (s, 1H), 7.49 - 7.12 (m, 3H), 3.84 (s, 2H), 2.13 (s,
3H), 1.79 (dt, J = 14.1, 7.3 Hz, 1H), 1.47 - 1.34 (m, 2H), 1.14 (s, 3H), 0.92 (dd, J =
11.3, 6.6 Hz, 6H); LCMS (ESI) m/e 392.3 [(M+H) , calcd C H F N O , 392.2];
21 28 2 3 2
LC/MS retention time (method A): t = 1.90 min.
Example 24
(S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)
(difluoromethyl)phenyl)pyridinyl)carbamate
Prepared as described in Example 19 to obtain (S)-methyl (4-(4-((2-amino-
2,4-dimethylpentyl)oxy)(difluoromethyl)phenyl)pyridinyl)carbamate (15.4 mg,
0.037 mmol, 35% yield) as an off-white solid. H NMR (500 MHz, DMSO-d ) δ
.26 (s, 1H), 8.31 (d, J = 5.3 Hz, 1H), 8.11 (s, 1H), 7.91 - 7.85 (m, 1H), 7.83 (s,
1H), 7.42 - 7.13 (m, 3H), 3.84 (s, 2H), 3.70 (s, 3H), 1.79 (dt, J = 12.8, 6.4 Hz, 1H),
1.41 (qd, J = 14.0, 5.6 Hz, 2H), 1.14 (s, 3H), 0.92 (dd, J = 11.4, 6.6 Hz, 6H); LCMS
(ESI) m/e 408.3 [(M+H) , calcd C H F N O , 408.2]; LC/MS retention time
21 28 2 3 3
(method A): t = 2.00 min.
Example 25
(S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)(trifluoromethoxy)phenyl)pyridin-
2-yl)acetamide
Prepared as described in Example 19.
Part A: (S)(4-bromo(trifluoromethoxy)phenoxy)-2,4-dimethylpentanamine.
H NMR (400 MHz, Chloroform-d) δ 7.41 - 7.34 (m, 2H), 6.87 (d, J = 8.6
Hz, 1H), 3.76 - 3.72 (m, 2H), 1.83 - 1.76 (m, 1H), 1.49 - 1.47 (m, 2H), 1.23 (s, 3H),
1.01 - 0.98 (m, 6H); F NMR (376 MHz, Chloroform-d) δ -58.22; LCMS (ESI) m/e
370.1 [(M+H) , calcd C H Br F N O , 370.1]; LC/MS retention time (method A):
14 20 1 3 1 2
t = 2.33 min.
Part B: (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)
(trifluoromethoxy)phenyl)pyridinyl)acetamide.
Obtained (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)
(trifluoromethoxy)phenyl)pyridinyl)acetamide (14.1 mg, 0.032 mmol, 36% yield)
as an off-white as solid. H NMR (500 MHz, DMSO-d ) δ 10.57 (s, 1H), 8.35 (d, J =
4.6 Hz, 2H), 7.74 (d, J = 8.8 Hz, 1H), 7.70 (s, 1H), 7.41 (d, J = 5.1 Hz, 1H), 7.38 (d,
J = 8.6 Hz, 1H), 3.83 (t, J = 7.3 Hz, 2H), 2.12 (s, 3H), 1.81 (dt, J = 13.1, 6.7 Hz,
1H), 1.39 (q, J = 7.6, 6.3 Hz, 2H), 1.13 (s, 3H), 0.92 (t, J = 5.1 Hz, 6H); LCMS
(ESI) m/e 426.2 [(M+H) , calcd C H F N O , 426.2]; LC/MS retention time
21 27 3 3 3
(method A): t = 2.08 min.
Example 26
(S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)
(trifluoromethoxy)phenyl)pyridinyl)carbamate
Prepared as described in Example 19 to obtain (S)-methyl (4-(4-((2-amino-
2,4-dimethylpentyl)oxy)(trifluoromethoxy)phenyl)pyridinyl)carbamate (11.5
mg, 0.026 mmol, 27% yield) as an off-white solid. H NMR (500 MHz, DMSO-d ) δ
.28 (s, 1H), 8.31 (d, J = 5.2 Hz, 1H), 8.10 (s, 1H), 7.75 (d, J = 8.6 Hz, 1H), 7.71
(s, 1H), 7.43 - 7.34 (m, 2H), 3.86 - 3.80 (m, 2H), 3.71 (s, 3H), 1.81 (dt, J = 12.7, 6.4
Hz, 1H), 1.39 (q, J = 8.2, 6.3 Hz, 2H), 1.13 (s, 3H), 0.92 (dd, J = 6.7, 3.8 Hz, 6H);
LCMS (ESI) m/e 442.2 [(M+H) , calcd C H F N O , 442.2]; LC/MS retention time
21 27 3 3 4
(method B): t = 2.00 min.
Example 27
(S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)fluorophenyl)pyridin
yl)acetamide
Prepared as described in Example 19.
Part A: (S)(2-fluorophenoxy)-2,4-dimethylpentanamine.
LCMS (ESI) m/e 226.3 [(M+H) , calcd C H F N O , 226.2]; LC/MS
13 21 1 1 1
retention time (method B): t = 1.93 min.
Part B: (S)(4-bromo(trifluoromethoxy)phenoxy)-2,4-dimethylpentanamine
To a 100 mL round-bottomed flask was added (S)(2-fluorophenoxy)-2,4-
dimethylpentanamine (83.4 mg, 0.370 mmol) in CHCl3 (2 mL) to give a colorless
solution. Br (0.021 mL, 0.407 mmol) was added. The mixture was stirred at 45 °C
for 15 h. The reaction mixture cooled to rt and was diluted with EtOAc then treated
with aqueous sodium bisulfite solution. The layers were separated. The organic
layer was washed with water, brine, dried (Na SO ) and concentrated under reduced
pressure to afford (S)(4-bromo(trifluoromethoxy)phenoxy)-2,4-dimethylpentan-
2-amine (84 mg, 0.276 mmol, 75% yield). The crude material was carried on as is.
LCMS (ESI) m/e 304.1 [(M+H) , calcd C H Br F N O , 304.1]; LC/MS retention
13 20 1 1 1 1
time (method A): t = 2.05 min.
Part C: (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)fluorophenyl)pyridin
yl)acetamide.
Obtained (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)
fluorophenyl)pyridinyl)acetamide (14.5 mg, 0.039 mmol, 31% yield) as an off-
white solid. H NMR (500 MHz, DMSO-d ) δ 10.55 (s, 1H), 8.33 (d, J = 6.0 Hz,
2H), 7.61 (d, J = 12.3 Hz, 1H), 7.52 (d, J = 8.8 Hz, 1H), 7.39 (d, J = 5.4 Hz, 1H),
7.30 (t, J = 8.8 Hz, 1H), 3.84 - 3.76 (m, 2H), 2.12 (s, 3H), 1.81 (p, J = 6.4 Hz, 1H),
1.38 (q, J = 7.9, 6.8 Hz, 2H), 1.12 (s, 3H), 0.93 (t, J = 6.6 Hz, 6H); LCMS (ESI) m/e
360.2 [(M+H) , calcd C H F N O , 360.2]; LC/MS retention time (method A): t =
27 1 3 2 R
1.82 min.
Example 28
(S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)fluorophenyl)pyridin
yl)carbamate
Prepared as described in Example 19 to obtain (S)-methyl (4-(4-((2-amino-
2,4-dimethylpentyl)oxy)fluorophenyl)pyridinyl)carbamate (17.1 mg, 0.044
mmol, 30% yield) as an off-white solid. H NMR (500 MHz, DMSO-d ) δ 10.25 (s,
1H), 8.29 (d, J = 5.3 Hz, 1H), 8.09 (s, 1H), 7.62 (d, J = 12.4 Hz, 1H), 7.53 (d, J =
8.6 Hz, 1H), 7.36 (d, J = 5.4 Hz, 1H), 7.30 (t, J = 8.7 Hz, 1H), 3.82 (d, J = 2.8 Hz,
2H), 3.70 (s, 3H), 1.86 - 1.74 (m, 1H), 1.46 - 1.33 (m, 2H), 1.13 (s, 3H), 0.93 (t, J =
6.8 Hz, 6H); LCMS (ESI) m/e 376.2 [(M+H) , calcd C H F N O , 376.2]; LC/MS
27 1 3 3
retention time (method A): t = 1.92 min.
Example 29
methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)chlorophenyl)pyridin
yl)carbamate
Part A: Benzyl (1-(4-bromochlorophenoxy)-2,4-dimethylpentanyl)carbamate
An NMP (0.3 mL) suspension of 4-bromochlorophenol (0.074 g, 0.354
mmol), potassium carbonate (0.037 g, 0.266 mmol) and benzyl 4-isobutylmethyl-
1,2,3-oxathiazolidinecarboxylate 2,2-dioxide (0.058 g, 0.177 mmol) was heated at
50 °C overnight. The reaction was diluted with ethyl acetate and washed with NaOH
(1N) (2X) and water (1X). The ethyl acetate layer was separated, dried (Na SO ),
filtered and concentrated under reduced pressure. The crude material was carried on
without further purification. LCMS (ESI) m/e 476.1 [(M+Na) , calcd
C H BrClNaNO , 476.1]; LC/MS retention time (method B): t = 2.56 min.
21 25 3 R
Part B: Cbz methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)chlorophenyl)pyridin-
2-yl)carbamate
A mixture of sodium carbonate (0.177 ml, 0.354 mmol), 1,1’-
bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex
(10.12 mg, 0.012 mmol), (2-((methoxycarbonyl)amino)pyridinyl)boronic acid
(0.035 g, 0.177 mmol) and benzyl (1-(4-bromochlorophenoxy)-2,4-
dimethylpentanyl)carbamate (0.080 g, 0.177 mmol) in dioxane (1 mL) (degassed)
was heated at 85 °C overnight. The reaction was diluted with ethyl acetate and
washed with water (3X). The aqueous layer was extract with ethyl acetate. The ethyl
acetate layers were combined, washed with brine, dried (Na SO ), filtered and
concentrated under reduced pressure. The residue was purified via silica gel
chromatography (from 0 to 30% ethyl acetate in hexanes) to give Cbz methyl (4-(4-
((2-amino-2,4-dimethylpentyl)oxy)chlorophenyl)pyridinyl)carbamate (56.5 mg,
0.107 mmol, 61% yield for two steps) as a tan foam. (0.565g, 61% yield). LCMS
(ESI) m/e 548.2 [(M+Na) , calcd C H ClN O Na, 548.2]; LC/MS retention time
28 32 3 5
(method B): t = 2.25 min.
Part C: methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)chlorophenyl)pyridin
yl)carbamate
Triethylsilane(0.026 mL, 0.161 mmol) was added to a CH Cl (0.5 mL)
suspension of palladium(II) acetate(2.2 mg, 9.80 µmol) and triethylamine(1 drop) at
rt. This solution was stirred at room temperature for 10 min before the addition of a
CH Cl (0.5 mL) solution of Cbz protected methyl (4-(4-((2-amino-2,4-
dimethylpentyl)oxy)chlorophenyl)pyridinyl)carbamate (0.0565 g, 0.107 mmol)
(the flask contain the Cbz protected methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)-
3-chlorophenyl)pyridinyl)carbamate (0.0565 g, 0.107 mmol) was rinsed with
CH Cl (0.5 mL) and added to the reaction mixture). The above reaction was stirred
at room temperature overnight. The solvent was removed under reduced pressure
and the residue was purified via reverse phase HPLC (acetonitrile/water/10 nM
ammonium acetate) to afford methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)
chlorophenyl)pyridinyl)carbamate (29.6mg, 0.076 mmol, 70% yield) as an off-
white solid. H NMR (500MHz, DMSO-d ) δ 10.27 (br. s., 1H), 8.30 (d, J=5.2 Hz,
1H), 8.08 (s, 1H), 7.79 (s, 1H), 7.68 (d, J=8.2 Hz, 1H), 7.37 (d, J=5.2 Hz, 1H), 7.26
(d, J=8.5 Hz, 1H), 3.82 (d, J=2.4 Hz, 2H), 3.70 (s, 3H), 1.85 - 1.77 (m, 1H), 1.42 (br.
s., 2H), 1.14 (s, 3H), 0.92 (m, 6H); LCMS (ESI) m/e 392.2 [(M+H) , calcd
C H ClN O , 392.2]; LC/MS retention time (method B): t = 1.75 min.
27 3 3 R
Example 30
methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)methylphenyl)pyridin
yl)carbamate
Prepared as described in Example 29.
Part A: Benzyl (1-(4-bromomethylphenoxy)-2,4-dimethylpentanyl)carbamate.
LCMS (ESI) m/e 456.1 [(M+Na) , calcd C H BrNO Na, 456.1]; LC/MS
22 28 3
retention time (method B): t = 2.56 min.
Part B: Cbz methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)methylphenyl)pyridin-
2-yl)carbamate.
LCMS (ESI) m/e 506.1 [(M+H) , calcd C H N O , 506.3]; LC/MS retention
29 36 3 5
time (method B): t = 2.21 min.
Part C: methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)methylphenyl)pyridin
yl)carbamate.
Obtained methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)
methylphenyl)pyridinyl)carbamate (3.7 mg, 9.96 umol, 35% yield) as an off white
solid. H NMR (600MHz, DMSO-d ) δ 10.11 (br. s., 1H), 8.26 (d, J=5.1 Hz, 1H),
8.08 (s, 1H), 7.53 (br. s., 2H), 7.34 - 7.27 (m, 1H), 7.03 (d, J=9.2 Hz, 1H), 3.77 -
3.68 (m, 5H), 2.28 (s, 3H), 1.86 - 1.76 (m, 1H), 1.42 (t, J=5.0 Hz, 2H), 1.14 (s, 3H),
0.93 (m, 6H); LCMS (ESI) m/e 372.3 [(M+H) , calcd C H N O , 372.2]; LC/MS
21 30 3 3
retention time (method B): t = 1.71 min.
Example 31
methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)-2,3-dimethylphenyl)pyridin
yl)carbamate
Prepared as described in Example 29.
Part A: Benzyl (1-((5-chloro-3,4-dimethylpyridinyl)oxy)-2,4-dimethylpentan
yl)carbamate.
LCMS (ESI) m/e 426.3 [(M+Na) , calcd C H ClN O Na, 427.2]; LC/MS
22 29 2 3
retention time (method B): t = 2.57 min.
Part B: Cbz methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)-2,3-
dimethylphenyl)pyridinyl)carbamate.
A mixture of 2 generation Xphos Precatalyst (4 mg, 5.08 µmol), potassium
phosphate tribasic (0.5 mL, 0.250 mmol), (2-((methoxycarbonyl)amino)pyridin
yl)boronic acid (0.044 g, 0.225 mmol) and benzyl (1-(4-chloro-2,3-
dimethylphenoxy)-2,4-dimethylpentanyl)carbamate (0.0385g, 0.095 mmol) in
THF (0.8 mL) was degassed via vacuum/ N fill cycle three times. The reaction
mixture was heated at 80 °C overnight. The reaction was diluted with ethyl acetate
and washed with water (2X) followed by brine. The ethyl acetate layer was
separated, dried (Na SO ), filtered and concentrated under reduced pressure . The
product was purified via silica gel chromatography (0-30% ethyl acetate in hexanes)
to afford Cbz methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)-2,3-
dimethylphenyl)pyridinyl)carbamate (25 mg, 0.025 mmol, 27% yield) as a white
solid. LCMS (ESI) m/e 520.5 [(M+H) , calcd C H N O , 520.3]; LC/MS retention
37 3 5
time (method A): t = 2.38 min.
Part C: methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)-2,3-dimethylphenyl)pyridin-
2-yl)carbamate
A mixture of Pd/C (6 mg, 5.64 µmol) and Cbz protected methyl (4-(4-((2-
amino-2,4-dimethylpentyl)oxy)-2,3-dimethylphenyl)pyridinyl)carbamate (0.025 g,
0.048 mmol) in ethanol (4 mL) was hydrogenated via a H balloon at room
temperature overnight. The reaction mixture was filtered through a celite pad and
washed with CH Cl . The filtrate was concentrated under reduced pressure and the
residue was purified by reverse phase HPLC (acetonitrile/water/10 mM ammonium
acetate) to afford methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)-2,3-
dimethylphenyl)pyridinyl)carbamate (2.8 mg, 7.26 umol, 15% yield) as an off-
white solid. H NMR (600MHz, DMSO-d ) δ 8.26 (d, J=4.8 Hz, 1H), 7.74 (s, 1H),
7.02 (d, J=8.4 Hz, 1H), 6.96 (d, J=5.1 Hz, 1H), 6.86 (d, J=8.8 Hz, 1H), 3.67 (s, 4H),
3.48 (d, J=10.6 Hz, 1H), 2.19 (s, 3H), 1.84 (s, 3H), 1.83 - 1.74 (m, 1H), 1.42 (t,
J=6.1 Hz, 2H), 1.14 (s, 3H), 0.92 (t, J=5.9 Hz, 6H). LCMS (ESI) m/e 369.2 [(M-
NH ) , calcd C H N O , 369.2]; LC/MS retention time (method B): t = 1.68 min.
2 22 29 2 3 R
Example 32
(S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)
(hydroxymethyl)phenyl)pyridinyl)carbamate
Part A. 4-methyl-5H-1,2,3-oxathiazole 2,2-dioxide
Step 1: Sulfamoyl chloride formation: In a 1000ml 4 neck round-bottomed
flask equipped with a mechanical stirring and an addition funnel, was charged DCM
(400 mL) and chlorosulfonyl isocyanate (124 mL, 1430 mmol). Under N , this
solution was cooled to 0 °C. Then formic acid (53.9 mL, 1430 mmol) was added to
DCM (100 mL) and this solution was transferred to the addition funnel and the
solution was added slowly to the vigorously stirring reaction mixture. Gradually a
thick slurry formed. A slow exotherm was observed so additional dry ice was added
to acetone bath. Once temperature was stabilized, addition of the formic acid was
continued. Addition was done in ~ 25 min. The mixture was allowed to gradually
warm to room temperature and was stirred overnight.
Step 2: In a separate 5L 4 neck reaction flask was charged hydroxyacetone
(72.5 mL, 953 mmol), pyridine (116 mL, 1430 mmol), and DCM (2000 mL). This
solution was cooled to -5°C under N . The sulfamoyl chloride solution was added
slowly via Teflon tube over 10 min. After the addition, the reaction was stirred for
min then the ice bath was removed and the reaction mixture allowed to warm to
room temperature. As the reaction progressed, a gummy material formed. The
material was purified via silica gel chromatography (300 g silica gel eluting with
DCM). Obtained 4-methyl-5H-1,2,3-oxathiazole 2,2-dioxide (72.4 g, 536 mmol, 56
% yield) as a colorless solid. H NMR (400MHz, CHLOROFORM-d) δ 5.09 (s, 2H),
2.44 (s, 3H); LCMS (ESI) m/e 136.0 [(M+H) , calcd for C H NO S 136.0].
3 6 3
Part B. 2-(tert-butoxycarbonylamino)-2,4-dimethylpentanoic acid 4-methyl(2-
methylallyl)-1,2,3-oxathiazolidine 2,2-dioxide
A suspension of 4-methyl-5H-1,2,3-oxathiazole 2,2-dioxide (0.541 g, 4mmol)
in methyl tert-butyl ether (30 mL) was cooled below 0 °C with an ice/IPA bath. To
the cooled solution was added a solution of (2-methylallyl)magnesium chloride, 0.5
M in THF (9.60 mL, 4.80 mmol). The reaction mixture was allowed to warm to rt
overnight. It was then quenched with a saturated solution of NH Cl (50 mL) and
EtOAc (20 mL) was added. The organic phase was separated, washed with brine (50
mL), dried over Na SO , filtered and concentrated under reduced pressure to give 2-
(tert-butoxycarbonylamino)-2,4-dimethylpentanoic acid 4-methyl(2-methylallyl)-
1,2,3-oxathiazolidine 2,2-dioxide (0.567 g, 2.96 mmol, 74 % yield). H NMR
(400MHz, CHLOROFORM-d) δ 5.06 (quin, J=1.5 Hz, 1H), 4.87 (dd, J=1.7, 0.8 Hz,
1H), 4.50 (br. s., 1H), 4.40 (d, J=8.6 Hz, 1H), 4.29 (d, J=8.7 Hz, 1H), 2.56 (d,
J=13.8 Hz, 1H), 2.40 - 2.30 (m, 1H), 1.86 (br. s, 3H), 1.49 (s, 3H); LCMS (ESI) m/e
192.1 [(M+H) , calcd for C H NO S 192.1].
7 14 3
Part C. benzyl 4-methyl(2-methylallyl)-1,2,3-oxathiazolidinecarboxylate 2,2-
dioxide
To a N flushed, 100 mL round-bottomed flask was added a solution of 4-
methyl(2-methylallyl)-1,2,3-oxathiazolidine 2,2-dioxide (0.55 g, 2.88 mmol) in
THF (10 mL). A solution of potassium tert-butoxide (4.31 mL, 4.31 mmol) in THF
was added The temperature rose to 27 °C and the solution became a suspension. The
mixture was stirred at room temperature for 1 h. Benzyl carbonochloridate (1.026
mL, 7.19 mmol) was added slowly. The reaction mixture was stirred at room
temperature for 2 h. The reaction mixture was then quenched with water (50 mL)
and extracted with EtOAc (2x70 mL). The organic extracts were washed with brine
(50 mL), dried over Na SO , filtered and concentrated under reduced pressure. The
residue was purified by silica gel chromatography (ethyl acetate/hexanes) to give
benzyl 4-methyl(2-methylallyl)-1,2,3-oxathiazolidinecarboxylate 2,2-dioxide
(0.66 g, 2.028 mmol, 71 % yield). H NMR (400MHz, CHLOROFORM-d) δ 7.58 -
7.32 (m, 5H), 5.43 - 5.25 (m, 2H), 5.01 (t, J=1.5 Hz, 1H), 4.81 (d, J=0.9 Hz, 1H),
4.63 (d, J=9.5 Hz, 1H), 4.21 (d, J=9.5 Hz, 1H), 2.87 (d, J=14.1 Hz, 1H), 2.56 (d,
J=14.1 Hz, 1H), 1.78 (br. s, 3H), 1.64 (s, 3H); LCMS (ESI) m/e 326.1 [(M+H) ,
calcd for C H NO S 326.1].
20 5
The racmeic compounds was separated by chiral super critical fluid
chromatography (Column: OJ-H (3x25cm, 5µm); Mobile Phase: CO / MeOH
(90/10)) to give the two enantiomers.
Analytical super critical fluid chromatography conditions: Column: OJ-H
(0.46x25cm, 5µm); BPR pressure: 100 bars; Temperature: 35 °C; Flow rate: 3.0
mL/min; Mobile Phase: CO / MeOH (90/10); Detector Wavelength: UV 200-400nm
Enantiomer 1: (S)-benzyl 4-methyl(2-methylallyl)-1,2,3-oxathiazolidine
carboxylate 2,2-dioxide HPLC retention time = 2.53 min.
Enantiomer 2: (R)-benzyl 4-methyl(2-methylallyl)-1,2,3-oxathiazolidine
carboxylate 2,2-dioxide HPLC retention time = 2.97 min.
Part D. (S)isobutylmethyl-1,2,3-oxathiazolidine 2,2-dioxide
To a stirred solution of (S)-benzyl 4-methyl(2-methylallyl)-1,2,3-
oxathiazolidinecarboxylate 2,2-dioxide (800 mg, 2.459 mmol) in MeOH (20 mL)
was added Pd/C (262 mg, 0.246 mmol) under a nitrogen atmosphere and the reaction
mixture was stirred under 1 atm hydrogen pressure for 16 h. The reaction mixture
was passed through celite pad and the celite pad was washed with EtOAc (15 mL).
The organic layer was evaporated under reduced pressure to afford (S)isobutyl
methyl-1,2,3-oxathiazolidine 2,2-dioxide (462 mg, 2.39 mmol, 97% yield, 95%
purity) as colorless oil. The material was carried forward without further
purification. H NMR (400 MHz, DMSO-d ) δ ppm 7.69 (br, 1H) 4.33 (d, J=8.03
Hz, 1 H) 4.17 - 4.26 (m, 1 H) 1.68 - 1.81 (m, 1 H) 1.53 - 1.63 (m, 1 H) 1.43 - 1.51
(m, 1 H) 1.34 (s, 3 H) 0.81 - 1.00 (m, 6 H).
Part E. (S)-tert-butyl 4-isobutylmethyl-1,2,3-oxathiazolidinecarboxylate 2,2-
dioxide
To a stirred solution of (S)isobutylmethyl-1,2,3-oxathiazolidine 2,2-
dioxide (7 g, 15.21 mmol) in DCM (70 mL) cooled to 0 °C was added DMAP (1.858
g, 15.21 mmol) and (BOC) O (5.30 mL, 22.82 mmol) The reaction mixture was
stirred at rt for 12 h. The reaction mixture was transfers to a separating funnel
containing water (20 ml) and was extracted with DCM (2 x 60 ml ). The combined
organic layers were washed with brine (50 mL), dried over (Na SO ), and
concentrated under reduced pressure. The residue was purified via silica gel
chromatography (30 % ethyl acetate in pet ether) to afford (S)-tert-butyl 4-isobutyl
methyl-1,2,3-oxathiazolidinecarboxylate 2,2-dioxide (4.4 g, 14.70 mmol, 97 %
yield) as a colorless oil. H NMR (400MHz, CHLOROFORM-d) δ 4.45 (d, J=9.0
Hz, 1H), 4.20 (d, J=9.0 Hz, 1H), 2.07 - 1.98 (m, J=8.0 Hz, 1H), 1.83 - 1.69 (m, 2H),
1.59 (s, 3H), 1.56 (s, 9H), 0.99 (dd, J=8.0, 6.5 Hz, 6H).
Part F: (S)-tert-butyl (1-(4-bromoformylphenoxy)-2,4-dimethylpentan
yl)carbamate.
To a 20 mL vial was added 5-bromohydroxybenzaldehyde (81 mg, 0.403
mmol), (S)-tert-butyl 4-isobutylmethyl-1,2,3-oxathiazolidinecarboxylate 2,2-
dioxide (107.4 mg, 0.366 mmol), and K CO (152 mg, 1.098 mmol) in DMF (1.2
mL) to give a white suspension. The vial was sealed and the mixture was heated at
80 °C for 17 h. The reaction mixture was cooled to rt and partitioned between water
and EtOAc. The layers were separated. The organic layer was washed with water,
brine, dried (Na SO ) and concentrated under reduced pressure. The crude residue
was purified by silica gel chromatography (up to 40% EtOAc/hexanes) to afford (S)-
tert-butyl (1-(4-bromoformylphenoxy)-2,4-dimethylpentanyl)carbamate (115
mg, 0.278 mmol, 76%) as a colorless oil. H NMR (400 MHz, Chloroform-d) δ
.43 (s, 1H), 7.89 (d, J = 2.6 Hz, 1H), 7.59 (dd, J = 8.9, 2.6 Hz, 1H), 6.93 (d, J =
8.8 Hz, 1H), 4.58 (s, 1H), 4.29 (d, J = 8.8 Hz, 1H), 4.09 (d, J = 8.8 Hz, 1H), 1.94 -
1.74 (m, 2H), 1.48 (dd, J = 13.9, 4.8 Hz, 1H), 1.39 (s, 3H), 1.37 (s, 9H), 0.98 (dd, J =
6.6, 4.8 Hz, 6H); (ESI) m/e 314.0, 316.0 Br pattern [(M-Boc+H) , calcd
C H BrNO , 414.1]; LC/MS retention time (method B): t = 2.39 min.
14 21 2 R
Part G: (S)-methyl (4-(4-((2-Boc-amino-2,4-dimethylpentyl)oxy)
carbonylphenyl)pyridinyl)carbamate.
To a 2 mL vial was added (S)-tert-butyl (1-(4-bromoformylphenoxy)-2,4-
dimethylpentanyl)carbamate (27.9 mg, 0.067 mmol), (2-
((methoxycarbonyl)amino)pyridinyl)boronic acid (19.79 mg, 0.101 mmol), and
Na CO (0.101 mL, 0.202 mmol) in dioxane (0.5 mL) under nitrogen to give a
colorless suspension. 1,1'-Bis(diphenylphosphino)ferrocenepalladium(II) dichloride,
toluene (2.77 mg, 3.37 µmol) was added under nitrogen. The vial was sealed and
heated at 100 °C (bath temp: 105°C) for 3 h. LCMS showed conversion to the
desired product (M + H = 486), but with some starting material left. A bit more
reagents was added and heating continued for another 3h. LCMS showed no more
starting material. The mixture was diluted with EtOAc and passed through a plug of
Na SO . The organic solution was concentrated. Obtained (S)-methyl (4-(4-((2-Boc-
amino-2,4-dimethylpentyl)oxy)carbonylphenyl)pyridinyl)carbamate as a tan
residue which was carried on without further purification. LCMS (ESI) m/e 486.4
[(M+H) , calcd C H N O , 486.3]; LC/MS retention time (method C): t = 4.23
26 36 3 6 R
min.
Part H: (S)-methyl (4-(4-((2-Boc-amino-2,4-dimethylpentyl)oxy)
(hydroxymethyl)phenyl)pyridinyl)carbamate
To a 2 mL vial was added crude aldehyde (10.68 mg, 0.022 mmol) in MeOH
(0.5 mL) to give a tan solution. NaBH (5 mg, 0.132 mmol) was added. The mixture
was stirred at rt for 1 h. The mixture was partitioned between water and EtOAc. The
layers were separated. The organic layer was washed with brine, dried (Na SO ) and
concentrated under reduced pressure . The tan residue was directly carried onto next
reaction. LCMS (ESI) m/e 488.2 [(M+H) , calcd C H N O , 488.3]; LC/MS
26 38 3 6
retention time (method B): t = 2.00 min.
Part I: (S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)
(hydroxymethyl)phenyl)pyridinyl)carbamate
To a 25 mL flask was added (S)-methyl (4-(4-((2-Boc-amino-2,4-
dimethylpentyl)oxy)(hydroxymethyl)phenyl)pyridinyl)carbamate (10.73 mg,
0.022 mmol) in CH Cl (1 mL) to give a tan solution. TFA (0.5 ml, 6.49 mmol) was
added under nitrogen. The mixture was stirred at rt for 1 h. The mixture was
concentrated. The residue was dissolved in MeOH, filtered, and purified by reverse
phase HPLC (acetonitrile/water/10 mM ammonium acetate) to afford (S)-methyl (4-
(4-((2-amino-2,4-dimethylpentyl)oxy)(hydroxymethyl)phenyl)pyridin
yl)carbamate (7.6 mg, 0.019 mmol, 86% yield for three steps) as a colorless solid. H
NMR (500 MHz, DMSO-d ) δ 8.28 (d, J = 5.2 Hz, 1H), 8.12 (s, 1H), 7.77 (d, J = 2.4
Hz, 1H), 7.61 (dd, J = 8.6, 2.4 Hz, 1H), 7.32 (d, J = 5.2 Hz, 1H), 7.06 (d, J = 8.5 Hz,
1H), 4.63 (s, 2H), 3.77 (s, 2H), 3.70 (s, 3H), 1.79 (td, J = 11.7, 10.6, 5.5 Hz, 1H),
1.42 (qd, J = 14.0, 5.6 Hz, 2H), 1.14 (s, 3H), 0.93 (t, J = 7.2 Hz, 6H); LCMS (ESI)
m/e 388.1 [(M+H) , calcd C H N O , 388.2]; LC/MS retention time (method B): t
21 30 3 4 R
= 1.55 min.
Example 33
(S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)cyclopropylphenyl)pyridin
yl)carbamate
Prepared as described in Example 32.
Part A: (S)-tert-butyl (1-(4-bromocyclopropylphenoxy)-2,4-dimethylpentan
yl)carbamate
To a 100 mL round-bottomed flask was added 2-cyclopropylphenol (584 mg,
4.35 mmol) in CH Cl (22 mL) to give a colorless solution. Br (0.224 mL, 4.35
2 2 2
mmol) was added dropwise at 0°C. The mixture was stirred at 0 °C for 1 h. The
mixture was concentrated under reduced pressure to afford (S)-tert-butyl (1-(4-
bromocyclopropylphenoxy)-2,4-dimethylpentanyl)carbamate (992 mg, 4.35
mmol, 100% yield) as a colorless oil. H NMR (400 MHz, Chloroform-d) δ 7.24 (dd,
J = 8.6, 2.5 Hz, 1H), 7.20 (dd, J = 2.5, 0.9 Hz, 1H), 6.76 (d, J = 8.5 Hz, 1H), 5.43 (s,
1H), 1.82 (tt, J = 8.3, 5.3 Hz, 1H), 1.04 - 0.97 (m, 2H), 0.70 - 0.64 (m, 2H); LC/MS
retention time (method B): t = 2.09 min.
Part B: (S)-tert-butyl (1-(4-bromocyclopropylphenoxy)-2,4-dimethylpentan
yl)carbamate.
H NMR (400 MHz, Chloroform-d) δ 7.21 (dd, J = 8.7, 2.5 Hz, 1H), 6.98 (d,
J = 2.5 Hz, 1H), 6.71 (d, J = 8.7 Hz, 1H), 4.67 (s, 1H), 4.10 (d, J = 9.0 Hz, 1H), 3.94
(d, J = 8.8 Hz, 1H), 2.16 - 2.08 (m, 1H), 1.84 (ddt, J = 13.0, 10.9, 6.5 Hz, 2H), 1.69 -
1.59 (m, 1H), 1.43 (s, 3H), 1.42 (s, 9H), 0.99 (dd, J = 6.5, 3.1 Hz, 6H), 0.97 - 0.92
(m, 2H), 0.68 - 0.61 (m, 2H); LCMS (ESI) m/e 447.9 [(M+Na) , calcd
C H Br N Na O , 448.2]; LC/MS retention time (method B): t = 2.59 min.
21 32 1 1 1 3 R
Part C: (S)-methyl (4-(4-((2-Boc-amino-2,4-dimethylpentyl)oxy)
cyclopropylphenyl)pyridinyl)carbamate.
LCMS (ESI) m/e 498.1 [(M+H) , calcd C H N O , 498.3]; LC/MS retention
28 40 3 5
time (method B): t = 2.24 min.
Part D: (S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)
cyclopropylphenyl)pyridinyl)carbamate.
H NMR (500 MHz, DMSO-d ) δ 8.25 (d, J = 5.3 Hz, 1H), 8.05 (s, 1H), 7.50
(dd, J = 8.5, 2.4 Hz, 1H), 7.32 (d, J = 5.4 Hz, 1H), 7.19 (d, J = 2.3 Hz, 1H), 7.04 (d,
J = 8.5 Hz, 1H), 3.81 - 3.73 (m, 2H), 3.70 (s, 3H), 2.20 (ddd, J = 13.9, 8.8, 5.4 Hz,
1H), 1.82 (dt, J = 12.8, 6.3 Hz, 1H), 1.49 - 1.38 (m, 2H), 1.16 (s, 3H), 0.94 (q, J =
6.2 Hz, 8H), 0.72 (q, J = 5.1 Hz, 2H); LCMS (ESI) m/e 398.1 [(M+H) , calcd
C23H32N3O3, 398.2]; LC/MS retention time (method B): tR = 1.73 min.
Example 34
(S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)(trifluoromethyl)phenyl)
(hydroxymethyl)pyridinyl)acetamide
Prepared as described in Example 19.
Part A: N-(4-chloro(hydroxymethyl)pyridinyl)acetamide
To a 25 mL vial was added (4,6-dichloropyridinyl)methanol (125.8 mg,
0.707 mmol), and acetamide (62.6 mg, 1.060 mmol) in 1,4-dioxane (4 mL) to give a
colorless solution. While degassing with N , PdOAc (7.93 mg, 0.035 mmol),
XANTPHOS (30.7 mg, 0.053 mmol), Cs CO (368 mg, 1.131 mmol) were added.
The vial was sealed under nitrogen and heated at 110 °C (bath: 112°C) for 22 h
(1:30pm). The reaction mixture was cooled to rt and partitioned between water and
EtOAc. There were some insoluble solids which were removed by filtration. The
layers were separated. The aqueous layer was extracted 4 times with EtOAc (there
were still product left in aq.). The combined organic layers were washed with brine,
dried and concentrated. The residue was purified by silica gel chromatography (up to
% MeOH/CH Cl ) to afford N-(4-chloro(hydroxymethyl)pyridinyl)acetamide
(90 mg, o.449 mmol, 64% yield) as a white solid: H NMR (400 MHz, Methanol-d )
δ 8.34 (s, 1H), 8.19 (s, 1H), 4.69 (s, 2H), 2.19 (s, 3H); LCMS (ESI) m/e 201.1
[(M+H) , calcd C H ClN O , 201.1]; LC/MS retention time (method B): t = 1.73
8 10 2 2 R
min.
Part B: (2-acetamido(hydroxymethyl)pyridinyl)boronic acid
To a 20 mL vial was added N-(4-chloro(hydroxymethyl)pyridin
yl)acetamide (48 mg, 0.239 mmol), hypodiboric acid (32.2 mg, 0.359 mmol),2-
(dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (2.281 mg, 4.79 µmol), Xphos
precatalyst (1.882 mg, 2.393 µmol) and potassium acetate (70.4 mg, 0.718 mmol) in
ethanol (2.2 mL) to give a tan suspension (degassed with N before adding reagents).
The bottle was capped and heated at 80 °C for 1.5 h. The mixture was cooled to rt
and concentrated under reduced pressure. The crude material was carried on without
purification.
Part C: (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)(trifluoromethyl)phenyl)
(hydroxymethyl)pyridinyl)acetamide
To a 20 mL vial was added (2-acetamido(hydroxymethyl)pyridin
yl)boronic acid (50.2 mg, 0.239 mmol) was added potassium phosphate tribasic (2
mL, 1.000 mmol). After degassing with N for 5 min, Xphos precatalyst (3.76 mg,
4.78 µmol) and (S)(4-bromo(trifluoromethyl)phenoxy)-2,4-dimethylpentan
amine (30 mg, 0.076 mmol) (prepared as described in Example 19. Part A) in
tetrahydrofuran (2 mL) were added. The vial was sealed and heated at 80 °C for 18
h. The reaction mixture was cooled to rt and the volatiles were removed under
reduced pressure. The residue was partitioned between water and EtOAc. The
organic layer was dried, filtered and concentrated. The residue was dissolved in
MeOH and purified by reverse phase HPLC (acetonitrile/water/10 mM ammonium
acetate) to afford (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)
(trifluoromethyl)phenyl)(hydroxymethyl)pyridinyl)acetamide (27.7 mg, 0.060
mmol, 79% yield) as an off-white solid. H NMR (600 MHz, DMSO-d ) δ 10.57 (s,
1H), 8.38 (s, 1H), 8.02 (s, 1H), 7.80 (s, 1H), 7.78 - 7.71 (m, 1H), 7.35 (d, J = 8.6 Hz,
1H), 4.36 (s, 2H), 3.86 (q, J = 8.8 Hz, 2H), 2.10 (s, 3H), 1.81 (dt, J = 12.6, 6.1 Hz,
1H), 1.45 - 1.37 (m, 2H), 1.13 (s, 3H), 0.92 (dd, J = 6.6, 3.4 Hz, 6H); LCMS (ESI)
m/e 440.2 [(M+H) , calcd C H F N O , 440.2]; LC/MS retention time (method B):
22 29 3 3 3
t = 1.67 min.
Example 35
(S)(4-(2-(difluoromethyl)pyridinyl)(trifluoromethyl)phenoxy)-2,4-
dimethylpentanamine
Prepared as described in Example 19. Obtained (S)(4-(2-
(difluoromethyl)pyridinyl)(trifluoromethyl)phenoxy)-2,4-dimethylpentan
amine (25.5 mg, 0.062 mmol, 54% yield) as an off-white solid. H NMR (600 MHz,
DMSO-d6) δ 8.74 (d, J = 5.1 Hz, 1H), 8.19 (d, J = 8.8 Hz, 1H), 8.11 (s, 1H), 8.06 (s,
1H), 7.96 (d, J = 5.1 Hz, 1H), 7.44 (d, J = 8.7 Hz, 1H), 7.01 (t, J = 54.9 Hz, 1H),
4.05 (q, J = 9.6 Hz, 2H), 1.81 (dt, J = 12.9, 6.6 Hz, 1H), 1.61 - 1.47 (m, 2H), 1.25 (s,
3H), 0.92 (t, J = 6.9 Hz, 6H); LCMS (ESI) m/e 403.4 [(M+H) , calcd C H F N O ,
24 5 2 1
403.2]; LC/MS retention time (method A): t = 2.13 min.
Example 36
(S)((2-amino-2,4-dimethylpentyl)oxy)(2-(difluoromethyl)pyridin
yl)benzonitrile
Prepared as described in Example 19. Obtained (S)((2-amino-2,4-
dimethylpentyl)oxy)(2-(difluoromethyl)pyridinyl)benzonitrile (32 mg, 0.086
mmol, 60% yield) as an off-white solid.. H NMR (500 MHz, DMSO-d ) δ 8.48 (d, J
= 5.2 Hz, 1H), 8.11 (d, J = 2.5 Hz, 1H), 7.95 (dd, J = 9.0, 2.4 Hz, 1H), 7.80 (s, 1H),
7.69 (d, J = 5.2 Hz, 1H), 7.14 (d, J = 8.9 Hz, 1H), 6.73 (t, J = 54.8 Hz, 1H), 3.80 -
3.68 (m, 2H), 1.56 (dp, J = 12.5, 6.4 Hz, 1H), 1.23 (qd, J = 14.0, 5.5 Hz, 2H), 0.95
(s, 3H), 0.68 (dd, J = 6.7, 4.7 Hz, 6H); F NMR (376 MHz, DMSO-d6) δ -115.30 (d,
J = 54.0 Hz); LCMS (ESI) m/e 360.2 [(M+H) , calcd C H F N O , 360.2]; LC/MS
24 2 3 1
retention time (method B): t = 1.69 min.
Example 37
(S)(2-(difluoromethyl)(2-(difluoromethyl)pyridinyl)phenoxy)-2,4-
dimethylpentanamine
Prepared as described in Example 19. Obtained (S)(2-(difluoromethyl)
(2-(difluoromethyl)pyridinyl)phenoxy)-2,4-dimethylpentanamine (31.9 mg,
0.080 mmol, 61% yield) as an off-white solid. H NMR (500 MHz, DMSO-d ) δ
8.48 (d, J = 5.1 Hz, 1H), 7.81 (dd, J = 8.9, 2.4 Hz, 1H), 7.76 (d, J = 3.6 Hz, 2H),
7.67 (d, J = 5.1 Hz, 1H), 7.22 - 6.94 (m, 2H), 6.76 (t, J = 54.9 Hz, 1H), 3.68 (d, J =
2.2 Hz, 2H), 1.54 (dp, J = 12.7, 6.3 Hz, 1H), 1.30 - 1.13 (m, 2H), 0.95 (s, 3H), 0.67
(dd, J = 15.9, 6.6 Hz, 6H); F NMR (376 MHz, DMSO-d6) δ -73.65 , -115.33;
LCMS (ESI) m/e 407.2 [(M+Na) , calcd C H F N Na O , 407.2]; LC/MS retention
24 4 2 1 1
time (method B): tR = 1.89 min.
Example 38
(S)(4-(2-(difluoromethyl)pyridinyl)(trifluoromethoxy)phenoxy)-2,4-
dimethylpentanamine
Prepared as described in Example 19. Obtained (S)(4-(2-
(difluoromethyl)pyridinyl)(trifluoromethoxy)phenoxy)-2,4-dimethylpentan
amine (21.1 mg, 0.050 mmol, 39% yield) as an off-white solid. H NMR (500 MHz,
DMSO-d ) δ 8.55 (d, J = 5.2 Hz, 1H), 7.85 (s, 1H), 7.78 (dd, J = 13.4, 5.4 Hz, 3H),
7.22 (d, J = 8.6 Hz, 1H), 6.83 (t, J = 54.9 Hz, 1H), 3.71 (d, J = 3.6 Hz, 2H), 1.64 (dt,
J = 12.7, 6.3 Hz, 1H), 1.26 (dq, J = 14.8, 8.3, 6.9 Hz, 2H), 0.98 (s, 3H), 0.75 (t, J =
5.9 Hz, 6H); LCMS (ESI) m/e 419.3 [(M+H) , calcd C H F N O , 419.2]; LC/MS
24 5 2 2
retention time (method B): t = 2.03 min.
Example 39
(S)(4-(3-chlorofluoropyridinyl)(trifluoromethyl)phenoxy)-2,4-
dimethylpentanamine
Prepared as described in Example 19. Obtained (S)(4-(3-chloro
fluoropyridinyl)(trifluoromethyl)phenoxy)-2,4-dimethylpentanamine (14
mg, 0.035 mmol, 42% yield) as an off-white solid. H NMR (500 MHz, DMSO-d ) δ
8.25 (d, J = 5.1 Hz, 1H), 7.88 - 7.79 (m, 2H), 7.53 (d, J = 5.1 Hz, 1H), 7.40 (d, J =
8.5 Hz, 1H), 3.87 (q, J = 8.9 Hz, 2H), 1.80 (hept, J = 6.5 Hz, 1H), 1.39 (d, J = 5.6
Hz, 2H), 1.12 (s, 3H), 0.92 (dd, J = 6.7, 2.4 Hz, 6H); F NMR (376 MHz, DMSO-
d ) δ -61.18 , -71.35; LCMS (ESI) m/e 405.1 [(M+H) , calcd C H Cl F N O ,
6 19 22 1 4 2 1
405.1]; LC/MS retention time (method B): t = 2.04 min.
Example 40
(S)(4-(5-chlorofluoropyridinyl)(trifluoromethyl)phenoxy)-2,4-
dimethylpentanamine
Prepared as described in Example 19. Obtained (S)(4-(5-chloro
fluoropyridinyl)(trifluoromethyl)phenoxy)-2,4-dimethylpentanamine (15.2
mg, 0.037 mmol, 43% yield) as an off-white solid. H NMR (500 MHz, DMSO-d ) δ
8.45 (s, 1H), 7.88 - 7.80 (m, 2H), 7.46 (d, J = 1.9 Hz, 1H), 7.39 (d, J = 8.5 Hz, 1H),
3.93 - 3.82 (m, 2H), 1.80 (dp, J = 12.8, 6.5 Hz, 1H), 1.40 (d, J = 5.5 Hz, 2H), 1.13 (s,
3H), 0.92 (dd, J = 6.6, 2.5 Hz, 6H); F NMR (376 MHz, DMSO-d6) δ -61.16 , -
71.37; LCMS (ESI) m/e 405.1 [(M+H) , calcd C H Cl F N O , 405.1]; LC/MS
19 22 1 4 2 1
retention time (method B): t = 2.04 min.
Example 41
(S)(4-(2-fluoromethylpyridinyl)(trifluoromethyl)phenoxy)-2,4-
dimethylpentanamine
Prepared as described in Example 19. Obtained (S)(4-(2-fluoro
methylpyridinyl)(trifluoromethyl)phenoxy)-2,4-dimethylpentanamine (14.1
mg, 0.036 mmol, 42% yield) as an off-white solid. H NMR (500 MHz, DMSO-d ) δ
8.10 (d, J = 5.1 Hz, 1H), 7.72 (dd, J = 8.6, 2.3 Hz, 1H), 7.67 (d, J = 2.2 Hz, 1H),
7.36 (d, J = 8.6 Hz, 1H), 7.29 (d, J = 5.1 Hz, 1H), 3.87 (q, J = 8.8 Hz, 2H), 2.17 (s,
3H), 1.81 (dp, J = 12.7, 6.4 Hz, 1H), 1.46 - 1.35 (m, 2H), 1.13 (s, 3H), 0.92 (dd, J =
6.7, 2.8 Hz, 6H); F NMR (376 MHz, DMSO-d6) δ -61.03 , -71.80; LCMS (ESI)
m/e 385.2 [(M+H) , calcd C H F N O , 385.2]; LC/MS retention time (method B):
25 4 2 1
t = 1.99 min.
Example 42
(S)(4-(2,3-difluoropyridinyl)(trifluoromethyl)phenoxy)-2,4-dimethylpentan-
2-amine
Prepared as described in Example 19. Obtained (S)(4-(2,3-difluoropyridin-
4-yl)(trifluoromethyl)phenoxy)-2,4-dimethylpentanamine (7 mg, 0.018 mmol,
21% yield) as an off-white solid. H NMR (500 MHz, DMSO-d ) δ 8.10 (d, J = 5.1
Hz, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.95 (d, J = 2.3 Hz, 1H), 7.66 (t, J = 5.1 Hz, 1H),
7.43 (d, J = 8.8 Hz, 1H), 3.90 (q, J = 8.8 Hz, 2H), 1.79 (dq, J = 12.8, 6.4 Hz, 1H),
1.40 (d, J = 5.5 Hz, 2H), 1.13 (s, 3H), 0.92 (dd, J = 6.6, 2.2 Hz, 6H); F NMR (376
MHz, DMSO-d6) δ -61.23 , -89.72 , -89.79; LCMS (ESI) m/e 389.2 [(M+H) , calcd
C H F N O , 389.2]; LC/MS retention time (method B): t = 2.01 min.
19 22 5 2 1 R
Example 43
(S)-2,4-dimethyl(4-(pyridinyl)(trifluoromethyl)phenoxy)pentanamine
Prepared as described in Example 19. A mixture of sodium carbonate(0.068
mL, 0.136 mmol), 1,1'- bis(diphenylphosphino)ferrocene-palladium(II) dichloride
dichloromethane complex(3.89 mg, 4.76 µmol), pyridinylboronic acid (8.36 mg,
0.068 mmol) and (S)(4-bromo(trifluoromethyl)phenoxy)-2,4-dimethylpentan
amine (0.0241 g, 0.068 mmol) in dioxane (0.5 mL) (degassed with N ) was heated at
80 °C overnight. The reaction mixture was cooled to rt and diluted with ethyl acetate
then washed with water (3X). The ethyl acetate layer was dried (Na SO ), filtered
and concentrated under reduced pressure. The residue was purified by reverse phase
HPLC (acetonitrile/water/10 mM ammonium acetate). Obtained (S)-2,4-dimethyl
(4-(pyridinyl)(trifluoromethyl)phenoxy)pentanamine (89 mg, 0.088 mmol,
46% yield) as an off-white solid. H NMR (500MHz, DMSO-d6) δ 8.62 (d, J=5.9
Hz, 2H), 8.09 (d, J=9.2 Hz, 1H), 8.01 (s, 1H), 7.75 (d, J=5.5 Hz, 2H), 7.37 (d, J=8.8
Hz, 1H), 3.87 (d, J=7.0 Hz, 2H), 1.84 - 1.74 (m, 1H), 1.39 (d, J=5.5 Hz, 2H), 1.12 (s,
3H), 0.91 (d, J=6.6 Hz, 6H) LCMS (ESI) m/e 353.2 [(M+H) , calcd C H F N O,
19 24 3 2
353.2]; LC/MS retention time (method B): t = 1.48 min.
Example 44
(S)(4-(2-fluoropyridinyl)(trifluoromethyl)phenoxy)-2,4-dimethylpentan
amine
Prepared as described in Example 43. Obtained (S)(4-(2-fluoropyridin
yl)(trifluoromethyl)phenoxy)-2,4-dimethylpentanamine (9.3 mg, 0.025 mmol,
36% yield) as an off-white solid.. H NMR (400MHz, METHANOL-d ) δ 8.27 (d,
J=5.4 Hz, 1H), 8.10 - 8.04 (m, 2H), 7.63 (d, J=5.4 Hz, 1H), 7.45 - 7.39 (m, 2H), 4.19
(d, J=3.2 Hz, 2H), 1.94 (s, 3H), 1.77 (d, J=5.6 Hz, 2H), 1.71 - 1.63 (m, 1H), 1.45 (s,
2H), 1.04 (d, J=6.6 Hz, 3H), 1.02 (d, J=6.6 Hz, 3H); LCMS (ESI) m/e 371.2
[(M+H) , calcd C H F N O, 371.2]; LC/MS retention time (method B): t = 1.95
19 23 4 2 R
min.
Example 45
(S)-2,4-dimethyl(4-(2-methylpyridinyl)(trifluoromethyl)phenoxy)pentan
amine
Prepared as described in Example 19. Obtained (S)-2,4-dimethyl(4-(2-
methylpyridinyl)(trifluoromethyl)phenoxy)pentanamine (16 mg, 0.044
mmol, 50% yield) as an off-white solid. H NMR (500 MHz, DMSO-d ) δ 8.68 (d, J
= 5.8 Hz, 1H), 8.26 (dd, J = 8.8, 2.6 Hz, 1H), 8.19 - 8.18 (m, 1H), 8.04 (s, 1H), 7.94
(d, J = 5.9 Hz, 1H), 7.51 (d, J = 8.8 Hz, 1H), 4.26 (q, J = 10.1 Hz, 2H), 2.66 (s, 3H),
1.83 (dq, J = 13.0, 6.5 Hz, 1H), 1.74 (dd, J = 14.3, 5.5 Hz, 1H), 1.62 (dd, J = 14.6,
5.8 Hz, 1H), 1.40 (s, 3H), 0.93 (dd, J = 8.6, 6.4 Hz, 6H); 19F NMR (376 MHz,
DMSO-d6) δ -60.51, -73.76 (TFA); LCMS (ESI) m/e 367.2 [(M+H) , calcd
C H F N O , 367.2]; LC/MS retention time (method B): t = 1.51 min.
26 3 2 1 R
Example 46
(S)(4-(3-methoxypyridinyl)(trifluoromethyl)phenoxy)-2,4-dimethylpentan
amine
Prepared as described in Example 19. Obtained (S)(4-(3-methoxypyridin-
4-yl)(trifluoromethyl)phenoxy)-2,4-dimethylpentanamine (8.5 mg, 0.021 mmol,
24% yield) as an off-white solid. H NMR (500 MHz, DMSO-d ) δ 8.47 (s, 1H),
8.28 (d, J = 4.8 Hz, 1H), 7.85 (d, J = 9.0 Hz, 1H), 7.82 (d, J = 2.3 Hz, 1H), 7.41 (d, J
= 4.8 Hz, 1H), 7.32 (d, J = 8.6 Hz, 1H), 3.91 (s, 3H), 3.86 (q, J = 8.9 Hz, 2H), 1.80
(hept, J = 6.4 Hz, 1H), 1.40 (d, J = 5.5 Hz, 2H), 1.13 (s, 3H), 0.92 (dd, J = 6.8, 2.5
19 +
Hz, 6H); F NMR (376 MHz, DMSO-d ) δ -61.00; LCMS (ESI) m/e 383.2 [(M+H) ,
calcd C H F N O , 383.2]; LC/MS retention time (method B): t = 1.58 min.
26 3 2 2 R
Example 47
(S)(4-(3-fluoropyridinyl)(trifluoromethyl)phenoxy)-2,4-dimethylpentan
amine
Prepared as described in Example 19. Obtained (S)(4-(3-fluoropyridin
yl)(trifluoromethyl)phenoxy)-2,4-dimethylpentanamin (8.9 mg, 0.023 mmol,
% yield) as an off-white solid. H NMR (500 MHz, DMSO-d ) δ 8.66 (d, J = 2.6
Hz, 1H), 8.51 (d, J = 4.9 Hz, 1H), 7.96 (d, J = 8.8 Hz, 1H), 7.91 (d, J = 2.3 Hz, 1H),
7.70 (dd, J = 7.1, 4.9 Hz, 1H), 7.41 (d, J = 8.7 Hz, 1H), 3.89 (q, J = 8.9 Hz, 2H),
1.80 (dp, J = 12.7, 6.4 Hz, 1H), 1.40 (d, J = 5.5 Hz, 2H), 1.13 (s, 3H), 0.92 (dd, J =
6.6, 2.3 Hz, 6H); F NMR (376 MHz, DMSO-d6) δ -61.17 , -133.88; LCMS (ESI)
m/e 371.2 [(M+H) , calcd C H F N O , 371.2]; LC/MS retention time (method B):
19 23 4 2 1
t = 1.88 min.
Example 48
(S)((2-amino-2,4-dimethylpentyl)oxy)(2-methylpyridinyl)benzonitrile
Prepared as described in Example 19. Obtained (S)((2-amino-2,4-
dimethylpentyl)oxy)(2-methylpyridinyl)benzonitrile (39.4 mg, 0.116 mmol,
80% yield) as an off-white solid. H NMR (500 MHz, DMSO-d ) δ 8.49 (d, J = 5.2
Hz, 1H), 8.23 (d, J = 2.4 Hz, 1H), 8.11 (dd, J = 8.9, 2.4 Hz, 1H), 7.64 (s, 1H), 7.54
(dd, J = 5.3, 1.9 Hz, 1H), 7.36 (d, J = 8.9 Hz, 1H), 3.98 - 3.87 (m, 2H), 3.58 (s, 2H),
2.52 (s, 3H), 1.82 (dt, J = 12.8, 6.4 Hz, 1H), 1.50 - 1.37 (m, 2H), 1.16 (s, 3H), 0.93
(dd, J = 6.6, 3.9 Hz, 6H); LCMS (ESI) m/e 324.1 [(M+H) , calcd C H N O ,
26 3 1
324.2]; LC/MS retention time (method B): t = 1.46 min.
Example 49
(S)(2-cyclopropyl(2-methylpyridinyl)phenoxy)-2,4-dimethylpentanamine
Prepared as described in Example 19. Obtained (S)(2-cyclopropyl(2-
methylpyridinyl)phenoxy)-2,4-dimethylpentanamine (13.8 mg, 0.040 mmol,
41% yield) as an off-white solid. H NMR (500 MHz, DMSO-d ) δ 8.42 (d, J = 5.3
Hz, 1H), 7.56 (dd, J = 8.4, 2.3 Hz, 1H), 7.53 (s, 1H), 7.44 (d, J = 5.3 Hz, 1H), 7.25
(d, J = 2.3 Hz, 1H), 7.02 (d, J = 8.5 Hz, 1H), 3.77 (d, J = 2.2 Hz, 2H), 2.22 (ddd, J =
13.9, 8.4, 5.3 Hz, 1H), 1.82 (dq, J = 12.7, 6.4 Hz, 1H), 1.52 - 1.39 (m, 2H), 1.17 (s,
3H), 0.93 (t, J = 6.5 Hz, 8H), 0.77 (q, J = 4.3, 3.5 Hz, 2H). (2-Py-Me was likely
buried in DMSO peak of 2.51); LCMS (ESI) m/e 339.1 [(M+H) , calcd C H N O ,
22 31 2 1
339.2]; LC/MS retention time (method B): t = 1.56 min.
Example 50
(S)(2-(difluoromethyl)(2-methylpyridinyl)phenoxy)-2,4-dimethylpentan
amine
Prepared as described in Example 19. Obtained (S)(2-(difluoromethyl)
(2-methylpyridinyl)phenoxy)-2,4-dimethylpentanamine (22 mg, 0.061 mmol,
69% yield) as an off-white solid. H NMR (500 MHz, DMSO-d ) δ 8.48 (d, J = 5.3
Hz, 1H), 7.96 (d, J = 8.9 Hz, 1H), 7.92 (d, J = 2.4 Hz, 1H), 7.60 (s, 1H), 7.54 - 7.47
(m, 1H), 7.43 - 7.16 (m, 2H), 3.87 (s, 2H), 2.53 (s, 3H), 1.80 (dt, J = 12.8, 6.4 Hz,
1H), 1.43 (qd, J = 14.1, 5.7 Hz, 2H), 1.16 (s, 3H), 0.94 (d, J = 6.6 Hz, 3H), 0.91 (d, J
= 6.7 Hz, 3H); LCMS (ESI) m/e 349.0 [(M+H) , calcd C H F N O , 349.2];
27 2 2 1
LC/MS retention time (method B): t = 1.47 min.
Example 51
methyl (6-((2-amino-2,4-dimethylpentyl)oxy)-[3,4'-bipyridin]-2'-yl)carbamate
Prepared as described in Example 29.
Part A: Benzyl (1-((5-chloropyridinyl)oxy)-2,4-dimethylpentanyl)carbamate
An NMP (0.3 mL) suspension of 5-chloropyridinol (0.023 g, 0.180 mmol),
sodium carbonate (0.019 g, 0.180 mmol) and benzyl 4-isobutylmethyl-1,2,3-
oxathiazolidinecarboxylate 2,2-dioxide (0.0392 g, 0.120 mmol) was heated to 80
°C overnight. The reaction mixture was cooled to rt and diluted with ethyl acetate
and washed with water (3X). The ethyl acetate layer was separated, dried (Na SO ),
filtered and concentrated under reduced pressure. The residue was purified via silica
gel chromatography (0-30% ethyl acetate in hexanes) to afford benzyl (1-((5-
chloropyridinyl)oxy)-2,4-dimethylpentanyl)carbamate (0.0387g, 0.103 mmol,
86%yield) as an off-white solid. H NMR (400MHz, CHLOROFORM-d) δ 8.08 (d,
J=2.3 Hz, 1H), 7.54 (dd, J=8.8, 2.8 Hz, 1H), 7.37 - 7.32 (m, 5H), 6.71 (d, J=8.8 Hz,
1H), 5.06 (s, 3H), 4.42 (d, J=10.5 Hz, 1H), 4.26 (d, J=10.8 Hz, 1H), 1.87 - 1.74 (m,
2H), 1.72 - 1.63 (m, 1H), 1.43 (s, 3H), 0.96 (dd, J=6.3, 4.8 Hz, 6H); LCMS (ESI) m/e
377.3 [(M+H) , calcd C H ClN O , 377.2]; LC/MS retention time (method A): t =
26 2 3 R
2.42 min.
Part B: Cbz methyl (6-((2-amino-2,4-dimethylpentyl)oxy)-[3,4'-bipyridin]-2'-
yl)carbamate
A mixture of 2 generation XPHOS precatalyst (1.587 mg, 2.017 µmol),
potassium phosphate tribasic (0.403 mL, 0.202 mmol), (2-
((methoxycarbonyl)amino)pyridinyl)boronic acid (0.020 g, 0.101 mmol) and
benzyl (1-((5-chloropyridinyl)oxy)-2,4-dimethylpentanyl)carbamate (0.038 g,
0.101 mmol) in THF (0.2 mL) was degassed via vacuum/ N fill cycle three times.
The reaction mixture was heated at 70 °C overnight. The reaction was cooled to rt
and diluted with ethyl acetate and washed with water (2X) followed by brine. The
ethyl acetate layer was separated, dried (Na SO ), filtered and concentrated. The
product was purified silica gel chromatography (50-100% ethyl acetate in hexanes) to
afford Cbz methyl (6-((2-amino-2,4-dimethylpentyl)oxy)-[3,4'-bipyridin]-2'-
yl)carbamate (0.011.g, 0.022 mmol, 22% yield) as a white solid. LCMS (ESI) m/e
493.3 [(M+H) , calcd C H N O , 493.3]; LC/MS retention time (method B): t =
27 33 4 5 R
2.13 min.
Part C: methyl (6-((2-amino-2,4-dimethylpentyl)oxy)-[3,4'-bipyridin]-2'-
yl)carbamate
A mixture of Pd/C (5 mg, 4.70 µmol) and Cbz methyl (6-((2-amino-2,4-
dimethylpentyl)oxy)-[3,4'-bipyridin]-2'-yl)carbamate (0.011 g, 0.022 mmol) in
ethanol (4 mL) was hydrogenated with a H balloon at room temperature overnight.
The reaction was filtered and washed with DCM. The filtrate was concentrated
under reduced pressure and the residue was purified via reverse phase HPLC
(acetonitrile/water/ 10 mM ammonium acetate) to afford methyl (6-((2-amino-2,4-
dimethylpentyl)oxy)-[3,4'-bipyridin]-2'-yl)carbamate (6.6.mg, 0.018 mmol, 82%
yield) as an off-white solid. H NMR (600MHz, DMSO-d ) δ 8.53 (s, 1H), 8.32 (d,
J=5.1 Hz, 1H), 8.08 (s, 1H), 8.06 (dd, J=8.6, 2.0 Hz, 1H), 7.38 (d, J=5.1 Hz, 1H),
7.00 (d, J=8.4 Hz, 1H), 4.14 - 4.00 (m, 2H), 3.70 (s, 3H), 1.89 (s, 3H), 1.80 (dt,
J=12.7, 6.1 Hz, 1H), 1.47 - 1.33 (m, 2H), 0.93 (d, J=6.6 Hz, 3H), 0.91 (d, J=6.6 Hz,
3H); LCMS (ESI) m/e 359.3 [(M+H) , calcd C H N O , 359.2]; LC/MS retention
19 27 4 3
time (method B): t = 1.55 min.
Example 52
(S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)methyl-[3,4'-bipyridin]-2'-
yl)carbamate
Prepared as in Example 51.
Part A: (S)((5-bromomethylpyridinyl)oxy)-2,4-dimethylpentanamine.
LCMS (ESI) m/e 323.1 [(M+Na) , calcd C H BrN ONa, 323.1]; LC/MS
13 21 2
retention time (method B): t = 1.96 min.
Part B: (S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)methyl-[3,4'-bipyridin]-
2'-yl)carbamate.
A mixture of sodium carbonate (0.149 mL, 0.299 mmol), 1,1'-
bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex
(6.10 mg, 7.47 µmol), (S)((5-bromomethylpyridinyl)oxy)-2,4-
dimethylpentanamine (0.045 g, 0.149 mmol) and (2-
((methoxycarbonyl)amino)pyridinyl)boronic acid (0.029 g, 0.149 mmol) in
dioxane (0.5 mL) (degassed with N ) was heated at 80 °C for 5 h. The reaction was
diluted with ethyl acetate and washed with water (3X). The ethyl acetate layer was
dried (Na SO ), filtered and concentrated under reduced pressure . The residue was
purified by reverse phase HPLC (acetonitrile/water/ 10 mM ammonium acetate to
afford (S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)methyl-[3,4'-bipyridin]-2'-
yl)carbamate (11.0 mg, 0.073 mmol, 20% yield) as an off-white solid. H NMR
(600MHz, DMSO-d ) δ 10.25 (br. s., 1H), 8.35 (s, 1H), 8.31 (d, J=5.1 Hz, 1H), 8.08
(s, 1H), 7.91 (s, 1H), 7.36 (d, J=5.1 Hz, 1H), 4.20 - 4.09 (m, 2H), 2.51 (br. s., 3H),
2.29 (s, 3H), 1.86 - 1.77 (m, 1H), 1.59 - 1.39 (m, 2H), 1.20 (d, J=5.1 Hz, 3H), 0.93
(d, J=6.6 Hz, 3H), 0.92 (d, J=6.6 Hz, 3H); LCMS (ESI) m/e 373.4 [(M+H) , calcd
C H N O3 373.2]; LC/MS retention time (method A): t = 1.89 min.
29 4 R
Example 53
(S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)cyano-[3,4'-bipyridin]-2'-
yl)carbamate
Prepared as in Example 51.
Part A: (S)-tert-butyl (1-((5-bromocyanopyridinyl)oxy)-2,4-dimethylpentan
yl)carbamate
A mixture of sodium carbonate (0.246 g, 2.323 mmol), (S)-tert-butyl 4-
isobutylmethyl-1,2,3-oxathiazolidinecarboxylate 2,2-dioxide (0.3408 g, 1.162
mmol) and 5-bromohydroxynicotinonitrile (0.277 g, 1.394 mmol) in DMF (4 mL)
was heated at 80 °C overnight. The reaction was cooled to rt and diluted with ethyl
acetate then washed with NaOH (1N) (2X) and water (1X). The ethyl acetate layer
was separated, dried (Na SO ), filtered and concentrated under reduced pressure .
The product was purified silica gel chromatography (0-25% ethyl acetate in hexanes)
to afford (S)-tert-butyl (1-((5-bromocyanopyridinyl)oxy)-2,4-dimethylpentan-
2-yl)carbamate (0.261.g, 0.633 mmol, 55% yield) as a clear oil. LCMS (ESI) m/e
436.1 [(M+Na) , calcd C H BrN O Na, 436.1]; LC/MS retention time (method B):
18 26 3 3
t = 2.38 min.
Part B: Boc-(S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)cyano-[3,4'-
bipyridin]-2'-yl)carbamate.
LCMS (ESI) m/e 484.4 [(M+H) , calcd C H N O , 484.3]; LC/MS retention
34 5 5
time (method A): t = 2.24 min.
Part C: (S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)cyano-[3,4'-bipyridin]-2'-
yl)carbamate.
Obtained (S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)cyano-[3,4'-
bipyridin]-2'-yl)carbamate (13.3 mg, 0.034 mmol, 36% yield) as a white solid. H
NMR (500MHz, DMSO-d ) δ 10.36 (s, 1H), 8.81 - 8.77 (m, 1H), 8.68 - 8.63 (m,
1H), 8.36 (d, J=5.1 Hz, 1H), 8.09 (s, 1H), 7.43 (d, J=4.0 Hz, 1H), 4.20 (d, J=5.9 Hz,
2H), 3.71 (s, 3H), 3.39 (br. s., 2H), 1.82 (d, J=6.2 Hz, 1H), 1.40 (t, J=5.5 Hz, 2H),
1.14 (s, 3H), 0.95 - 0.90 (m, 6H); LCMS (ESI) m/e 367.2 [(M-NH ), calcd
C H N O3, 367.2]; LC/MS retention time (method B): t = 1.63 min.
23 4 R
Example 54
(S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)methyl-[3,4'-bipyridin]-2'-
yl)carbamate
Prepared as in Example 51.
Part A: (S)((5-bromomethylpyridinyl)oxy)-2,4-dimethylpentanamine.
LCMS (ESI) m/e 301.2 [(M+H) , calcd C13H22BrN2O, 301.1]; LC/MS
retention time (method A): t = 1.77 min.
Part B: (S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)methyl-[3,4'-bipyridin]-
2'-yl)carbamate.
Obtained (S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)methyl-[3,4'-
bipyridin]-2'-yl)carbamate (15.3 mg, 0.041 mmol, 32% yield) as an off-white solid.
H NMR (500MHz, DMSO-d ) δ 8.34 - 8.30 (m, 1H), 8.00 (s, 1H), 7.81 (s, 1H),
7.11 - 7.08 (m, 1H), 6.85 (s, 1H), 4.01 (d, J=5.5 Hz, 2H), 3.68 (s, 3H), 2.26 (s, 3H),
1.88 (s, 1H), 1.85 - 1.77 (m, 1H), 1.37 (s, 2H), 1.10 (s, 3H), 0.93 (m, 6H); LCMS
(ESI) m/e 373.3 [(M+H) , calcd C H N O3, 373.2]; LC/MS retention time (method
29 4
B): t = 1.60 min.
Example 55
(S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)chloro-[3,4'-bipyridin]-2'-
yl)carbamate
Prepared as in Example 51.
Part A: (S)-tert-butyl (1-((5-bromochloropyridinyl)oxy)-2,4-dimethylpentan
yl)carbamate.
H NMR (400MHz, CHLOROFORM-d) δ 8.07 (d, J=2.3 Hz, 1H), 7.76 (d,
J=2.3 Hz, 1H), 4.65 (br. s., 1H), 4.48 (d, J=10.3 Hz, 1H), 4.32 (d, J=10.3 Hz, 1H),
1.90 - 1.75 (m, 2H), 1.67 - 1.53 (m, 1H), 1.41 (s, 9H), 1.39 (s, 3H), 0.99 (d, J=2.0 Hz,
3H), 0.97 (d, J=2.0 Hz, 3H); LCMS (ESI) m/e 443.1 [(M+Na) , calcd
C H BrClN O Na, 443.1]; LC/MS retention time (method B): t = 2.55 min.
17 26 2 3 R
Part B: Boc-(S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)chloro-[3,4'-
bipyridin]-2'-yl)carbamate.
LCMS (ESI) m/e 493.4 [(M+H) , calcd C H ClN O , 493.2]; LC/MS
24 34 4 5
retention time (method A): t = 2.38 min.
Part C: (S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)chloro-[3,4'-bipyridin]-
2'-yl)carbamate.
Obtained (S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)chloro-[3,4'-
bipyridin]-2'-yl)carbamate(19.6 mg, 0.047 mmol, 85% yield) as an off-white solid.
H NMR (500MHz, DMSO-d6) δ 8.49 (d, J=2.2 Hz, 1H), 8.34 (d, J=5.1 Hz, 1H),
8.25 (d, J=2.2 Hz, 1H), 8.07 (s, 1H), 7.42 (dd, J=5.1, 1.5 Hz, 1H), 4.22 - 4.06 (m,
2H), 3.71 (s, 3H), 1.87 - 1.75 (m, 1H), 1.48 - 1.34 (m, 2H), 1.14 (s, 3H), 0.93 (d,
J=3.7 Hz, 3H), 0.92 (d, J=3.7 Hz, 3H); LCMS (ESI) m/e 393.3 [(M+H) , calcd
C H ClN O , 393.2]; LC/MS retention time (method A): t = 1.98 min.
19 26 4 3 R
Example 56
(S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)methoxy-[3,4'-bipyridin]-2'-
yl)carbamate
Prepared as in Example 51.
Part A: (S)((5-bromomethoxypyridinyl)oxy)-2,4-dimethylpentanamine.
LCMS (ESI) m/e 338.9 [(M+Na) , calcd C H BrN O Na, 339.1]; LC/MS
13 21 2 2
retention time (method B): t = 1.87 min.
Part B: (S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)methoxy-[3,4'-bipyridin]-
2'-yl)carbamate.
Obtained (S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)methoxy-[3,4'-
bipyridin]-2'-yl)carbamate (8.4 mg, 0.021 mmol, 29% yield) as an off-white solid.
H NMR (500MHz, DMSO-d ) δ 8.32 (d, J=5.1 Hz, 1H), 8.09 (s, 1H), 8.04 (d, J=1.8
Hz, 1H), 7.56 (d, J=1.5 Hz, 1H), 7.41 (d, J=4.0 Hz, 1H), 4.08 (q, J=10.3 Hz, 2H),
3.92 (s, 3H), 3.70 (s, 3H), 3.45 (br. s., 3H), 1.81 (dt, J=13.0, 6.3 Hz, 1H), 1.47 - 1.31
(m, 2H), 1.12 (s, 3H), 0.92 (m, 6H); LCMS (ESI) m/e 389.1 [(M+H) , calcd
C H N O4, 389.2]; LC/MS retention time (method B): t = 1.64 min.
29 4 R
Example 57
(S)((2'-chloromethyl-[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine
Prepared as in Example 51. Obtained (S)((2'-chloromethyl-[3,4'-
bipyridin]yl)oxy)-2,4-dimethylpentanamine (15 mg, 0.044 mmol, 49% yield) as
an off-white solid. H NMR (600MHz, DMSO-d ) δ 8.51 (br. s., 1H), 8.44 (d,
J=5.1 Hz, 1H), 8.09 (br. s., 1H), 7.87 (s, 1H), 7.76 (d, J=4.0 Hz, 1H), 4.10 - 4.04 (m,
2H), 2.26 (s, 3H), 1.84 - 1.75 (m, 1H), 1.40 (t, J=6.2 Hz, 2H), 1.13 (s, 3H), 0.92 (t,
J=6.4 Hz, 6H); LCMS (ESI) m/e 334.3 [(M-NH ) , calcd C H ClN O, 334.2];
2 18 25 3
LC/MS retention time (method B): t = 1.94 min.
Example 58
(S)((2'-(difluoromethyl)methyl-[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentan-
2-amine
Prepared as in Example 51. Obtained (S)((2'-(difluoromethyl)methyl-
[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine (15.1 mg, 0.043 mmol, 81%
yield) as an off-white solid.. H NMR (500 MHz, DMSO-d ) δ 8.72 (d, J = 5.2 Hz,
1H), 8.53 (d, J = 2.5 Hz, 1H), 8.12 (d, J = 2.5 Hz, 1H), 8.01 (s, 1H), 7.92 (d, J = 5.2
Hz, 1H), 6.99 (t, J = 54.9 Hz, 1H), 4.16 - 4.02 (m, 2H), 2.28 (s, 3H), 1.80 (tt, J =
11.5, 5.7 Hz, 1H), 1.49 - 1.35 (m, 2H), 1.14 (s, 3H), 0.92 (m, 6H); LCMS (ESI) m/e
350.3 [(M+H) , calcd C H F N O, 350.2]; LC/MS retention time (method A): t =
19 26 2 3 R
1.80 min.
Example 59
(S)((2-amino-2,4-dimethylpentyl)oxy)-2'-(difluoromethyl)-[3,4'-bipyridine]
carbonitrile
Prepared as in Example 51.
Part A: (S)-tert-butyl (1-((3-cyano(4,4,5,5-tetramethyl-1,3,2-dioxaborolan
yl)pyridinyl)oxy)-2,4-dimethylpentanyl)carbamate
To a 20 mL vial was added (S)-tert-butyl (1-((5-bromocyanopyridin
yl)oxy)-2,4-dimethylpentanyl)carbamate (73 mg, 0.177 mmol), 4,4,4',4',5,5,5',5'-
octamethyl-2,2'-bi(1,3,2-dioxaborolane) (54.0 mg, 0.212 mmol), and potassium
acetate (52.1 mg, 0.531 mmol) in dioxane (2 mL) with nitrogen bubbling to give a
colorless suspension. PdCl (dppf) (3.89 mg, 5.31 µmol) was added under nitrogen.
The vial was sealed and the mixture was heated at 80 °C for 4 h. The reaction
mixture was cooled to rt and concentrated under reduced pressure. The crude
material was used directly in the next step.
Part B: (S)-tert-butyl (1-((5-cyano-2'-(difluoromethyl)-[3,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanyl)carbamate
The mixture of (S)-tert-butyl (1-((3-cyano(4,4,5,5-tetramethyl-1,3,2-
dioxaborolanyl)pyridinyl)oxy)-2,4-dimethylpentanyl)carbamate (0.040 g,
0.088 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloromethane
complex (5.03 mg, 6.16 µmol) , 4-chloro(difluoromethyl)pyridine hydrochloride
(0.018 g, 0.088 mmol) and Na CO (0.176 mL, 0.352 mmol) in dioxane (1 mL)
(degassed with N ) was heated at 120 °C for 16 h. The reaction mixture was cooled
to rt, diluted with ethyl acetate and washed with water (3X). The ethyl acetate layer
was dried (Na SO ), filtered and concentrated under reduced pressure. The residue
was directly carried onto next reaction. LCMS (ESI) m/e 483.2 [(M+Na) , calcd
C H F N Na O , 483.2]; LC/MS retention time (method B): t = 2.30 min.
24 30 2 4 1 3 R
Part C: (S)((2-amino-2,4-dimethylpentyl)oxy)-2'-(difluoromethyl)-[3,4'-
bipyridine]carbonitrile.
Prepared using procedure described in Example 51 to afford (S)((2-amino-
2,4-dimethylpentyl)oxy)-2'-(difluoromethyl)-[3,4'-bipyridine]carbonitrile (4.7 mg,
0.013 mmol, 15% yield) as an off-white solid. H NMR (500 MHz, DMSO-d6) δ
9.02 (d, J = 2.5 Hz, 1H), 8.95 (d, J = 2.6 Hz, 1H), 8.80 (d, J = 5.1 Hz, 1H), 8.15 (s,
1H), 8.02 (d, J = 5.0 Hz, 1H), 7.01 (t, J = 54.8 Hz, 1H), 4.63 (d, J = 11.6 Hz, 1H),
4.51 (d, J = 11.5 Hz, 1H), 1.86 (dq, J = 12.4, 6.2 Hz, 1H), 1.79 (dd, J = 14.4, 5.5 Hz,
1H), 1.62 (dd, J = 14.3, 5.5 Hz, 1H), 1.41 (s, 3H), 0.98 (dd, J = 6.7, 2.2 Hz, 6H); F
NMR (376 MHz, DMSO-d6) δ -73.65; LCMS (ESI) m/e 383.3 [(M+Na) , calcd
C H F N Na O , 383.2]; LC/MS retention time (method B): t = 1.77 min.
19 22 2 4 1 1 R
Example 60
(S)((5-chloro-2'-methyl-[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine
Prepared as in Example 51. Obtained (S)((5-chloro-2'-methyl-[3,4'-
bipyridin]yl)oxy)-2,4-dimethylpentanamine (2 mg, 5.99 umol, 31% yield) as an
off-white solid. H NMR (500MHz, DMSO-d ) δ 8.59 (d, J=1.8 Hz, 1H), 8.50 (d,
J=5.1 Hz, 1H), 8.39 (d, J=1.8 Hz, 1H), 7.67 (s, 1H), 7.57 (d, J=4.4 Hz, 1H), 4.19 -
4.10 (m, 2H), 2.53 (s, 3H), 1.86 - 1.77 (m, 1H), 1.47 - 1.37 (m, 2H), 1.15 (s, 3H),
0.99 - 0.88 (m, 6H); LCMS (ESI) m/e 334.3 [(M+H) , calcd C H ClN O, 334.2];
18 25 3
LC/MS retention time (method A): t = 1.90 min.
Example 61
(S)((2',5-dimethyl-[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine
Prepared as in Example 51. Obtained (S)((5-chloro-2'-methyl-[3,4'-
bipyridin]yl)oxy)-2,4-dimethylpentanamine (20.5 mg, 0.065 mmol, 41% yield)
as an off-white solid. H NMR (500MHz, DMSO-d6) δ 8.47 (d, J=5.1 Hz, 1H), 8.43
(d, J=2.2 Hz, 1H), 8.01 (s, 1H), 7.59 (s, 1H), 7.50 (d, J=5.5 Hz, 1H), 4.11 - 4.00 (m,
2H), 2.52 (s, 3H), 2.26 (s, 3H), 1.80 (dq, J=12.6, 6.3 Hz, 1H), 1.46 - 1.35 (m, 2H),
1.13 (s, 3H), 0.93 (d, J=4.8 Hz, 3H), 0.92 (d, J=4.8 Hz, 3H); LCMS (ESI) m/e 297.1
[(M-NH ) , calcd C H ClN O, 297.2]; LC/MS retention time (method B): t = 1.51
2 19 25 2 R
min.
Example 62
(S)((5-methoxy-2'-methyl-[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine
Prepared as in Example 51. Obtained (S)((5-methoxy-2'-methyl-[3,4'-
bipyridin]yl)oxy)-2,4-dimethylpentanamine (20.5 mg, 0.065 mmol, 41% yield)
as an off-white solid. H NMR (500MHz, DMSO-d ) δ 8.48 (d, J=5.1 Hz, 1H), 8.14
(s, 1H), 7.65 (d, J=4.0 Hz, 2H), 7.55 (d, J=3.7 Hz, 1H), 4.06 (q, J=10.1 Hz, 2H), 3.93
(s, 3H), 2.53 (s, 3H), 1.85 - 1.70 (m, 1H), 1.42 - 1.31 (m, 2H), 1.11 (s, 3H), 0.92 (t,
J=7.0 Hz, 6H); LCMS (ESI) m/e 330.1 [(M+H) , calcd C H N O , 330.2]; LC/MS
19 28 3 2
retention time (method B): t = 1.42 min.
Example 63
methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-[2,4'-bipyridin]-2'-yl)carbamate
Prepared as in Example 29.
Part A: Benzyl (1-((5-chloropyridinyl)oxy)-2,4-dimethylpentanyl)carbamate.
LCMS (ESI) m/e 377.3 [(M+H) , calcd C H ClN O , 377.2]; LC/MS
26 2 3
retention time (method A): t = 2.42 min.
Part B: Cbz methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-[2,4'-bipyridin]-2'-
yl)carbamate.
LCMS (ESI) m/e 493.0 [(M+H) , calcd C H N O , 493.2]; LC/MS retention
27 33 4 5
time (method B): t = 2.15 min.
Part C: methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-[2,4'-bipyridin]-2'-
yl)carbamate
A mixture of Pd/C (4 mg, 3.76 µmol) and Cbz protected methyl (5-((2-amino-
2,4-dimethylpentyl)oxy)-[2,4'-bipyridin]-2'-yl)carbamate (0.0123 g, 0.025 mmol) in
ethanol (4 mL) was stirred under H balloon at room temperature overnight. The
reaction mixture was filtered and the flask was rinsed with CH Cl . The filter cake
was washed with CH Cl The filtrate was concentrated under reduced pressure and
2 2.
the residue was purified by reverse phase HPLC (acetonitrile/water/10 mM
ammonium acetate) to afford methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-[2,4'-
bipyridin]-2'-yl)carbamate (12.1 mg, 0.032 mmol, 98% yield) as an off-white solid.
H NMR (600MHz, DMSO-d ) δ 10.14 (br. s., 1H), 8.49 (s, 1H), 8.45 (d, J=2.8 Hz,
1H), 8.32 (d, J=5.1 Hz, 1H), 7.97 (d, J=8.8 Hz, 1H), 7.63 (d, J=5.1 Hz, 1H), 7.54 (dd,
J=8.7, 2.8 Hz, 1H), 3.84 (s, 2H), 3.71 (s, 3H), 1.82 (tt, J=12.7, 6.5 Hz, 1H), 1.46 -
1.35 (m, 2H), 1.14 (s, 3H), 0.95 (d, J=6.8 Hz, 3H), 0.93 (d, J=6.6 Hz, 3H); LCMS
(ESI) m/e 359.3 [(M+H) , calcd C H N O3, 359.2]; LC/MS retention time (method
19 27 4
A): tR = 1.48 min.
Example 64
(S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)methyl-[2,4'-bipyridin]-2'-
yl)carbamate
Prepared as in Example 19.
Part A: (S)((6-bromomethylpyridinyl)oxy)-2,4-dimethylpentanamine.
LCMS (ESI) m/e 284.2 [(M-NH ) , calcd C H BrNO, 284.1]; LC/MS
2 13 19
retention time (method A): t = 1.78 min (SM: t = 1.61 min).
Part B: (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)methyl-[2,4'-bipyridin]-
2'-yl)carbamate.
Obtained (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)methyl-[2,4'-
bipyridin]-2'-yl)carbamate (8.5 mg, 0.022 mmol, 34% yield) as an off-white solid. .
H NMR (500 MHz, DMSO-d ) δ 8.48 (s, 1H), 8.30 (d, J = 5.3 Hz, 1H), 7.83 (d, J =
8.6 Hz, 1H), 7.67 - 7.60 (m, 1H), 7.43 (d, J = 8.6 Hz, 1H), 3.79 (d, J = 2.0 Hz, 2H),
3. 58 (s, 3H), 2.50 (s, 3H), 1.79 (m, 1H), 1.51 - 1.34 (m, 2H), 1.16 (s, 3H), 0.93 (t, J
= 6.4 Hz, 6H); LCMS (ESI) m/e 373.3 [(M+H) , calcd C H N O , 373.2]; LC/MS
29 4 3
retention time (method A): t = 1.82 min.
Example 65
(S)((2',6-dimethyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine
Prepared as in Example 51. Obtained ((S)((2',6-dimethyl-[2,4'-bipyridin]-
5-yl)oxy)-2,4-dimethylpentanamine (7.2 mg, 0.022 mmol, 29% yield) as an off-
white solid. H NMR (500 MHz, DMSO-d ) δ 8.49 (d, J = 5.3 Hz, 1H), 7.92 (d, J =
8.5 Hz, 1H), 7.87 (s, 1H), 7.78 (d, J = 5.3 Hz, 1H), 7.43 (d, J = 8.5 Hz, 1H), 3.78 (s,
2H), 2.54 (s, 3H), 2.51 (s, 3H), 1.83 (dt, J = 12.8, 6.4 Hz, 1H), 1.42 (t, J = 5.2 Hz,
2H), 1.15 (s, 3H), 0.94 (t, J = 6.2 Hz, 6H); LCMS (ESI) m/e 314.4 [(M+H) , calcd
C H N O, 314.2]; LC/MS retention time (method A): t = 1.84 min.
19 28 3 R
Example 66
(S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)chloro-[2,4'-bipyridin]-2'-
yl)carbamate
Prepared as in Example 32.
Part A: (S)-tert-butyl (1-((2-chloroiodopyridinyl)oxy)-2,4-dimethylpentan
yl)carbamate.
LCMS (ESI) m/e 490.9 [(M+Na) , calcd C H ClIN NaO , 491.1]; LC/MS
17 26 2 3
retention time (method B): t = 2.40 min.
Part B: (S)-methyl (5-((2-Boc-amino-2,4-dimethylpentyl)oxy)chloro-[2,4'-
bipyridin]-2'-yl)carbamate.
LCMS (ESI) m/e 493.0 [(M+H) , calcd C H ClN O , 493.2]; LC/MS
24 34 4 5
retention time (method B): t = 2.19 min.
Part C: (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)chloro-[2,4'-bipyridin]-
2'-yl)carbamate.
Obtained (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)chloro-[2,4'-
bipyridin]-2'-yl)carbamate (12.6 mg, 0.032 mmol, 69% yield) as an off-white solid.
H NMR (500 MHz, DMSO-d ) δ 8.45 (s, 1H), 8.35 (d, J = 5.3 Hz, 1H), 8.04 (d, J =
8.4 Hz, 1H), 7.71 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 5.2 Hz, 1H), 3.93 (s, 2H), 3.71 (s,
3H), 1.81 (dq, J = 13.1, 6.5 Hz, 1H), 1.45 (qd, J = 14.0, 5.5 Hz, 2H), 1.18 (s, 3H),
0.93 (t, J = 6.4 Hz, 6H); LCMS (ESI) m/e 393.0 [(M+H) , calcd C H Cl N O ,
19 26 1 4 3
393.2]; LC/MS retention time (method A): t = 1.66 min.
Example 67
(S)((6-chloro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine
Prepared as in Example 32.
Part A: (S)-tert-butyl (1-((6-chloro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanyl)carbamate.
Synthesis followed previous procedure. LCMS (ESI) m/e 434.0 [(M+H) ,
calcd C23H33Cl1N3O3, 434.2]; LC/MS retention time (method B): tR = 1.96 min.
Part B: (S)((6-chloro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
amine.
Obtained (S)((6-chloro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine (4.6 mg, 0.013 mmol, 30% yield) as an off-white solid. H
NMR (500 MHz, DMSO-d ) δ 8.53 (d, J = 5.2 Hz, 1H), 8.13 (d, J = 8.4 Hz, 1H),
7.85 (s, 1H), 7.76 (d, J = 5.3 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 3.91 (s, 2H), 2.55 (s,
3H), 1.82 (p, J = 6.4 Hz, 1H), 1.52 - 1.38 (m, 2H), 1.17 (s, 3H), 0.94 (t, J = 6.3 Hz,
6H); LCMS (ESI) m/e 334.1 [(M+H) , calcd C H Cl N O , 334.2]; LC/MS
18 25 1 3 1
retention time (method A): t = 1.48 min.
Example 68
(S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)methyl-[2,4'-bipyridin]-2'-
yl)carbamate
Prepared as in Example 32.
Part A: (S)-tert-butyl (1-((6-chloromethylpyridinyl)oxy)-2,4-dimethylpentan
yl)carbamate.
LCMS (ESI) m/e 357.3 [(M+H) , calcd C H ClN O , 357.2]; LC/MS
18 30 2 3
retention time (method A): t = 2.23 min.
Part B: (S)-tert-butyl (1-((6-chloromethylpyridinyl)oxy)-2,4-dimethylpentan
yl)carbamate.
LCMS (ESI) m/e 357.3 [(M+H) , calcd C H ClN O , 357.2]; LC/MS
18 30 2 3
retention time (method A): t = 2.23 min.
Part C: (S)((6-chloromethylpyridinyl)oxy)-2,4-dimethylpentanamine.
LCMS (ESI) m/e 257.0 [(M+H) , calcd C H ClN O, 257.1]; LC/MS
13 22 2
retention time (method B): t = 1.70 min.
Part D: (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)methyl-[2,4'-bipyridin]-
2'-yl)carbamate.
Obtained (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)methyl-[2,4'-
bipyridin]-2'-yl)carbamate (1.1 mg, 2.92 umol, 5% yield) as an off-white solid. H
NMR (500MHz, DMSO-d ) δ 8.49 (s, 1H), 8.36 (s, 1H), 8.32 (d, J=5.1 Hz, 1H),
7.87 (s, 1H), 7.63 (d, J=5.5 Hz, 1H), 3.89 (s, 2H), 3.71 (s, 3H), 2.32 (s, 3H), 1.86 -
1.79 (m, 1H), 1.42 (t, J=5.7 Hz, 2H), 1.15 (s, 3H), 0.93 (t, J=6.6 Hz, 6H) ;LCMS
(ESI) m/e 373.1 [(M+H) , calcd C H N O , 373.2]; LC/MS retention time (method
29 4 3
B): t = 1.67 min.
Example 69
(S)-2,4-dimethyl(4-(quinolinyl)(trifluoromethyl)phenoxy)pentanamine
Prepared as in Example 32. Obtained (S)-2,4-dimethyl(4-(quinolinyl)-
2-(trifluoromethyl)phenoxy)pentanamine (50 mg, 0.123 mmol, 17%yield) as a
brown solid. H NMR (400MHz, CHLOROFORM-d) δ 8.96 (d, J=4.5 Hz, 1H), 8.20
(d, J=8.5 Hz, 1H), 7.87 (dd, J=8.4, 0.9 Hz, 1H), 7.75 (td, J=4.2, 1.4 Hz, 2H), 7.65
(dd, J=8.5, 2.0 Hz, 1H), 7.58 - 7.52 (m, 1H), 7.33 (d, J=4.5 Hz, 1H), 7.14 (d, J=8.5
Hz, 1H), 3.93 - 3.86 (m, 2H), 1.82 (d, J=6.5 Hz, 1H), 1.68 - 1.59 (m, 2H), 1.54 (t,
J=5.5 Hz, 2H), 1.28 (s, 3H), 1.06 - 0.98 (m, 6H); F NMR (376MHz,
CHLOROFORM-d) δ -62.29 (s, 3F); LCMS (ESI) m/e 403.2 [(M+H) , calcd
C H F N O, 403.2]; LC/MS retention time (method B): t = 1.73 min.
23 26 3 2 R
Example 70
(S)-2,4-dimethyl(2-(trifluoromethyl)(7-(trifluoromethyl)quinolin
yl)phenoxy)pentanamine
Prepared as in Example 32. A mixture of 2-(dicyclohexylphosphino)-
2’,4’,6’-triisopropylbiphenyl (2.90 mg, 6.09 µmol), potassium acetate (0.090 g, 0.913
mmol), 2 generation Xphos precatalyst (2.395 mg, 3.04 µmol), 4-chloro
(trifluoromethyl)quinoline (0.0705 g, 0.304 mmol) and hypodiboric acid (0.041 g,
0.457 mmol) in ethanol (4 mL) was degassed three times via vacuum/N fill cycle.
The reaction mixture was heated at 80 °C for 3 h. The reaction was cooled to room
temperature. (S)(4-bromo(trifluoromethyl)phenoxy)-2,4-dimethylpentan
amine (0.026 g, 0.073 mmol) and 2 generation Xphos precatalyst (2.395 mg, 3.04
µmol) in THF (4 mL) was added to the reaction mixture, followed by addition of
potassium phosphate tribasic (3 mL, 1.500 mmol) at room temperature. The reaction
mixture was underwent vacuum/N2 fill cycle three times before heated at 80 °C
overnight. The reaction was cooled to rt then diluted with ethyl acetate and washed
with water (3X). The ethyl acetate layer was separated, dried (Na SO ), filtered and
concentrated under reduced pressure. The crude was purified by reverse phase HPLC
(acetonitrile/water/10 mM ammonium acetate to afford (S)-2,4-dimethyl(2-
(trifluoromethyl)(7-(trifluoromethyl)quinolinyl)phenoxy)pentanamine (8.9
mg, 0.018 mmol, 5%yield) as an off-white solid. H NMR (500MHz, DMSO-d ) δ
9.11 (d, J=4.3 Hz, 1H), 8.46 (s, 1H), 8.08 (d, J=8.5 Hz, 1H), 7.90 (d, J=8.9 Hz, 1H),
7.86 (d, J=8.2 Hz, 1H), 7.83 (s, 1H), 7.70 (d, J=4.3 Hz, 1H), 7.45 (d, J=8.5 Hz, 1H),
3.94 - 3.87 (m, 2H), 1.82 (d, J=6.1 Hz, 1H), 1.42 (d, J=5.5 Hz, 2H), 1.15 (s, 3H),
0.94 (dd, J=6.4, 2.1 Hz, 6H); LCMS (ESI) m/e 471.3 [(M+H) , calcd C H F N O,
24 25 6 2
471.2]; LC/MS retention time (method A): t = 2.28 min.
Example 71
(S)(4-(7-fluoroquinolinyl)(trifluoromethyl)phenoxy)-2,4-dimethylpentan
amine
Prepared as in Example 32. Obtained (S)(4-(7-fluoroquinolinyl)
(trifluoromethyl)phenoxy)-2,4-dimethylpentanamine (4.2 mg, 9.89 umol,2%yield)
as an off-white solid. H NMR (500MHz, DMSO-d ) δ 8.96 (d, J=4.0 Hz, 1H), 7.97
- 7.79 (m, 3H), 7.77 (s, 1H), 7.60 - 7.53 (m, 1H), 7.50 (d, J=4.0 Hz, 1H), 7.43 (d,
J=8.5 Hz, 1H), 3.89 (d, J=7.6 Hz, 2H), 1.81 (d, J=6.4 Hz, 1H), 1.41 (d, J=5.2 Hz,
2H), 1.14 (s, 3H), 0.93 (d, J=4.9 Hz, 6H); LCMS (ESI) m/e 404.2 [(M-NH ) , calcd
C H F NO, 404.2]; LC/MS retention time (method B): t = 1.88 min.
23 22 4 R
Example 72
(S)(4-(5,7-difluoroquinolinyl)(trifluoromethyl)phenoxy)-2,4-
dimethylpentanamine
Prepared as in Example 32. Obtained (S)(4-(5,7-difluoroquinolinyl)
(trifluoromethyl)phenoxy)-2,4-dimethylpentanamine (17.5 mg, 0.039 mmol,
23%yield) as an off-white solid. H NMR (500MHz, DMSO-d ) δ 9.02 - 8.96 (m,
1H), 7.82 - 7.76 (m, 1H), 7.73 (br. s., 2H), 7.56 (br. s., 1H), 7.46 (d, J=4.3 Hz, 1H),
7.33 (d, J=8.5 Hz, 1H), 3.88 (d, J=6.4 Hz, 2H), 1.82 (br. s., 1H), 1.42 (d, J=5.2 Hz,
2H), 1.15 (s, 3H), 0.93 (d, J=6.6 Hz, 6H);LCMS (ESI) m/e 439.4 [(M+H) , calcd
C H F N O, 439.2]; LC/MS retention time (method A): t = 2.14 min.
23 24 5 2 R
Example 73
(S)(4-(6-fluoroquinolinyl)(trifluoromethyl)phenoxy)-2,4-dimethylpentan
amine
Prepared as in Example 32. Obtained (S)(4-(6-fluoroquinolinyl)
(trifluoromethyl)phenoxy)-2,4-dimethylpentanamine (9.6 mg, 0.023 mmol,
22%yield) as an off-white solid. H NMR (500 MHz, DMSO-d ) δ 8.95 (d, J = 4.4
Hz, 1H), 8.21 (dd, J = 9.2, 5.5 Hz, 1H), 7.85 (d, J = 8.5 Hz, 1H), 7.79 (d, J = 2.6 Hz,
1H), 7.75 (td, J = 8.9, 2.9 Hz, 1H), 7.57 (d, J = 4.4 Hz, 1H), 7.50 (dd, J = 10.3, 3.0
Hz, 1H), 7.44 (d, J = 8.6 Hz, 1H), 3.92 (q, J = 8.9 Hz, 2H), 1.83 (dt, J = 13.1, 6.7
Hz, 1H), 1.43 (d, J = 5.5 Hz, 2H), 1.16 (s, 3H), 0.94 (dd, J = 6.7, 3.2 Hz, 6H); F
NMR (376 MHz, DMSO-d6) δ -61.01 , -244.69; LCMS (ESI) m/e 421.2 [(M+H) ,
calcd C H F N O , 421.2]; LC/MS retention time (method B): t = 1.80 min.
23 25 4 2 1 R
Example 74
(S)(2-cyclopropyl(quinolinyl)phenoxy)-2,4-dimethylpentanamine
Prepared as in Example 32.
Part A: (S)-tert-butyl (1-(2-cyclopropyl(quinolinyl)phenoxy)-2,4-
dimethylpentanyl)carbamate.
LCMS (ESI) m/e 475.1 [(M+H) , calcd C H N O , 475.3]; LC/MS retention
39 2 3
time (method B): t = 2.21 min.
Part B: (S)(2-cyclopropyl(quinolinyl)phenoxy)-2,4-dimethylpentanamine.
Obtained (12.7 mg, 0.032 mmol, 33%yield) as an off-white solid. H NMR
(500 MHz, DMSO-d6) δ 8.90 (d, J = 4.4 Hz, 1H), 8.09 (d, J = 8.3 Hz, 1H), 7.90 (d, J
= 8.5 Hz, 1H), 7.78 (t, J = 7.6 Hz, 1H), 7.60 (t, J = 7.6 Hz, 1H), 7.42 (d, J = 4.4 Hz,
1H), 7.32 (d, J = 8.2 Hz, 1H), 7.10 (d, J = 8.3 Hz, 1H), 7.03 (s, 1H), 3.82 (s, 2H),
2.27 (p, J = 6.9 Hz, 1H), 1.85 (dt, J = 12.7, 6.6 Hz, 1H), 1.47 (q, J = 8.2, 7.0 Hz,
2H), 1.20 (s, 3H), 0.95 (q, J = 7.9, 7.2 Hz, 8H), 0.71 (t, J = 4.1 Hz, 2H); LCMS
(ESI) m/e 375.1 [(M+H) , calcd C H N O , 375.2]; LC/MS retention time (method
31 2 1
B): t = 1.69 min.
Example 75
1-(2-chlorofluoro(quinolinyl)phenoxy)-2,4-dimethylpentanamine
Prepared as in Example 29.
Part A: Benzyl (1-(4-bromochlorofluorophenoxy)-2,4-dimethylpentan
yl)carbamate.
An NMP (0.3 mL) suspension of 4-bromochlorofluorophenol (23.00
mg, 0.102 mmol), sodium carbonate (35 mg, 0.330 mmol) and benzyl 4-isobutyl
methyl-1,2,3-oxathiazolidinecarboxylate 2,2-dioxide (0.0334 g, 0.102 mmol) was
heated at 50 °C overnight. The reaction was diluted with ethyl acetate and washed
with water (3X). The ethyl acetate layer was separated, dried (Na SO ), filtered and
concentrated under reduced pressure . The crude material was carried on without
further purification. LCMS (ESI) m/e 496.0 [(M+Na) , calcd C H ClBrFNO Na,
21 24 3
494.1]; LC/MS retention time (method B): t = 2.59 min.
Part B: Benzyl (1-(2-chlorofluoro(quinolinyl)phenoxy)-2,4-dimethylpentan-
2-yl)carbamate.
LCMS (ESI) m/e 521.4 [(M+H) , calcd C H ClFN O , 521.2]; LC/MS
31 2 3
retention time (method A): t = 2.38 min.
Part C: 1-(2-chlorofluoro(quinolinyl)phenoxy)-2,4-dimethylpentanamine
Triethylsilane(0.1 ml, 0.626 mmol) was added to a CH Cl (0.2 mL)
suspension of palladium(II) acetate(2 mg, 8.91 µmol) and triethylamine(0.1 ml, 0.717
mmol) at rt. The reaction turned black. The solution was stirred at room temperature
for 10 min before addition of CH Cl (0.2 mL) solution of benzyl (1-(2-chloro
fluoro(quinolinyl)phenoxy)-2,4-dimethylpentanyl)carbamate (0.0441 g,
0.085 mmol) (the flask contain the benzyl (1-(2-chlorofluoro(quinolin
yl)phenoxy)-2,4-dimethylpentanyl)carbamate (0.0441 g, 0.085 mmol) was rinsed
with CH Cl (0.2 mL) and added to the reaction mixture). The reaction was stirred at
room temperature overnight. The solvent was removed under reduced pressure and
the crude material was purified via reverse phase HPLC (acetonitrile/water/10 mM
ammonium acetate) to afford 1-(2-chlorofluoro(quinolinyl)phenoxy)-2,4-
dimethylpentanamine (8.9 mg, 0.022 mmol, 26% yield.) H NMR (500MHz,
DMSO-d6) δ 8.96 (d, J=4.4 Hz, 1H), 8.13 (d, J=8.4 Hz, 1H), 7.88 (s, 1H), 7.83 (s,
1H), 7.66 (s, 1H), 7.60 - 7.50 (m, 3H), 3.98 - 3.90 (m, 2H), 1.89 - 1.81 (m, 1H), 1.44
(dd, J=14.9, 5.7 Hz, 2H), 1.18 (s, 3H), 0.97 (dd, J=9.4, 6.8 Hz, 6H); LCMS (ESI)
m/e 387.2 [(M+H) , calcd C H FClN O, 387.2]; LC/MS retention time (method B):
22 25 2
t = 1.70 min.
Example 76
(S)((5-(7-fluoroquinolinyl)methylpyridinyl)oxy)-2,4-dimethylpentan
amine
Intermediates prepared as described in Example 19. A mixture of potassium
acetate (0.026 g, 0.266 mmol), (S)((5-bromomethylpyridinyl)oxy)-2,4-
dimethylpentanamine (0.0267 g, 0.089 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-
bi(1,3,2-dioxaborolane) (0.027 g, 0.106 mmol) in dioxane (1 mL) underwent
vacuum/backfill N (5X). PdCl (dppf) (1.946 mg, 2.66 µmol) was added to the
reaction mixture and the reaction was heated at 80 °C overnight. The reaction
mixture was cooled to room temperature. PdCl (dppf) (3.26 mg, 4.45 µmol), sodium
carbonate (0.089 mL, 0.178 mmol, 2N), 4-chlorofluoroquinoline (16.16 mg, 0.089
mmol) and (S)-2,4-dimethyl((3-methyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)pyridinyl)oxy)pentanamine (31.0 mg, 0.089 mmol) in dioxane (1.2 mL)
were added to the vessel mixture and the mixture was degassed via vacuum/ N fill
cycle three times. The reaction mixture was heated at 130 °C for 4 h. The reaction
was cooled to rt then diluted with ethyl acetate and washed with water (2X) followed
by brine. The ethyl acetate layer was separated, dried (Na SO ), filtered and
concentrated under reduced pressure . The crude was purified via reverse phase
HPLC (acetonitrile/water/10 mM ammonium acetate) to afford (S)((5-(7-
fluoroquinolinyl)methylpyridinyl)oxy)-2,4-dimethylpentanamine (15.2
mg, 0.041 mmol, 47%yield) as an off-white solid. H NMR (500MHz, DMSO-d ) δ
8.99 - 8.95 (m, 1H), 8.20 - 8.16 (m, 1H), 7.98 (dd, J=9.2, 6.2 Hz, 1H), 7.88 - 7.83 (m,
1H), 7.81 (s, 1H), 7.59 - 7.53 (m, 1H), 7.49 (d, J=4.4 Hz, 1H), 4.11 (d, J=4.4 Hz,
2H), 3.46 (br. s., 2H), 1.90 (s, 3H), 1.87 - 1.79 (m, 1H), 1.45 (t, J=6.2 Hz, 2H), 1.17
(s, 3H), 0.95 (t, J=6.1 Hz, 6H); LCMS (ESI) m/e 386.2 [(M+H) , calcd C H FN O,
22 27 3
386.2]; LC/MS retention time (method B): t = 1.78 min.
Example 77
(S)((2-amino-2,4-dimethylpentyl)oxy)(5,7-difluoroquinolinyl)nicotinonitrile
Prepared as in Example 53.
Part A: (S)-tert-butyl (1-((5-bromocyanopyridinyl)oxy)-2,4-dimethylpentan
yl)carbamate.
LCMS (ESI) m/e 434.1 [(M+Na) , calcd C H BrN O Na, 434.1]; LC/MS
18 26 3 3
retention time (method B): t = 2.38 min.
Part B: 4-bromo-5,7-difluoroquinoline
To a 20 mL microwave tube was added 4-chloro-5,7-difluoroquinoline (0.159
g, 0.795 mmol) and propionitrile (1mL), followed by TMS-Br (0.206 mL, 1.59
mmol) at room temperature. A precipitate formed. The tube was sealed and heated
to 100°C overnight. The reaction was cooled to room temperature. The crude
mixture was poured into iced NaOH (1N, 3 mL) and the tube was washed with water.
The aqueous layer was extracted with diethyl ether (3X). The diethyl ether layers
were combined, dried (Na SO ), filtered and concentrated under reduced pressure to
give 4-bromo-5,7-difluoroquinoline (14.2 mg, 0.582 mmol, 73% yield) as a yellow
solid. LCMS (ESI) m/e 243.8 [(M+Na) , calcd C H BrNF , 244.0]; LC/MS
9 5 2
retention time (method B): t = 2.04 min.
Part C: 5,7-difluoro(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)quinoline
A mixture of potassium acetate (0.122 g, 1.242 mmol), 4-bromo-5,7-
difluoroquinoline (0.1010 g, 0.414 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-
dioxaborolane) (0.126 g, 0.497 mmol) in dioxane (3 mL) underwent a cycle of
vacuum/backfill with nitrogen 5 times. PdCl (dppf) (9.09 mg, 0.012 mmol) was
added to the reaction mixture at room temperature and the reaction was heated at 80
°C overnight. The crude was used as it is in the next step.
Part D: (S)-tert-butyl (1-((3-cyano(5,7-difluoroquinolinyl)pyridinyl)oxy)-
2,4-dimethylpentanyl)carbamate
A mixture of sodium carbonate (0.138 mL, 0.276 mmol), 1,1'-
bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex
(7.89 mg, 9.66 µmol), 5,7-difluoro(4,4,5,5-tetramethyl-1,3,2-dioxaborolan
yl)quinoline (0.040 g, 0.138 mmol) and (S)-tert-butyl (1-((5-bromocyanopyridin-
2-yl)oxy)-2,4-dimethylpentanyl)carbamate (0.057 g, 0.138 mmol) in dioxane (2
mL) (degassed) was heated at 100 °C for 3 h. The reaction was diluted with ethyl
acetate and washed with water (3X). The ethyl acetate layer was dried (Na SO ),
filtered and concentrated under reduced pressure . The residue was purified by silica
gel chromatography (025% ethyl acetate in hexanes) to afford (S)-tert-butyl (1-
((3-cyano(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentan
yl)carbamate (0.0372g, 0.075 mmol, 54% yield) as a brown solid. LCMS (ESI) m/e
519.0 [(M+Na) , calcd C H F N O Na, 519.2]; LC/MS retention time (method B):
27 30 2 4 3
t = 2.38 min.
Part E: (S)((2-amino-2,4-dimethylpentyl)oxy)(5,7-difluoroquinolin
yl)nicotinonitrile.
H NMR (500MHz, DMSO-d ) δ 9.04 (d, J=4.4 Hz, 1H), 8.59 (s, 1H), 8.54
(br. s., 1H), 7.82 (d, J=9.2 Hz, 1H), 7.70 - 7.59 (m, 1H), 7.54 (d, J=4.4 Hz, 1H), 4.30
- 4.17 (m, 2H), 3.44 (br. s., 2H), 1.87 - 1.79 (m, 1H), 1.50 - 1.36 (m, 2H), 1.16 (s,
3H), 0.96 (d, J=2.9 Hz, 3H), 0.94 (d, J=2.9 Hz, 3H); LCMS (ESI) m/e 397.2
[(M+H) , calcd C H F N O, 397.2]; LC/MS retention time (method B): t = 2.39
22 23 2 4 R
min.
Example 78
(S)((3-chloro(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentanamine
Prepared as in example 77.
Part A: Boc (S)((3-chloro(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentan-
2-amine.
(ESI) m/e 470.4 [(M+H) , calcd C H ClN O , 470.2]; LC/MS retention time
26 33 3 3
(method A): t = 2.45 min.
Part B: (S)((3-chloro(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentan
amine.
H NMR (500MHz, DMSO-d ) δ 8.99 (d, J=4.4 Hz, 1H), 8.36 (d, J=1.8 Hz,
1H), 8.25 (d, J=1.8 Hz, 1H), 7.96 (s, 1H), 7.89 - 7.80 (m, 2H), 7.67 (t, J=7.5 Hz, 1H),
7.55 (d, J=4.4 Hz, 1H), 4.59 - 4.42 (m, 2H), 1.94 - 1.61 (m, 3H), 1.43 (s, 3H), 0.98 (t,
J=6.4 Hz, 6H); LCMS (ESI) m/e 370.3 [(M+H) , calcd C H ClN O, 370.2];
21 25 3
LC/MS retention time (method A): t = 2.09 min.
Example 79
(S)((3-methoxy(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentanamine
Prepared as in Example 77. Obtained (S)((3-methoxy(quinolin
yl)pyridinyl)oxy)-2,4-dimethylpentanamine (5.4 mg, 0.014 mmol, 23%yield) as
an off-white solid. H NMR (500MHz, DMSO-d ) δ 8.96 (d, J=4.4 Hz, 1H), 8.12 (d,
J=8.4 Hz, 1H), 7.97 (d, J=8.4 Hz, 1H), 7.86 (d, J=1.5 Hz, 1H), 7.82 (t, J=7.5 Hz,
1H), 7.64 (t, J=7.7 Hz, 1H), 7.53 (d, J=4.4 Hz, 1H), 7.51 (d, J=1.5 Hz, 1H), 4.17 -
4.06 (m, 2H), 3.60 (br. s., 3H), 1.84 (dt, J=12.8, 6.4 Hz, 1H), 1.47 - 1.36 (m, 2H),
1.15 (s, 3H), 0.95 (t, J=7.2 Hz, 6H); LCMS (ESI) m/e 366.0 [(M+H) , calcd
C H N O , 366.2]; LC/MS retention time (method B): t = 1.55 min.
22 28 3 2 R
Example 80
(S)((2-amino-2,4-dimethylpentyl)oxy)(1,6-naphthyridinyl)nicotinonitrile
Prepared as in Example 77.
Part A: (S)-tert-butyl (1-((3-cyano(1,6-naphthyridinyl)pyridinyl)oxy)-2,4-
dimethylpentanyl)carbamate.
LCMS (ESI) m/e 484.2 [(M+Na) , calcd C H F N Na O , 484.2]; LC/MS
26 31 2 5 1 3
retention time (method B): t = 2.14 min.
Part B: (S)((2-amino-2,4-dimethylpentyl)oxy)(1,6-naphthyridin
yl)nicotinonitrile.
Obtained (S)((2-amino-2,4-dimethylpentyl)oxy)(1,6-naphthyridin
yl)nicotinonitrile (22 mg, 0.058 mmol, 66% yield) as an off-white solid. H NMR
(500 MHz, DMSO-d ) δ 9.28 (s, 1H), 9.23 (d, J = 4.4 Hz, 1H), 8.84 (d, J = 5.7 Hz,
1H), 8.78 (d, J = 2.4 Hz, 1H), 8.75 (d, J = 2.5 Hz, 1H), 8.04 (d, J = 5.8 Hz, 1H), 7.74
(d, J = 4.5 Hz, 1H), 4.68 (d, J = 11.6 Hz, 1H), 4.56 (d, J = 11.5 Hz, 1H), 1.89 (dq, J
= 12.7, 6.2 Hz, 1H), 1.81 (dd, J = 14.4, 5.5 Hz, 1H), 1.64 (dd, J = 14.4, 5.6 Hz, 1H),
1.44 (s, 3H), 1.01 (d, J = 6.6 Hz, 6H); LCMS (ESI) m/e 362.2 [(M+H) , calcd
C H N O , 362.2]; LC/MS retention time (method B): t = 1.56 min.
21 24 5 1 R
Example 81
(S)-2,4-dimethyl((2-methyl(quinolinyl)pyridinyl)oxy)pentanamine
Prepared as in Example 77. Obtained (S)-2,4-dimethyl((2-methyl
(quinolinyl)pyridinyl)oxy)pentanamine (10.3 mg, 0.028 mmol, 43%yield) as
an off-white solid. H NMR (500 MHz, DMSO-d ) δ 8.96 (d, J = 4.4 Hz, 1H), 8.25
(d, J = 8.5 Hz, 1H), 8.10 (d, J = 8.5 Hz, 1H), 7.79 (t, J = 7.6 Hz, 1H), 7.65 - 7.56 (m,
3H), 7.51 (d, J = 8.4 Hz, 1H), 3.81 (d, J = 2.2 Hz, 2H), 2.53 (s, 3H), 1.84 (dq, J =
12.6, 6.4 Hz, 1H), 1.50 - 1.38 (m, 2H), 1.17 (s, 3H), 0.96 (t, J = 6.2 Hz, 6H); LCMS
(ESI) m/e 350.3 [(M+H) , calcd C H N O , 350.2]; LC/MS retention time (method
22 28 3 1
A): t = 1.86 min.
Example 82
(S)-2,4-dimethyl((4-methyl(quinolinyl)pyridinyl)oxy)pentanamine
Prepared as in Example 77. Obtained (S)-2,4-dimethyl((4-methyl
(quinolinyl)pyridinyl)oxy)pentanamine (11 mg, 0.030 mmol, 39%yield) as
an off-white solid. H NMR (500MHz, DMSO-d ) δ 8.97 (d, J=4.4 Hz, 1H), 8.44
(s, 1H), 8.25 (d, J=8.8 Hz, 1H), 8.10 (d, J=8.4 Hz, 1H), 7.80 (t, J=7.7 Hz, 1H), 7.67
- 7.57 (m, 3H), 3.94 (s, 2H), 2.34 (s, 3H), 1.87 - 1.81 (m, 1H), 1.52 - 1.40 (m, 2H),
1.18 (s, 3H), 0.96 (t, J=6.8 Hz, 6H); LCMS (ESI) m/e 350.1 [(M+H) , calcd
C H N O, 350.2]; LC/MS retention time (method B): t = 1.67 min.
22 28 3 R
Example 83
(S)((2-chloro(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentanamine
Prepared as in Example 77.
Part A: (S)-tert-butyl (1-((2-chloro(quinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanyl)carbamate.
LCMS (ESI) m/e 470.0 [(M+H) , calcd C H Cl N O , 470.2]; LC/MS
26 33 1 3 3
retention time (method B): t = 2.15 min.
Part B: (S)((2-chloro(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentan
amine
Obtained (6.3 mg, 0.016 mmol, 36%yield) as an off-white solid. . H NMR
(500 MHz, DMSO-d ) δ 9.00 (d, J = 4.4 Hz, 1H), 8.20 (d, J = 8.5 Hz, 1H), 8.13 (d, J
= 8.4 Hz, 1H), 7.86 - 7.77 (m, 3H), 7.69 - 7.60 (m, 2H), 3.97 - 3.87 (m, 2H), 1.85 (dt,
J = 12.8, 6.5 Hz, 1H), 1.44 (t, J = 4.8 Hz, 2H), 1.17 (s, 3H), 0.96 (t, J = 6.0 Hz, 6H);
LCMS (ESI) m/e 370.0 [(M+H) , calcd C H Cl N O , 370.2]; LC/MS retention
21 25 1 3 1
time (method B): t = 1.57 min.
Example 84
(S)(4-(1H-pyrrolo[2,3-b]pyridinyl)(trifluoromethyl)phenoxy)-2,4-
dimethylpentanamine
Prepared as in example 19 to obtain (S)(4-(1H-pyrrolo[2,3-b]pyridinyl)-
2-(trifluoromethyl)phenoxy)-2,4-dimethylpentanamine (27 mg, 0.069 mmol, 79%
yield) as an off-white solid. H NMR (400MHz, CHLOROFORM-d) δ 8.36 (d,
J=5.0 Hz, 1H), 8.00 (d, J=2.0 Hz, 1H), 7.89 (dd, J=8.5, 2.0 Hz, 1H), 7.41 (d, J=3.5
Hz, 1H), 7.18 - 7.08 (m, 2H), 6.68 (d, J=3.5 Hz, 1H), 3.92 - 3.84 (m, 2H), 1.82 - 1.77
(m, 1H), 1.60 - 1.48 (m, 2H), 1.28 (s, 3H), 1.01 (dd, J=9.0, 6.8 Hz, 6H); F NMR
(376MHz, CHLOROFORM-d) δ -62.31 (s, 3F); LCMS (ESI) m/e 392.2 [(M+H) ,
calcd C H F N O, 392.2]; LC/MS retention time (method B): t = 1.81 min.
21 25 3 3 R
Example 85
(S)(4-(1,6-naphthyridinyl)(trifluoromethyl)phenoxy)-2,4-dimethylpentan
amine
Part A: 4-(4-methoxy(trifluoromethyl)phenyl)-1,6-naphthyridine.
To a 20 mL vial was added 4-chloro-1,6-naphthyridine (200 mg, 1.215
mmol), (4-methoxy(trifluoromethyl)phenyl)boronic acid (321 mg, 1.458 mmol),
and potassium phosphate tribasic (4.86 mL, 2.430 mmol) in THF (2.5 mL) to give a
yellow suspension. After degassing with N for 5 min, 2 generation XPHOS
precatalyst (19.12 mg, 0.024 mmol) was added. The mixture was sealed under
nitrogen and heated at 40 °C for 2 h. The reaction mixture was cooled to rt and
diluted with water and EtOAc. The layers were separated. The organic layer was
washed with brine, dried (Na SO ) and concentrated under reduced pressure . The
residue was purified by silica gel chromatography (up to 8% MeOH/CH Cl ) to
afford 4-(4-methoxy(trifluoromethyl)phenyl)-1,6-naphthyridine (369 mg, 1.213
mmol, quantitative yield) as a light yellow solid: H NMR (400 MHz, Chloroform-d)
δ 9.37 (d, J = 0.9 Hz, 1H), 9.14 (d, J = 4.5 Hz, 1H), 8.83 (d, J = 5.9 Hz, 1H), 8.03
(dd, J = 6.0, 0.9 Hz, 1H), 7.80 (d, J = 2.2 Hz, 1H), 7.73 (dd, J = 8.5, 2.2 Hz, 1H),
7.47 (d, J = 4.5 Hz, 1H), 7.23 (d, J = 8.6 Hz, 1H), 4.05 (s, 3H); F NMR (376 MHz,
Chloroform-d) δ -62.63; LCMS (ESI) m/e 305.2 [(M+H) , calcd C H F N O ,
16 12 3 2 1
305.1]; LC/MS retention time (method A): t = 1.86 min.
Part B: 4-(1,6-naphthyridinyl)(trifluoromethyl)phenol
To a 250 mL round-bottomed flask was added 4-(4-methoxy
(trifluoromethyl)phenyl)-1,6-naphthyridine (369 mg, 1.213 mmol) in CH Cl (5 mL)
under nitrogen to give a yellow solution. BBr (12.13 mL, 12.13 mmol) was slowly
added. The mixture was refluxed under nitrogen for 5 h. The reaction was slowly
quenched with 1N NaOH to adjust the pH to ~5. EtOAc was added. The layers were
separated. The aqueous layer was extracted with EtOAc. The combined organic
layers were washed with brine, dried (Na SO ) and concentrated under reduced
pressure . The residue was purified by silica gel chromatography (up to 8%
MeOH/CH2Cl2) to afford 4-(1,6-naphthyridinyl)(trifluoromethyl)phenol (124
mg, 0.427 mmol, 35%) as a white solid: H NMR (400 MHz, Chloroform-d) δ 9.45
(s, 1H), 9.21 (d, J = 4.7 Hz, 1H), 8.84 (d, J = 6.1 Hz, 1H), 8.16 (d, J = 6.1 Hz, 1H),
7.89 - 7.75 (m, 1H), 7.60 (q, J = 3.4 Hz, 2H), 7.34 (d, J = 8.4 Hz, 1H); F NMR
(376 MHz, Chloroform-d) δ -62.58; LCMS (ESI) m/e 291.2 [(M+H) , calcd
C H F N O , 291.2]; LC/MS retention time (method B): t = 1.59 min.
10 3 2 1 R
Part C: (S)-tert-butyl (1-(4-(1,6-naphthyridinyl)(trifluoromethyl)phenoxy)-2,4-
dimethylpentanyl)carbamate.
LCMS (ESI) m/e 526.2 [(M+Na) , calcd C H F N Na O , 526.2]; LC/MS
27 32 3 3 1 3
retention time (method B): t = 2.31 min.
Part D: (S)(4-(1,6-naphthyridinyl)(trifluoromethyl)phenoxy)-2,4-
dimethylpentanamine.
Obtained (35.7 mg, 0.087 mmol, 99% yield) as an off-white solid. H NMR
(500 MHz, DMSO-d6) δ 9.26 (s, 1H), 9.17 (d, J = 4.5 Hz, 1H), 8.80 (d, J = 5.8 Hz,
1H), 8.01 (d, J = 5.9 Hz, 1H), 7.95 (d, J = 8.7 Hz, 1H), 7.90 (s, 1H), 7.69 (d, J = 4.4
Hz, 1H), 7.47 (d, J = 8.6 Hz, 1H), 3.94 (q, J = 9.0 Hz, 2H), 1.83 (dq, J = 12.9, 6.4
Hz, 1H), 1.44 (dd, J = 5.8, 2.6 Hz, 2H), 1.17 (s, 3H), 0.94 (dd, J = 6.8, 3.3 Hz, 6H);
19F NMR (376 MHz, DMSO-d6) δ -61.02; LCMS (ESI) m/e 404.2 [(M+H) , calcd
C H F N O , 362.2]; LC/MS retention time (method B): t = 1.79 min.
22 25 3 3 1 R
Example 86
(S)((2-amino-2,4-dimethylpentyl)oxy)(1,6-naphthyridinyl)benzonitrile
Prepared as in Example 51.
Part A: (S)-tert-butyl (1-(4-bromocyanophenoxy)-2,4-dimethylpentan
yl)carbamate.
H NMR (400 MHz, Chloroform-d) δ 7.63 (d, J = 2.5 Hz, 1H), 7.58 (dd, J =
9.0, 2.5 Hz, 1H), 6.91 (d, J = 9.0 Hz, 1H), 4.57 (s, 1H), 4.31 (d, J = 9.0 Hz, 1H), 4.09
(d, J = 9.0 Hz, 1H), 1.90 (dd, J = 14.0, 6.5 Hz, 1H), 1.86 - 1.75 (m, 1H), 1.47 (dd, J
= 14.0, 5.0 Hz, 1H), 1.39 (s, 3H), 1.37 (s, 9H), 0.99 (d, J = 1.9 Hz, 3H), 0.97 (d, J =
1.9 Hz, 3H); LCMS (ESI) m/e 432.9 [(M+Na) , calcd C H Br N Na O , 433.1];
19 27 1 2 1 3
LC/MS retention time (method B): t = 2.38 min.
Part B: (S)-tert-butyl (1-(2-cyano(4,4,5,5-tetramethyl-1,3,2-dioxaborolan
yl)phenoxy)-2,4-dimethylpentanyl)carbamate.
LCMS (ESI) m/e 481.1 [(M+Na) , calcd C H BN NaO , 481.3]; LC/MS
39 2 5
retention time (method B): t = 2.49 min.
Part C: (S)-tert-butyl (1-(2-cyano(1,6-naphthyridinyl)phenoxy)-2,4-
dimethylpentanyl)carbamate.
LCMS (ESI) m/e 483.1 [(M+Na) , calcd C H N Na O , 483.2]; LC/MS
27 32 4 1 3
retention time (method B): t = 2.10 min.
Part D: (S)((2-amino-2,4-dimethylpentyl)oxy)(1,6-naphthyridin
yl)benzonitrile.
Obtained (S)((2-amino-2,4-dimethylpentyl)oxy)(1,6-naphthyridin
yl)benzonitrile (6.7 mg, 0.017 mmol, 34% yield) as an off-white solid. H NMR (500
MHz, DMSO-d ) δ 9.27 (s, 1H), 9.17 (d, J = 4.5 Hz, 1H), 8.80 (d, J = 5.8 Hz, 1H),
8.11 (d, J = 2.2 Hz, 1H), 8.01 (d, J = 5.8 Hz, 1H), 7.97 (dd, J = 8.7, 2.3 Hz, 1H),
7.67 (d, J = 4.5 Hz, 1H), 7.47 (d, J = 8.8 Hz, 1H), 4.03 - 3.92 (m, 2H), 1.85 (dt, J =
12.6, 6.3 Hz, 1H), 1.51 - 1.40 (m, 2H), 1.18 (s, 3H), 0.96 (dd, J = 6.7, 4.3 Hz, 6H);
LCMS (ESI) m/e 361.0 [(M+H) , calcd C H N O , 361.2]; LC/MS retention time
22 25 4 1
(method B): t = 1.58 min.
Example 87
(S)((2-amino-2,4-dimethylpentyl)oxy)(1,5-naphthyridinyl)benzonitrile
Prepared as in Example 51.
Part A: (S)-tert-butyl (1-(2-cyano(1,5-naphthyridinyl)phenoxy)-2,4-
dimethylpentanyl)carbamate.
LCMS (ESI) m/e 483.1 [(M+Na) , calcd C27H32N4Na1O3, 483.2]; LC/MS
retention time (method B): t = 2.22 min.
Part B: (S)((2-amino-2,4-dimethylpentyl)oxy)(1,5-naphthyridin
yl)benzonitrile.
Obtained (5.5 mg, 0.015 mmol, 29% yield) as an off-white solid. H NMR
(500 MHz, DMSO-d ) δ 9.06 (t, J = 4.6 Hz, 2H), 8.51 (d, J = 8.4 Hz, 1H), 8.23 (d, J
= 2.3 Hz, 1H), 8.18 - 8.11 (m, 1H), 7.90 - 7.82 (m, 2H), 7.41 (d, J = 8.9 Hz, 1H),
3.65 (s, 2H), 1.84 (dt, J = 12.4, 6.5 Hz, 1H), 1.45 (dd, J = 5.6, 2.5 Hz, 2H), 1.17 (s,
3H), 0.95 (dd, J = 6.7, 3.9 Hz, 6H). (OCH2 was likely buried in a broad peak);
LCMS (ESI) m/e 361.0 [(M+H) , calcd C H N O , 361.2]; LC/MS retention time
22 25 4 1
(method B): t = 1.68 min.
Example 88
(S)(4-(7-chloroquinolinyl)(trifluoromethyl)phenoxy)-2,4-dimethylpentan
amine
Part A: 7-chloro(4-methoxy(trifluoromethyl)phenyl)quinoline
A mixture of 4,7-dichloroquinoline (810 mg, 4.09 mmol), (4-methoxy
(trifluoromethyl)phenyl)boronic acid (900 mg, 4.09 mmol), PdCl (dppf) (150 mg,
0.205 mmol), cesium carbonate (2000 mg, 6.14 mmol), and 1,4-dioxane (10 mL)
were charged to a 20 mL pressure rated vial and a stream of nitrogen was bubbled
through for 10 minutes. The vial was sealed, purged of oxygen, and stirred at 90 °C
overnight. The resultant mixture was vacuum filtered and the filtrate concentrated
under reduced pressure. The reside was purified by silica gel chromatography (5-40
% ethyl acetate/hexanes gradient elution) to afford7-chloro(4-methoxy
(trifluoromethyl)phenyl)quinoline (1.04 g, 3.08 mmol, 75% yield) as a white solid.
The material was carried on without further purification. LCMS (ESI) m/e 338.1
[(M+H) , calcd C H ClF NO, 338.1]; LC/MS retention time (method D): t = 1.13
17 12 3 R
min.
Part B: 4-(7-chloroquinolinyl)(trifluoromethyl)phenol
A solution of 7-chloro(4-methoxy(trifluoromethyl)phenyl)quinoline
(0.51 g, 1.510 mmol) in dichloromethane (10 mL) 0 °C was treated with BBr (3.02
mL, 3.02 mmol). The cooling bath was removed and the reaction solution stirred at
ambient temperature overnight. The resultant was cooled to 0 °C and quenched with
saturated aqueous sodium bicarbonate. The layers were separated and the aqueous
layer was extracted with ethyl acetate (2x10 mL). The combined organics were dried
over magnesium sulfate, filtered, and concentrated under reduced pressure to give an
orange solid. The crude residue was adsorbed onto silica gel and purified by silica
gel chromatography (10-80 % ethyl acetate/hexanes) to afford 4-(7-chloroquinolin
yl)(trifluoromethyl)phenol (195 mg, 0.271 mmol, 18% yield) as a pale yellow
solid. LCMS (ESI) m/e 323.9 [(M+H) , calcd C H ClF NO, 324.0]; LC/MS
16 10 3
retention time (method D): t = 1.00 min.
Part C: (S)-tert-butyl (1-(4-(7-chloroquinolinyl)(trifluoromethyl)phenoxy)-2,4-
dimethylpentanyl)carbamate
A mixture of 4-(7-chloroquinolinyl)(trifluoromethyl)phenol (195 mg,
0.602 mmol), (S)-tert-butyl 4-isobutylmethyl-1,2,3-oxathiazolidinecarboxylate
2,2-dioxide (194 mg, 0.663 mmol), cesium carbonate (393 mg, 1.205 mmol), and
N,N-dimethylformamide (4 mL) was heated to 80 °C overnight. The resultant
mixture was cooled to room temperature and diluted with ethyl acetate (40 mL). The
organic layer was washed with brine (3x15 mL), dried over magnesium sulfate,
filtered, and concentrated under reduced pressure. The residue was purified by
purified by silica gel chromatography to afford (S)-tert-butyl (1-(4-(7-chloroquinolin-
4-yl)(trifluoromethyl)phenoxy)-2,4-dimethylpentanyl)carbamate (160 mg,
0.298 mmol, 50% yield) as a pale purple oil. LCMS (ESI) m/e 537.4 [(M+H) , calcd
C H ClF N O , 537.2]; LC/MS retention time (method A): t = 2.60 min; H NMR
28 33 3 2 3 R
(400MHz, CHLOROFORM-d) δ 8.95 (d, J=4.3 Hz, 1H), 8.19 (d, J=2.3 Hz, 1H), 7.81
(d, J=9.0 Hz, 1H), 7.71 (d, J=2.0 Hz, 1H), 7.62 (dd, J=8.5, 2.0 Hz, 1H), 7.50 (dd,
J=8.9, 2.1 Hz, 1H), 7.33 (d, J=4.5 Hz, 1H), 7.20 (d, J=8.5 Hz, 1H), 4.39 - 4.17 (m,
2H), 2.00 - 1.79 (m, 3H), 1.44 (s, 3H), 1.42 (s, 9H), 1.03 (d, J=6.5 Hz, 3H), 1.01 (d,
J=6.5 Hz, 3H).
Part D: (S)(4-(7-chloroquinolinyl)(trifluoromethyl)phenoxy)-2,4-
dimethylpentanamine
(S)-tert-Butyl (1-(4-(7-chloroquinolinyl)(trifluoromethyl)phenoxy)-2,4-
dimethylpentanyl)carbamate (40 mg, 0.074 mmol) was treated with TFA (1 mL,
12.98 mmol) and stirred at ambient temperature for 30 min. The resultant was
concentrated under reduced pressure. The residue was purified via preparative
LC/MS (Column: XBridge C18, 19 x 200 mm, 5-μm; Mobile Phase A: 5:95
acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5
acetonitrile: water with 10-mM ammonium acetate; Gradient: 45-85% B over 15
minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min.). Obtained (S)(4-(7-
chloroquinolinyl)(trifluoromethyl)phenoxy)-2,4-dimethylpentanamine
carbamate (160 mg, 0.298 mmol, 50% yield) as a colorless solid. LCMS (ESI) m/e
437.2 [(M+H) , calcd C H ClF N O, 437.2]; LC/MS retention time (method D): t
23 25 3 2 R
= 0.97 min; H NMR (500MHz, DMSO-d ) δ 8.98 (d, J=4.4 Hz, 1H), 8.17 (d, J=1.8
Hz, 1H), 7.88 (d, J=9.2 Hz, 1H), 7.83 (d, J=8.8 Hz, 1H), 7.78 (s, 1H), 7.66 (dd,
J=9.2, 1.8 Hz, 1H), 7.55 (d, J=4.4 Hz, 1H), 7.44 (d, J=8.4 Hz, 1H), 3.96 - 3.83 (m,
2H), 1.86 - 1.77 (m, 1H), 1.41 (d, J=5.5 Hz, 2H), 1.14 (s, 3H), 0.94 (d, J=6.6 Hz,
3H), 0.93 (d, J=6.6 Hz, 3H).
Example 89
(S)(4-((2-amino-2,4-dimethylpentyl)oxy)(trifluoromethyl)phenyl)quinoline
carbonitrile
Part A: (S)-tert-butyl (1-(4-(7-cyanoquinolinyl)(trifluoromethyl)phenoxy)-2,4-
dimethylpentanyl)carbamate
(S)-tert-butyl (1-(4-(7-chloroquinolinyl)(trifluoromethyl)phenoxy)-2,4-
dimethylpentanyl)carbamate (84 mg, 0.156 mmol) (prepared as described in
Example 88), zinc cyanide (20.20 mg, 0.172 mmol), 1,1'-
bis(diphenylphosphino)ferrocene (13.01 mg, 0.023 mmol), Pd2(dba)3 (7.16 mg, 7.82
µmol), N,N-dimethylformamide (1 mL), and water (0.10 mL) were charged to a
pressure rated vial and the mixture was sparged with nitrogen for 5 minutes. The vial
was sealed, purged of oxygen, and heated under nitrogen at 115 °C overnight. The
resultant mixture was cooled to ambient temperature, vacuum filtered, and
concentrated under reduced pressure. The residue was purified by silica gel
chromatography (10-80 % ethyl acetate/hexanes gradient elution) to afford (S)-tert-
butyl (1-(4-(7-cyanoquinolinyl)(trifluoromethyl)phenoxy)-2,4-dimethylpentan-
2-yl)carbamate (22.5 mg, 0.043 mmol, 27% yield) as a near colorless film. LCMS
(ESI) m/e 528.2 [(M+H) , calcd C H F N O , 528.3]; LC/MS retention time
29 33 3 3 3
(method D): t = 1.30 min.
Part B: (S)(4-((2-amino-2,4-dimethylpentyl)oxy)
(trifluoromethyl)phenyl)quinolinecarbonitrile
(S)-tert-Butyl (1-(4-(7-cyanoquinolinyl)(trifluoromethyl)phenoxy)-2,4-
dimethylpentanyl)carbamate (22 mg, 0.042 mmol) was treated with TFA (964 µL,
12.51 mmol) and stirred at room temperature for 30 minutes. The resultant was
concentrated under reduced pressure. The residue was purified via preparative
LC/MS (Column: XBridge C18, 19 x 200 mm, 5-μm; Mobile Phase A: 5:95
acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5
acetonitrile: water with 10-mM ammonium acetate; Gradient: 45-85% B over 15
minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min.). Obtained (S)(4-((2-
amino-2,4-dimethylpentyl)oxy)(trifluoromethyl)phenyl)quinolinecarbonitrile
(13.3 mg, 0.031 mmol, 75% yield) as a colorless solid. LCMS (ESI) m/e 428.2
[(M+H) , calcd C H F N O, 428.2]; LC/MS retention time (method D): t = 0.97
24 25 3 3 R
min; H NMR (500MHz, DMSO-d ) δ 9.11 (d, J=4.4 Hz, 1H), 8.68 (s, 1H), 8.06 -
7.98 (m, 1H), 7.92 (d, J=8.8 Hz, 1H), 7.84 (d, J=8.8 Hz, 1H), 7.81 (s, 1H), 7.70 (d,
J=4.4 Hz, 1H), 7.45 (d, J=8.8 Hz, 1H), 4.00 - 3.77 (m, 2H), 1.82 (dt, J=12.7, 6.3 Hz,
1H), 1.41 (d, J=5.5 Hz, 2H), 1.14 (s, 3H), 0.94 (d, J=6.5 Hz, 3H), 0.93 (d, J=6.5 Hz,
3H).
Example 90
(S)-2,4-dimethyl(2-methyl(2-methylpyridinyl)phenoxy)pentanamine
Prepared as described in Example 32 to afford (S)-2,4-dimethyl(2-methyl-
4-(2-methylpyridinyl)phenoxy)pentanamine carbonitrile (17 mg, 0.054 mmol,
98% yield for the final step) as a colorless solid. LCMS (ESI) m/e 313.1 [(M+H) ,
calcd C H N O, 313.2]; LC/MS retention time (method D): t = 0.65 min; H NMR
29 2 R
(500MHz, DMSO-d ) δ 8.44 (d, J=5.1 Hz, 1H), 7.67 - 7.60 (m, 2H), 7.54 (s, 1H),
7.45 (d, J=5.1 Hz, 1H), 7.05 (d, J=8.1 Hz, 1H), ), 3.88 – 3.29 (m, 2H), 2.30 (s, 3H),
1.91 (s, 3H), 1.81 (dt, J=12.8, 6.4 Hz, 1H), 1.64 - 1.55 (m, 1H), 1.53 - 1.44 (m, 1H),
1.26 (s, 3H), 0.95 (d, J=6.6 Hz, 3H), 0.92 (d, J=6.6 Hz, 3H).
Example 91
(S)(2-fluoro(2-methylpyridinyl)phenoxy)-2,4-dimethylpentanamine
Prepared as described in Example 32 to afford (S)(2-fluoro(2-
methylpyridinyl)phenoxy)-2,4-dimethylpentanamine (12 mg, 0.037 mmol, 96%
yield for the final step) as a colorless solid. LCMS (ESI) m/e 317.1 [(M+H) , calcd
C H FN O, 317.2]; LC/MS retention time (method D): t = 0.62 min; H NMR
19 26 2 R
(500MHz, DMSO-d ) δ 8.57 (d, J=5.5 Hz, 1H), 8.13 (br. s., 2H), 7.87 (d, J=12.5 Hz,
1H), 7.80 (s, 1H), 7.74 (d, J=9.2 Hz, 1H), 7.70 (d, J=5.1 Hz, 1H), 7.42 (t, J=8.6 Hz,
1H), 4.23 - 4.08 (m, 2H), 2.58 (s, 3H), 1.82 (dt, J=12.7, 6.1 Hz, 1H), 1.77 - 1.69 (m,
1H), 1.60 (dd, J=14.3, 5.1 Hz, 1H), 1.38 (s, 3H), 0.97 (d, J=6.6 Hz, 3H), 0.93 (d,
J=6.2 Hz, 3H).
Example 92
(S)(4-(2-fluoropyridinyl)methylphenoxy)-2,4-dimethylpentanamine
Prepared as described in Example 32 to afford (S)(4-(2-fluoropyridin
yl)methylphenoxy)-2,4-dimethylpentanamine (4.8 mg, 0.015 mmol, 90% yield
for the final step) as a colorless solid. LCMS (ESI) m/e 317.1 [(M+H) , calcd
C H FN O, 317.2]; LC/MS retention time (method D): t = 0.96 min; H NMR
19 26 2 R
(500MHz, DMSO-d ) δ 8.24 (d, J=5.1 Hz, 1H), 7.80 - 7.69 (m, 2H), 7.66 (d, J=5.1
Hz, 1H), 7.47 (s, 1H), 7.03 (d, J=8.1 Hz, 1H), 3.80 – 3.38 (m, 2H), 2.28 (s, 3H), 1.86
- 1.77 (m, 1H), 1.49 - 1.35 (m, 2H), 1.15 (s, 3H), 0.93 (t, J=6.2 Hz, 6H).
Example 93
(S)(2-fluoro(2-fluoropyridinyl)phenoxy)-2,4-dimethylpentanamine
Prepared as described in Example 32 to afford (S)(2-fluoro(2-
fluoropyridinyl)phenoxy)-2,4-dimethylpentanamine (10.8 mg, 0.034 mmol,
75% yield for the final step) as a colorless solid. LCMS (ESI) m/e 321.1 [(M+H) ,
calcd C H F N O, 321.2]; LC/MS retention time (method D): t = 0.90 min; H
18 23 2 2 R
NMR (500MHz, DMSO-d ) δ 8.27 (d, J=5.1 Hz, 1H), 7.86 (dd, J=12.7, 2.0 Hz, 1H),
7.72 (d, J=5.9 Hz, 2H), 7.55 (s, 1H), 7.30 (t, J=8.8 Hz, 1H), 3.88 - 3.75 (m, 2H), 1.81
(dquin, J=12.7, 6.3 Hz, 1H), 1.48 - 1.31 (m, 2H), 1.13 (s, 3H), 0.93 (t, J=7.2 Hz, 6H).
Example 94
(S)((2-amino-2,4-dimethylpentyl)oxy)(2-fluoropyridinyl)benzonitrile
Prepared as described in Example 32 to afford (S)((2-amino-2,4-
dimethylpentyl)oxy)(2-fluoropyridinyl)benzonitrile (16.9 mg, 0.051 mmol,
80% yield for the final step) as a colorless solid. LCMS (ESI) m/e 328.1 [(M+H) ,
calcd C H FN O, 328.2]; LC/MS retention time (method D): t = 0.94 min; H
19 23 3 R
NMR (500MHz, DMSO-d ) δ 8.37 (d, J=2.2 Hz, 1H), 8.31 (d, J=5.1 Hz, 1H), 8.22
(dd, J=8.8, 2.2 Hz, 1H), 7.78 (d, J=5.1 Hz, 1H), 7.63 (s, 1H), 7.43 (d, J=9.2 Hz, 1H),
4.12 - 3.99 (m, 2H), 1.83 (dt, J=12.7, 6.3 Hz, 1H), 1.60 - 1.43 (m, 2H), 1.24 (s, 3H),
0.95 (t, J=6.4 Hz, 6H).
Example 95
(S)((2'-fluoromethyl-[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine
Prepared as described in Example 32 to afford (S)((2'-fluoromethyl-
[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine (6.5 mg, 0.020 mmol, 57%
yield for the final step) as a colorless solid. LCMS (ESI) m/e 318.1 [(M+H) , calcd
C H FN O, 318.2]; LC/MS retention time (method D): t = 0.95 min; H NMR
18 25 3 R
(500MHz, DMSO-d ) δ 8.54 (d, J=2.2 Hz, 1H), 8.29 (d, J=5.1 Hz, 1H), 8.12 (s, 1H),
7.73 (d, J=5.1 Hz, 1H), 7.57 (s, 1H), 4.22 - 4.08 (m, 2H), 1.91 (s, 3H), 1.81 (dq,
J=12.7, 6.2 Hz, 1H), 1.55 - 1.39 (m, 2H), 1.20 (s, 3H), 0.93 (dd, J=8.8, 6.6 Hz, 6H).
Example 96
(S)(6-((2-amino-2,4-dimethylpentyl)oxy)methylpyridinyl)quinoline
carbonitrile
Prepared as described in Example 89 to afford (S)(6-((2-amino-2,4-
dimethylpentyl)oxy)methylpyridinyl)quinolinecarbonitrile (9.9 mg, 0.026
mmol, 35% yield for the final step) as a colorless solid. LCMS (ESI) m/e 375.1
[(M+H) , calcd C H N O, 375.2]; LC/MS retention time (method D): t = 0.94
23 27 4 R
min; H NMR (600MHz, DMSO-d ) δ 9.10 (d, J=4.4 Hz, 1H), 8.68 (s, 1H), 8.18 (s,
1H), 8.07 (d, J=8.8 Hz, 1H), 7.92 (d, J=8.4 Hz, 1H), 7.82 (br. s., 1H), 7.68 (d, J=4.0
Hz, 1H), 4.17 - 4.05 (m, 2H), 2.29 (s, 3H), 1.90 - 1.79 (m, 1H), 1.49 - 1.37 (m, 2H),
1.16 (s, 3H), 0.95 (t, J=6.2 Hz, 6H).
Example 97
(S)((5-fluoro-2'-methyl-[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine
Prepared as described in Example 32 to afford (S)((5-fluoro-2'-methyl-
[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine (4.8 mg, 0.015 mmol, 90%
yield for the final step) as a colorless solid. LCMS (ESI) m/e 318.2 [(M+H) , calcd
C H FN O, 318.2]; LC/MS retention time (method D): t = 0.60 min; H NMR
18 25 3 R
(500MHz, DMSO-d ) δ 8.51 (d, J=5.1 Hz, 1H), 8.48 (s, 1H), 8.23 (d, J=11.4 Hz,
1H), 7.66 (s, 1H), 7.57 (d, J=5.1 Hz, 1H), 4.32 - 4.21 (m, 2H), 1.91 (s, 3H), 1.87 -
1.77 (m, 1H), 1.57 - 1.41 (m, 2H), 1.22 (s, 3H), 0.95 (d, J=6.6 Hz, 3H), 0.93 (d, J=6.6
Hz, 3H).
Example 98
(S)((3-fluoro(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentanamine
Prepared as described in Example 32 to afford (S)((3-fluoro(quinolin
yl)pyridinyl)oxy)-2,4-dimethylpentanamine (8.4 mg, 0.024 mmol, 59% yield
for the final step) as a colorless solid. LCMS (ESI) m/e 354.1 [(M+H) , calcd
C H FN O, 354.2]; LC/MS retention time (method D): t = 0.74 min; H NMR
21 25 3 R
(500MHz, DMSO-d ) δ 8.98 (d, J=4.0 Hz, 1H), 8.18 (d, J=1.8 Hz, 1H), 8.14 (d,
J=8.4 Hz, 1H), 8.03 (d, J=11.0 Hz, 1H), 7.91 (d, J=8.4 Hz, 1H), 7.84 (t, J=7.5 Hz,
1H), 7.70 - 7.62 (m, 1H), 7.54 (d, J=4.4 Hz, 1H), 4.27 - 4.17 (m, 2H), 1.85 (dt,
J=12.7, 6.1 Hz, 1H), 1.53 - 1.38 (m, 2H), 1.19 (s, 3H), 0.96 (t, J=7.0 Hz, 6H).
Example 99
(S)(6-((2-amino-2,4-dimethylpentyl)oxy)fluoropyridinyl)quinoline
carbonitrile
Prepared as described in Example 88 to (S)(6-((2-amino-2,4-
dimethylpentyl)oxy)fluoropyridinyl)quinolinecarbonitrile (5.6 mg, 0.014
mmol, 62% yield for the final step) as a colorless solid. LCMS (ESI) m/e 379.1
[(M+H) , calcd C H FN O, 379.2]; LC/MS retention time (method D): t = 0.91
22 24 4 R
min; H NMR (500MHz, DMSO-d ) δ 9.13 (d, J=4.4 Hz, 1H), 8.70 (s, 1H), 8.19 (d,
J=1.8 Hz, 1H), 8.09 (d, J=8.8 Hz, 1H), 8.06 - 8.01 (m, 1H), 7.98 - 7.90 (m, 1H), 7.73
(d, J=4.4 Hz, 1H), 4.22 - 4.10 (m, 2H), 1.85 (dt, J=12.7, 6.3 Hz, 1H), 1.50 - 1.35 (m,
2H), 1.15 (s, 3H), 0.95 (t, J=6.6 Hz, 6H).
Example 100
(S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)cyanophenyl)
fluoropyridinyl)carbamate
Part A: (S)-tert-butyl (1-(4-bromocyanophenoxy)-2,4-dimethylpentan
yl)carbamate
Prepared as in Example 32 Parts A-F to yield (S)-tert-butyl (1-(4-bromo
cyanophenoxy)-2,4-dimethylpentanyl)carbamate. LC/MS retention time (method
D): t = 1.29 min.
Part B: (S)-tert-butyl (1-(2-cyano(4,4,5,5-tetramethyl-1,3,2-dioxaborolan
yl)phenoxy)-2,4-dimethylpentanyl)carbamate
(S)-tert-butyl (1-(4-bromocyanophenoxy)-2,4-dimethylpentan
yl)carbamate (0.57 g, 1.386 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-
dioxaborolane) (0.422 g, 1.663 mmol), PdCl (dppf) (0.051 g, 0.069 mmol),
potassium acetate (0.408 g, 4.16 mmol), and dioxane (5 mL) were charged to a
pressure rated vial. The vial was purged of oxygen and the mixture stirred under
nitrogen at 80 °C overnight. The mixture was cooled to ambient temperature,
vacuum filtered, and concentrated under reduced pressure. Obtained (S)-tert-butyl
(1-(2-cyano(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)phenoxy)-2,4-
dimethylpentanyl)carbamate (600 mg, 1.30 mmol, 100% crude yield) as a brown
oil that was used without further purification. LCMS (ESI) m/e 481.1 [(M+Na) ,
calcd C H BN NaO , 481.3]; LC/MS retention time (method B): t = 2.49 min.
39 2 5 R
Part C: (S)-tert-butyl (1-(4-(2-chlorofluoropyridinyl)cyanophenoxy)-2,4-
dimethylpentanyl)carbamate
A mixture of 2-chlorofluoroiodopyridine (105 mg, 0.408 mmol), (S)-
tert-butyl (1-(2-cyano(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)phenoxy)-2,4-
dimethylpentanyl)carbamate (374 mg, 0.816 mmol), potassium carbonate (169
mg, 1.224 mmol), and Pd(Ph P) (14.14 mg, 0.012 mmol) in toluene (1 mL), water
(0.050 mL), and ethanol (0.100 mL) in a pressure rated 1 dram vial was purged of
oxygen, and stirred under nitrogen at 80 °C overnight. The mixture was filtered via
syringe tip filter and concentrated under reduced pressure. The residue was purified
by silica gel chromatography (10-80 % ethyl acetate/hexanes gradient elution) to
afford (S)-tert-butyl (1-(4-(2-chlorofluoropyridinyl)cyanophenoxy)-2,4-
dimethylpentanyl)carbamate (49 mg, 0.106 mmol, 26% yield) as a light yellow
film. LCMS (ESI) m/e 462.0 (M+H) , calcd C H ClFN O , 462.2]; LC/MS
23 30 3 3
retention time (method D): t = 1.30 min; H NMR (400MHz, CHLOROFORM-d) δ
8.28 (d, J=5.0 Hz, 1H), 7.82 (dd, J=2.0, 1.0 Hz, 1H), 7.77 (dt, J=8.8, 1.9 Hz, 1H),
7.33 - 7.29 (m, 1H), 7.18 (d, J=9.0 Hz, 1H), 4.59 (s, 1H), 4.45 (d, J=8.8 Hz, 1H),
4.22 (d, J=9.0 Hz, 1H), 2.01 - 1.92 (m, 1H), 1.91 - 1.79 (m, 1H), 1.56 - 1.50 (m, 1H),
1.46 (s, 3H), 1.40 (s, 9H), 1.03 (d, J=6.8 Hz, 6H).
Part D: (S)-methyl (4-(4-((2-Boc-amino-2,4-dimethylpentyl)oxy)cyanophenyl)
fluoropyridinyl)carbamate
A solution of (S)-tert-butyl (1-(4-(2-aminofluoropyridinyl)
cyanophenoxy)-2,4-dimethylpentanyl)carbamate (40 mg, 0.090 mmol) cooled to 0
°C was added methyl chloroformate (0.035 mL, 0.452 mmol) and pyridine (0.073
mL, 0.904 mmol) followed by DMAP (1.104 mg, 9.04 µmol). The cooling bath was
removed and the mixture stirred overnight. The reaction mixture was concentrated
under reduced pressure. Obtained (S)-methyl (4-(4-((2-Boc-amino-2,4-
dimethylpentyl)oxy)cyanophenyl)fluoropyridinyl)carbamate (20 mg, 0.040
mmol, 44% crude yield) which was used without further purification. LCMS (ESI)
m/e 501.1 (M+H) , calcd C H ClFN O , 501.3]; LC/MS retention time (method D):
23 30 3 3
t = 1.17 min.
Part E: (S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)cyanophenyl)
fluoropyridinyl)carbamate
(S)-Methyl (4-(4-((2-Boc-amino-2,4-dimethylpentyl)oxy)cyanophenyl)
fluoropyridinyl)carbamate (20 mg, 0.040 mmol) and TFA (1 mL, 12.98 mmol)
were stored at ambient temperature for 2 hours. The resultant was concentrated
under reduced pressure. The residue was purified via preparative LC/MS (Column:
XBridge C18, 19 x 200 mm, 5-μm; Mobile Phase A: 5:95 acetonitrile: water with 10-
mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM
ammonium acetate; Gradient: 45-85% B over 15 minutes, then a 5-minute hold at
100% B; Flow: 20 mL/min.). Obtained (S)-methyl (4-(4-((2-amino-2,4-
dimethylpentyl)oxy)cyanophenyl)fluoropyridinyl)carbamate (4.1 mg, 10.14
mol, 25% yield for two steps) as a colorless solid. LCMS (ESI) m/e 401.0 (M+H) ,
calcd C H FN O , 401.2]; LC/MS retention time (method D): t = 0.82 min; H
21 26 4 3 R
NMR (500MHz, DMSO-d ) δ 8.26 (d, J=4.8 Hz, 1H), 8.05 (s, 1H), 7.95 (d, J=9.5
Hz, 1H), 7.50 (t, J=5.1 Hz, 1H), 7.43 (d, J=8.8 Hz, 1H), 4.13 - 3.99 (m, 2H), 1.91 (s,
3H), 1.86 - 1.78 (m, 1H), 1.60 - 1.44 (m, 2H), 1.24 (s, 3H), 0.94 (t, J=5.9 Hz, 6H).
Example 101
(S)((2-amino-2,4-dimethylpentyl)oxy)-2'-methyl-[3,4'-bipyridine]carbonitrile
Prepared as described in Example 32 to afford (S)((2-amino-2,4-
dimethylpentyl)oxy)-2'-methyl-[3,4'-bipyridine]carbonitrile (16 mg, 0.054 mmol,
44% yield for the final step) as a pale yellow oil. LCMS (ESI) m/e 325.1 [(M+H) ,
calcd C H N O, 325.2]; LC/MS retention time (method D): t = 0.58 min; H NMR
19 25 4 R
(500MHz, DMSO-d ) δ 9.02 (d, J=2.2 Hz, 1H), 8.92 (d, J=2.6 Hz, 1H), 8.68 (d,
J=5.5 Hz, 1H), 8.42 (br. s., 2H), 7.99 (s, 1H), 7.89 (d, J=4.8 Hz, 1H), 4.74 - 4.47 (m,
2H), 2.64 (s, 3H), 1.89 (dt, J=12.6, 6.4 Hz, 1H), 1.83 - 1.74 (m, 1H), 1.65 (dd,
J=14.3, 5.5 Hz, 1H), 1.43 (s, 3H), 0.98 (d, J=1.8 Hz, 3H), 0.96 (d, J=1.8 Hz, 3H).
Example 102
(S)((2-amino-2,4-dimethylpentyl)oxy)(7-methylquinolinyl)benzonitrile
Prepared as described in Example 32 to afford (S)((2-amino-2,4-
dimethylpentyl)oxy)(7-methylquinolinyl)benzonitrile (76 mg, 0.195 mmol,
53% yield for the final step) as a colorless film. LCMS (ESI) m/e 374.0 [(M+H) ,
calcd C24H28N3O, 374.2]; LC/MS retention time (method D): tR = 0.76 min; H NMR
(600MHz, DMSO-d ) δ 8.90 (d, J=4.0 Hz, 1H), 7.98 (s, 1H), 7.91 (s, 1H), 7.87 (dd,
J=8.8, 2.2 Hz, 1H), 7.73 (d, J=8.4 Hz, 1H), 7.48 (dd, J=8.1, 4.8 Hz, 2H), 7.42 (d,
J=4.0 Hz, 1H), 4.29 - 4.09 (m, 2H), 2.55 (s, 3H), 1.86 (dt, J=12.3, 6.3 Hz, 1H), 1.72
(dd, J=13.9, 5.1 Hz, 1H), 1.58 (dd, J=14.1, 5.7 Hz, 1H), 1.35 (s, 3H), 0.97 (t, J=6.2
Hz, 6H).
Example 103
(S)((2-amino-2,4-dimethylpentyl)oxy)(3-fluoromethylpyridin
yl)benzonitrile
Prepared as described in Example 32 to afford (S)((2-amino-2,4-
dimethylpentyl)oxy)(3-fluoromethylpyridinyl)benzonitrile (7.7 mg, 0.022
mmol, 74% yield for the final step) as a colorless film. LCMS (ESI) m/e 342.0
[(M+H) , calcd C20H25FN3O, 342.2]; LC/MS retention time (method D): tR = 0.79
min; H NMR (600MHz, DMSO-d ) δ 8.35 (d, J=4.8 Hz, 1H), 8.05 (s, 1H), 7.95 (d,
J=8.8 Hz, 1H), 7.48 (br. s., 1H), 7.39 (d, J=8.8 Hz, 1H), 3.96 - 3.83 (m, 2H), 2.51 (s,
3H), 1.82 (dt, J=12.1, 6.1 Hz, 1H), 1.52 - 1.37 (m, 2H), 1.15 (s, 3H), 0.93 (t, J=5.0
Hz, 6H).
Example 104
(S)((2-amino-2,4-dimethylpentyl)oxy)(quinolinyl)benzonitrile
Prepared as described in Example 32 to afford (S)((2-amino-2,4-
dimethylpentyl)oxy)(quinolinyl)benzonitrile (23 mg, 0.061 mmol, 14% yield
for the final step) as a colorless film. LCMS (ESI) m/e 360.0 [(M+H) , calcd
C H N O, 360.2]; LC/MS retention time (method D): t = 0.69 min; H NMR
23 26 3 R
(600MHz, DMSO-d ) δ 8.97 (d, J=4.4 Hz, 1H), 8.13 (d, J=8.4 Hz, 1H), 7.99 (s, 1H),
7.90 - 7.79 (m, 3H), 7.64 (t, J=7.2 Hz, 1H), 7.50 (d, J=4.4 Hz, 1H), 7.47 (d, J=8.8
Hz, 1H), 4.11 - 3.98 (m, 2H), 1.86 (dquin, J=12.5, 6.4 Hz, 1H), 1.63 - 1.45 (m, 2H),
1.25 (s, 3H), 0.97 (t, J=6.2 Hz, 6H).
Example 105
(S)((2-amino-2,4-dimethylpentyl)oxy)(5-fluoromethylpyridin
yl)benzonitrile
Prepared as described in Example 32 to afford (S)((2-amino-2,4-
dimethylpentyl)oxy)(5-fluoromethylpyridinyl)benzonitrile (9.5 mg, 0.026
mmol, 25% yield for the final step) as a pale yellow film. LCMS (ESI) m/e 342.0
[(M+H) , calcd C H FN O, 342.2]; LC/MS retention time (method D): t = 0.80
25 3 R
min; H NMR (500MHz, DMSO-d ) δ 8.50 (d, J=2.6 Hz, 1H), 8.08 (d, J=1.8 Hz,
1H), 7.97 (d, J=8.1 Hz, 1H), 7.56 (d, J=6.6 Hz, 1H), 7.40 (d, J=8.8 Hz, 1H), 3.96 -
3.85 (m, 2H), 2.52 (s, 3H), 1.86 - 1.77 (m, 1H), 1.51 - 1.36 (m, 2H), 1.15 (s, 3H),
0.94 (d, J=3.7 Hz, 3H), 0.93 (d, J=3.7 Hz, 3H).
Example 106
(S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)cyanophenyl)
fluoropyridinyl)carbamate
Prepared as described in Example 100 to afford (S)-methyl (4-(4-((2-amino-
2,4-dimethylpentyl)oxy)cyanophenyl)fluoropyridinyl)carbamate (20.5 mg,
0.050 mmol, 36% yield for the final step) as a colorless film. LCMS (ESI) m/e 401.0
(M+H) , calcd C H FN O , 401.2]; LC/MS retention time (method D): t = 0.91
21 26 4 3 R
min; H NMR (500MHz, DMSO-d ) δ 8.38 (s, 1H), 8.02 (s, 1H), 7.97 (d, J=5.9 Hz,
1H), 7.91 (d, J=9.2 Hz, 1H), 7.41 (d, J=8.8 Hz, 1H), 3.96 - 3.84 (m, 2H), 2.52 (s,
3H), 1.82 (dt, J=12.7, 6.3 Hz, 1H), 1.49 - 1.34 (m, 2H), 1.15 (s, 3H), 0.94 (d, J=3.7
Hz, 3H), 0.93 (d, J=3.7 Hz, 3H).
Example 107
(S)((6-fluoro-2',4-dimethyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine
Part A: (6-chlorofluoropyridinyl)boronic acid
A solution of LDA (1M in THF) (8.36 ml, 8.36 mmol) at -78 °C was treated
dropwise with a solution of 2-chlorofluoropyridine (1.0 g, 7.60 mmol) in THF (2
mL). The mixture was maintained at -78 °C for 1 h and then treated with a solution
of triisopropyl borate (1.765 ml, 7.60 mmol) in THF (1 mL). The reaction mixture
was treated with water (4 mL) and concentrated under reduced pressure to afford (6-
chlorofluoropyridinyl)boronic acid (1.33 g, 7.60 mmol, 100% crude yield) as a
pale orange waxy solid that was used without further purification. LCMS (ESI) m/e
176.0 (M+H) , calcd C H BClFNO , 176.0]; LC/MS retention time (method D): t =
5 2 R
0.71 min.
Part B: 6-chlorofluoropyridinol
A suspension of (6-chlorofluoropyridinyl)boronic acid (1.3 g, 7.41
mmol) in NaOH (4.45 ml, 22.24 mmol) at 0 °C was treated all at once with hydrogen
peroxide (0.500 ml, 8.15 mmol). The mixture was stirred at ambient temperature
overnight. The resulting solution was quenched with ice water, acidified with 3 N
aqueous hydrochloric acid to pH = 5, and extracted three times with ethyl acetate.
The pooled organics were dried over sodium sulfate and concentrated under reduced
pressure to afford 6-chlorofluoropyridinol (1.08 g, 7.32 mmol, 99% crude
yield) as a waxy solid that was used without further purification. LCMS (ESI) m/e
148.0 (M+H) , calcd C H ClFNO, 148.0]; LC/MS retention time (method D): t =
4 R
0.83 min.
Part C: 6-chlorofluoro(methoxymethoxy)pyridine
A solution of 6-chlorofluoropyridinol (0.49 g, 3.32 mmol), MOM-Cl
(0.277 mL, 3.65 mmol), potassium carbonate (0.551 g, 3.99 mmol) in acetone (20
mL) was stirred at 60 °C for 3 h. The mixture was cooled to ambient temperature
and vacuum filtered. The filtrate was concentrated under reduced pressure. The
residue was purified by silica gel chromatography (5-30 % ethyl acetate/hexanes) to
afford 6-chlorofluoro(methoxymethoxy)pyridine (0.24 g, 1.25 mmol, 38% yield
for three steps) as a near colorless oil. LCMS (ESI) m/e 192.0 (M+H) , calcd
C H ClFNO , 192.0]; LC/MS retention time (method D): t = 1.20 min; H NMR
7 8 2 R
(400MHz, CHLOROFORM-d) δ 7.57 (dd, J=9.8, 8.3 Hz, 1H), 7.16 (d, J=8.3 Hz,
1H), 5.24 (s, 2H), 3.56 - 3.52 (m, 3H).
Part D: 6-chlorofluoro(methoxymethoxy)methylpyridine
A solution of 6-chlorofluoro(methoxymethoxy)pyridine (0.24 g, 1.253
mmol) in tetrahydrofuran (9 mL) at -78 °C was treated dropwise with LDA (1.378
mL, 1.378 mmol). The resulting orange solution was maintained at -78 °C for 1 h
and then treated dropwise with a solution of methyl iodide (0.094 mL, 1.503 mmol)
in THF (0.5 mL). The resulting solution was stirred at -78 °C for 30 min. The
resulting solution was warmed to ambient temperature, quenched with saturated
aqueous ammonium chloride (5 mL), and stirred overnight. The layers were
separated and the aqueous layer was extracted with ethyl acetate. The pooled
organics were dried over sodium sulfate and concentrated under reduced pressure.
The residue was purified by silica gel chromatography (5-30 % ethyl
acetate/hexanes) afforded 6-chlorofluoro(methoxymethoxy)methylpyridine
(0.22 g, 1.07 mmol, 85% yield) as a colorless oil. LCMS (ESI) m/e 206.1 (M+H) ,
calcd C H ClFNO , 206.0]; LC/MS retention time (method D): t = 1.05 min; H
8 10 2 R
NMR (400MHz, CHLOROFORM-d) δ 7.07 (s, 1H), 5.21 - 5.10 (m, 2H), 3.64 - 3.54
(m, 3H), 2.37 (d, J=1.0 Hz, 3H).
Part E: 6-fluoro(methoxymethoxy)-2',4-dimethyl-2,4'-bipyridine
To a pressure rated vial was added 6-chlorofluoro(methoxymethoxy)
methylpyridine (110 mg, 0.535 mmol), (2-methylpyridinyl)boronic acid (81 mg,
0.588 mmol), cesium carbonate (349 mg, 1.070 mmol), toluene (1 mL), and ethanol
(0.200 mL). The solution was sparged with a stream of nitrogen for 5 min.
Tetrakis(triphenylphosphine)palladium(0) (43.3 mg, 0.037 mmol) was added and the
vial was sealed, purged of oxygen, and stirred under nitrogen at 85 °C overnight.
The resulting suspension was vacuum filtered and concentrated under reduced
pressure. The residue was purified by silica gel chromatography (5-40 % ethyl
acetate/hexanes gradient elution) to afford 6-fluoro(methoxymethoxy)-2',4-
dimethyl-2,4'-bipyridine (40 mg, 0.153 mmol, 29 % yield) as a near colorless oil.
LCMS (ESI) m/e 263.1 (M+H) , calcd C H FN O , 263.1]; LC/MS retention time
14 16 2 2
(method D): t = 0.80 min; H NMR (400MHz, CHLOROFORM-d) δ 8.59 (d, J=5.3
Hz, 1H), 7.73 (s, 1H), 7.61 (dd, J=5.3, 1.3 Hz, 1H), 7.55 (s, 1H), 5.24 (d, J=1.0 Hz,
2H), 3.63 (s, 3H), 2.65 (s, 3H), 2.47 (s, 3H).
Part F: 6-fluoro-2',4-dimethyl-[2,4'-bipyridin]ol
A solution of 6-fluoro(methoxymethoxy)-2',4-dimethyl-2,4'-bipyridine (40
mg, 0.153 mmol) in methanol (5 mL) and HCl (conc.) (0.05 mL, 0.600 mmol) was
stirred at 65 °C for 1 h and then concentrated under reduced pressure to afford 6-
fluoro-2',4-dimethyl-[2,4'-bipyridin]ol (30 mg, 0.137 mmol, 90 % yield) as a pale
tan solid. Used without further purification. LCMS (ESI) m/e 219.1 (M+H) , calcd
C H FN O, 219.1]; LC/MS retention time (method D): t = 0.59 min.
12 12 2 R
Part G: (S)-tert-butyl (1-((6-fluoro-2',4-dimethyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanyl)carbamate
A solution of 6-fluoro-2',4-dimethyl-[2,4'-bipyridin]ol (30 mg, 0.137
mmol), (S)-tert-butyl 4-isobutylmethyl-1,2,3-oxathiazolidinecarboxylate 2,2-
dioxide (48.4 mg, 0.165 mmol), and cesium carbonate (134 mg, 0.412 mmol) in N,N-
dimethylformamide (1 mL) in a pressure rated vial was stirred at 80 °C overnight.
The mixture was cooled to ambient temperature and filtered through a syringe tip
filter. Obtained (S)-tert-butyl (1-((6-fluoro-2',4-dimethyl-[2,4'-bipyridin]yl)oxy)-
2,4-dimethylpentanyl)carbamate (38.6 mg, 0.089 mmol, 65% crude yield) as a
colorless oil that was used without further purification. LCMS (ESI) m/e 432.2
(M+H) , calcd C H FN O , 432.3]; LC/MS retention time (method D): t = 1.08
24 35 3 3 R
min.
Part H: (S)((6-fluoro-2',4-dimethyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan-
2-amine
A solution of (S)-tert-butyl (1-((6-fluoro-2',4-dimethyl-[2,4'-bipyridin]
yl)oxy)-2,4-dimethylpentanyl)carbamate (38 mg, 0.088 mmol) in DMF (1 mL)
was treated with TFA (1 mL, 12.98 mmol) and stirred at ambient temperature
overnight. The solution was concentrated under reduced pressure. The crude
material was purified via preparative LC/MS (Column: XBridge C18, 19 x 200 mm,
-μm; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate;
Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient:
-60% B over 15 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min).
Obtained (S)((6-fluoro-2',4-dimethyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine (20 mg, 0.060 mmol, 68% crude yield) as a colorless oil that
was used without further purification. LCMS (ESI) m/e 332.3 (M+H) , calcd
C H FN O, 332.2]; LC/MS retention time (method D): t = 0.64 min; H NMR
19 27 3 R
(500MHz, DMSO-d ) δ 8.54 (d, J=5.1 Hz, 1H), 7.99 (s, 1H), 7.83 (s, 1H), 7.74 (d,
J=4.4 Hz, 1H), 3.84 – 3.80 (m, 2H), 2.55 (s, 3H), 2.41 (s, 3H), 1.88 - 1.75 (m, 1H),
1.49 - 1.31 (m, 2H), 1.15 (s, 3H), 1.00 - 0.90 (m, 6H).
Example 108
methyl (5-((3-isobutylazetidinyl)methoxy)methyl-[2,4'-bipyridin]-2'-
yl)carbamate
Part A: 1-tert-butyl 3-methyl 3-isobutylazetidine-1,3-dicarboxylate
A solution of 1-tert-butyl 3-methyl azetidine-1,3-dicarboxylate (5.0 g, 23.23
mmol) and 1-iodomethylpropane (21.37 g, 116 mmol) in tetrahydrofuran (100
mL) at -78 °C was treated dropwise with KHMDS (69.7 mL, 34.8 mmol). The
solution was stirred at ambient temperature overnight. The resulting suspension was
diluted with ethyl acetate (500 mL), washed with 0.5 N aqueous hydrochloric acid
(2x100 mL), and brine (1x100 mL), dried over sodium sulfate and concentrated. The
residue was purified via silica gel chromatography purification (2-20 % ethyl
acetate/hexanes gradient elution) to afford 1-tert-butyl 3-methyl 3-isobutylazetidine-
1,3-dicarboxylate (3.37 g, 12.42mmol, 54% yield) as an amber oil. H NMR
(400MHz, CHLOROFORM-d) δ 4.22 (d, J=8.8 Hz, 2H), 3.82 - 3.70 (m, 5H), 1.87
(d, J=7.0 Hz, 2H), 1.63 - 1.51 (m, 1H), 1.45 (s, 9H), 0.89 (d, J=6.8 Hz, 6H).
Part B: tert-butyl 3-isobutyl(methoxymethyl)azetidinecarboxylate
A solution of 1-tert-butyl 3-methyl 3-isobutylazetidine-1,3-dicarboxylate
(2.51 g, 9.25 mmol) in tetrahydrofuran (40 mL) at ambient temperature was treated
with lithium borohydride (0.403 g, 18.50 mmol) and stirred at 70 °C for 3 h. TLC
indicated 50 % consumption of starting material. The reaction mixture was treated
with additional lithium borohydride (0.302 g, 13.97 mmol) and stirred for 1.5 h at 70
°C. TLC indicated complete consumption of starting material. The reaction mixture
was cooled to 0 °C, quenched with 0.1N aqueous hydrochloric acid, and then diluted
with ethyl acetate. The layers were separated and the aqueous extracted with ethyl
acetate (2x). The pooled organics were dried over sodium sulfate, filtered, and
concentrated under reduced pressure. The residue was purified by silica gel
chromatography (10-80 % ethyl acetate/hexanes gradient elution) to afford tert-butyl
3-isobutyl(methoxymethyl)azetidinecarboxylate (2.07 g, 8.51 mmol, 92%
yield) as a colorless oil. H NMR (400MHz, CHLOROFORM-d) δ 3.81 - 3.70 (m,
4H), 3.64 (d, J=8.5 Hz, 2H), 1.74 (tt, J=13.5, 6.7 Hz, 2H), 1.60 (d, J=7.0 Hz, 2H),
1.46 (s, 9H), 0.91 (d, J=6.5 Hz, 6H).
Part C: tert-butyl 3-(((6-bromomethylpyridinyl)oxy)methyl)
isobutylazetidinecarboxylate
A solution of tert-butyl 3-(hydroxymethyl)isobutylazetidinecarboxylate
(0.582 g, 2.392 mmol) in tetrahydrofuran (4 mL) was charged to a pressure rated vial
and treated dropwise with KOtBu (1M in THF) (2.392 mL, 2.392 mmol). After 5
minutes, 6-bromofluoromethylpyridine (0.50 g, 2.63 mmol) in THF (2 mL) was
added all at once. The vial was sealed and heated to 80 °C overnight. The mixture
was partitioned between ethyl acetate and brine. The layers were separated and the
aqueous extracted with ethyl acetate (2x). The pooled organics were dried over
sodium sulfate and concentrated under reduced pressure. The residue was purified
via silica gel chromatography to afford tert-butyl 3-(((6-bromomethylpyridin
yl)oxy)methyl)isobutylazetidinecarboxylate (50 mg, 0.121 mmol, 5% yield) as
a near colorless oil. LCMS (ESI) m/e 313.0 (M-Boc+H) , calcd C H BrN O,
14 22 2
313.1]; LC/MS retention time (method D): t = 0.92 min.
Part D: tert-butyl 3-isobutyl(((2'-((methoxycarbonyl)amino)methyl-[2,4'-
bipyridin]yl)oxy)methyl)azetidinecarboxylate
A solution of (2-((methoxycarbonyl)amino)pyridinyl)boronic acid (50 mg,
0.255 mmol), tert-butyl 3-(((6-bromomethylpyridinyl)oxy)methyl)
isobutylazetidinecarboxylate (70.3 mg, 0.170 mmol), Pd(Ph P) (13.76 mg, 0.012
mmol), and cesium carbonate (111 mg, 0.340 mmol) in toluene (1 mL), and ethanol
(0.1 mL) was charged to a pressure rated vial and sparged with a stream of nitrogen
for 5 min. The vial was sealed, purged of oxygen, and stirred under nitrogen at 80 °C
overnight. The mixture was cooled to ambient temperature and concentrated under
reduced pressure. The residue was purified by silica gel chromatography (10-80 %
ethyl acetate/hexanes gradient elution) to afford tert-butyl 3-isobutyl(((2'-
((methoxycarbonyl)amino)methyl-[2,4'-bipyridin]yl)oxy)methyl)azetidine
carboxylate (29 mg, 0.060 mmol, 35% yield) as a pale yellow film. LCMS (ESI) m/e
485.1 (M+H) , calcd C H N O , 485.3]; LC/MS retention time (method D): t =
26 37 4 5 R
1.14 min.
Part D: methyl (5-((3-isobutylazetidinyl)methoxy)methyl-[2,4'-bipyridin]-2'-
yl)carbamate
Tert-butyl 3-isobutyl(((2'-((methoxycarbonyl)amino)methyl-[2,4'-
bipyridin]yl)oxy)methyl)azetidinecarboxylate (29 mg, 0.060 mmol) and TFA (1
mL, 12.98 mmol) were stirred at ambient temperature for 3 h. The solution was
concentrated under reduced pressure. The crude material was purified via
preparative HPLC (Column: XBridge C18, 19 x 200 mm, 5-μm; Mobile Phase A:
:95 methanol: water with 10-mM ammonium acetate; Mobile Phase B: 95:5
methanol: water with 10-mM ammonium acetate; Gradient: 40-80% B over 40
minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min). Obtained methyl (5-
((3-isobutylazetidinyl)methoxy)methyl-[2,4'-bipyridin]-2'-yl)carbamate (11.5
mg, 0.030 mmol, 50% yield) as a colorless film. LCMS (ESI) m/e 385.1 (M+H) ,
calcd C H N O , 385.3]; LC/MS retention time (method D): t = 0.76 min; H
21 29 4 3 R
NMR (500MHz, DMSO-d ) δ 8.49 (s, 1H), 8.31 (d, J=5.1 Hz, 1H), 7.86 (d, J=8.4
Hz, 1H), 7.64 (d, J=4.4 Hz, 1H), 7.56 (d, J=8.4 Hz, 1H), 4.27 (s, 2H), 3.54 - 3.38 (m,
4H), 2.46 (s, 3H), 1.86 (m, 3H), 1.73 - 1.59 (m, 3H), 0.86 (d, J=5.9 Hz, 6H).
Example 109
(S)((2-aminomethylpentyl)oxy)(6-methylpyridazinyl)benzonitrile
Part A: (S)-tert-butyl (1-(2-cyano(6-methylpyridazinyl)phenoxy)
methylpentanyl)carbamate
To a 2 mL vial was added (6-methylpyridazinyl)boronic acid (20.56 mg,
0.149 mmol), (S)-tert-butyl (1-(4-bromocyanophenoxy)methylpentan
yl)carbamate (42.3 mg, 0.106 mmol), and Na CO (0.160 mL, 0.319 mmol) in
dioxane (0.5 mL) to give a colorless suspension under nitrogen. 1,1'-
bis(diphenylphosphino)ferrocenepalladium(II) dichloride, toluene (4.38 mg, 5.32
µmol) was added under nitrogen. The vial was sealed and heated at 100 °C (bath:
108 °C) for 2 h. The mixture was diluted with EtOAc, dried with Na SO , and
passed through a plug of Na SO . The organic solution was concentrated to afford
the desired product (70 mg, 100% crude yield) as a tan oil, which was directly used
in the next step. LCMS (ESI) m/e 411.2 [(M+H) , calcd C H N O , 411.2].
23 31 4 3
Part B: (S)((2-aminomethylpentyl)oxy)(6-methylpyridazinyl)benzonitrile
Prepared as previously described in Example 7, Part B to afford (S)((2-
aminomethylpentyl)oxy)(6-methylpyridazinyl)benzonitrile (20.8 mg, 63%
for 2 steps) as a colorless solid. H NMR (500 MHz, DMSO-d ) δ 9.51 (d, J = 2.4
Hz, 1H), 8.40 (d, J = 2.4 Hz, 1H), 8.24 (dd, J = 8.9, 2.5 Hz, 1H), 7.96 (d, J = 2.4 Hz,
1H), 7.44 (d, J = 9.0 Hz, 1H), 4.11 (dd, J = 9.7, 5.1 Hz, 1H), 4.04 (dd, J = 9.6, 6.3
Hz, 1H), 3.17 (t, J = 6.6 Hz, 1H), 2.67 (s, 3H), 1.84 (p, J = 6.6 Hz, 1H), 1.38 (ddd, J
= 13.5, 8.3, 5.0 Hz, 1H), 1.30 (dq, J = 13.9, 7.0, 6.4 Hz, 1H), 0.93 (d, J = 6.6 Hz,
3H), 0.89 (d, J = 6.6 Hz, 3H); LCMS (ESI) m/e 311.2 [(M+H) , calcd C H N O,
18 23 4
311.2]; LC/MS retention time (method B): t = 1.46 min.
Example 110
(S)(2-(isoxazolyl)(quinolinyl)phenoxy)methylpentanamine
Part A: (S)-tert-butyl (1-(4-bromo(isoxazolyl)phenoxy)methylpentan
yl)carbamate
To a 15 mL vial was added (S)-tert-butyl (1-hydroxymethylpentan
yl)carbamate (204 mg, 0.939 mmol), Ph3P (320 mg, 1.220 mmol), and 4-bromo
(isoxazolyl)phenol (225 mg, 0.939 mmol) in tetrahydrofuran (3 mL) to give a tan
solution. DIAD (0.256 mL, 1.314 mmol) was added at rt. The resultant clear tan
solution was stirred at rt overnight for18h. The solution was concentrated to a dense
oil and was directly purified by silica gel chromatography (up to 40% EtOAc/hexane)
to afford (S)-tert-butyl (1-(4-bromo(isoxazolyl)phenoxy)methylpentan
yl)carbamate (319 mg, 77%) as a white solid: H NMR (400 MHz, Chloroform-d) δ
8.31 (s, 1H), 8.09 (d, J = 2.4 Hz, 1H), 7.46 (dd, J = 9.1, 2.6 Hz, 1H), 6.88 (d, J = 9.0
Hz, 2H), 4.60 (d, J = 8.9 Hz, 1H), 4.19 (d, J = 7.0 Hz, 1H), 4.02 (qd, J = 9.2, 5.2 Hz,
2H), 1.75 (dq, J = 13.6, 6.7 Hz, 1H), 1.46 (d, J = 12.0 Hz, 11H), 0.98 (d, J = 6.6 Hz,
6H).
Part B: (S)-tert-butyl (1-(2-(isoxazolyl)(quinolinyl)phenoxy)
methylpentanyl)carbamate
Prepared as previously described in Example 109 to afford (S)-tert-butyl (1-
(2-(isoxazolyl)(quinolinyl)phenoxy)methylpentanyl)carbamate.
LCMS (ESI) m/e 488.4 [(M+H) , calcd C H N O , 488.2]; LC/MS retention time
29 34 3 4
(method A): t = 2.27 min.
Part C: (S)(2-(isoxazolyl)(quinolinyl)phenoxy)methylpentanamine
Prepared as previously described in Example 7, Part B to afford (S)(2-
(isoxazolyl)(quinolinyl)phenoxy)methylpentanamine (12.9 mg, 44%
for two steps): H NMR (500 MHz, DMSO-d ) δ 8.97 (d, J = 4.4 Hz, 1H), 8.72 (d, J
= 1.8 Hz, 1H), 8.14 (d, J = 8.5 Hz, 1H), 8.02 (d, J = 2.3 Hz, 1H), 7.95 (d, J = 8.5 Hz,
1H), 7.82 (t, J = 7.6 Hz, 1H), 7.70 (dd, J = 8.5, 2.3 Hz, 1H), 7.64 (t, J = 7.6 Hz, 1H),
7.54 (d, J = 4.4 Hz, 1H), 7.45 (d, J = 8.6 Hz, 1H), 7.06 (d, J = 1.9 Hz, 1H), 4.13 (dd,
J = 9.4, 4.9 Hz, 1H), 4.05 (dd, J = 9.4, 6.2 Hz, 1H), 3.25 (dq, J = 10.4, 5.6 Hz, 1H),
1.85 (dt, J = 13.4, 7.5 Hz, 1H), 1.41 (ddd, J = 13.4, 8.4, 4.7 Hz, 1H), 1.32 (ddd, J =
13.8, 8.7, 5.6 Hz, 1H), 0.93 (dd, J = 9.2, 6.6 Hz, 6H); LCMS (ESI) m/e 388.1
[(M+H) , calcd C H N O , 388.2]; LC/MS retention time (method B): t = 1.59
24 26 3 2 R
min.
Example 111
(S)(4-((2-amino-2,4-dimethylpentyl)oxy)(trifluoromethyl)phenyl)
methylnicotinic acid
Part A: (3-(methoxycarbonyl)methylpyridinyl)boronic acid
To a vial was added methyl 4-chloromethylnicotinate (52 mg, 0.280
mmol), hypodiboric acid (37.7 mg, 0.420 mmol), 2-(dicyclohexylphosphino))-2',4',6'-
triisopropylbiphenyl (2.67 mg, 5.60 µmol), Xphos precatalyst (2.204 mg, 2.80 µmol)
and potassium acetate (82 mg, 0.840 mmol) in ethanol (2.6 mL) to give a tan
suspension (degassed before adding reagents). The vial was capped and heated at 80
°C for 1 h. LCMS showed conversion of the starting material to a new polar peak but
with no parent ion. The mixture was directly used in the next step.
Part B: (S)(4-((2-amino-2,4-dimethylpentyl)oxy)(trifluoromethyl)phenyl)
methylnicotinic acid
To a 20 mL vial was added (3-(methoxycarbonyl)methylpyridin
yl)boronic acid (48.9 mg, 0.251 mmol) (previous reaction vessel) was added
potassium phosphate tribasic (2.2 mL, 1.100 mmol). After degassing for 5 min,
Xphos precatalyst (4.5 mg, 5.72 µmol) and (S)(4-bromo
(trifluoromethyl)phenoxy)-2,4-dimethylpentanamine (33 mg, 0.084 mmol) and
tetrahydrofuran (2.2 mL) were added. The vial was sealed and heated at 80 °C
overnight for 18 h. Volatiles were blown off. The residue was partitioned between
EtOAc and water. The organic layer was dried, filtered and concentrated. The
residue was dissolved in MeOH and purified by prep-HPLC to afford (S)(4-((2-
amino-2,4-dimethylpentyl)oxy)(trifluoromethyl)phenyl)methylnicotinic acid
(18.8 mg, 53%): H NMR (600 MHz, DMSO-d ) δ 8.27 (d, J = 5.1 Hz, 1H), 7.88 (s,
1H), 7.83 (d, J = 8.6 Hz, 1H), 7.08 (d, J = 5.2 Hz, 1H), 6.96 (d, J = 8.6 Hz, 1H), 3.99
- 3.92 (m, 2H), 2.47 (s, 3H), 1.88 - 1.72 (m, 1H), 1.60 - 1.45 (m, 2H), 1.24 (s, 3H),
0.89 (d, J = 6.5 Hz, 6H); LCMS (ESI) m/e 433.2 [(M+Na) , calcd C H F N O Na,
21 25 3 2 3
433.2]; LC/MS retention time (method C): t = 2.60 min.
Example 112
(S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)
((dimethylamino)methyl)phenyl)pyridinyl)carbamate
Part A: (S)-methyl (4-(4-((2-Boc-amino-2,4-dimethylpentyl)oxy)
((dimethylamino)methyl)phenyl)pyridinyl)carbamate
To a 2 mL vial was added crude aldehyde (prepared as described in Example
32 (10.68 mg, 0.022 mmol) in CH Cl (0.5 mL) to give a tan solution.
Dimethylamine (0.110 mL, 0.220 mmol) (2.0 M in THF, excess) was added,
followed by sodium triacetoxyborohydride (0.019 g, 0.088 mmol). The mixture was
stirred at rt overnight for 16 h. LCMS showed complete conversion to the desired
product (M + H = 515.2). The mixture was partitioned between water and EtOAc.
The layers were separated. The organic layer was washed with brine, dried and
concentrated. The tan residue was directly carried onto next reaction.
Part B: (S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)
((dimethylamino)methyl)phenyl)pyridinyl)carbamate
Prepared as previously described in Example 7, Part B to afford (S)-methyl
(4-(4-((2-amino-2,4-dimethylpentyl)oxy)((dimethylamino)methyl)phenyl)pyridin-
2-yl)carbamate (5.5 mg, 60% for three steps): H NMR (500 MHz, DMSO-d ) δ 8.28
(d, J = 5.3 Hz, 1H), 8.10 (s, 1H), 7.64 (d, J = 6.8 Hz, 2H), 7.32 (d, J = 5.4 Hz, 1H),
7.12 (d, J = 8.8 Hz, 1H), 3.83 (s, 2H), 3.70 (s, 3H), 3.51 (s, 2H), 2.20 (s, 6H), 1.81
(dt, J = 12.6, 6.4 Hz, 1H), 1.46 (qd, J = 14.0, 5.6 Hz, 2H), 1.19 (s, 3H), 0.94 (t, J =
6.1 Hz, 6H); LCMS (ESI) m/e 415.1 [(M+H) , calcd C H N O , 415.3]; LC/MS
23 35 4 3
retention time (method B): t = 1.43 min.
Example 113
(S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)
(methylsulfonyl)phenyl)pyridinyl)carbamate
Part A: (S)(4-bromo(methylsulfonyl)phenoxy)-2,4-dimethylpentanamine
To a 5 mL vial was added (S)amino-2,4-dimethylpentanol (120 mg,
0.915 mmol) in tetrahydrofuran (1.2 mL) to give a colorless solution. Potassium tert-
butoxide (1.097 mL, 1.097 mmol) (1.0 M in THF) was added dropwise under
nitrogen. After 5 min, 4-bromofluoro(methylsulfonyl)benzene (243 mg, 0.960
mmol) was added in one portion. The bottle was sealed and the mixture was stirred
at 70 °C for 18 h. The mixture was partitioned between water and EtOAc. The
layers were separated. The aqueous layer was extracted with EtOAc. The combined
organic solution was washed with brine, dried and concentrated to a red oil (313 mg,
94%): H NMR (400 MHz, Chloroform-d) δ 8.10 (d, J = 2.6 Hz, 1H), 7.69 (dd, J =
8.8, 2.5 Hz, 1H), 6.94 (d, J = 8.8 Hz, 1H), 3.90 (q, J = 8.5 Hz, 2H), 3.24 (s, 3H), 1.90
- 1.75 (m, 1H), 1.52 (dd, J = 5.7, 3.5 Hz, 2H), 1.28 (s, 3H), 1.01 (dd, J = 10.6, 6.7
Hz, 6H); LCMS (ESI) m/e 363.9 [(M+H) , calcd C14H23BrNO S, 364.1]; LC/MS
retention time (method B): t = 1.64 min.
Part B: (S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)
(methylsulfonyl)phenyl)pyridinyl)carbamate
Prepared as previously described in Example 109 to afford (S)-methyl (4-(4-
((2-amino-2,4-dimethylpentyl)oxy)(methylsulfonyl)phenyl)pyridinyl)carbamate
(25.6 mg, 75%): H NMR (500 MHz, DMSO-d ) δ 8.34 (d, J = 5.2 Hz, 1H), 8.14 (s,
1H), 8.12 - 8.03 (m, 2H), 7.45 (d, J = 8.6 Hz, 1H), 7.38 (d, J = 5.3 Hz, 1H), 3.97 (s,
2H), 3.71 (s, 3H), 3.42 (s, 3H), 1.83 (dt, J = 12.2, 6.2 Hz, 1H), 1.49 - 1.37 (m, 2H),
1.17 (s, 3H), 0.94 (dd, J = 8.7, 6.6 Hz, 6H); LCMS (ESI) m/e 436.0 [(M+H) , calcd
C H N O S, 436.2]; LC/MS retention time (method B): t = 1.52 min.
21 30 3 5 R
Example 114
(S)-2,4-dimethyl(4-(2-methylpyridinyl)(methylsulfonyl)phenoxy)pentan
amine
Prepared as described in Example 113 to afford (S)-2,4-dimethyl(4-(2-
methylpyridinyl)(methylsulfonyl)phenoxy)pentanamine (19 mg, 0.049
mmol, 83%): H NMR (500 MHz, DMSO-d ) δ 8.51 (d, J = 5.3 Hz, 1H), 8.17 - 8.10
(m, 2H), 7.59 (s, 1H), 7.52 - 7.46 (m, 1H), 7.43 (d, J = 9.2 Hz, 1H), 3.97 (s, 2H),
3.55 (s, 3H), 2.55 (s, 3H), 1.83 (dt, J = 13.0, 6.3 Hz, 1H), 1.50 - 1.37 (m, 2H), 1.17
(s, 3H), 0.94 (dd, J = 8.8, 6.5 Hz, 6H); LCMS (ESI) m/e 377.0 [(M+H) , calcd
C H N O S, 377.2]; LC/MS retention time (method B): t = 1.32 min.
29 2 3 R
Example 115
(S)-2,4-dimethyl(2-(methylsulfonyl)(quinolinyl)phenoxy)pentanamine
Prepared as described in Example 113 to afford (S)-2,4-dimethyl(2-
(methylsulfonyl)(quinolinyl)phenoxy)pentanamine (12.2 mg, 0.029 mmol,
58%): H NMR (500 MHz, DMSO-d ) δ 8.97 (d, J = 4.4 Hz, 1H), 8.14 (d, J = 8.3
Hz, 1H), 7.95 - 7.87 (m, 3H), 7.83 (t, J = 7.7 Hz, 1H), 7.65 (t, J = 7.7 Hz, 1H), 7.55 -
7.47 (m, 2H), 4.01 (s, 2H), 3.49 (s, 3H), 1.85 (dt, J = 12.9, 6.5 Hz, 1H), 1.53 - 1.39
(m, 2H), 1.19 (s, 3H), 0.97 (dd, J = 8.4, 6.6 Hz, 6H); LCMS (ESI) m/e 413.0
[(M+H) , calcd C H N O S, 413.2]; LC/MS retention time (method B): t = 1.41
23 29 2 3 R
min.
Example 116
(S)(2-(difluoromethyl)(6-fluoroquinolinyl)phenoxy)-2,4-dimethylpentan
amine
Part A: (S)(2-(difluoromethyl)(4,4,5,5-tetramethyl-1,3,2-dioxaborolan
yl)phenoxy)-2,4-dimethylpentanamine
To a 5 mL vial was added (S)(4-bromo(difluoromethyl)phenoxy)-2,4-
dimethylpentanamine (16.2 mg, 0.048 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-
bi(1,3,2-dioxaborolane) (14.68 mg, 0.058 mmol), and potassium acetate (14.19 mg,
0.145 mmol) in dioxane (0.5 mL) to give a colorless suspension with nitrogen
bubbling. PdCl (dppf) (1.058 mg, 1.446 µmol) was added under nitrogen. The vial
was sealed and the mixture was heated at 80 °C for 4 h. LCMS showed most starting
material was gone and several peaks. It was used directly in the next step.
Part B: (S)(2-(difluoromethyl)(6-fluoroquinolinyl)phenoxy)-2,4-
dimethylpentanamine
The mixture of (S)(2-(difluoromethyl)(4,4,5,5-tetramethyl-1,3,2-
dioxaborolanyl)phenoxy)-2,4-dimethylpentanamine (18.40 mg, 0.048 mmol),
1,1'-bis(diphenylphosphino)ferrocenepalladium(II) dichloride, dichloromethane
complex (2.74 mg, 3.36 µmol) , Na CO (0.096 mL, 0.192 mmol) and 4-chloro
fluoroquinoline (8.72 mg, 0.048 mmol) in dioxane (0.5 mL) (degassed) (previous
vial) was heated at 120 °C for 16 h. The reaction mixture was diluted with ethyl
acetate and dried (Na SO ), filtered and concentrated. The residue was dissolved in
MeOH and purified by prep-HPLC to afford (S)(2-(difluoromethyl)(6-
fluoroquinolinyl)phenoxy)-2,4-dimethylpentanamine (6.7 mg, 35% for two
steps): H NMR (500 MHz, DMSO-d ) δ 8.95 (d, J = 4.5 Hz, 1H), 8.20 (dd, J = 9.2,
.7 Hz, 1H), 7.74 (ddd, J = 13.0, 8.0, 3.4 Hz, 2H), 7.68 (d, J = 2.3 Hz, 1H), 7.54 (d, J
= 4.4 Hz, 1H), 7.50 (dd, J = 10.3, 2.9 Hz, 1H), 7.44 - 7.17 (m, 2H), 3.61 (s, 2H), 1.82
(dq, J = 12.8, 6.4 Hz, 1H), 1.50 - 1.37 (m, 2H), 1.16 (s, 3H), 0.95 (dd, J = 10.2, 6.6
Hz, 6H); LCMS (ESI) m/e 403.0 [(M+H) , calcd C H F N O, 403.2]; LC/MS
23 26 3 2
retention time (method B): t = 1.78 min.
Example 117
(S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)(difluoromethyl)-[2,4'-
bipyridin]-2'-yl)carbamate
Part A: 6-bromo(difluoromethyl)fluoropyridine
To a 100 mL round-bottomed flask was added 6-bromo
fluoropicolinaldehyde (459.8 mg, 2.254 mmol) in CH Cl (10 mL) to give a tan
solution. After cooling to -20 °C, DAST (0.596 mL, 4.51 mmol) was added dropwise
under nitrogen. The mixture was gradually warmed up to rt. The mixture was stirred
at rt for 3 h. TLC (3/1 hexane/EtOAc) showed complete conversion to a less polar
spot. The reaction was slowly quenched by saturated NaHCO solution and diluted
with ether. The layers were separated. The organic layer was washed with water,
brine, dried and concentrated to 6-bromo(difluoromethyl)fluoropyridine (509
mg, 100%) as a tan solid: H NMR (400 MHz, Chloroform-d) δ 7.65 (ddt, J = 8.6,
3.5, 1.0 Hz, 1H), 7.46 (t, J = 8.7 Hz, 1H), 6.73 (t, J = 53.4 Hz, 1H); F NMR (376
MHz, Chloroform-d) δ -116.97, -127.89.
Part B: (S)((6-bromo(difluoromethyl)pyridinyl)oxy)-2,4-dimethylpentan
amine
To a 5 mL pressure bottle was added (S)amino-2,4-dimethylpentanol
(140 mg, 1.067 mmol) in tetrahydrofuran (1.3 mL) to give a colorless solution.
Potassium tert-butoxide (1.280 mL, 1.280 mmol) (1.0 M in THF) was added
dropwise under nitrogen. After 5 min, 6-bromo(difluoromethyl)fluoropyridine
(241 mg, 1.067 mmol) was added in one portion. The bottle was sealed and the
mixture was stirred at 80 °C for 18 h. The mixture was partitioned between water
and EtOAc. The layers were separated. The aqueous layer was extracted with
EtOAc. The combined organic solution was washed with brine, dried and
concentrated to a tan oil (338 mg, 94%): H NMR (400 MHz, Chloroform-d) δ 7.54
(dt, J = 9.0, 1.1 Hz, 1H), 7.22 (d, J = 8.8 Hz, 1H), 6.74 (t, J = 53.9 Hz, 1H), 3.79 (d,
J = 1.7 Hz, 2H), 1.80 (dtd, J = 13.3, 6.7, 1.1 Hz, 1H), 1.54 (s, 2H), 1.52 - 1.47 (m,
2H), 1.25 (s, 3H), 1.00 (dd, J = 8.3, 6.6 Hz, 6H); F NMR (376 MHz, Chloroform-d)
δ -117.98.; LCMS (ESI) m/e 336.9 [(M+H) , calcd C H BrF N O, 337.1]; LC/MS
13 20 2 2
retention time (method B): t = 1.67 min.
Part C: (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)(difluoromethyl)-[2,4'-
bipyridin]-2'-yl)carbamate
To a 2 mL vial was added (S)((6-bromo(difluoromethyl)pyridin
yl)oxy)-2,4-dimethylpentanamine (28.4 mg, 0.084 mmol), (2-
((methoxycarbonyl)amino)pyridinyl)boronic acid (41.3 mg, 0.211 mmol), and
Na CO (0.126 mL, 0.253 mmol) in dioxane (0.6 mL) to give a colorless suspension
under nitrogen. 1,1'-bis(diphenylphosphino)ferrocenepalladium(II) dichloride,
toluene (3.46 mg, 4.21 µmol) was added under nitrogen. The vial was sealed and
heated at 100 °C (bath temp: 110 °C) for 3 h. The mixture was diluted with EtOAc
and passed through a plug of Na SO . The organic solution was concentrated. The
residue was purified twice by prep-HPLC to afford (S)-methyl (5-((2-amino-2,4-
dimethylpentyl)oxy)(difluoromethyl)-[2,4'-bipyridin]-2'-yl)carbamate (12.6 mg,
37%): H NMR (500 MHz, DMSO-d ) δ 8.50 (s, 1H), 8.36 (d, J = 5.2 Hz, 1H), 8.17
(d, J = 8.8 Hz, 1H), 7.78 (d, J = 8.8 Hz, 1H), 7.67 (dd, J = 5.1, 1.7 Hz, 1H), 7.22 (t, J
= 53.6 Hz, 1H), 3.88 (s, 2H), 3.52 (s, 3H), 1.86 - 1.73 (m, 1H), 1.47 - 1.33 (m, 2H),
1.13 (s, 3H), 0.93 (dd, J = 10.0, 6.6 Hz, 6H); LCMS (ESI) m/e 409.0 (M+H) , calcd
C H F N O , 409.2]; LC/MS retention time (method B): t = 1.66 min.
27 2 4 3 R
Example 118
(S)((2-(difluoromethyl)(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentan
amine
Prepared as described in Example 117 to afford (S)((2-(difluoromethyl)
(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentanamine (10.6 mg, 0.027 mmol,
60% yield for three steps): H NMR (500 MHz, DMSO-d ) δ 9.01 (d, J = 4.4 Hz,
1H), 8.21 (d, J = 8.5 Hz, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.97 (d, J = 8.7 Hz, 1H), 7.87
(d, J = 8.7 Hz, 1H), 7.82 (t, J = 7.7 Hz, 1H), 7.64 (dd, J = 9.5, 6.0 Hz, 2H), 7.28 (t, J
= 53.6 Hz, 1H), 3.53 (s, 2H), 1.83 (dt, J = 13.2, 6.6 Hz, 1H), 1.50 - 1.37 (m, 2H),
1.16 (s, 3H), 0.95 (dd, J = 10.0, 6.7 Hz, 6H); LCMS (ESI) m/e 386.0 [(M+H) , calcd
C H F N O, 386.2]; LC/MS retention time (method B): t = 1.54 min.
22 26 2 3 R
Example 119
(S)((6-(difluoromethyl)-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan-
2-amine
Prepared as described in Example 117 to afford (S)((6-(difluoromethyl)-2'-
methyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine (18.3 mg, 0.051
mmol, 92% yield for three steps): H NMR (500 MHz, DMSO-d ) δ 8.54 (d, J = 5.2
Hz, 1H), 8.26 (d, J = 8.8 Hz, 1H), 7.90 (s, 1H), 7.82 (d, J = 5.3 Hz, 1H), 7.78 (d, J =
8.8 Hz, 1H), 7.23 (t, J = 53.6 Hz, 1H), 3.89 (s, 2H), 2.56 (s, 3H), 1.81 (dq, J = 12.8,
6.5 Hz, 1H), 1.50 - 1.34 (m, 2H), 1.14 (s, 3H), 0.92 (dd, J = 10.5, 6.6 Hz, 6H);
LCMS (ESI) m/e 350.0 [(M+H) , calcd C H F N O, 350.2]; LC/MS retention time
19 26 2 3
(method B): t = 1.45 min.
Example 120
(S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)(difluoromethyl)-[2,4'-
bipyridin]-2'-yl)carbamate
Part A: 2-bromo(difluoromethyl)fluoropyridine
To a 100 mL round-bottomed flask was added 2-bromo
fluoroisonicotinaldehyde (605 mg, 2.97 mmol) in CH Cl (12 mL) to give a tan
solution. After cooling to -20 °C, DAST (0.705 mL, 5.34 mmol) was added dropwise
under nitrogen. The mixture was gradually warmed up to rt. The mixture was stirred
at rt for 3 h. TLC (3/1 hexane/EtOAc) showed complete conversion to a less polar
spot. The reaction was slowly quenched by saturated NaHCO3 solution and diluted
with ether. The layers were separated. The organic layer was washed with water,
brine, dried and concentrated to afford 2-bromo(difluoromethyl)fluoropyridine
(639 mg, 95%) as a tan oil: H NMR (400 MHz, Chloroform-d) δ 8.39 (q, J = 1.2 Hz,
1H), 7.77 - 7.68 (m, 1H), 6.86 (t, J = 54.0 Hz, 1H); F NMR (376 MHz,
Chloroform-d) δ -117.92 , -135.51.
Part B: (S)((6-bromo(difluoromethyl)pyridinyl)oxy)-2,4-dimethylpentan
amine
To a 20 mL pressure bottle was added (S)amino-2,4-dimethylpentanol
(146 mg, 1.113 mmol) and 2-bromo(difluoromethyl)fluoropyridine (251 mg,
1.113 mmol) in tetrahydrofuran (1.5 mL) to give a tan solution. Potassium tert-
butoxide (1.335 mL, 1.335 mmol) (1.0 M in THF) was added dropwise under
nitrogen. After 5 min stirring at rt, the bottle was sealed and the mixture was stirred
at 80 °C for 18 h. The mixture was partitioned between water and EtOAc. The
layers were separated. The aqueous layer was extracted with EtOAc. The combined
organic solution was washed with brine, dried and concentrated to a tan oil (361 mg,
96%): H NMR (400 MHz, Chloroform-d) δ 8.13 (s, 1H), 7.62 (s, 1H), 6.85 (t, J =
54.4 Hz, 1H), 3.87 (s, 2H), 1.80 (dtd, J = 13.2, 6.7, 1.0 Hz, 1H), 1.61 - 1.50 (m, 2H),
1.50 - 1.47 (m, 2H), 1.24 (s, 3H), 1.00 (dd, J = 7.4, 6.7 Hz, 6H); F NMR (376 MHz,
Chloroform-d) δ -119.58; LCMS (ESI) m/e 336.9 [(M+H) , calcd C H BrF N O,
13 20 2 2
337.1]; LC/MS retention time (method B): t = 1.79 min.
Part C: (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)(difluoromethyl)-[2,4'-
bipyridin]-2'-yl)carbamate
Prepared as described in Example 117 to afford (S)-methyl (5-((2-amino-2,4-
dimethylpentyl)oxy)(difluoromethyl)-[2,4'-bipyridin]-2'-yl)carbamate (2.5 mg,
0.006 mmol, 6% yield for three steps): H NMR (500 MHz, DMSO-d6) δ 8.71 (s,
1H), 8.53 (s, 1H), 8.36 (d, J = 5.2 Hz, 1H), 8.08 (s, 1H), 7.71 (d, J = 5.2 Hz, 1H),
7.48 (t, J = 53.9 Hz, 1H), 4.12 (s, 2H), 3.71 (s, 3H), 1.82 (dt, J = 12.9, 6.4 Hz, 1H),
1.53 (dd, J = 14.2, 5.3 Hz, 1H), 1.46 (dd, J = 14.2, 5.8 Hz, 1H), 1.22 (s, 3H), 0.95 (d,
J = 6.6 Hz, 3H), 0.91 (d, J = 6.6 Hz, 3H); LCMS (ESI) m/e 408.9 (M+H) , calcd
C H F N O , 409.2]; LC/MS retention time (method B): t = 1.66 min.
27 2 4 3 R
Example 121
(S)((4-(difluoromethyl)(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentan
amine
Prepared as described in Example 117 to afford (S)((4-(difluoromethyl)
(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentanamine (11.7 mg, 0.030 mmol,
69% yield for three steps): H NMR (500 MHz, DMSO-d ) δ 9.00 (d, J = 4.4 Hz,
1H), 8.78 (s, 1H), 8.18 (d, J = 8.5 Hz, 1H), 8.13 (d, J = 8.5 Hz, 1H), 7.88 (s, 1H),
7.82 (t, J = 7.6 Hz, 1H), 7.69 - 7.60 (m, 2H), 7.39 (t, J = 53.8 Hz, 1H), 4.06 (s, 2H),
1.84 (dt, J = 12.9, 6.3 Hz, 1H), 1.51 - 1.37 (m, 2H), 1.17 (s, 3H), 0.96 (dd, J = 11.7,
6.7 Hz, 6H); LCMS (ESI) m/e 386.0 [(M+H) , calcd C H F N O, 386.2]; LC/MS
22 26 2 3
retention time (method B): t = 1.58 min.
Example 122
(S)((4-(difluoromethyl)-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan-
2-amine
Prepared as described in Example 117 to afford (S)((4-(difluoromethyl)-2'-
methyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine (13.6 mg, 0.039
mmol, 74% yield for three steps): H NMR (500 MHz, DMSO-d ) δ 8.68 (s, 1H),
8.54 (d, J = 5.3 Hz, 1H), 8.19 (s, 1H), 7.94 (s, 1H), 7.84 (d, J = 5.2 Hz, 1H), 7.39 (t,
J = 53.9 Hz, 1H), 4.06 (s, 2H), 2.56 (s, 3H), 1.81 (dt, J = 12.8, 6.4 Hz, 1H), 1.45 (qd,
J = 14.2, 5.7 Hz, 2H), 1.18 (s, 3H), 0.94 (d, J = 6.6 Hz, 3H), 0.91 (d, J = 6.6 Hz,
3H); LCMS (ESI) m/e 350.0 [(M+H) , calcd C H F N O, 350.2]; LC/MS retention
19 26 2 3
time (method B): t = 1.46 min.
Example 123
(S)((2',6-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
amine
Part A: (2-(difluoromethyl)pyridinyl)boronic acid
To a 20 mL vial was added 4-chloro(difluoromethyl)pyridine
hydrochloride (180 mg, 0.900 mmol), hypodiboric acid (121 mg, 1.350 mmol), 2-
(dicyclohexylphosphino))-2',4',6'-triisopropylbiphenyl (8.58 mg, 0.018 mmol), Xphos
precatalyst (7.08 mg, 9.00 µmol) and potassium acetate (265 mg, 2.70 mmol) in
ethanol (8.5 mL) to give a tan suspension (degassed before adding agents). The
bottle was capped and heated at 80 °C for 1.5 h. LCMS showed the consumption of
the starting material and formation of a new spot: (2-(difluoromethyl)pyridin
yl)boronic acid. The mixture was divided into parts and directly used in the next step
of different reactions.
Part B: (S)((2',6-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine
To a 5 mL vial was added (2-(difluoromethyl)pyridinyl)boronic acid (25.9
mg, 0.15 mmol) was added potassium phosphate tribasic (1 mL, 0.500 mmol). After
degassing for 5 min, Xphos precatalyst (4 mg, 5.08 µmol) and (S)((6-bromo
(difluoromethyl)pyridinyl)oxy)-2,4-dimethylpentanamine (26.5 mg, 0.079
mmol) and tetrahydrofuran (1mL) were added. The vial was sealed and heated at 80
°C overnight for 18 h. Volatiles were blown off. The residue was partitioned
between EtOAc and water. The organic layer was dried, filtered and concentrated.
The residue was dissolved in MeOH and purified by prep-HPLC to afford (S)
((2',6-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine
(29.8 mg, 98%) as a colorless solid. H NMR (500 MHz, DMSO-d6) δ 8.79 (d, J =
.2 Hz, 1H), 8.40 (d, J = 8.8 Hz, 1H), 8.32 (s, 1H), 8.21 (d, J = 5.1 Hz, 1H), 7.82 (d,
J = 8.9 Hz, 1H), 7.31 (t, J = 53.5 Hz, 1H), 7.04 (t, J = 54.9 Hz, 1H), 3.96 (s, 2H),
3.46 (s, 2H), 1.80 (dp, J = 12.5, 6.7, 6.3 Hz, 1H), 1.45 (qd, J = 14.1, 5.6 Hz, 2H),
1.17 (s, 3H), 0.92 (dd, J = 13.6, 6.6 Hz, 6H); F NMR (376 MHz, DMSO-d ) δ -
115.43 (d, J = 55.2 Hz), -117.78 - -119.55 (m); LCMS (ESI) m/e 386.0 [(M+H) ,
calcd C H F N O, 386.2]; LC/MS retention time (method B): t = 1.85 min.
19 24 4 3 R
Example 124
(S)((2',4-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
amine
Prepared as described in Example 123 to afford (S)((2',4-
bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine (25.9 mg,
0.067 mmol, 77% yield) as a colorless solid. H NMR (500 MHz, DMSO-d ) δ 8.79
(d, J = 5.2 Hz, 1H), 8.71 (s, 1H), 8.36 (s, 1H), 8.32 (s, 1H), 8.25 (d, J = 5.1 Hz, 1H),
7.35 (t, J = 53.9 Hz, 1H), 7.04 (t, J = 54.9 Hz, 1H), 4.03 (s, 2H), 1.81 (dt, J = 12.8,
6.4 Hz, 1H), 1.48 - 1.33 (m, 2H), 1.14 (s, 3H), 0.93 (dd, J = 12.3, 6.6 Hz, 6H); F
NMR (376 MHz, DMSO-d ) δ -115.44 (d, J = 54.7 Hz), -116.34 - -119.67 (m);
LCMS (ESI) m/e 386.0 [(M+H) , calcd C H F N O, 386.2]; LC/MS retention time
19 24 4 3
(method B): tR = 1.83 min.
Example 125
(S)((2'-(difluoromethyl)methyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan-
2-amine
Part A: (S)-tert-butyl (1-((2'-(difluoromethyl)methyl-[2,4'-bipyridin]yl)oxy)-
2,4-dimethylpentanyl)carbamate
Prepared as described in Example 123 to afford (S)-tert-butyl (1-((2'-
(difluoromethyl)methyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
yl)carbamate (38.5 mg, 0.086 mmol, 80% yield) as a colorless solid. H NMR (400
MHz, Chloroform-d) δ 8.71 (d, J = 5.2 Hz, 1H), 8.31 (s, 1H), 8.18 (d, J = 1.7 Hz,
1H), 7.98 (dd, J = 5.2, 1.7 Hz, 1H), 7.66 (s, 1H), 6.72 (t, J = 55.5 Hz, 1H), 4.63 (s,
1H), 4.32 (d, J = 8.7 Hz, 1H), 4.14 (d, J = 8.8 Hz, 1H), 2.36 (s, 3H), 1.96 - 1.77 (m,
2H), 1.65 - 1.54 (m, 1H), 1.44 (s, 3H), 1.42 (s, 9H), 1.01 (dd, J = 6.6, 3.5 Hz, 6H);
19 +
F NMR (376 MHz, Chloroform-d) δ -115.81; LCMS (ESI) m/e 450.1 [(M+H) ,
calcd C H F N O , 450.2]; LC/MS retention time (method B): t = 2.31 min.
24 34 2 3 3 R
Part B: (S)((2'-(difluoromethyl)methyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine
Prepared as previously described in Example 7, Part B (34.9 mg, 100%): H
NMR (500 MHz, DMSO-d6) δ 8.76 (d, J = 5.1 Hz, 1H), 8.42 (s, 1H), 8.31 (s, 1H),
8.22 - 8.15 (m, 1H), 8.12 (s, 1H), 7.03 (t, J = 55.0 Hz, 1H), 4.13 - 4.00 (m, 2H), 2.36
(s, 3H), 1.83 (dp, J = 12.7, 6.5 Hz, 1H), 1.60 (dd, J = 14.1, 5.5 Hz, 1H), 1.52 (dd, J =
14.1, 5.6 Hz, 1H), 1.27 (s, 3H), 0.95 (d, J = 6.6 Hz, 3H), 0.92 (d, J = 6.6 Hz, 3H); F
NMR (376 MHz, DMSO-d6) δ -115.37 (d, J = 54.8 Hz); LCMS (ESI) m/e 350.0
[(M+H) , calcd C H F N O, 350.2]; LC/MS retention time (method B): t = 1.80
19 26 2 3 R
min.
Example 126
(S)(2-cyclopropyl(2-(difluoromethyl)pyridinyl)phenoxy)-2,4-
dimethylpentanamine
Part A: (S)-tert-butyl (1-(2-cyclopropyl(2-(difluoromethyl)pyridinyl)phenoxy)-
2,4-dimethylpentanyl)carbamate
Prepared as described in Example 123 to afford (S)-tert-butyl (1-(2-
cyclopropyl(2-(difluoromethyl)pyridinyl)phenoxy)-2,4-dimethylpentan
yl)carbamate (31.4 mg, 0.066 mmol, 79% yield) as a colorless solid. H NMR (400
MHz, Chloroform-d) δ 8.65 (d, J = 5.1 Hz, 1H), 7.79 (d, J = 1.7 Hz, 1H), 7.56 (dd, J
= 5.2, 1.8 Hz, 1H), 7.47 (dd, J = 8.4, 2.4 Hz, 1H), 7.23 (d, J = 2.3 Hz, 1H), 6.97 (d, J
= 8.4 Hz, 1H), 6.71 (t, J = 55.5 Hz, 1H), 4.73 (s, 1H), 4.21 (d, J = 8.8 Hz, 1H), 4.05
(d, J = 8.8 Hz, 1H), 2.19 (tt, J = 8.6, 5.4 Hz, 1H), 1.87 (ddt, J = 13.1, 11.4, 6.8 Hz,
2H), 1.72 - 1.62 (m, 1H), 1.47 (s, 3H), 1.43 (s, 9H), 1.01 (dt, J = 5.5, 2.7 Hz, 8H),
0.74 (td, J = 5.7, 4.0 Hz, 2H); F NMR (376 MHz, Chloroform-d) δ -115.77; LCMS
(ESI) m/e 475.0 [(M+H) , calcd C H F N O , 475.3]; LC/MS retention time
27 37 2 2 3
(method B): t = 2.48 min.
Part B: (S)(2-cyclopropyl(2-(difluoromethyl)pyridinyl)phenoxy)-2,4-
dimethylpentanamine
Prepared as previously described in Example 7, Part B (25.8 mg, 100%) as a
colorless solid. H NMR (500 MHz, DMSO-d ) δ 8.66 (d, J = 5.3 Hz, 1H), 7.94 (s,
1H), 7.86 (d, J = 5.3 Hz, 1H), 7.66 (dd, J = 8.6, 2.3 Hz, 1H), 7.32 (d, J = 2.4 Hz,
1H), 7.11 - 6.84 (m, 2H), 3.90 - 3.79 (m, 2H), 2.26 (td, J = 8.5, 4.2 Hz, 1H), 1.82
(hept, J = 6.4 Hz, 1H), 1.50 (qd, J = 14.1, 5.6 Hz, 2H), 1.21 (s, 3H), 0.98 - 0.88 (m,
8H), 0.86 - 0.73 (m, 2H); F NMR (376 MHz, DMSO-d6) δ -115.05 (d, J = 54.9
Hz); LCMS (ESI) m/e 375.0 [(M+H) , calcd C H F N O, 375.2]; LC/MS retention
22 29 2 2
time (method B): t = 1.97 min.
Example 127
(S)((2-(difluoromethyl)(6-fluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Part A: (S)((2-(difluoromethyl)(4,4,5,5-tetramethyl-1,3,2-dioxaborolan
yl)pyridinyl)oxy)-2,4-dimethylpentanamine
To a 5 mL vial was added (S)((6-bromo(difluoromethyl)pyridin
yl)oxy)-2,4-dimethylpentanamine (79.5 mg, 0.236 mmol), 4,4,4',4',5,5,5',5'-
octamethyl-2,2'-bi(1,3,2-dioxaborolane) (71.8 mg, 0.283 mmol), and potassium
acetate (69.4 mg, 0.707 mmol) in dioxane (2.4 mL) to give a colorless suspension
with nitrogen bubbling. PdCl (dppf) (5.18 mg, 7.07 µmol) was added under
nitrogen. The vial was sealed and the mixture was heated at 80 °C for 20 h. LC/MS
showed complete conversion to a new peak. It was divided into parts and used
directly in the next step. LC/MS retention time (method B): t = 1.52 min.
Part B: (S)((2-(difluoromethyl)(6-fluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Prepared as previously described in Example 116 to afford (S)((2-
(difluoromethyl)(6-fluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentan
amine (5.3 mg, 16% for 2 steps)as a colorless solid. H NMR (400MHz,
CHLOROFORM-d) δ 8.97 (d, J=4.5 Hz, 1H), 8.19 (dd, J=9.3, 5.5 Hz, 1H), 7.85 (dd,
J=10.4, 2.9 Hz, 1H), 7.73 (d, J=8.5 Hz, 1H), 7.59 - 7.43 (m, 3H), 7.09 - 6.72 (t,
J=54.0 Hz, 1H), 4.01 - 3.84 (m, 2H), 1.91 - 1.78 (m, 1H), 1.61 - 1.49 (m, 2H), 1.31
(s, 3H), 1.03 (app t, J=7.0 Hz, 6H), two exchangeable protons not observed; LCMS
(ESI) m/e 404.0 [(M+H) , calcd C H F N O, 404.2]; LC/MS retention time
22 25 3 3
(method B): t = 1.81 min.
Example 128
(S)((2-(difluoromethyl)(7-fluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Prepared as previously described in Example 116 to afford (S)((2-
(difluoromethyl)(7-fluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentan
amine (11.1 mg, 35% for 2 steps) as a colorless solid. H NMR (400MHz,
CHLOROFORM-d) δ 8.98 (d, J=4.5 Hz, 1H), 8.21 (dd, J=9.3, 6.0 Hz, 1H), 7.81 (dd,
J=9.9, 2.6 Hz, 1H), 7.72 (d, J=8.5 Hz, 1H), 7.50 (d, J=8.8 Hz, 1H), 7.45 (d, J=4.5 Hz,
1H), 7.35 (ddd, J=9.3, 8.0, 2.8 Hz, 1H), 6.98 (t, J=55.0 Hz, 1H), 3.98 (s, 2H), 1.85
(tt, J=12.7, 6.4 Hz, 1H), 1.68 - 1.56 (m, 2H), 1.36 (s, 3H), 1.03 (d, J=6.8 Hz, 3H),
1.01 (d, J=6.8 Hz, 3H), two exchangeable protons not observed; LCMS (ESI) m/e
404.0 [(M+H) , calcd C H F N O, 404.2]; LC/MS retention time (method B): t =
22 25 3 3 R
1.68 min.
Example 129
(S)((2-(difluoromethyl)(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Prepared as previously described in Example 16 to afford (S)((2-
(difluoromethyl)(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentan-
2-amine (25.9 mg, 75% for 2 steps) as a colorless solid. H NMR (600 MHz, DMSO-
d ) δ 9.13 - 9.02 (m, 1H), 7.93 - 7.73 (m, 3H), 7.56 (dt, J = 23.8, 6.1 Hz, 2H), 7.38 -
7.09 (m, 1H), 3.95 (d, J = 22.2 Hz, 2H), 1.84 (dt, J = 18.4, 6.3 Hz, 1H), 1.45 (dtd, J
= 23.9, 14.0, 11.7, 5.4 Hz, 2H), 1.27 - 1.14 (m, 3H), 0.96 (ddd, J = 23.9, 13.5, 6.6
Hz, 6H); LCMS (ESI) m/e 421.9 [(M+H) , calcd C H F N O, 422.2]; LC/MS
22 24 4 3
retention time (method B): t = 1.82 min.
Example 130
(S)((4-(difluoromethyl)(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Part A: 5,7-difluoro(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)quinoline
Prepared as previously described in Example 127. Obtained 5,7-difluoro
(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)quinoline which was divided into parts
and used directly in the next step. LC/MS retention time (method A): t = 1.93 min.
Part B: (S)((4-(difluoromethyl)(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Prepared as previously described in Example 16 to afford (S)((4-
(difluoromethyl)(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentan-
2-amine (14.7 mg, 49% for 2 steps) as a colorless solid. H NMR (600 MHz, DMSO-
d ) δ 9.04 (d, J = 4.7 Hz, 1H), 8.62 (d, J = 5.7 Hz, 1H), 7.80 (d, J = 9.6 Hz, 1H),
7.75 (d, J = 6.5 Hz, 1H), 7.56 (qd, J = 8.5, 7.9, 4.9 Hz, 2H), 7.36 (t, J = 53.9 Hz,
1H), 4.01 (s, 2H), 1.82 (q, J = 6.5 Hz, 1H), 1.43 (qd, J = 14.0, 5.9 Hz, 2H), 1.16 (s,
3H), 0.94 (dd, J = 14.6, 6.7 Hz, 6H); F NMR (376 MHz, DMSO-d6) δ -102.43 (d, J
= 9.6 Hz), -107.91 (d, J = 9.0 Hz), -116.03 - -119.87 (m); LCMS (ESI) m/e 422.0
[(M+H) , calcd C H F N O, 422.2]; LC/MS retention time (method B): t = 1.88
22 24 4 3 R
min.
Example 131
(S)((4-(difluoromethyl)(7-fluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Part A: 7-fluoro(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)quinoline
Prepared as previously described in Example 127. Obtained 7-fluoro
(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)quinoline which was divided into parts
and used directly in the next step. LC/MS retention time (method A): t = 1.19 min.
Part B: (S)((4-(difluoromethyl)(7-fluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Prepared as previously described in Example 16 to afford (S)((4-
(difluoromethyl)(7-fluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentan
amine (11.1 mg, 39% for 2 steps) as a colorless solid. H NMR (600 MHz, DMSO-
d ) δ 9.02 (d, J = 4.3 Hz, 1H), 8.77 (s, 1H), 8.30 (ddd, J = 9.0, 6.3, 2.4 Hz, 1H), 7.90
(s, 1H), 7.86 (dd, J = 10.2, 2.7 Hz, 1H), 7.67 (d, J = 4.3 Hz, 1H), 7.58 (td, J = 8.8,
2.7 Hz, 1H), 7.37 (t, J = 53.9 Hz, 1H), 4.05 (s, 2H), 1.83 (p, J = 6.5 Hz, 1H), 1.43
(qd, J = 14.0, 5.4 Hz, 2H), 1.16 (s, 3H), 0.95 (ddd, J = 13.9, 6.8, 2.1 Hz, 6H); F
NMR (376 MHz, DMSO-d ) δ -110.25 , -115.90 - -119.14 (m); LCMS (ESI) m/e
404.0 [(M+H) , calcd C H F N O, 404.2]; LC/MS retention time (method B): t =
22 25 3 3 R
1.78 min.
Example 132
(S)((4-(difluoromethyl)(6-fluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Part A: (S)((4-(difluoromethyl)(4,4,5,5-tetramethyl-1,3,2-dioxaborolan
yl)pyridinyl)oxy)-2,4-dimethylpentanamine
To a 5 mL vial was added (S)((6-bromo(difluoromethyl)pyridin
yl)oxy)-2,4-dimethylpentanamine (82.5 mg, 0.245 mmol), 4,4,4',4',5,5,5',5'-
octamethyl-2,2'-bi(1,3,2-dioxaborolane) (74.6 mg, 0.294 mmol), and potassium
acetate (72.0 mg, 0.734 mmol) in dioxane (2.4 mL) to give a colorless suspension
with nitrogen bubbling. PdCl (dppf) (5.37 mg, 7.34 µmol) was added under
nitrogen. The vial was sealed and the mixture was heated at 80 °C for 20 h. LCMS
showed mainly the starting material (dark red color mixture). The temperature was
raised to 100 °C. After 4 h, LCMS showed a little better conversion. The reaction
continued for another 16 h at 100 °C. LCMS showed better conversion but there was
still some starting material left. The temperature was raised to 110 °C and the
reaction continued for 5 h. LCMS showed only a little starting material left. The
reaction continued at 110 °C for another 5 h. After cooling down, the reaction
mixture was divided into parts and used directly in the next step.
Part B: (S)((4-(difluoromethyl)(6-fluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Prepared as previously described in Example 116 to afford (S)((4-
(difluoromethyl)(6-fluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentan
amine (1.6 mg, 5% for 2 steps) as a colorless solid. H NMR (600 MHz, DMSO-d )
δ 8.99 (d, J = 4.4 Hz, 1H), 8.80 (s, 1H), 8.20 (dd, J = 9.3, 5.6 Hz, 1H), 8.01 (dd, J =
11.0, 2.9 Hz, 1H), 7.94 (s, 1H), 7.79 - 7.70 (m, 2H), 7.40 (t, J = 53.9 Hz, 1H), 4.09
(s, 2H), 1.84 (dt, J = 12.8, 6.5 Hz, 1H), 1.46 (qd, J = 14.0, 5.6 Hz, 2H), 1.19 (s, 3H),
0.97 (d, J = 6.6 Hz, 3H), 0.94 (d, J = 6.6 Hz, 3H); F NMR (376 MHz, DMSO-d ) δ
-112.45 , -118.42 (dd, J = 134.0, 57.0 Hz); LCMS (ESI) m/e 404.0 [(M+H) , calcd
C22H25F3N3O, 404.2]; LC/MS retention time (method B): tR = 1.79 min.
Example 133
((S)((4-(difluoromethyl)(6-(trifluoromethyl)quinolinyl)pyridinyl)oxy)-
2,4-dimethylpentanamine
Prepared as previously described in Example 132 to afford ((S)((4-
(difluoromethyl)(6-(trifluoromethyl)quinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine (2.1 mg, 6% for 2 steps) as a colorless solid. H NMR (600
MHz, DMSO-d ) δ 9.17 (d, J = 4.4 Hz, 1H), 8.85 (s, 1H), 8.75 (s, 1H), 8.34 (d, J =
8.8 Hz, 1H), 8.08 (dd, J = 8.8, 2.1 Hz, 1H), 8.02 (s, 1H), 7.88 (d, J = 4.3 Hz, 1H),
7.43 (t, J = 53.9 Hz, 1H), 4.13 (d, J = 3.0 Hz, 2H), 1.84 (p, J = 6.2 Hz, 1H), 1.57 -
1.41 (m, 2H), 1.21 (s, 3H), 0.97 (d, J = 6.6 Hz, 3H), 0.94 (d, J = 6.5 Hz, 3H); LCMS
(ESI) m/e 454.0 [(M+H) , calcd C H F N O, 454.2]; LC/MS retention time
23 25 5 3
(method B): t = 2.02 min.
Example 134
(S)((4-(difluoromethyl)(6-(trifluoromethoxy)quinolinyl)pyridinyl)oxy)-
2,4-dimethylpentanamine
Prepared as previously described in Example 132 to afford (S)((4-
(difluoromethyl)(6-(trifluoromethoxy)quinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine (1.5 mg, 4% for 2 steps) as a colorless solid. H NMR (600
MHz, DMSO-d ) δ 9.07 (d, J = 4.4 Hz, 1H), 8.80 (s, 1H), 8.29 (s, 1H), 8.27 (d, J =
9.2 Hz, 1H), 7.97 (s, 1H), 7.83 (dd, J = 8.7, 3.2 Hz, 2H), 7.38 (t, J = 53.9 Hz, 1H),
4.06 (s, 2H), 1.84 (dt, J = 12.7, 6.3 Hz, 1H), 1.42 (qd, J = 14.0, 5.6 Hz, 2H), 1.16 (s,
3H), 0.96 (d, J = 6.5 Hz, 3H), 0.94 (d, J = 6.6 Hz, 3H); LCMS (ESI) m/e 470.0
[(M+H) , calcd C H F N O , 470.2]; LC/MS retention time (method B): t = 2.00
23 25 5 3 2 R
min.
Example 135
(S)((2-chloro(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentan-
2-amine
Part A: (S)-tert-butyl (1-((2-chloro(5,7-difluoroquinolinyl)pyridinyl)oxy)-
2,4-dimethylpentanyl)carbamate
Prepared as previously described in Example 66. The intermediates were as
described in Example 66 and Example 130 to afford (S)-tert-butyl (1-((2-chloro
(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentanyl)carbamate
(12.1 mg, 34%) as a colorless solid. H NMR (400 MHz, Chloroform-d) δ 8.97 (d, J
= 4.4 Hz, 1H), 7.68 (ddd, J = 9.5, 2.6, 1.5 Hz, 1H), 7.42 - 7.32 (m, 3H), 7.05 (ddd, J
= 11.5, 8.8, 2.6 Hz, 1H), 4.64 (s, 1H), 4.37 (d, J = 8.9 Hz, 1H), 4.18 (d, J = 8.9 Hz,
1H), 1.96 (dd, J = 13.9, 6.4 Hz, 1H), 1.87 (ddd, J = 13.1, 6.5, 4.9 Hz, 1H), 1.58 (dd,
J = 13.9, 4.9 Hz, 1H), 1.47 (s, 3H), 1.42 (s, 9H), 1.04 (s, 3H), 1.02 (s, 3H); F NMR
(376 MHz, Chloroform-d) δ -102.47 , -107.56.; LCMS (ESI) m/e 506.0 [(M+H) ,
calcd C H ClF N O , 506.2]; LC/MS retention time (method B): t = 2.36 min.
26 31 2 3 3 R
Part B: (S)((2-chloro(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Prepared as previously described in Example 7, Part B to afford (S)((2-
chloro(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentanamine
(10.6 mg, 100%) as a colorless solid. H NMR (400MHz, CHLOROFORM-d) δ 8.97
(d, J=4.3 Hz, 1H), 7.77 - 7.62 (m, 1H), 7.40 (d, J=4.3 Hz, 1H), 7.38 - 7.34 (m, 1H),
7.33 - 7.28 (m, 1H), 7.05 (ddd, J=11.6, 8.8, 2.6 Hz, 1H), 3.93 - 3.84 (m, 2H), 1.92 -
1.73 (m, 1H), 1.66 - 1.50 (m, 2H), 1.32 (s, 3H), 1.04 (d, J=6.8 Hz, 3H), 1.02 (d, J=6.5
Hz, 3H), two exchangeable protons not observed; F NMR (376 MHz, DMSO-d6) δ
-101.38 - -103.03 (m), -105.03 - -107.99 (m); LCMS (ESI) m/e 405.9 [(M+H) , calcd
C H ClF N O, 406.1]; LC/MS retention time (method B): t = 1.84 min.
21 23 2 3 R
Example 136
(S)((2-chloro(7-fluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentan
amine
Part A: (S)-tert-butyl (1-((2-chloro(7-fluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanyl)carbamate
Prepared as previously described in Example 66. The intermediates were as
described in Example 66 and Example 131 to afford (S)-tert-butyl (1-((2-chloro(7-
fluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentanyl)carbamate (12.4 mg,
36%) as a colorless solid. H NMR (400 MHz, Chloroform-d) δ 8.98 (d, J = 4.5 Hz,
1H), 8.24 (dd, J = 9.4, 6.1 Hz, 1H), 7.81 (dd, J = 9.9, 2.6 Hz, 1H), 7.53 (d, J = 8.2
Hz, 1H), 7.49 - 7.43 (m, 2H), 7.37 (ddd, J = 9.3, 8.0, 2.7 Hz, 1H), 4.64 (s, 1H), 4.41
(d, J = 9.0 Hz, 1H), 4.21 (d, J = 9.0 Hz, 1H), 2.01 - 1.82 (m, 2H), 1.58 (dd, J = 13.9,
.0 Hz, 1H), 1.48 (s, 3H), 1.42 (s, 9H), 1.05 (s, 3H), 1.03 (s, 3H); F NMR (376
MHz, Chloroform-d) δ -109.85; LCMS (ESI) m/e 488.0 [(M+H) , calcd
C H ClFN O , 488.2]; LC/MS retention time (method B): t = 2.28 min.
26 32 3 3 R
Part B: (S)((2-chloro(7-fluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Prepared as previously described in Example 7, Part B to afford (S)((2-
chloro(7-fluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentanamine (11.1
mg, 100%) as a colorless solid. H NMR (600 MHz, DMSO-d ) δ 9.01 (d, J = 4.4
Hz, 1H), 8.32 (dd, J = 9.4, 6.1 Hz, 1H), 7.88 - 7.77 (m, 3H), 7.63 (d, J = 4.2 Hz, 1H),
7.60 (td, J = 8.8, 2.7 Hz, 1H), 3.98 - 3.89 (m, 2H), 1.85 (dq, J = 12.8, 6.4 Hz, 1H),
1.50 - 1.40 (m, 2H), 1.18 (s, 3H), 0.95 (dd, J = 7.5, 5.4 Hz, 6H); 19F NMR (376
MHz, DMSO-d6) δ -110.18; LCMS (ESI) m/e 388.0 [(M+H) , calcd C H ClFN O,
21 24 3
388.2]; LC/MS retention time (method B): t = 1.76 min.
Example 137
(S)((6-(7-fluoroquinolinyl)methylpyridinyl)oxy)-2,4-dimethylpentan
amine
Part A: (S)((6-bromomethylpyridinyl)oxy)-2,4-dimethylpentanamine
To a 20 mL pressure bottle was added (S)amino-2,4-dimethylpentanol
(214.8 mg, 1.637 mmol) in tetrahydrofuran (2.2 mL) to give a colorless solution.
Potassium tert-butoxide (2.128 mL, 2.128 mmol) (1.0 M in THF) was added
dropwise under nitrogen. After 5 min, 6-bromofluoromethylpyridine (311 mg,
1.637 mmol) was added in one portion. The bottle was sealed and the mixture was
stirred at 80 °C for 20 h. The mixture was partitioned between water and EtOAc.
The layers were separated. The aqueous layer was extracted with EtOAc. The
combined organic solution was washed with brine, dried and concentrated to a tan
oil. It was purified by silica gel chromatography up to 10% MeOH (2N NH ) in
CH Cl to afford (S)((6-bromomethylpyridinyl)oxy)-2,4-dimethylpentan
amine (220 mg, 45% with one unknown impurity-likely substitution at Br). LCMS
(ESI) m/e 283.9 [(M-NH ) , calcd C H BrNO, 284.1]; LC/MS retention time
2 13 19
(method B): t = 1.70 min (impurity: 1.81 min).
Part B: (S)-2,4-dimethyl((2-methyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolan
yl)pyridinyl)oxy)pentanamine
To a 5 mL vial was added (S)((6-bromomethylpyridinyl)oxy)-2,4-
dimethylpentanamine (89.5 mg, 0.267 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-
bi(1,3,2-dioxaborolane) (81 mg, 0.321 mmol), and potassium acetate (79 mg, 0.802
mmol) in dioxane (2.8 mL) to give a colorless suspension with nitrogen bubbling.
PdCl (dppf) (5.87 mg, 8.02 µmol) was added under nitrogen. The vial was sealed
and the mixture was heated at 80 °C for 18 h. LCMS showed there was substantial
amount of starting material. The reaction mixture was heated at 100 °C for 4 h.
LCMS showed the majority of starting material was gone (the side product from
previous reaction remained). It was divided into parts and used directly in the next
step.
Part C: (S)((6-(7-fluoroquinolinyl)methylpyridinyl)oxy)-2,4-
dimethylpentanamine
Prepared as previously described in Example 132 to afford (S)((6-(7-
fluoroquinolinyl)methylpyridinyl)oxy)-2,4-dimethylpentanamine (1.0 mg,
3%) as a colorless solid. H NMR (500 MHz, DMSO-d ) δ 8.99 (d, J = 4.5 Hz, 1H),
8.37 (dd, J = 9.3, 6.4 Hz, 1H), 7.84 (dd, J = 10.4, 2.7 Hz, 1H), 7.65 (d, J = 8.4 Hz,
1H), 7.62 - 7.54 (m, 3H), 3.98 (s, 2H), 2.57 (s, 3H), 1.90 - 1.80 (m, 1H), 1.61 (d, J =
.3 Hz, 1H), 1.53 (dd, J = 14.0, 5.5 Hz, 1H), 1.30 (s, 3H), 0.98 (d, J = 6.6 Hz, 3H),
0.96 (d, J = 6.7 Hz, 3H). LCMS (ESI) m/e 368.2 [(M+H) , calcd C H FN O, 368.2]
22 27 3
Example 138
(S)((6-(6-fluoroquinolinyl)methylpyridinyl)oxy)-2,4-dimethylpentan
amine
Prepared as previously described in Example 132 with intermediate from
Example 137 to afford (S)((6-(6-fluoroquinolinyl)methylpyridinyl)oxy)-
2,4-dimethylpentanamine (1.5 mg, 3%, 64% purity by analytical HPLC): H NMR
(500MHz, DMSO-d ) δ 8.96 (d, J=4.4 Hz, 1H), 8.17 (dd, J=9.4, 5.7 Hz, 1H), 8.07
(dd, J=10.8, 2.8 Hz, 1H), 7.78 - 7.51 (m, 5H), 6.70 (dd, J=8.8, 2.6 Hz, 1H), 3.93 -
3.77 (m, 2H), 2.55 (s, 3H), 1.87 - 1.72 (m, 1H), 1.58 - 1.30 (m, 2H), 1.15 (s, 3H),
1.00 - 0.83 (m, 6H) LCMS (ESI) m/e 368.2 [(M+H) , calcd C H FN O, 368.2].
22 27 3
Example 139
(S)((2-(difluoromethyl)(2-methylpyrimidinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Prepared as previously described in Example 127 with intermediate as
described in Example 127 and 4-bromomethylpyrimidine to afford (S)((2-
(difluoromethyl)(2-methylpyrimidinyl)pyridinyl)oxy)-2,4-dimethylpentan
amine (15.9 mg, 45%): H NMR (500 MHz, DMSO-d ) δ 8.82 (d, J = 5.2 Hz, 1H),
8.57 (d, J = 8.9 Hz, 1H), 8.07 (d, J = 5.3 Hz, 1H), 7.83 (d, J = 8.9 Hz, 1H), 7.26 (t, J
= 53.6 Hz, 1H), 3.92 (s, 2H), 2.71 (s, 3H), 1.81 (dd, J = 12.9, 6.6 Hz, 1H), 1.47 -
1.36 (m, 2H), 1.15 (s, 3H), 0.93 (dd, J = 11.0, 6.8 Hz, 6H); LCMS (ESI) m/e 373.1
[(M+Na) , calcd C H F N NaO, 373.2]; LC/MS retention time (method B): t =
18 24 2 4 R
1.73 min.
Example 140
(S)((2-(difluoromethyl)(6-methylpyrimidinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Prepared as previously described in Example 127 with intermediate as
described in Example 127 and 4-bromomethylpyrimidine to afford (S)((2-
(difluoromethyl)(6-methylpyrimidinyl)pyridinyl)oxy)-2,4-dimethylpentan
amine (3.5 mg, 6.8%): H NMR (400MHz, CHLOROFORM-d) δ 9.11 (d, J=1.3 Hz,
1H), 8.58 (d, J=8.8 Hz, 1H), 8.21 (s, 1H), 7.43 (d, J=8.8 Hz, 1H), 7.10 - 6.72 (t,
J=53.0 Hz, 1H), 3.96 (s, 2H), 2.63 (s, 3H), 1.88 - 1.75 (m, 1H), 1.66 - 1.52 (m, 2H),
1.26 (s, 3H), 1.01 (d, J=6.5 Hz, 3H), 0.98 (d, J=6.8 Hz, 3H), two exchangeable
protons not observed; LCMS (ESI) m/e 334.1 [(M-NH ) , calcd C H F N O,
2 18 22 2 3
334.2]; LC/MS retention time (method B): t = 1.78 min.
Example 141
(S)((4-(difluoromethyl)-2'-ethyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
amine
Prepared as previously described in Example 117 with intermediate as
described in Example 120 and (2-ethylpyridinyl)boronic acid to afford (S)((4-
(difluoromethyl)-2'-ethyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine (8.0
mg, 39%): H NMR (500 MHz, DMSO-d ) δ 8.67 (s, 1H), 8.57 (d, J = 5.2 Hz, 1H),
8.20 (s, 1H), 7.93 (s, 1H), 7.85 (dd, J = 5.2, 1.6 Hz, 1H), 7.34 (t, J = 53.9 Hz, 1H),
4.01 (s, 2H), 2.84 (q, J = 7.6 Hz, 2H), 1.80 (dq, J = 12.5, 6.2 Hz, 1H), 1.47 - 1.35 (m,
2H), 1.28 (t, J = 7.6 Hz, 3H), 1.14 (s, 3H), 0.93 (dd, J = 12.6, 6.6 Hz, 6H); LCMS
(ESI) m/e 364.2 [(M+H) , calcd C H F N O, 364.2]; LC/MS retention time
28 2 3
(method B): t = 1.54 min.
Example 142
(S)((2'-chloro(difluoromethyl)-3'-fluoro-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine
Prepared as previously described in Example 117 with intermediate as
described in Example 120 and (2-chlorofluoro-pyridinyl)boronic acid to afford
(S)((2'-chloro(difluoromethyl)-3'-fluoro-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine (10.8 mg, 13%): H NMR (500 MHz, DMSO-d ) δ 8.76 (s,
1H), 8.38 (d, J = 5.0 Hz, 1H), 8.05 (s, 1H), 7.97 (t, J = 5.3 Hz, 1H), 7.37 (t, J = 53.9
Hz, 1H), 4.03 (s, 2H), 1.81 (dt, J = 12.8, 6.4 Hz, 1H), 1.45 - 1.35 (m, 2H), 1.14 (s,
3H), 0.93 (dd, J = 12.4, 6.7 Hz, 7H); LCMS (ESI) m/e 371.1 [(M-NH2) , calcd
C H ClF N O, 371.1]; LC/MS retention time (method B): t = 1.98 min.
18 19 3 2 R
Example 143
(S)((2'-chloro(difluoromethyl)-5'-fluoro-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine
Prepared as previously described in Example 117 with intermediate as
described in Example 120 and (2-chlorofluoro-pyridinyl)boronic acid to afford
(S)((2'-chloro(difluoromethyl)-5'-fluoro-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine (9.6 mg, 11%): H NMR (500 MHz, DMSO-d ) δ 8.76 (s,
1H), 8.61 (d, J = 2.6 Hz, 1H), 8.05 (s, 1H), 8.02 (d, J = 5.5 Hz, 1H), 7.37 (t, J = 53.9
Hz, 1H), 4.04 (s, 2H), 1.81 (dt, J = 12.6, 6.4 Hz, 1H), 1.46 - 1.35 (m, 2H), 1.14 (s,
3H), 0.93 (dd, J = 12.8, 6.6 Hz, 6H); LCMS (ESI) m/e 371.1 [(M-NH ) , calcd
C H ClF N O, 371.1]; LC/MS retention time (method B): t = 1.97 min.
18 19 3 2 R
Example 144
(S)-2,4-dimethyl((2'-methyl(trifluoromethyl)-[2,4'-bipyridin]yl)oxy)pentan-
2-amine
Part A: (S)((6-bromo(difluoromethyl)pyridinyl)oxy)-2,4-dimethylpentan
amine
To a 20 mL pressure vial was added (S)amino-2,4-dimethylpentanol
(323 mg, 2.462 mmol) and 2-bromofluoro(trifluoromethyl)pyridine (601 mg,
2.462 mmol) in tetrahydrofuran (3.3 mL) to give a tan solution. Potassium tert-
butoxide (2.95 mL, 2.95 mmol) (1.0 M in THF) was added dropwise under nitrogen.
After 5 min stirring at rt, the vial was sealed and the mixture was stirred at 80 °C for
18 h. The mixture was partitioned between water and EtOAc. The layers were
separated. The aqueous layer was extracted with EtOAc. The combined organic
solution was washed with brine, dried and concentrated to a tan oil. The crude was
purified by silica gel chromatography up to 10% MeOH/CH Cl to afford (S)((6-
bromo(difluoromethyl)pyridinyl)oxy)-2,4-dimethylpentanamine (0.42 g,
48%) as a tan oil: H NMR (400 MHz, Chloroform-d) δ 8.19 (s, 1H), 7.64 (s, 1H),
3.95 - 3.86 (m, 2H), 1.80 (dt, J = 12.8, 6.4 Hz, 1H), 1.65 (s, 2H), 1.50 (dd, J = 5.7,
4.0 Hz, 2H), 1.25 (s, 3H), 0.99 (dd, J = 9.1, 6.6 Hz, 6H); F NMR (376 MHz,
Chloroform-d) δ -64.37; LCMS (ESI) m/e 338.0 [(M+H) , calcd C H BrF NO,
13 16 3
338.1]; LC/MS retention time (method B): t = 1.88 min.
Part B: (S)-2,4-dimethyl((2'-methyl(trifluoromethyl)-[2,4'-bipyridin]
yl)oxy)pentanamine
Prepared as described in Example 117 to afford (S)-2,4-dimethyl((2'-
methyl(trifluoromethyl)-[2,4'-bipyridin]yl)oxy)pentanamine (25.2 mg, 0.066
mmol, 61% yield): H NMR (500 MHz, DMSO-d ) δ 8.79 (s, 1H), 8.55 (d, J = 5.2
Hz, 1H), 8.28 (s, 1H), 7.96 (s, 1H), 7.87 (d, J = 5.4 Hz, 1H), 4.05 (d, J = 5.5 Hz,
2H), 2.56 (s, 3H), 1.81 (dt, J = 12.6, 6.3 Hz, 1H), 1.45 - 1.33 (m, 2H), 1.12 (s, 3H),
0.92 (dd, J = 6.6, 3.0 Hz, 6H); LCMS (ESI) m/e 368.2 (M+H) , calcd C H F N O,
19 25 3 3
368.2]; LC/MS retention time (method B): t = 1.48 min.
Example 145
(S)-2,4-dimethyl((6-(quinolinyl)(trifluoromethyl)pyridinyl)oxy)pentan
amine
Prepared as described in Example 117 to afford (S)-2,4-dimethyl((6-
(quinolinyl)(trifluoromethyl)pyridinyl)oxy)pentanamine (16.2 mg, 0.038
mmol, 58% yield): H NMR (500 MHz, DMSO-d6) δ 9.01 (d, J = 4.6 Hz, 1H), 8.92
(s, 1H), 8.17 (d, J = 8.3 Hz, 1H), 8.13 (d, J = 8.5 Hz, 1H), 8.03 (s, 1H), 7.82 (t, J =
7.6 Hz, 1H), 7.70 (d, J = 4.4 Hz, 1H), 7.64 (t, J = 7.7 Hz, 1H), 4.20 (d, J = 3.9 Hz,
2H), 1.84 (d, J = 10.3 Hz, 1H), 1.50 (qd, J = 14.1, 5.5 Hz, 2H), 1.23 (s, 3H), 0.95 (t,
J = 6.1 Hz, 6H); LCMS (ESI) m/e 404.2 (M+H) , calcd C H F N O, 404.2];
22 25 3 3
LC/MS retention time (method B): t = 1.71 min.
Example 146
(S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)(trifluoromethyl)-[2,4'-
bipyridin]-2'-yl)carbamate
Prepared as described in Example 117 to afford (S)-methyl (5-((2-amino-2,4-
dimethylpentyl)oxy)(trifluoromethyl)-[2,4'-bipyridin]-2'-yl)carbamate (4.4 mg,
0.010 mmol, 18% yield): H NMR (500 MHz, DMSO-d ) δ 10.31 (s, 1H), 8.82 (s,
1H), 8.55 (s, 1H), 8.37 (d, J = 5.5 Hz, 1H), 8.18 (s, 1H), 7.74 (d, J = 5.4 Hz, 1H),
4.12 - 3.99 (m, 2H), 3.71 (s, 3H – under solvent peak), 1.81 (dt, J = 13.2, 6.6 Hz,
1H), 1.39 (d, J = 5.6 Hz, 2H), 1.12 (s, 3H), 0.92 (dd, J = 6.6, 2.9 Hz, 6H); LCMS
(ESI) m/e 449.2 (M+Na) , calcd C H F N NaO , 449.2]; LC/MS retention time
25 3 4 3
(method B): t = 1.79 min.
Example 147
(S)((2'-chloro(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
amine
Prepared as previously described in Example 117 with intermediate as
described in Example 120 and (2-chloro-pyridinyl)boronic acid to afford (S)
((2'-chloro(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine
(13.5 mg, 53%): H NMR (500 MHz, DMSO-d ) δ 8.69 (s, 1H), 8.51 (d, J = 5.2 Hz,
1H), 8.30 (s, 1H), 8.17 (s, 1H), 8.09 (d, J = 5.3 Hz, 1H), 7.33 (t, J = 53.8 Hz, 1H),
4.03 (s, 2H), 1.80 (p, J = 6.2 Hz, 1H), 1.41 (qd, J = 14.0, 5.5 Hz, 2H), 1.14 (s, 3H),
0.92 (dd, J = 13.2, 6.6 Hz, 6H); LCMS (ESI) m/e 370.1 [(M+H) , calcd
C H ClF N O, 370.1]; LC/MS retention time (method B): t = 1.91 min.
18 23 2 3 R
Example 148
(S)((4-(difluoromethyl)-5'-fluoro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine
To a 2 mL vial was added (S)((2'-chloro(difluoromethyl)-5'-fluoro-[2,4'-
bipyridin]yl)oxy)-2,4-dimethylpentanamine (Example 143) (7.42 mg, 0.019
mmol), 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (2.402 mg, 0.019 mmol), and
Cs CO (9.35 mg, 0.029 mmol) in dioxane (0.2 mL) and water (0.1 mL) to give a
colorless suspension under nitrogen (degassed for 5 min). 1,1'-
Bis(diphenylphosphino)ferrocenepalladium(II) dichloride, toluene (0.787 mg, 0.957
µmol) was added under nitrogen. The vial was sealed and heated at 100 °C for 20 h.
The mixture was dried, and diluted with MeOH, filtered and purified by prep-HPLC
to afford (S)((4-(difluoromethyl)-5'-fluoro-2'-methyl-[2,4'-bipyridin]yl)oxy)-
2,4-dimethylpentanamine (1.8 mg, 26%): H NMR (500 MHz, DMSO-d ) δ 8.73
(s, 1H), 8.54 (d, J = 2.9 Hz, 1H), 7.99 (s, 1H), 7.80 (d, J = 6.5 Hz, 1H), 7.38 (t, J =
53.9 Hz, 1H), 4.12 - 4.02 (m, 2H), 2.54 (s, 3H), 1.79 (dq, J = 12.6, 6.2 Hz, 1H), 1.44
(qd, J = 14.0, 5.6 Hz, 2H), 1.17 (s, 3H), 0.94 (d, J = 6.6 Hz, 3H), 0.91 (d, J = 6.6 Hz,
3H); LCMS (ESI) m/e 351.1 [(M-NH ) , calcd C H F N O, 351.2]; LC/MS
2 19 22 3 2
retention time (method B): t = 1.81 min.
Example 149
(S)((4-(difluoromethyl)-3'-fluoro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine
Prepared as previously described in Example 148 with Example 142 as the
starting material to afford (S)((4-(difluoromethyl)-3'-fluoro-2'-methyl-[2,4'-
bipyridin]yl)oxy)-2,4-dimethylpentanamine (2.0 mg, 25%): H NMR (500
MHz, DMSO-d ) δ 8.74 (s, 1H), 8.39 (d, J = 5.1 Hz, 1H), 8.01 (s, 1H), 7.77 (t, J =
5.5 Hz, 1H), 7.38 (t, J = 53.9 Hz, 1H), 4.06 (d, J = 3.0 Hz, 2H), 2.54 (d, J = 3.4 Hz,
3H), 1.86 - 1.76 (m, 1H), 1.50 - 1.37 (m, 2H), 1.17 (s, 3H), 0.95 (d, J = 6.6 Hz, 3H),
0.92 (d, J = 6.7 Hz, 3H); LCMS (ESI) m/e 351.1 [(M-NH ) , calcd C H F N O,
2 19 22 3 2
351.2]; LC/MS retention time (method B): t = 1.78 min.
Example 150
(S)((4-(difluoromethyl)(2-methylpyrimidinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Prepared as previously described in Example 132 to afford (S)((4-
(difluoromethyl)(2-methylpyrimidinyl)pyridinyl)oxy)-2,4-dimethylpentan
amine (0.8 mg, 2.3% for 2 steps) as a colorless solid. H NMR (500 MHz, DMSO-d )
δ 8.83 (d, J = 5.2 Hz, 1H), 8.71 (s, 1H), 8.53 (s, 1H), 8.10 (d, J = 5.2 Hz, 1H), 7.41
(s, 1H), 4.08 (d, J = 2.2 Hz, 2H), 2.72 (s, 3H), 1.81 (dt, J = 12.9, 6.5 Hz, 1H), 1.44
(qd, J = 14.0, 5.5 Hz, 2H), 1.17 (s, 3H), 0.95 (d, J = 6.6 Hz, 3H), 0.92 (d, J = 6.7 Hz,
3H); LCMS (ESI) m/e 334.1 [(M-NH ) , calcd C H F N O, 334.2]; LC/MS
2 18 22 2 3
retention time (method B): t = 1.83 min.
Example 152
(S)(2-(difluoromethyl)(2-methylpyrimidinyl)phenoxy)-2,4-dimethylpentan-
2-amine
Prepared as previously described in Example 116 with 4-bromo
methylpyrimidine to afford (S)(2-(difluoromethyl)(2-methylpyrimidin
yl)phenoxy)-2,4-dimethylpentanamine (32.2 mg, 56% for 2 steps) as a colorless
solid. H NMR (500 MHz, DMSO-d ) δ 8.72 (d, J = 5.4 Hz, 1H), 8.38 (d, J = 2.2 Hz,
1H), 8.35 (dd, J = 8.8, 2.3 Hz, 1H), 7.89 (d, J = 5.4 Hz, 1H), 7.43 - 7.16 (m, 2H),
3.87 (s, 2H), 2.68 (s, 3H), 1.80 (dp, J = 12.8, 6.3 Hz, 1H), 1.48 - 1.35 (m, 2H), 1.14
(s, 3H), 0.93 (d, J = 6.6 Hz, 3H), 0.91 (d, J = 6.7 Hz, 3H); LCMS (ESI) m/e 333.2
[(M-NH ) , calcd C H F N O, 333.2]; LC/MS retention time (method B): t = 1.85
2 19 23 2 2 R
min.
Example 153
(S)((2-amino-2,4-dimethylpentyl)oxy)-3'-fluoromethyl-[2,4'-bipyridin]-2'-
amine
Part A: 6-iodomethylpyridinol
To a 500 mL round-bottomed flask was added 2-methylpyridinol (4.0 g,
36.7 mmol) and Na CO (7.8 g, 73.6 mmol) in water (100 mL) to give a slightly tan
solution/suspension. I (9.6 g, 37.8 mmol) was added in one portion. The mixture
was stirred at rt for 3 h. There were noticeable I left. The mixture was stirred
overnight and there was still I left. The reaction mixture was heated at 42 °C (bath
temp) for 5 h (most I disappeared). The reaction was slowly neutralized with 1N
HCl (150 mL) to pH~5. Precipitate was collected by filtration, rinsed with water,
aqueous sodium bisulfite solution, and dried under vacuum to yield a yellowish gray
powder (7 g). The solids were purified by silica gel chromatography up to 30%
EtOAc/hexane to afford 6-iodomethylpyridinol (4.58 g, 53%) as a light yellow
solid: H NMR (400 MHz, Chloroform-d) δ 7.42 (dd, J = 8.3, 0.7 Hz, 1H), 6.81 (d, J
= 8.3 Hz, 1H), 2.48 (s, 3H); LCMS (ESI) m/e 235.8 [(M+H) , calcd C H INO,
236.0]; LC/MS retention time (method B): t = 1.14 min.
Part B: (S)-tert-butyl (1-((6-iodomethylpyridinyl)oxy)-2,4-dimethylpentan-2
yl)carbamate
Prepared as previously described in Example 32 to afford (S)-tert-butyl (1-
((6-iodomethylpyridinyl)oxy)-2,4-dimethylpentan-2 yl)carbamate (528 mg,
100%) as a tan oil: H NMR (400 MHz, Chloroform-d) δ 7.46 (d, J = 8.4 Hz, 1H),
6.83 (d, J = 8.4 Hz, 1H), 4.53 (s, 1H), 4.14 (d, J = 8.9 Hz, 1H), 3.96 (d, J = 8.9 Hz,
1H), 2.46 (s, 3H), 1.83 (tdt, J = 13.2, 11.6, 6.5 Hz, 2H), 1.53 (d, J = 4.7 Hz, 1H),
1.40 (s, 9H), 1.39 (s, 3H), 1.00 (d, J = 3.0 Hz, 3H), 0.98 (d, J = 3.0 Hz, 3H); LCMS
(ESI) m/e 448.9 [(M+H) , calcd C H IN O , 449.1]; LC/MS retention time (method
18 30 2 3
B): t = 2.38 min.
Part C: (S)-tert-butyl (1-((2'-chloro-3'-fluoromethyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanyl)carbamate
Prepared as previously described in Example 66 to afford (S)-tert-butyl (1-
((2'-chloro-3'-fluoromethyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
yl)carbamate (18.9 mg, 17%): LCMS (ESI) m/e 452.2 [(M+H) , calcd
C H ClFN O , 452.2]; LC/MS retention time (method B): t = 2.46 min.
23 32 3 3 R
Part D: (S)-tert-butyl (1-((2'-amino-3'-fluoromethyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanyl)carbamate
To a 20 mL pressure vial was added (S)-tert-butyl (1-((2'-chloro-3'-fluoro
methyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanyl)carbamate (18.9 mg,
0.042 mmol), and methyl carbamate (4.39 mg, 0.059 mmol) in 1,4-dioxane (0.4 mL)
to give a colorless solution. While degassing, PdOAc (0.939 mg, 4.18 µmol),
XANTPHOS (4.84 mg, 8.36 µmol), Cs CO (20.44 mg, 0.063 mmol) were added.
The vial was sealed under nitrogen and heated at 90 °C for 20 h. LCMS showed
partial conversion but the carbamate was completely hydrolyzed. The mixture was
diluted with EtOAc, dried, filtered, and concentrated. The residue (containing a
mixture of the starting material chloride and the hydrolyzed amine product) was
directly used in the next step. The amine: LCMS (ESI) m/e 433.3 (M+H) , calcd
C H FN O , 433.3]; LC/MS retention time (method B): t = 1.99 min; The
23 34 4 3 R
chloride: LCMS (ESI) m/e 452.1 [(M+H) , calcd C H ClFN O , 452.2]; LC/MS
23 32 3 3
retention time (method B): t = 2.48 min.
Part E: (S)((2-amino-2,4-dimethylpentyl)oxy)-3'-fluoromethyl-[2,4'-bipyridin]-
2'-amine
Prepared as previously described in Example 7, Part B to afford a mixture of
the amine and chloride. The mixture was purified by prep-HPLC to afford (S)((2-
amino-2,4-dimethylpentyl)oxy)-3'-fluoromethyl-[2,4'-bipyridin]-2'-amine (4.3 mg,
31% for 2 steps): H NMR (500 MHz, DMSO-d ) δ 7.79 (d, J = 5.3 Hz, 1H), 7.69 (d,
J = 8.5 Hz, 1H), 7.45 (d, J = 8.5 Hz, 1H), 7.02 (t, J = 5.2 Hz, 1H), 6.22 (s, 2H), 3.86
(s, 2H), 2.50 (s, 3H), 1.81 (dq, J = 12.8, 6.5 Hz, 1H), 1.56 - 1.42 (m, 2H), 1.21 (s,
3H), 0.94 (dd, J = 10.3, 6.7 Hz, 6H); LCMS (ESI) m/e 333.2 [(M+H) , calcd
C H FN O, 333.2]; LC/MS retention time (method B): t = 1.48 min.
18 26 4 R
Example 154
(S)((2'-chloro-3'-fluoromethyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
amine
Part A: (S)-tert-butyl (1-((2'-amino-3'-fluoromethyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanyl)carbamate
Obtained as a mixture with the amine from Example 153, Part D. LCMS
(ESI) m/e 452.1 [(M+H) , calcd C H ClFN O , 452.2]; LC/MS retention time
23 32 3 3
(method B): t = 2.48 min.
Part B: (S)((2'-chloro-3'-fluoromethyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine
The crude mixture from Example 153, Part D was deprotected as previously
described in Example 7, Part B to afford a mixture of the amine and chloride. The
mixture was separated and purified by prep-HPLC to afford (S)((2'-chloro-3'-
fluoromethyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine: (2.6 mg,
17% for 2 steps): H NMR (500 MHz, DMSO-d ) δ 8.33 (d, J = 5.0 Hz, 1H), 7.99 (t,
J = 5.3 Hz, 1H), 7.82 (d, J = 8.3 Hz, 1H), 7.49 (d, J = 8.6 Hz, 1H), 3.83 (s, 2H), 2.51
(s, 3H – OCH3 protons under DMSO peak – predicted shift = 2.47 ppm), 1.82 (p, J =
6.2 Hz, 1H), 1.53 - 1.38 (m, 2H), 1.18 (s, 3H), 0.94 (t, J = 7.2 Hz, 6H); LCMS (ESI)
m/e 335.1 [(M-NH ) , calcd C H ClFN O, 335.1]; LC/MS retention time (method
2 18 21 2
B): t = 1.91 min.
Example 155
(S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-5'-fluoromethyl-[2,4'-bipyridin]-
2'-yl)carbamate
Part A: (S)-tert-butyl (1-((2'-chloro-5'-fluoromethyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanyl)carbamate
Prepared as previously described in Example 66 with intermediate from
Example 153 and (2-chlorofluoro-pyridin-4yl)boronic acid to afford (S)-tert-butyl
(1-((2'-chloro-5'-fluoromethyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
yl)carbamate (13.4 mg, 13%): LCMS (ESI) m/e 452.1 [(M+H) , calcd
C H ClFN O , 452.2]; LC/MS retention time (method B): t = 2.49 min.
23 32 3 3 R
Part B: (S)-methyl (5-((2-Boc-amino-2,4-dimethylpentyl)oxy)-5'-fluoromethyl-
[2,4'-bipyridin]-2'-yl)carbamate
Prepared as previously described in Example 153 to afford (S)-methyl (5-((2-
Boc-amino-2,4-dimethylpentyl)oxy)-5'-fluoromethyl-[2,4'-bipyridin]-2'-
yl)carbamate (no carbamate hydrolysis observed) contaminated with left over starting
material ((S)-tert-butyl (1-((2'-chloro-5'-fluoromethyl-[2,4'-bipyridin]yl)oxy)-
2,4-dimethylpentanyl)carbamate). The crude mixture was carried on without
further purification. Carbamate: LCMS (ESI) m/e 491.2 (M+H) , calcd C H FN O ,
36 4 5
491.3]; LC/MS retention time (method B): t = 2.30 min.
Part C: (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-5'-fluoromethyl-[2,4'-
bipyridin]-2'-yl)carbamate
Prepared as previously described in Example 7, Part B. The crude mixture
was separated and purified by prep-HPLC to afford (S)-methyl (5-((2-amino-2,4-
dimethylpentyl)oxy)-5'-fluoromethyl-[2,4'-bipyridin]-2'-yl)carbamate (0.3 mg,
2.5% for 2 steps) as a colorless solid. H NMR (400 MHz, Methanol-d ) δ 8.45 (d, J
= 5.9 Hz, 1H), 8.21 (d, J = 2.7 Hz, 1H), 7.79 - 7.73 (m, 1H), 7.46 (d, J = 8.6 Hz,
1H), 4.07 - 3.96 (m, 2H), 3.80 (s, 3H), 2.61 (s, 3H), 1.87 (dt, J = 12.5, 6.4 Hz, 1H),
1.73 (dd, J = 14.3, 5.6 Hz, 1H), 1.62 (dd, J = 14.2, 5.5 Hz, 1H), 1.39 (s, 3H), 1.04
(dd, J = 10.9, 6.6 Hz, 6H); LCMS (ESI) m/e 391.4 [(M+H) , calcd C H FN O ,
28 4 3
391.2].
Example 156
(S)((2'-chloro-5'-fluoromethyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
amine
Part C: (S)((2'-chloro-5'-fluoromethyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine
Recovered from mixture obtained in Example 155, Part C. The mixture was
separated and purified by prep-HPLC to afford (S)((2'-chloro-5'-fluoromethyl-
[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine (5.2 mg, 49% for 2 steps) as a
colorless solid. H NMR (500 MHz, DMSO-d ) δ 8.54 (d, J = 2.6 Hz, 1H), 8.03 (d, J
= 5.5 Hz, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.48 (d, J = 8.6 Hz, 1H), 3.81 (s, 2H), 2.51
(s, 3H – OCH3 protons under DMSO peak – predicted shift = 2.47 ppm), 1.81 (dq, J
= 12.6, 6.5 Hz, 1H), 1.49 - 1.36 (m, 2H), 1.16 (s, 3H), 0.93 (t, J = 6.3 Hz, 6H);
LCMS (ESI) m/e 335.1 [(M-NH ) , calcd C H ClFN O, 335.1]; LC/MS retention
2 18 21 2
time (method B): t = 1.93 min.
Example 157
(S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-3'-fluoromethyl-[2,4'-bipyridin]-
2'-yl)carbamate
Part A: (S)-methyl (5-((2-Boc-amino-2,4-dimethylpentyl)oxy)-3'-fluoromethyl-
[2,4'-bipyridin]-2'-yl)carbamate
Prepared as previously described in Example 153 with reaction running at 80
°C for 30 h resulting in the carbamate after prep-HPLC purification (7.1 mg, 19%):
LCMS (ESI) m/e 491.4 (M+H) , calcd C H FN O , 491.3]; LC/MS retention time
36 4 5
(method A): t = 1.99 min.
Part B: (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-3'-fluoromethyl-[2,4'-
bipyridin]-2'-yl)carbamate
Prepared as previously described in Example 7, Part B to afford (S)-methyl
(5-((2-amino-2,4-dimethylpentyl)oxy)-3'-fluoromethyl-[2,4'-bipyridin]-2'-
yl)carbamate (5.2 mg, 90%): H NMR (500 MHz, DMSO-d ) δ 8.25 (d, J = 5.1 Hz,
1H), 7.79 (t, J = 5.2 Hz, 1H), 7.74 (d, J = 8.4 Hz, 1H), 7.46 (d, J = 8.7 Hz, 1H), 3.80
(s, 2H), 3.68 (s, 3H), 2.50 (s, 3H), 1.81 (dt, J = 12.5, 6.5 Hz, 1H), 1.48 - 1.38 (m,
2H), 1.15 (s, 3H), 0.93 (t, J = 6.3 Hz, 6H); LCMS (ESI) m/e 413.1 [(M+Na) , calcd
C H FN NaO , 413.2]; LC/MS retention time (method B): t = 1.66 min.
27 4 3 R
Example 158
(S)((2'-chloro(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
amine
Prepared as described in Example 117 with (2-chloropyridinyl)boronic
acid to afford (S)((2'-chloro(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine (26.3 mg, 0.068 mmol, 49%): H NMR (500 MHz, DMSO-
d ) δ 8.52 (d, J = 5.2 Hz, 1H), 8.37 (d, J = 8.8 Hz, 1H), 8.13 (s, 1H), 8.07 (d, J = 5.2
Hz, 1H), 7.81 (d, J = 8.8 Hz, 1H), 7.27 (t, J = 53.6 Hz, 1H), 3.94 (s, 2H), 1.79 (dt, J
= 12.6, 6.4 Hz, 1H), 1.43 (qd, J = 14.1, 5.6 Hz, 2H), 1.16 (s, 3H), 0.92 (dd, J = 12.8,
6.6 Hz, 6H); LCMS (ESI) m/e 370.1 [(M+H) , calcd C H F N O, 370.1]; LC/MS
19 26 2 3
retention time (method B): t = 1.91 min.
Example 159
(S)((2'-chloro(difluoromethyl)-3'-fluoro-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine
Prepared as described in Example 117 with (2-chlorofluoropyridin
yl)boronic acid to afford (S)((2'-chloro(difluoromethyl)-3'-fluoro-[2,4'-
bipyridin]yl)oxy)-2,4-dimethylpentanamine (25 mg, 0.064 mmol, 9.6%): H
NMR (500 MHz, DMSO-d ) δ 8.38 (dd, J = 5.3, 2.4 Hz, 1H), 8.12 (d, J = 8.9 Hz,
1H), 7.96 (td, J = 5.3, 2.2 Hz, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.25 (t, J = 53.5 Hz,
1H), 3.91 (d, J = 2.0 Hz, 2H), 1.86 - 1.75 (m, 1H), 1.40 (t, J = 6.2 Hz, 2H), 1.14 (d, J
= 2.2 Hz, 3H), 0.92 (ddd, J = 9.7, 6.8, 2.3 Hz, 6H); LCMS (ESI) m/e 388.1 [(M+H) ,
calcd C H ClF N O, 388.1]; LC/MS retention time (method B): t = 1.94 min.
18 22 3 3 R
Example 160
(S)((6-(difluoromethyl)-3'-fluoro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine
Prepared as described in Example 148 to afford (S)((6-(difluoromethyl)-3'-
fluoro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine (12.8 mg,
0.033 mmol, 55%): H NMR (500 MHz, DMSO-d ) δ 8.39 (d, J = 5.0 Hz, 1H), 8.07
(d, J = 8.8 Hz, 1H), 7.80 (d, J = 8.9 Hz, 1H), 7.75 (t, J = 5.5 Hz, 1H), 7.24 (t, J =
53.5 Hz, 1H), 3.92 (s, 2H), 2.54 (d, J = 3.3 Hz, 3H), 1.80 (dt, J = 12.6, 6.3 Hz, 1H),
1.50 - 1.36 (m, 2H), 1.15 (s, 3H), 0.92 (dd, J = 11.5, 6.6 Hz, 6H); LCMS (ESI) m/e
368.2 [(M+H) , calcd C H F N O, 368.2]; LC/MS retention time (method B): t =
19 25 3 3 R
1.72 min.
Example 161
((S)((6-chloro-2'-(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan-
2-amine
Part A: (S)-tert-butyl (1-((6-chloro-2'-(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanyl)carbamate
Prepared as previously described in Example 66 with intermediates iodide as
described in Example 66 and (2-(difluoromethyl)pyridinyl)boronic acid as
described in Example 123 (concentrated to dryness and used as is) to afford (S)-tert-
butyl (1-((6-chloro-2'-(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanyl)carbamate (70 mg, 19%): H NMR (400 MHz, Chloroform-d) δ
8.74 (d, J = 5.2 Hz, 1H), 8.18 (d, J = 1.7 Hz, 1H), 8.04 - 7.97 (m, 1H), 7.77 (d, J =
8.4 Hz, 1H), 7.38 (d, J = 8.5 Hz, 1H), 6.73 (t, J = 55.5 Hz, 1H), 4.59 (s, 1H), 4.38 (d,
J = 8.9 Hz, 1H), 4.18 (d, J = 8.8 Hz, 1H), 1.99 - 1.81 (m, 2H), 1.57 - 1.52 (m, 1H),
1.46 (s, 3H), 1.40 (s, 9H), 1.03 (d, J = 6.6 Hz, 6H); F NMR (376 MHz,
Chloroform-d) δ -115.83; LCMS (ESI) m/e 470.2 (M+H) , calcd C H ClF N O ,
23 31 2 3 3
470.2]; LC/MS retention time (method A): t = 2.50 min.
Part B: ((S)((6-chloro-2'-(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine
Prepared as previously described in Example 7, Part B to afford ((S)((6-
chloro-2'-(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine
(40.6 mg, 74%): H NMR (500 MHz, DMSO-d ) δ 8.77 (d, J = 5.1 Hz, 1H), 8.22 (d,
J = 8.1 Hz, 2H), 8.13 (d, J = 5.2 Hz, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.01 (t, J = 55.0
Hz, 1H), 3.92 (s, 2H), 1.79 (dt, J = 12.5, 6.6 Hz, 1H), 1.44 (qd, J = 14.1, 5.5 Hz,
2H), 1.16 (s, 3H), 0.91 (t, J = 6.2 Hz, 6H); F NMR (376 MHz, DMSO-d6) δ -
115.46 (d, J = 55.0 Hz); LCMS (ESI) m/e 392.1 [(M+Na) , calcd C H ClF N NaO,
18 22 2 3
392.1]; LC/MS retention time (method B): t = 1.94 min.
Example 162
(S)((4-(difluoromethyl)(6-methylpyridazinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Prepared as described in Example 117 with 3-methyl(4,4,5,5-tetramethyl-
1,3,2-dioxaborolanyl)pyridazine to afford (S)((4-(difluoromethyl)(6-
methylpyridazinyl)pyridinyl)oxy)-2,4-dimethylpentanamine (23.6 mg, 0.066
mmol, 48%): H NMR (500 MHz, DMSO-d ) δ 9.72 (d, J = 2.1 Hz, 1H), 8.72 (s,
1H), 8.34 (s, 1H), 8.19 (d, J = 2.0 Hz, 1H), 7.35 (t, J = 54.0 Hz, 1H), 4.04 (s, 2H),
2.71 (s, 3H), 1.85 - 1.74 (m, 1H), 1.42 (qd, J = 13.7, 5.3 Hz, 2H), 1.15 (s, 3H), 0.92
(dd, J = 13.3, 6.7 Hz, 6H); LCMS (ESI) m/e 373.2 [(M+Na) , calcd C H F N NaO,
18 24 2 4
373.2]; LC/MS retention time (method B): t = 1.59 min.
Example 163
(S)((2-(difluoromethyl)(6-methylpyridazinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Prepared as described in Example 117 with 3-methyl(4,4,5,5-tetramethyl-
1,3,2-dioxaborolanyl)pyridazine to afford (S)((2-(difluoromethyl)(6-
methylpyridazinyl)pyridinyl)oxy)-2,4-dimethylpentanamine (37.2 mg, 0.105
mmol, 85%): H NMR (500 MHz, DMSO-d ) δ 9.71 (d, J = 2.1 Hz, 1H), 8.40 (d, J =
8.8 Hz, 1H), 8.13 (d, J = 2.1 Hz, 1H), 7.84 (d, J = 8.9 Hz, 1H), 7.24 (t, J = 53.6 Hz,
1H), 3.91 (s, 2H), 2.71 (s, 3H), 1.80 (dt, J = 13.2, 6.3 Hz, 1H), 1.46 - 1.34 (m, 2H),
1.13 (s, 3H), 0.92 (dd, J = 10.5, 6.6 Hz, 6H); LCMS (ESI) m/e 373.2 [(M+Na) ,
calcd C H F N NaO, 373.2]; LC/MS retention time (method B): t = 1.62 min.
18 24 2 4 R
Example 164
(R)-2,4-dimethyl((2'-methyl(trifluoromethyl)-[2,4'-bipyridin]yl)oxy)pentan-
2-amine
Part A: (R)((6-bromo(difluoromethyl)pyridinyl)oxy)-2,4-dimethylpentan
amine
Prepared as previously described in Example 144 with R-enantiomer of the
amino alcohol to afford (R)((6-bromo(difluoromethyl)pyridinyl)oxy)-2,4-
dimethylpentanamine (0.58 g, 97%) as a tan oil: H NMR (400 MHz, Chloroform-
d) δ 8.19 (s, 1H), 7.64 (s, 1H), 3.97 - 3.83 (m, 2H), 1.85 - 1.73 (m, 1H), 1.49 (dd, J =
.7, 4.0 Hz, 2H), 1.24 (s, 3H), 0.99 (dd, J = 9.3, 6.6 Hz, 6H); F NMR (376 MHz,
Chloroform-d) δ -64.39; LCMS (ESI) m/e 338.0 [(M+H) , calcd C H BrF NO,
13 16 3
338.1]; LC/MS retention time (method B): t = 1.87 min.
Part B: (R)-2,4-dimethyl((2'-methyl(trifluoromethyl)-[2,4'-bipyridin]
yl)oxy)pentanamine
Prepared as described in Example 144 to afford (R)-2,4-dimethyl((2'-
methyl(trifluoromethyl)-[2,4'-bipyridin]yl)oxy)pentanamine (7.6 mg, 0.020
mmol, 23% yield): H NMR (500 MHz, DMSO-d ) δ 8.79 (s, 1H), 8.55 (d, J = 5.2
Hz, 1H), 8.29 (s, 1H), 7.97 (s, 1H), 7.88 (d, J = 5.2 Hz, 1H), 4.11 - 4.02 (m, 2H),
2.56 (s, 3H), 1.81 (dt, J = 12.9, 6.5 Hz, 1H), 1.40 (dd, J = 5.6, 2.8 Hz, 2H), 1.13 (s,
3H), 0.92 (dd, J = 6.6, 3.2 Hz, 6H); LCMS (ESI) m/e 368.2 (M+H) , calcd
C H F N O, 368.2]; LC/MS retention time (method B): t = 1.44 min.
19 25 3 3 R
Example 165
(R)-2,4-dimethyl((6-(quinolinyl)(trifluoromethyl)pyridinyl)oxy)pentan
amine
Prepared as described in Example 144 to afford (R)-2,4-dimethyl((6-
(quinolinyl)(trifluoromethyl)pyridinyl)oxy)pentanamine (14.9 mg, 0.037
mmol, 45% yield): H NMR (500 MHz, DMSO-d ) δ 9.01 (d, J = 4.4 Hz, 1H), 8.90
(s, 1H), 8.18 (d, J = 8.5 Hz, 1H), 8.13 (d, J = 8.5 Hz, 1H), 8.02 (s, 1H), 7.82 (t, J =
7.6 Hz, 1H), 7.70 (d, J = 4.4 Hz, 1H), 7.64 (t, J = 7.7 Hz, 1H), 4.15 - 4.05 (m, 2H),
1.83 (dq, J = 12.6, 6.3 Hz, 1H), 1.42 (dd, J = 5.7, 2.0 Hz, 2H), 1.16 (s, 3H), 0.95 (dd,
J = 6.6, 3.5 Hz, 6H); LCMS (ESI) m/e 404.2 (M+H) , calcd C H F N O, 404.2];
22 25 3 3
LC/MS retention time (method B): t = 1.66 min.
Example 166
(R)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)(trifluoromethyl)-[2,4'-
bipyridin]-2'-yl)carbamate
Prepared as described in Example 144 to afford (R)-methyl (5-((2-amino-2,4-
dimethylpentyl)oxy)(trifluoromethyl)-[2,4'-bipyridin]-2'-yl)carbamate (7.8 mg,
0.018 mmol, 35% yield): H NMR (500 MHz, DMSO-d ) δ 8.81 (s, 1H), 8.54 (s,
1H), 8.37 (d, J = 5.2 Hz, 1H), 8.18 (s, 1H), 7.74 (dd, J = 5.3, 1.6 Hz, 1H), 4.10 - 4.00
(m, 2H), 3.71 (s, 3H), 1.81 (hept, J = 6.1 Hz, 1H), 1.41 - 1.34 (m, 2H), 1.12 (s, 3H),
0.92 (dd, J = 6.8, 2.7 Hz, 6H); LCMS (ESI) m/e 449.1 (M+Na) , calcd
C H F N NaO , 449.2]; LC/MS retention time (method B): t = 1.72 min.
25 3 4 3 R
Example 167
(R)((2'-chloro(difluoromethyl)-3'-fluoro-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine
Part A: (R)((6-bromo(difluoromethyl)pyridinyl)oxy)-2,4-dimethylpentan
amine
Prepared as previously described in Example 142 with R-enantiomer of the
amino alcohol to afford (R)((6-bromo(difluoromethyl)pyridinyl)oxy)-2,4-
dimethylpentanamine (740 mg, 95%): LCMS (ESI) m/e 336.9 [(M+H) , calcd
C H BrF N O, 337.1]; LC/MS retention time (method B): t = 1.83 min. The
13 20 2 2 R
material was used as is.
Prepared as previously described in Example 142 with intermediate as
described above and (2-chlorofluoro-pyridinyl)boronic acid (6.7 mg, 11%): H
NMR (500 MHz, DMSO-d ) δ 8.76 (s, 1H), 8.38 (d, J = 5.0 Hz, 1H), 8.06 (s, 1H),
7.97 (t, J = 5.4 Hz, 1H), 7.38 (t, J = 53.9 Hz, 1H), 4.05 (s, 2H), 1.81 (dt, J = 12.9,
6.4 Hz, 1H), 1.42 (tt, J = 14.1, 6.8 Hz, 2H), 1.15 (d, J = 3.5 Hz, 3H), 0.94 (d, J = 6.6
Hz, 3H), 0.91 (d, J = 6.6 Hz, 3H); LCMS (ESI) m/e 371.1 [(M-NH ) , calcd
C H ClF N O, 371.1]; LC/MS retention time (method B): t = 2.02 min.
18 19 3 2 R
Example 168
(R)((2'-chloro(difluoromethyl)-5'-fluoro-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine
Prepared as previously described in Example 142 with intermediate as
described in Example 167 and (2-chlorofluoro-pyridinyl)boronic acid to afford
(R)((2'-chloro(difluoromethyl)-5'-fluoro-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine (14 mg, 20%): H NMR (500 MHz, DMSO-d6) δ 8.75 (s,
1H), 8.60 (d, J = 2.3 Hz, 1H), 8.05 (s, 1H), 8.02 (d, J = 5.5 Hz, 1H), 7.36 (t, J = 53.9
Hz, 1H), 4.04 (s, 2H), 1.81 (hept, J = 6.4 Hz, 1H), 1.48 - 1.35 (m, 2H), 1.14 (d, J =
3.3 Hz, 3H), 0.93 (dd, J = 12.6, 6.6 Hz, 6H); LCMS (ESI) m/e 371.1 [(M-NH ) ,
calcd C H ClF N O, 371.1]; LC/MS retention time (method B): t = 1.98 min.
18 19 3 2 R
Example 169
(R)((2'-chloro(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
amine
Prepared as previously described in Example 142 with intermediate as
described in Example 167 and (2-chloro-pyridinyl)boronic acid to afford (R)
((2'-chloro(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine
(10.2 mg, 49%): H NMR (500 MHz, DMSO-d ) δ 8.70 (s, 1H), 8.51 (d, J = 5.3 Hz,
1H), 8.31 (s, 1H), 8.18 (s, 1H), 8.11 (d, J = 5.3 Hz, 1H), 7.33 (t, J = 53.9 Hz, 1H),
4.02 (s, 2H), 1.80 (q, J = 6.3 Hz, 1H), 1.40 (tt, J = 14.0, 7.4 Hz, 2H), 1.14 (s, 3H),
0.93 (dd, J = 12.5, 6.6 Hz, 6H); LCMS (ESI) m/e 353.1 [(M-NH ) , calcd
C H ClF N O, 353.1]; LC/MS retention time (method B): t = 1.90 min.
18 20 2 2 R
Example 170
(R)((4-(difluoromethyl)-2'-ethyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
amine
Prepared as previously described in Example 141 with intermediate as
described in Example 167 and (2-ethylpyridinyl)boronic acid to afford (R)((4-
(difluoromethyl)-2'-ethyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine
(12.3 mg, 60%): H NMR (500 MHz, DMSO-d ) δ 8.68 (s, 1H), 8.57 (d, J = 5.3 Hz,
1H), 8.20 (s, 1H), 7.94 (s, 1H), 7.88 - 7.84 (m, 1H), 7.35 (t, J = 53.9 Hz, 1H), 4.02 (s,
2H), 2.84 (q, J = 7.6 Hz, 2H), 1.81 (dt, J = 12.7, 6.5 Hz, 1H), 1.42 (qd, J = 14.0, 5.5
Hz, 2H), 1.29 (t, J = 7.6 Hz, 3H), 1.15 (s, 3H), 0.93 (dd, J = 13.5, 6.6 Hz, 6H);
LCMS (ESI) m/e 364.2 [(M+H) , calcd C20H28F2N3O, 364.2]; LC/MS retention time
(method B): t = 1.48 min.
Example 171
(R)((4-(difluoromethyl)-5'-fluoro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine
Prepared as previously described in Example 148 with Example 168 to afford
(R)((4-(difluoromethyl)-5'-fluoro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine (1.2 mg, 10%): H NMR (500 MHz, DMSO-d ) δ 8.74 (s,
1H), 8.55 (d, J = 2.9 Hz, 1H), 7.99 (s, 1H), 7.81 (d, J = 6.5 Hz, 1H), 7.40 (t, J = 53.8
Hz, 1H), 4.15 - 4.05 (m, 2H), 2.54 (s, 3H), 1.81 (dt, J = 12.8, 6.3 Hz, 1H), 1.54 - 1.39
(m, 2H), 1.19 (s, 3H), 0.95 (d, J = 6.6 Hz, 3H), 0.92 (d, J = 6.6 Hz, 3H); LCMS
(ESI) m/e 351.1 [(M-NH ) , calcd C H F N O, 351.2]; LC/MS retention time
2 19 22 3 2
(method B): t = 1.80 min.
Example 172
(R)((4-(difluoromethyl)-3'-fluoro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine
Prepared as previously described in Example 148 with Example 167 as the
starting material to afford (R)((4-(difluoromethyl)-3'-fluoro-2'-methyl-[2,4'-
bipyridin]yl)oxy)-2,4-dimethylpentanamine (1.1 mg, 24%): H NMR (500
MHz, DMSO-d ) δ 8.76 (s, 1H), 8.40 (d, J = 5.0 Hz, 1H), 8.02 (s, 1H), 7.77 (t, J =
.5 Hz, 1H), 7.43 (t, J = 53.9 Hz, 1H), 4.13 (q, J = 9.5 Hz, 2H), 2.54 (d, J = 3.3 Hz,
3H), 1.81 (dt, J = 12.9, 6.4 Hz, 1H), 1.57 - 1.41 (m, 2H), 1.22 (s, 3H), 0.95 (d, J =
6.6 Hz, 3H), 0.92 (d, J = 6.6 Hz, 3H); LCMS (ESI) m/e 351.1 [(M-NH ) , calcd
C19H22F3N2O, 351.2]; LC/MS retention time (method B): tR = 1.79 min.
Example 173
(R)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)methyl-[2,4'-bipyridin]-2'-
yl)carbamate
Prepared as previously described in Example 164 using the R-enantiomer of
the amino alcohol to afford (R)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)
methyl-[2,4'-bipyridin]-2'-yl)carbamate (26 mg, 0.050 mmol, 26%) as a pale yellow
film. H NMR (400MHz, MeOH-d ) δ 8.36 (d, J=6.5 Hz, 1H), 8.24 (d, J=1.3 Hz,
1H), 8.05 (m, 2H), 7.58 (d, J=8.5 Hz, 1H), 4.25 (m, 2H), 3.94 (s, 3H), 3.38 (s, 2 H),
2.66 (s, 3H), 1.95-1.85 (m, 2H), 1.81-1.71 (m, 1H), 1.55 (s, 3H), 1.09 (d, J=6.5 Hz,
3H), 1.04 (d, J=6.4 Hz, 3H); LCMS (ESI) m/e 373.4 (M+H) , calcd C H N O ,
29 4 3
373.2]; LC/MS retention time (method D): tR = 1.81 min.
Example 174
(R)((2',6-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
amine
Prepared as previously described in Example 123 using the R-enantiomer of
the amino alcohol to afford (R)((2',6-bis(difluoromethyl)-[2,4'-bipyridin]
yl)oxy)-2,4-dimethylpentanamine (6.6 mg, 0.017 mmol, 15%) as a film. H NMR
(500MHz, DMSO-d ) δ 8.79 (d, J=5.1 Hz, 1H), 8.40 (d, J=8.8 Hz, 1H), 8.33 (s, 1H),
8.22 (d, J=5.1 Hz, 1H), 7.82 (d, J=8.8 Hz, 1H), 7.25 (t, J=53.5 Hz, 1H), 7.05 (t,
J=54.9 Hz, 1H), 3.91 (s, 2H), 3.36 (m 2H), 1.81(m, 1H), 1.40 (m, 2H), 1.13 (s, 3H)
0.94 (d, J=6.5 Hz, 3H), 0.92 (d, J=6.4 Hz, 3H); LCMS (ESI) m/e 386.4 (M+H)+,
calcd C19H24F4N3O, 386.2]; LC/MS retention time (method D): t = 2.62 min.
Example 175
(R)((2',4-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
amine
Prepared as previously described in Example 124 using the R-enantiomer of
the amino alcohol to afford (R)((2',4-bis(difluoromethyl)-[2,4'-bipyridin]
yl)oxy)-2,4-dimethylpentanamine (9.3 mg, 0.024 mmol, 21%) as a film. H NMR
(500MHz, DMSO-d ) δ 8.79 (d, J=5.1 Hz, 1H), 8.71 (s, 1H), 8.37 (s, 1H), 8.32 (s,
1H), 8.25 (d, J=4.8 Hz, 1H), 7.33 (t, J=53.5 Hz, 1H), 7.04 (t, J=54.9 Hz, 1H), 4.01 (s,
2H), 3.32 (m, 2H), 1.81(m, 1H), 1.40 (m, 2H), 1.13 (s, 3H) 0.94 (d, J=6.5 Hz, 3H),
0.92 (d, J=6.4 Hz, 3H); LCMS (ESI) m/e 386.4 (M+H)+, calcd C19H24F4N3O,
386.2]; LC/MS retention time (method D): t = 2.66 min.
Example 176
(S)((4-(difluoromethyl)(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentan
Part A: (S)-2,4-dimethylpentane-1,2-diol
To a 500 mL round-bottomed flask was added AD-MIX-ALPHA (3.60 g,
2.60 mmol) in BuOH (13 mL) and water (13 mL) to give a yellow solution under
vigorously stirring. The resulting mixture was stirred at rt for 30 min and then cooled
to 0 °C. A precipitate appeared and 2,4-dimethylpentene (0.364 mL, 2.60 mmol)
was added in one portion. The resulting mixture was stirred vigorously at 0 °C for 6
h and 3.86 g (30.6 mmol) of sodium sulfite was added. The mixture was allowed to
warm to rt and was stirred for 30 min. CH Cl (40 mL) and water (80 mL) was then
added successively and the layers were separated. The aqueous layer was extracted
twice with CH Cl . The combined organic phase was dried , filtered, and
concentrated to afford (S)-2,4-dimethylpentane-1,2-diol (308 mg, 90%) as a colorless
oil: H NMR (400 MHz, Chloroform-d) δ 3.52 - 3.38 (m, 2H), 1.85 - 1.79 (m, 1H),
1.42 (dd, J = 6.0, 2.0 Hz, 2H), 1.22 (s, 3H), 0.99 (dd, J = 11.7, 6.6 Hz, 6H).
Reference: S. J. Leiris et al. Bioorg. Med. Chem. 2010, 18, 3481-3493.
Part B: (S)((6-bromo(difluoromethyl)pyridinyl)oxy)-2,4-dimethylpentanol
To a 20 mL pressure bottle was added (S)-2,4-dimethylpentane-1,2-diol (125
mg, 0.946 mmol) and 2-bromo(difluoromethyl)fluoropyridine (214 mg, 0.946
mmol) in tetrahydrofuran (1.3 mL) to give a tan solution. Potassium tert-butoxide
(1.229 mL, 1.229 mmol) (1.0 M in THF) was added dropwise under nitrogen. After
min stirring at rt, the bottle was sealed and the mixture was stirred at 80 °C for 18
h. The mixture was partitioned between water and EtOAc. The layers were
separated. The aqueous layer was extracted with EtOAc. The combined organic
solution was washed with brine, dried and concentrated to afford (S)((6-bromo
(difluoromethyl)pyridinyl)oxy)-2,4-dimethylpentanol (300 mg, 94%) as a tan
oil. The material was used as is. LCMS (ESI) m/e 338.0 [(M+H) , calcd
C H BrF NO , 338.0]; LC/MS retention time (method B): t = 2.30 min.
13 19 2 2 R
Part C: (S)((4-(difluoromethyl)(quinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanol
Prepared as previously described in Example 117 to afford (S)((4-
(difluoromethyl)(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentanol (3.6
mg, 14%): H NMR (500 MHz, DMSO-d ) δ 9.00 (d, J = 4.4 Hz, 1H), 8.80 (s, 1H),
8.18 (d, J = 8.4 Hz, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.87 (s, 1H), 7.82 (t, J = 7.7 Hz,
1H), 7.69 - 7.61 (m, 2H), 7.35 (s, 1H), 4.09 (q, J = 9.2 Hz, 2H), 1.86 (dt, J = 12.7,
6.5 Hz, 1H), 1.50 (d, J = 5.9 Hz, 2H), 1.27 (s, 3H), 0.96 (d, J = 6.5 Hz, 6H); LCMS
(ESI) m/e 387.1 [(M+H) , calcd C H F N O , 387.2]; LC/MS retention time
22 25 2 2 2
(method B): t = 2.06 min.
Example 177
(S)-methyl (4-(difluoromethyl)((2-hydroxy-2,4-dimethylpentyl)oxy)-[2,4'-
bipyridin]-2'-yl)carbamate
Prepared as previously described in Example 117 with intermediate from
Example 176 (1.8 mg, 6.5%): H NMR (500 MHz, DMSO-d ) δ 8.71 (s, 1H), 8.53 (s,
1H), 8.36 (d, J = 5.4 Hz, 1H), 8.07 (s, 1H), 7.77 - 7.67 (m, 1H), 7.31 (s, 1H), 4.05 (q,
J = 9.3 Hz, 2H), 3.71 (s, 3H), 1.83 (dt, J = 12.6, 6.3 Hz, 1H), 1.47 (d, J = 5.9 Hz,
2H), 1.24 (s, 3H), 0.94 (d, J = 6.6 Hz, 6H); LCMS (ESI) m/e 410.1 [(M+H) , calcd
C H F N O , 410.2]; LC/MS retention time (method B): t = 2.07 min.
26 2 3 4 R
Example 178
(S)((4-(difluoromethyl)-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan-
2-ol
Prepared as previously described in Example 117 with intermediate from
Example 176 to afford (S)((4-(difluoromethyl)-2'-methyl-[2,4'-bipyridin]
yl)oxy)-2,4-dimethylpentanol (2.2 mg, 7.2%): H NMR (500 MHz, DMSO-d ) δ
8.69 (s, 1H), 8.54 (d, J = 5.3 Hz, 1H), 8.17 (s, 1H), 7.94 (s, 1H), 7.84 (d, J = 5.7 Hz,
1H), 7.30 (t, J = 54.1 Hz, 1H), 4.04 (q, J = 9.2 Hz, 2H), 2.56 (s, 3H), 1.83 (dt, J =
12.8, 6.4 Hz, 1H), 1.46 (d, J = 5.9 Hz, 2H), 1.24 (s, 3H), 0.94 (dd, J = 6.7, 1.6 Hz,
6H); LCMS (ESI) m/e 351.1 [(M+H) , calcd C H F N O , 351.2]; LC/MS retention
19 25 2 2 2
time (method B): t = 1.91 min.
Example 179
(S)-methyl (5-((2-amino(fluoromethyl)methylpentyl)oxy)(difluoromethyl)-
[2,4'-bipyridin]-2'-yl)carbamate
Part A: (E/Z)((benzyloxy)imino)fluoropropanoic acid
To a 250 mL round-bottomed flask was added O-benzylhydroxylamine
(1.5338 g, 12.45 mmol) and sodium 3-fluorooxopropanoate (1.595 g, 12.45 mmol)
in ethanol (36 mL) to give a white suspension. The mixture was heated at 80 °C for
h. The ethanol was stripped off. The off-white solid was dissolved in EtOAc and
mL 1N HCl. The layer was separated. The aqueous layer was extracted three
time with EtOAc. The combined organic solution was dried and concentrated to
afford (E/Z)((benzyloxy)imino)fluoropropanoic acid (2.51 g, 96%) as a tan
solid. LCMS indicated likely E/Z isomers (about ¼ ratio). The material was used as
Part B: 2-((benzyloxy)amino)(fluoromethyl)methylpentenoic acid
To a 250 mL round-bottomed flask was added (E/Z)((benzyloxy)imino)
fluoropropanoic acid (2.32 g, 10.99 mmol) and 3-bromomethylpropene (4.43 mL,
43.9 mmol) in THF (10.00 mL) and aqueous NH Cl (50 mL) to give a tan solution.
Zinc (3.59 g, 54.9 mmol) was added portionwise. The mixture was stirred at rt for 30
min. The mixture was diluted with water and EtOAc. The layers were separated.
The aqueous layer was extracted twice with EtOAc. The combined organic layers
were washed with brine, dried and concentrated to a dense semi-solid. First silica gel
chromatography up to 50% EtOAc/hexane did not purify the desired product and the
2nd silica gel chromatography up to 10% MeOH/CH Cl (Rf~0.3) afforded 2-
((benzyloxy)amino)(fluoromethyl)methylpentenoic acid (2.33 g, 76%) as a
white solid: H NMR (400 MHz, Chloroform-d) δ 7.44 - 7.31 (m, 5H), 6.94 (s, 1H),
4.98 (p, J = 1.6 Hz, 1H), 4.88 (d, J = 2.3 Hz, 1H), 4.87 - 4.61 (m, 4H), 2.40 (d, J =
1.2 Hz, 2H), 1.77 (s, 3H); F NMR (376 MHz, Chloroform-d) δ -233.34; LCMS
(ESI) m/e 290.1 [(M+Na) , calcd C H FNNaO , 290.1]; LC/MS retention time
14 18 3
(method B): t = 2.04 min.
The racmeic compound (2 g) was separated by chiral super critical fluid
chromatography (Column: ChiralPak AD-H, 30 x 250mm, 5 μm); Mobile Phase: 10
% EtOH / 90% CO to give the two enantiomers.
Analytical super critical fluid chromatography conditions: Column: ChiralPak
AD-H,4.6 x 250mm, 5 μm; BPR pressure: 100 bars; Temperature: 35 °C; Flow rate:
2.0 mL/min; Mobile Phase: 20 % EtOH / 80% CO ; Detector Wavelength: UV 205
Enantiomer 1 (0.9 g, 90% recovery, e.e.% > 99.9%, α = +7.87° (CHCl , 3.05
mg/ml)): (S)-benzyl 4-methyl(2-methylallyl)-1,2,3-oxathiazolidinecarboxylate
2,2-dioxide HPLC retention time = 3.00 min.
Enantiomer 2 (0.9 g, 90% recovery, e.e.% = 92.6%, α = -9.20° (CHCl , 3.15
mg/ml)): (R)-benzyl 4-methyl(2-methylallyl)-1,2,3-oxathiazolidinecarboxylate
2,2-dioxide HPLC retention time = 3.52 min.
The absolute structures were assigned based on the comparison of the optical
rotations of the free amino alcohol below with the des-F analogs, and were further
proved by the biology data of the final examples (analogs made from the S-
enantiomer (1) were more potent than analogs made from the R-enantiomer (2) as
was seen with the other examples).
Part C: (S)amino(fluoromethyl)methylpentanoic acid
To a 1 L round-bottomed flask was added (S)((benzyloxy)amino)
(fluoromethyl)methylpentenoic acid (0.89 g, 3.33 mmol) in MeOH (30 mL) to
give a colorless solution. Pd-C (0.709 g, 0.666 mmol) was added. The mixture was
stirred under hydrogen (balloon) for 16 h. LCMS showed complete disappearance of
starting material. The mixture was filtered and rinsed with MeOH. The filtered clear
solution was concentrated to afford (S)amino(fluoromethyl)methylpentanoic
acid (510 mg, 94%) as a white solid: H NMR (400 MHz, Methanol-d4) δ 4.62 (ddd,
J = 62.0, 47.4, 10.0 Hz, 2H), 1.94 - 1.66 (m, 3H), 1.01 (dd, J = 6.3, 3.9 Hz, 6H); F
NMR (376 MHz, Methanol-d4) δ -229.19; α = +21.61° (MeOH, 2.85 mg/mL).
Part D: (S)amino(fluoromethyl)methylpentanol
To a 250 mL round-bottomed flask was added (S)amino(fluoromethyl)-
4-methylpentanoic acid (496 mg, 3.04 mmol) in tetrahydrofuran (15 mL) to give a
colorless solution under nitrogen. BH .THF (12.16 mL, 12.16 mmol) was added
under nitrogen. The mixture was stirred at rt over the weekend for 66 h. TLC
showed (10% MeOH/CH2Cl , I stain) a new peak above the baseline. The reaction
was quenched with MeOH. Volatiles were removed. The residue was treated with 30
mL 1N HCl and heated at 50 °C for 1 h. After cooling down, the mixture was then
basified with 40 mL 1N NaOH and extracted three times with CH Cl . The
combined organic solution was dried and concentrated to give (S)amino
(fluoromethyl)methylpentanol (377 mg, 83%) as a colorless oil: H NMR (400
MHz, Chloroform-d) δ 4.31 (dd, J = 47.7, 0.9 Hz, 2H), 3.53 (dd, J = 10.8, 1.3 Hz,
1H), 3.42 (dd, J = 10.8, 3.0 Hz, 1H), 1.79 (m, 4H), 1.44 - 1.32 (m, 2H), 1.00 (d, J =
1.8 Hz, 3H), 0.99 (d, J = 1.8 Hz, 3H); F NMR (376 MHz, Chloroform-d) δ -227.90;
α = -1.00° (CHCl , 2.40 mg/mL).
Part E: (S)((6-bromo(difluoromethyl)pyridinyl)oxy)(fluoromethyl)
methylpentanamine
To a 2 mL pressure bottle was added (S)amino(fluoromethyl)
methylpentanol (65.7 mg, 0.440 mmol) and 6-bromo(difluoromethyl)
fluoropyridine (100 mg, 0.440 mmol) in tetrahydrofuran (0.6 mL) to give a colorless
solution. Potassium tert-butoxide (0.528 mL, 0.528 mmol) (1.0 M in THF) was
added under nitrogen. The bottle was sealed and the mixture was stirred at 70 °C for
16 h. The mixture was partitioned between water and EtOAc. The layers were
separated. The aqueous layer was extracted with EtOAc. The combined organic
solution was washed with brine, dried and concentrated to a tan oil (140 mg, 90%):
H NMR (400 MHz, Chloroform-d) δ 7.56 (dt, J = 8.7, 1.0 Hz, 1H), 7.26 (d, J = 8.8
Hz, 1H), 6.68 (t, J = 53.8 Hz, 1H), 4.50 - 4.25 (m, 2H), 3.93 (ddd, J = 32.5, 8.5, 1.8
Hz, 2H), 1.87 (dq, J = 12.7, 6.3 Hz, 1H), 1.52 - 1.44 (m, 2H), 1.03 (d, J = 6.7 Hz,
3H), 1.00 (d, J = 6.7 Hz, 3H); F NMR (376 MHz, Chloroform-d) δ -117.34 , -
225.58; LCMS (ESI) m/e 355.1 [(M+H) , calcd C H BrF N O, 355.1]; LC/MS
13 19 3 2
retention time (method B): t = 1.69 min.
Part F. (S)-methyl (5-((2-amino(fluoromethyl)methylpentyl)oxy)
(difluoromethyl)-[2,4'-bipyridin]-2'-yl)carbamate
Prepared as previously described for Example 117 but at 80 °C for 5 h to
afford the titled product (9.7 mg, 36%): H NMR (500 MHz, DMSO-d ) δ 8.50 (s,
1H), 8.36 (d, J = 5.2 Hz, 1H), 8.18 (d, J = 8.8 Hz, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.67
(d, J = 5.3 Hz, 1H), 7.23 (t, J = 53.5 Hz, 1H), 4.33 (dq, J = 47.8, 8.9 Hz, 2H), 4.07 -
3.92 (m, 2H), 3.71 (s, 3H), 1.89 (dd, J = 12.7, 6.5 Hz, 1H), 1.50 - 1.31 (m, 2H), 0.96
(d, J = 6.6 Hz, 3H), 0.93 (d, J = 6.6 Hz, 3H); LCMS (ESI) m/e 427.3 [(M+H) , calcd
C H F N O , 427.2]; LC/MS retention time (method B): t = 1.66 min.
26 3 4 3 R
Example 180
(R)-methyl (5-((2-amino(fluoromethyl)methylpentyl)oxy)(difluoromethyl)-
[2,4'-bipyridin]-2'-yl)carbamate
Part A: (R)amino(fluoromethyl)methylpentanoic acid
Prepared as previously described in Example 179, Part C to afford (R)
amino(fluoromethyl)methylpentanoic acid (512 mg, 94%) as a white solid: H
NMR (400 MHz, Methanol-d ) δ 4.62 (ddd, J = 62.0, 47.4, 10.0 Hz, 2H), 1.94 - 1.66
(m, 3H), 1.01 (dd, J = 6.3, 3.9 Hz, 6H); F NMR (376 MHz, Methanol-d4) δ -
229.19; α = -20.29° (MeOH, 2.70 mg/mL).
Part B: (R)amino(fluoromethyl)methylpentanol
Prepared as previously described in Example 179, Part D to afford (R)
amino(fluoromethyl)methylpentanol (362 mg, 80%) as a colorless oil: H
NMR (400 MHz, Methanol-d ) δ 4.31 (d, J = 47.7 Hz, 2H), 3.53 (dd, J = 10.8, 1.3
Hz, 1H), 3.42 (dd, J = 10.8, 3.0 Hz, 1H), 1.79 (tt, J = 12.8, 6.4 Hz, 4H), 1.38 (td, J =
.6, 1.8 Hz, 2H), 1.00 (d, J = 1.8 Hz, 3H), 0.99 (d, J = 1.9 Hz, 3H); F NMR (376
MHz, Chloroform-d) δ -227.87; α = +1.11° (CHCl , 2.70 mg/mL).
Part C: (R)((6-bromo(difluoromethyl)pyridinyl)oxy)(fluoromethyl)
methylpentanamine
Prepared as previously described in Example 179, Part E to afford (R)((6-
bromo(difluoromethyl)pyridinyl)oxy)(fluoromethyl)methylpentan
amine (145 mg, 96%) as a colorless oil: H NMR (400 MHz, Methanol-d ) δ 7.56 (dt,
J = 8.6, 1.0 Hz, 1H), 7.26 (d, J = 8.7 Hz, 1H), 6.69 (t, J = 53.8 Hz, 1H), 4.49 - 4.26
(m, 2H), 3.93 (ddd, J = 32.8, 8.6, 1.8 Hz, 2H), 1.88 (dp, J = 12.8, 6.4 Hz, 1H), 1.56 -
1.41 (m, 4H), 1.03 (d, J = 6.6 Hz, 3H), 1.00 (d, J = 6.6 Hz, 3H); F NMR (376
MHz, Chloroform-d) δ -117.50 , -225.55; LCMS (ESI) m/e 355.1 [(M+H) , calcd
C H BrF N O, 355.1]; LC/MS retention time (method B): t = 1.68 min.
13 19 3 2 R
Part D: (R)-methyl (5-((2-amino(fluoromethyl)methylpentyl)oxy)
(difluoromethyl)-[2,4'-bipyridin]-2'-yl)carbamate
Prepared as previously described In Example 179 to afford (R)-methyl (5-((2-
amino(fluoromethyl)methylpentyl)oxy)(difluoromethyl)-[2,4'-bipyridin]-2'-
yl)carbamate (8.8 mg, 33%): H NMR (500 MHz, DMSO-d ) δ 8.50 (s, 1H), 8.36 (d,
J = 5.4 Hz, 1H), 8.18 (d, J = 8.7 Hz, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.67 (d, J = 5.2
Hz, 1H), 7.23 (t, J = 53.5 Hz, 1H), 4.33 (dq, J = 47.7, 9.0 Hz, 2H), 4.11 - 3.93 (m,
2H), 3.71 (s, 3H), 1.89 (p, J = 6.4 Hz, 1H), 1.50 - 1.32 (m, 2H), 0.96 (d, J = 6.7 Hz,
3H), 0.93 (d, J = 6.6 Hz, 3H); LCMS (ESI) m/e 427.3 [(M+H) , calcd C H F N O ,
26 3 4 3
427.2]; LC/MS retention time (method B): t = 1.62 min.
Example 181
(S)-methyl (5-((2-amino(fluoromethyl)methylpentyl)oxy)(difluoromethyl)-
[2,4'-bipyridin]-2'-yl)carbamate
Part A: (S)((6-bromo(difluoromethyl)pyridinyl)oxy)(fluoromethyl)
methylpentanamine
Prepared as previously described in Example 19 to afford (S)((6-bromo
(difluoromethyl)pyridinyl)oxy)(fluoromethyl)methylpentanamine (157
mg, 98%) as a tan oil: H NMR (400 MHz, Methanol-d ) δ 8.16 (s, 1H), 7.62 (s, 1H),
6.80 (t, J = 54.4 Hz, 1H), 4.35 (ddd, J = 47.4, 36.8, 9.0 Hz, 2H), 4.01 (qd, J = 8.7,
1.7 Hz, 2H), 1.87 (dp, J = 12.9, 6.4 Hz, 1H), 1.48 - 1.43 (m, 2H), 1.03 (d, J = 6.6 Hz,
3H), 1.00 (d, J = 6.6 Hz, 3H); F NMR (376 MHz, Chloroform-d) δ -119.66 , -
226.04; LCMS (ESI) m/e 355.1 [(M+H) , calcd C H BrF N O, 355.1]; LC/MS
13 19 3 2
retention time (method B): t = 1.78 min.
Part B: (S)-methyl (5-((2-amino(fluoromethyl)methylpentyl)oxy)
(difluoromethyl)-[2,4'-bipyridin]-2'-yl)carbamate
Prepared as previously described for Example 179 to afford the titled product
(4.0 mg, 17%): H NMR (500 MHz, DMSO-d ) δ 8.73 (s, 1H), 8.53 (s, 1H), 8.36 (d,
J = 5.2 Hz, 1H), 8.08 (s, 1H), 7.70 (d, J = 5.3 Hz, 1H), 7.35 (t, J = 53.9 Hz, 1H),
4.45 - 4.23 (m, 2H), 4.20 - 4.05 (m, 2H), 3.71 (s, 3H), 1.90 (p, J = 6.5 Hz, 1H), 1.40
(qd, J = 13.9, 5.7 Hz, 2H), 0.96 (d, J = 6.6 Hz, 3H), 0.94 (d, J = 6.6 Hz, 3H); LCMS
(ESI) m/e 427.3 [(M+H) , calcd C H F N O , 427.2]; LC/MS retention time
26 3 4 3
(method B): t = 1.67 min.
Example 182
(R)-methyl (5-((2-amino(fluoromethyl)methylpentyl)oxy)(difluoromethyl)-
[2,4'-bipyridin]-2'-yl)carbamate
Part A: (R)((6-bromo(difluoromethyl)pyridinyl)oxy)(fluoromethyl)
methylpentanamine
Prepared as previously described in Example 19 to afford (R)((6-bromo
(difluoromethyl)pyridinyl)oxy)(fluoromethyl)methylpentanamine (163
mg, 100%) as a tan oil: H NMR (400 MHz, Methanol-d ) δ 8.17 (s, 1H), 7.62 (s,
1H), 6.80 (t, J = 54.4 Hz, 1H), 4.35 (ddd, J = 47.5, 36.9, 9.0 Hz, 2H), 4.01 (qd, J =
8.7, 1.7 Hz, 2H), 1.87 (dp, J = 12.8, 6.4 Hz, 1H), 1.54 - 1.43 (m, 4H), 1.03 (d, J = 6.6
Hz, 3H), 1.00 (d, J = 6.6 Hz, 3H); F NMR (376 MHz, Chloroform-d) δ -119.62 , -
226.06; LCMS (ESI) m/e 355.1 [(M+H) , calcd C H BrF N O, 355.1]; LC/MS
13 19 3 2
retention time (method B): t = 1.79 min.
Part B: (R)-methyl (5-((2-amino(fluoromethyl)methylpentyl)oxy)
(difluoromethyl)-[2,4'-bipyridin]-2'-yl)carbamate
Prepared as previously described for Example 179 to afford (R)-methyl (5-
((2-amino(fluoromethyl)methylpentyl)oxy)(difluoromethyl)-[2,4'-bipyridin]-
2'-yl)carbamate (3.4 mg, 13%): H NMR (500 MHz, DMSO-d ) δ 8.73 (s, 1H), 8.53
(s, 1H), 8.36 (d, J = 5.2 Hz, 1H), 8.08 (s, 1H), 7.70 (d, J = 5.3 Hz, 1H), 7.35 (t, J =
53.9 Hz, 1H), 4.43 - 4.24 (m, 2H), 4.20 - 4.04 (m, 2H), 3.71 (s, 3H), 1.90 (dt, J =
12.6, 6.2 Hz, 1H), 1.40 (qd, J = 14.4, 5.7 Hz, 2H), 0.96 (d, J = 6.6 Hz, 3H), 0.94 (d, J
= 6.7 Hz, 3H); LCMS (ESI) m/e 427.3 [(M+H) , calcd C H F N O , 427.2];
26 3 4 3
LC/MS retention time (method B): t = 1.65 min.
Example 183
(S)((2',6-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)(fluoromethyl)
methylpentanamine
Prepared as previously described for Example 179 but for 3 h to afford (S)
((2',6-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)(fluoromethyl)
methylpentanamine (10 mg, 28%): H NMR (500 MHz, DMSO-d ) δ 8.80 (d, J =
.1 Hz, 1H), 8.41 (d, J = 8.8 Hz, 1H), 8.33 (s, 1H), 8.22 (d, J = 5.2 Hz, 1H), 7.88 (d,
J = 8.9 Hz, 1H), 7.39 - 7.14 (m, 1H), 7.00 (d, J = 54.8 Hz, 1H), 4.43 - 4.23 (m, 2H),
4.10 - 3.96 (m, 2H), 1.90 (dt, J = 12.8, 6.4 Hz, 1H), 1.49 - 1.32 (m, 2H), 0.96 (d, J =
6.6 Hz, 3H), 0.93 (d, J = 6.5 Hz, 3H); LCMS (ESI) m/e 404.3 [(M+H) , calcd
C H F N O, 404.2]; LC/MS retention time (method B): t = 1.90 min.
19 23 5 3 R
Example 184
(S)((2',4-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)(fluoromethyl)
methylpentanamine
Prepared as previously described for Example 179 but for 3 h to afford (S)
((2',4-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)(fluoromethyl)
methylpentanamine (15.1 mg, 45%): H NMR (500 MHz, DMSO-d ) δ 8.79 (d, J
= 5.3 Hz, 1H), 8.76 (s, 1H), 8.37 (s, 1H), 8.33 (s, 1H), 8.26 (d, J = 5.2 Hz, 1H), 7.35
(t, J = 53.8 Hz, 1H), 7.05 (t, J = 54.9 Hz, 1H), 4.43 - 4.25 (m, 2H), 4.21 - 4.04 (m,
2H), 1.90 (dt, J = 12.8, 6.4 Hz, 1H), 1.48 - 1.33 (m, 2H), 0.96 (d, J = 6.6 Hz, 3H),
0.94 (d, J = 6.6 Hz, 3H); LCMS (ESI) m/e 404.3 [(M+H) , calcd C H F N O,
19 23 5 3
404.2]; LC/MS retention time (method B): t = 1.86 min.
Example 185
(R)((2',6-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)(fluoromethyl)
methylpentanamine
Prepared as previously described for Example 179 but for 3 h to afford (R)
((2',6-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)(fluoromethyl)
methylpentanamine (10 mg, 28%): H NMR (500 MHz, DMSO-d6) δ 8.80 (d, J =
.1 Hz, 1H), 8.41 (d, J = 8.8 Hz, 1H), 8.33 (s, 1H), 8.22 (d, J = 5.2 Hz, 1H), 7.87 (d,
J = 8.8 Hz, 1H), 7.40 - 7.15 (m, 1H), 6.99 (d, J = 54.9 Hz, 1H), 4.44 - 4.23 (m, 2H),
4.11 - 3.95 (m, 2H), 1.90 (dt, J = 12.7, 6.3 Hz, 1H), 1.49 - 1.32 (m, 2H), 0.96 (d, J =
6.7 Hz, 3H), 0.93 (d, J = 6.6 Hz, 3H); LCMS (ESI) m/e 404.3 [(M+H) , calcd
C H F N O, 404.2]; LC/MS retention time (method B): t = 1.87 min.
19 23 5 3 R
Example 186
(R)((2',4-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)(fluoromethyl)
methylpentanamine
Prepared as previously described for Example 179 to afford (R)((2',4-
bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)(fluoromethyl)methylpentan
amine (7.7 mg, 16%): H NMR (500 MHz, DMSO-d ) δ 8.79 (d, J = 5.1 Hz, 1H),
8.76 (s, 1H), 8.37 (s, 1H), 8.33 (s, 1H), 8.26 (d, J = 5.3 Hz, 1H), 7.35 (t, J = 53.8 Hz,
1H), 7.05 (t, J = 54.8 Hz, 1H), 4.45 - 4.24 (m, 2H), 4.21 - 4.03 (m, 2H), 1.90 (p, J =
6.4 Hz, 1H), 1.50 - 1.33 (m, 2H), 0.97 (d, J = 6.6 Hz, 3H), 0.94 (d, J = 6.6 Hz, 3H);
LCMS (ESI) m/e 404.3 [(M+H) , calcd C H F N O, 404.2]; LC/MS retention time
19 23 5 3
(method B): t = 1.87 min.
Example 187
(S)((4-(difluoromethyl)-2'-methyl-[2,4'-bipyridin]yl)oxy)(fluoromethyl)
methylpentanamine
Prepared as previously described for Example 179 to afford (S)((4-
(difluoromethyl)-2'-methyl-[2,4'-bipyridin]yl)oxy)(fluoromethyl)
methylpentanamine (16.8 mg, 50%): H NMR (500 MHz, DMSO-d6) δ 8.71 (s,
1H), 8.54 (d, J = 5.4 Hz, 1H), 8.19 (s, 1H), 7.94 (s, 1H), 7.84 (d, J = 5.2 Hz, 1H),
7.34 (t, J = 53.9 Hz, 1H), 4.42 - 4.25 (m, 2H), 4.18 - 4.03 (m, 2H), 2.56 (s, 3H), 1.90
(dt, J = 13.1, 6.5 Hz, 1H), 1.40 (qd, J = 14.3, 5.7 Hz, 2H), 0.96 (d, J = 6.6 Hz, 3H),
0.94 (d, J = 6.7 Hz, 3H); LCMS (ESI) m/e 368.3 [(M+H) , calcd C H F N O,
19 25 3 3
368.2]; LC/MS retention time (method B): t = 1.39 min.
Example 188
(R)((4-(difluoromethyl)-2'-methyl-[2,4'-bipyridin]yl)oxy)(fluoromethyl)
methylpentanamine
Prepared as previously described for Example 179 to afford (R)((4-
(difluoromethyl)-2'-methyl-[2,4'-bipyridin]yl)oxy)(fluoromethyl)
methylpentanamine (20.5 mg, 59%): H NMR (500 MHz, DMSO-d ) δ 8.71 (s,
1H), 8.54 (d, J = 5.4 Hz, 1H), 8.19 (s, 1H), 7.94 (s, 1H), 7.84 (d, J = 5.2 Hz, 1H),
7.34 (t, J = 53.9 Hz, 1H), 4.44 - 4.24 (m, 2H), 4.18 - 4.02 (m, 2H), 2.56 (s, 3H), 1.90
(dt, J = 12.9, 6.3 Hz, 1H), 1.40 (qd, J = 14.2, 5.8 Hz, 2H), 0.96 (d, J = 6.6 Hz, 3H),
0.94 (d, J = 6.7 Hz, 3H); LCMS (ESI) m/e 368.3 [(M+H) , calcd C H F N O,
19 25 3 3
368.2]; LC/MS retention time (method B): t = 1.47 min.
Example 189
(S)-N-(4-(4-((2-aminomethylpentyl)oxy)fluorophenyl)pyridinyl)acetamide
Part A: (S)-tert-butyl (1-((3-chloro(5,7-difluoroquinolinyl)pyridinyl)oxy)-
2,4-dimethylpentanyl)carbamate
Prepared as described in Example 77. Obtained (S)-tert-butyl (1-((3-chloro-
-(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentanyl)carbamate
(33.4 mg, 48%). LCMS (ESI) m/e 506.0 [(M+H) , calcd C H F N Cl O , 506.2];
26 31 2 3 1 3
LC/MS retention time (method B): tR = 2.48 min.
Part B: (S)-N-(4-(4-((2-aminomethylpentyl)oxy)fluorophenyl)pyridin
yl)acetamide
TFA deprotection was carried out as described in Example 32. Obtained (S)-
N-(4-(4-((2-aminomethylpentyl)oxy)fluorophenyl)pyridinyl)acetamide (27
mg, 100%) as a colorless solid. H NMR (500 MHz, DMSO-d ) δ 10.53 (s, 1H), 8.33
(d, J = 4.9 Hz, 2H), 7.61 (dd, J = 12.5, 2.2 Hz, 1H), 7.52 (dd, J = 8.5, 2.2 Hz, 1H),
7.43 - 7.37 (m, 1H), 7.32 (t, J = 8.7 Hz, 1H), 3.97 (dd, J = 9.5, 4.9 Hz, 1H), 3.90 (dd,
J = 9.5, 6.5 Hz, 1H), 3.12 (dt, J = 11.9, 5.4 Hz, 1H), 2.12 (s, 3H), 1.81 (dq, J = 13.0,
6.5 Hz, 1H), 1.33 (ddd, J = 13.5, 8.5, 5.0 Hz, 1H), 1.26 (ddd, J = 13.5, 8.5, 5.5 Hz,
1H), 0.92 (d, J = 6.6 Hz, 3H), 0.88 (d, J = 6.5 Hz, 3H); LCMS (ESI) m/e 406.0
[(M+H) , calcd C H F N Cl O , 406.1]; LC/MS retention time (method B): t =
21 23 2 3 1 1 R
2.03 min.
Example 190
(S)((3-chloro(7-fluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentan
amine
Part A: (S)-tert-butyl (1-((3-chloro(7-fluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanyl)carbamate
Intermediate 7-fluoro(4,4,5,5-tetramethyl-1,3,2-dioxaborolan
yl)quinoline was prepared as described in Example 77, Part C. Suzuki coupling was
performed as described in Example 77, Part D. Obtained (S)-tert-butyl (1-((3-chloro-
-(7-fluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentanyl)carbamate (10.6
mg, 76% yield). H NMR (400MHz, CHLOROFORM-d) δ 8.97 (d, J=4.3 Hz, 1H),
8.18 (d, J=2.0 Hz, 1H), 7.91 - 7.80 (m, 3H), 7.37 (ddd, J=9.3, 8.0, 2.5 Hz, 1H), 7.30
(d, J=4.0 Hz, 1H), 4.63 (d, J=10.5 Hz, 1H), 4.47 (d, J=10.5 Hz, 1H), 1.93 - 1.83 (m,
2H), 1.68 (d, J=8.8 Hz, 1H), 1.46 (s, 3H), 1.44 (s, 9H), 1.02 (m, 6H). F NMR
(376MHz, CHLOROFORM-d) δ -109.18 (s, 1F). LCMS (ESI) m/e 488.0 [(M+H) ,
calcd C H F N Cl O , 488.2]; LC/MS retention time (method B): t = 2.39 min.
26 32 1 3 1 3 R
Part B: (S)((3-chloro(7-fluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
TFA deprotection was performed as described in Example 32. Obtained (S)
((3-chloro(7-fluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentanamine
(4.4 mg, 50% yield). H NMR (600MHz, DMSO-d ) δ 9.06 - 8.97 (m, 1H), 8.38 -
8.29 (m, 1H), 8.25 - 8.16 (m, 1H), 8.04 - 7.83 (m, 2H), 7.65 - 7.51 (m, 2H), 4.27 -
4.13 (m, 2H), 1.95 - 1.79 (m, 1H), 1.56 - 1.40 (m, 2H), 1.26 - 1.16 (m, 3H), 1.03 -
0.91 (m, 6H). LCMS (ESI) m/e 409.9 [(M+Na) , calcd C21H23F1N3Cl1O1Na1, 410.1];
LC/MS retention time (method B): t = 1.85 min.
Example 191
(S)((3-chloro(6-fluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentan
amine
Prepared as described in Example 191 to afford (S)((3-chloro(6-
fluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentanamine (9.4 mg, 0.024
mmol, 50% yield for the final step) as a colorless solid. H NMR (600MHz, DMSO-
d ) δ 9.06 - 8.97 (m, 1H), 8.38 - 8.29 (m, 1H), 8.25 - 8.16 (m, 1H), 8.04 - 7.83 (m,
2H), 7.65 - 7.51 (m, 2H), 4.27 - 4.13 (m, 2H), 1.95 - 1.79 (m, 1H), 1.56 - 1.40 (m,
2H), 1.26 - 1.16 (m, 3H), 1.03 - 0.91 (m, 6H), two exchangeable protons not
observed; LCMS (ESI) m/e 388.1 [(M+H) , calcd C H FN ClO, 388.2]; LC/MS
21 24 3
retention time (method E): t = 1.82 min.
Example 192
(S)((3-chloro(2-methylpyrimidinyl)pyridinyl)oxy)-2,4-dimethylpentan
amine
Part A: (S)-tert-butyl (1-((3-chloro(2-methylpyrimidinyl)pyridinyl)oxy)-2,4-
dimethylpentanyl)carbamate
Intermediate (S)-tert-butyl (1-((3-chloro(4,4,5,5-tetramethyl-1,3,2-
dioxaborolanyl)pyridinyl)oxy)-2,4-dimethylpentanyl)carbamate was
prepared as described in Example 77, Part C. Suzuki coupling was performed as
described in Example 77, Part D.(Crude was carried on next step). LCMS (ESI) m/e
457.1 [(M+Na) , calcd C H N ClO Na, 457.2]; LC/MS retention time (method B):
23 31 4 3
t = 2.41 min.
Part B: (S)((3-chloro(2-methylpyrimidinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
TFA deprotection was performed as described in Example 32 to obtain (S)
((3-chloro(2-methylpyrimidinyl)pyridinyl)oxy)-2,4-dimethylpentanamine
.1 mg, 0.030 mmol, 51% yield in two steps). H NMR (500MHz, DMSO-d ) δ
8.94 (d, J=2.2 Hz, 1H), 8.76 (d, J=5.5 Hz, 1H), 8.63 (d, J=1.8 Hz, 1H), 7.95 (d,
J=5.5 Hz, 1H), 4.22 - 4.14 (m, 2H), 2.68 (s, 3H), 1.85 - 1.78 (m, 1H), 1.42 (dd,
J=9.0, 5.3 Hz, 2H), 1.15 (s, 3H), 0.92 (m, 6H); LCMS (ESI) m/e 318.1 [(M-NH ) ,
calcd C H N ClO, 318.1]; LC/MS retention time (method B): t = 1.83 min.
17 21 3 R
Example 193
(S)((2'-chloro(difluoromethyl)-[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
amine
Part A: 5-Bromo(difluoromethyl)fluoropyridine
To a solution of 5-bromofluoronicotinaldehyde (0.8212 g, 4.03 mmol) in
CH Cl (15 mL) at 0 °C was added DAST (1.064 mL, 8.05 mmol). The reaction was
stirred at 0 °C for 1 h then warmed to room temperature. The stirring was continued
for 3 h. The reaction was poured into an ice cold 1N NaOH solution. The organic
layer was separated and the aqueous layer was extracted DCM (2x). The DCM
layers were combined, dried (Na SO ), filtered and concentrated under reduced
pressure to give crude 5-bromo(difluoromethyl)fluoropyridine (0.81 g, 3.58
mmol, 89% yield) as a brown solid. H NMR (400MHz, CHLOROFORM-d) δ 8.43
- 8.38 (m, 1H), 8.18 - 8.13 (m, 1H), 6.82 (t, J=52.0 Hz, 1H); F NMR (376MHz,
CHLOROFORM-d) δ -74.33 (br. s., 1F), -115.87 (s, 2F); LCMS (ESI) m/e 205.9
[(M-F) , calcd C H BrNF , 205.9]; LC/MS retention time (method B): t = 1.88 min.
6 3 2 R
Part B: (S)((5-bromo(difluoromethyl)pyridinyl)oxy)-2,4-dimethylpentan
amine
To (S)amino-2,4-dimethylpentanol (0.3359 g, 2.56 mmol) and 5-bromo-
3-(difluoromethyl)fluoropyridine (0.579 g, 2.56 mmol) in THF (5 mL) at room
temperature was added potassium tert-butoxide(3.07 mL, 3.07 mmol). The reaction
was stirred at room temperature overnight. The reaction was quenched by addition of
water and the crude solution was diluted with ethyl acetate. The ethyl acetate layer
was separated and washed with water (3x), dried (Na SO ), filtered and concentrated
under reduced pressure. The product was purified by silica gel chromatography
(eluted with 0- 10% methanol in CH Cl ) to obtain (S)((5-bromo
(difluoromethyl)pyridinyl)oxy)-2,4-dimethylpentanamine (0.63 g, 0.923 mmol,
73% yield) as a yellow liquid. H NMR (400MHz, CHLOROFORM-d) δ 8.31 - 8.27
(m, 1H), 7.96 - 7.93 (m, 1H), 6.97 - 6.64 (m, 1H), 4.15 (s, 2H), 1.85 - 1.74 (m, 1H),
1.45 (t, J=5.8 Hz, 2H), 1.20 (s, 3H), 0.98 (m, 6H). F NMR (376MHz,
CHLOROFORM-d) δ -117.61 (s, 2F); LCMS (ESI) m/e 320.1 [(M-NH ) , calcd
C H BrNF O, 320.1]; LC/MS retention time (method B): t = 1.99 min.
13 17 2 R
Part C: (S)((2'-chloro(difluoromethyl)-[3,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine
A mixture of 2N sodium carbonate solution (0.050 ml, 0.099 mmol), 1,1'-
bis(diphenylphosphine)ferrocene-palladium(II)dichloride dichoromethane complex
(2.022 mg, 2.476 µmol) , 2-chloro(4,4,5,5-tetramethyl-1,3,2-dioxaborolan
yl)pyridine (0.018 g, 0.074 mmol) and (S)((5-bromo(difluoromethyl)pyridin
yl)oxy)-2,4-dimethylpentanamine (0.0167 g, 0.050 mmol) in dioxane (0.8 mL)
(degassed) was heated at 80 °C for 2 h. The reaction was filtered through celite and
purified by reverse phase Prep HPLC. Obtained (S)((2'-chloro(difluoromethyl)-
[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine (13.1 mg, 0.035 mmol, 72%
yield) as an off-white solid. H NMR (500MHz, DMSO-d ) δ 8.83 (s, 1H), 8.48 (d,
J=5.1 Hz, 1H), 8.43 (s, 1H), 7.98 (s, 1H), 7.84 (d, J=4.8 Hz, 1H), 7.27 (t, J=55.0 Hz,
1H), 4.22 - 4.14 (m, 2H), 1.83 - 1.73 (m, 1H), 1.48 - 1.37 (m, 2H), 1.15 (s, 3H), 0.91
(m, 6H). LCMS (ESI) m/e 353.1 [(M-NH ) , calcd C H N ClF O, 353.1]; LC/MS
2 18 20 2 2
retention time (method B): t = 1.96 min.
Example 194
(S)((5-(difluoromethyl)-2'-methyl-[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentan-
2-amine
Prepared as described in Example 193 to afford (S)((5-(difluoromethyl)-2'-
methyl-[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine (9.2 mg, 0.026 mmol,
45% yield for the final step) as a colorless solid. H NMR (500MHz, DMSO-d ) δ
8.76 (s, 1H), 8.50 (d, J=5.2 Hz, 1H), 8.33 (s, 1H), 7.66 (s, 1H), 7.57 (d, J=4.9 Hz,
1H), 7.45 - 7.11 (m, 1H), 4.24 - 4.11 (m, 2H), 2.53 (s, 3H), 1.82 - 1.72 (m, 1H), 1.44
(qd, J=13.9, 5.5 Hz, 2H), 1.16 (s, 3H), 0.92 (d, J=6.7 Hz, 3H), 0.89 (d, J=6.4 Hz, 3H)
two exchangeable protons not observed; LCMS (ESI) m/e 350.0 [(M+H) , calcd
C H F N O, 350.2]; LC/MS retention time (method E): t = 2.62 min.
19 26 2 3 R
Example 195
(S)((3-(difluoromethyl)(7-fluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Part A: (S)((3-(difluoromethyl)(7-fluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Intermediate 7-fluoro(4,4,5,5-tetramethyl-1,3,2-dioxaborolan
yl)quinoline was prepared as described in Example 77, Part C. Final product was
prepared as described in Example 193 to obtain (S)((3-(difluoromethyl)(7-
fluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentanamine (13.9 mg, 0.034
mmol, 34% yield). H NMR (500MHz, DMSO-d ) δ 9.00 (d, J=4.4 Hz, 1H), 8.51
(s, 1H), 8.15 (s, 1H), 7.97 - 7.85 (m, 2H), 7.59 (td, J=8.8, 2.6 Hz, 1H), 7.56 (d, J=4.4
Hz, 1H), 7.28 (t, J=55.0 Hz, 1H), 4.18 (s, 2H), 1.86 - 1.76 (m, 1H), 1.48 - 1.36 (m,
2H), 1.15 (s, 3H), 0.94 (m, 6H); LCMS (ESI) m/e 387.1 [(M-NH ) , calcd
C H N F O, 387.2]; LC/MS retention time (method B): t = 1.86 min.
22 22 2 3 R
Example 196
(S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)(difluoromethyl)-[3,4'-
bipyridin]-2'-yl)carbamate
Prepared as described in Example 193. Obtained (S)-methyl (6-((2-amino-2,4-
dimethylpentyl)oxy)(difluoromethyl)-[3,4'-bipyridin]-2'-yl)carbamate (8.0mg,
0.018 mmol, 40% yield). H NMR (400MHz, CHLOROFORM-d) δ 8.56 (br. s.,
1H), 8.34 (d, J=4.8 Hz, 1H), 8.24 (br. s., 1H), 8.13 (br. s., 2H), 7.19 (d, J=3.8 Hz,
1H), 7.11 - 6.73 (m, 1H), 4.26 (br. s., 2H), 3.85 (s, 3H), 1.77 (m 1H), 1.50 (br. s.,
2H), 1.25 (br. s., 3H), 1.00 (t, J=7.4 Hz, 6H), two exchangeable protons not observed;
LCMS (ESI) m/e 431.1 [(M+Na) , calcd C H N F O Na, 431.2]; LC/MS retention
26 4 2 3
time (method B): t = 1.78 min.
Example 197
(S)((5-(7-chloroquinolinyl)(difluoromethyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Intermediate (S)((3-(difluoromethyl)(4,4,5,5-tetramethyl-1,3,2-
dioxaborolanyl)pyridinyl)oxy)-2,4-dimethylpentanamine was prepared as
described in Example 77, Part C. Intermediate 4-bromochloroquinoline was
prepared as described in Example 77, Part B. Suzuki reaction was performed as
described in Example 193. Obtained (S)((5-(7-chloroquinolinyl)
(difluoromethyl)pyridinyl)oxy)-2,4-dimethylpentanamine (7.8 mg, 0.019 mmol,
34% yield). H NMR (500MHz, DMSO-d ) δ 9.02 (d, J=4.6 Hz, 1H), 8.53 (s, 1H),
8.20 (d, J=1.8 Hz, 1H), 8.16 (s, 1H), 7.88 (d, J=9.2 Hz, 1H), 7.69 (dd, J=9.0, 2.0 Hz,
1H), 7.61 (d, J=4.3 Hz, 1H), 7.29 (t, J=55.0 Hz, 1H), 4.22 - 4.16 (m, 2H), 1.83 (dt,
J=12.5, 6.3 Hz, 1H), 1.49 - 1.38 (m, 2H), 1.17 (s, 3H), 0.97 - 0.92 (m, 6H), two
exchangeable protons not observed; LCMS (ESI) m/e 442.0 [(M+Na) , calcd
C H ClN F ONa, 442.2]; LC/MS retention time (method B): t = 2.09 min.
22 24 3 2 R
Example 198
(S)((3-(difluoromethyl)(2-methylpyrimidinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Intermediate (S)((3-(difluoromethyl)(4,4,5,5-tetramethyl-1,3,2-
dioxaborolanyl)pyridinyl)oxy)-2,4-dimethylpentanamine was prepared as
described in Example 77, Part C. Suzuki reaction was performed as described in
Example 193. Obtained (S)((3-(difluoromethyl)(2-methylpyrimidin
yl)pyridinyl)oxy)-2,4-dimethylpentanamine (7.7 mg, 0.036 mmol, 37% yield).
H NMR (500MHz, DMSO-d ) δ 9.13 (s, 1H), 8.78 (d, J=5.2 Hz, 1H), 8.69 (s, 1H),
7.99 (d, J=5.2 Hz, 1H), 7.29 (t, J=55.0 Hz, 1H), 4.19 (d, J=1.8 Hz, 2H), 2.70 (s, 3H),
1.85 - 1.76 (m, 1H), 1.46 - 1.36 (m, 2H), 1.14 (s, 3H), 0.92 (m, 6H); LCMS (ESI)
m/e 334.1 [(M-NH ) , calcd C H N F O, 334.2]; LC/MS retention time (method
2 18 22 3 2
B): t = 1.91 min.
Example 199
(S)((2',5-bis(difluoromethyl)-[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
amine
Intermediate (S)((3-(difluoromethyl)(4,4,5,5-tetramethyl-1,3,2-
dioxaborolanyl)pyridinyl)oxy)-2,4-dimethylpentanamine was prepared as
described in Example 77, Part C. Suzuki reaction was performed as described in
Example 193. Obtained (S)((2',5-bis(difluoromethyl)-[3,4'-bipyridin]yl)oxy)-
2,4-dimethylpentanamine (9.2 mg, 0.023 mmol, 39% yield). H NMR (500MHz,
DMSO-d6) δ 8.86 (s, 1H), 8.77 (d, J=5.2 Hz, 1H), 8.45 (s, 1H), 8.10 (s, 1H), 8.00 (d,
J=4.6 Hz, 1H), 7.26 (t, J=55.0 Hz, 1H), 7.02 (t, J=55.0 Hz, 1H), 4.18 (d, J=1.8 Hz,
2H), 1.85 - 1.75 (m, 1H), 1.48 - 1.36 (m, 2H), 1.15 (s, 3H), 0.94 (d, J=6.7 Hz, 3H),
0.92 (d, J=6.7 Hz, 3H), two exchangeable protons not observed; LCMS (ESI) m/e
369.1 [(M-NH ) , calcd C H N F O, 369.2]; LC/MS retention time (method B): t
2 19 21 2 4 R
= 1.91 min.
Example 200
(S)((3-(difluoromethyl)(6-fluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Intermediate 6-fluoro(4,4,5,5-tetramethyl-1,3,2-dioxaborolan
yl)quinoline was prepared as described in Example 77, Part B and C. Suzuki reaction
was performed as described in Example 193. Obtained (S)((3-(difluoromethyl)
(6-fluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentanamine (27.2 mg,
0.067 mmol, 39% yield). H NMR (500MHz, DMSO-d6) δ 8.97 (d, J=4.4 Hz, 1H),
8.52 (s, 1H), 8.22 (dd, J=9.2, 5.9 Hz, 1H), 8.16 (s, 1H), 7.81 - 7.72 (m, 1H), 7.61 (d,
J=4.4 Hz, 1H), 7.51 (dd, J=10.1, 2.8 Hz, 1H), 7.28 (t, J=55.0 Hz, 1H), 4.19 (s, 2H),
1.86 - 1.77 (m, 1H), 1.49 - 1.37 (m, 2H), 1.16 (s, 3H), 0.94 (m, 6H), two
exchangeable protons not observed; LCMS (ESI) m/e 426.2 [(M+Na) , calcd
C H N F ONa, 426.2]; LC/MS retention time (method B): t = 1.93 min.
22 24 3 3 R
Example 201
(S)((3-(difluoromethyl)(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Intermediate (S)-tert-butyl (1-((3-chloro(5,7-difluoroquinolinyl)pyridin-
2-yl)oxy)-2,4-dimethylpentanyl)carbamate was prepared in Example 189. Suzuki
reaction was performed as described in Example 193. Obtained (S)((3-
(difluoromethyl)(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentan-
2-amine (13.0 mg, 0.031 mmol, 37% yield). H NMR (500MHz, DMSO-d )δ 9.02 (d,
J=4.4 Hz, 1H), 8.43 (s, 1H), 8.10 (br. s., 1H), 7.80 (d, J=8.4 Hz, 1H), 7.63 - 7.55 (m,
1H), 7.51 (d, J=4.4 Hz, 1H), 7.25 (t, J=55.0 Hz, 1H), 4.16 (s, 2H), 1.81 (dt, J=12.5,
6.2 Hz, 1H), 1.41 (t, J=6.4 Hz, 2H), 1.14 (s, 3H), 0.93 (m, 6H), two exchangeable
protons not observed; LCMS (ESI) m/e 405.7 [(M-NH ) , calcd C H N F O,
2 22 21 2 4
405.2]; LC/MS retention time (method B): t = 2.02 min.
Example 202
(S)((3-(difluoromethyl)(7-(trifluoromethyl)quinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Intermediate 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)
(trifluoromethyl)quinoline was prepared as described in Example 77, Part C. Suzuki
reaction was performed as described in Example 193. Obtained (S)((3-
(difluoromethyl)(7-(trifluoromethyl)quinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine (25.3 mg, 0.055 mmol, 37% yield). H NMR (500MHz,
DMSO-d ) δ 9.14 (d, J=4.4 Hz, 1H), 8.56 (s, 1H), 8.48 (s, 1H), 8.20 (s, 1H), 8.08 (d,
J=8.8 Hz, 1H), 7.92 (d, J=8.8 Hz, 1H), 7.75 (d, J=4.4 Hz, 1H), 7.29 (t, J=55.0 Hz,
1H), 4.20 (s, 2H), 1.87 - 1.79 (m, 1H), 1.49 - 1.38 (m, 2H), 1.16 (s, 3H), 0.95 (m,
6H), two exchangeable protons not observed; LCMS (ESI) m/e 437.1 [(M-NH ) ,
calcd C H N F O, 437.2]; LC/MS retention time (method B): t = 2.13 min.
23 22 2 5 R
Example 203
(S)((5-(difluoromethyl)-2',3'-dimethyl-[3,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine
Intermediate 2,3-dimethyl(4,4,5,5-tetramethyl-1,3,2-dioxaborolan
yl)pyridine was prepared as described in Example 77, Part C. Suzuki reaction was
performed as described in Example 193. Obtained (S)((5-(difluoromethyl)-2',3'-
dimethyl-[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine (20.4 mg, 0.056
mmol, 26% yield). H NMR (500MHz, DMSO-d ) δ 8.32 (d, J=4.0 Hz, 2H), 7.95
(s, 1H), 7.38 - 7.11 (m, 2H), 4.15 (s, 2H), 2.52 (br. s., 3H), 2.17 (s, 3H), 1.84 - 1.75
(m, 1H), 1.42 (dd, J=10.5, 5.3 Hz, 2H), 1.15 (s, 3H), 0.93 (m, 6H), two exchangeable
protons not observed; LCMS (ESI) m/e 347.1 [(M-NH ) , calcd C H N F O,
2 20 25 2 2
347.2]; LC/MS retention time (method B): t = 1.48 min.
Example 204
(S)((3-(difluoromethyl)(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentan
amine
Suzuki reaction was performed as described in Example 193. Obtained (S)
((3-(difluoromethyl)(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentanamine
(17.4 mg, 0.045 mmol 66% yield). H NMR (500MHz, DMSO-d ) δ 9.05 (d, J=4.0
Hz, 1H), 8.57 (br. s., 1H), 8.34 (br. s., 2H), 8.21 (br. s., 1H), 8.18 (d, J=8.5 Hz, 1H),
7.89 (t, J=7.5 Hz, 1H), 7.85 (d, J=8.5 Hz, 1H), 7.70 (t, J=7.5 Hz, 1H), 7.65 (d, J=4.3
Hz, 1H), 7.63 - 7.40 (m, 1H), 4.64-4.39 (m, 2H), 1.89 - 1.73 (m, 2H), 1.65 (dd,
J=13.7, 4.6 Hz, 1H), 1.42 (s, 3H), 0.97 (d, J=6.4 Hz, 3H), 0.93 (d, J=6.1 Hz, 3H);
LCMS (ESI) m/e 386.1 [(M+H) , calcd C H N F O, 386.2]; LC/MS retention time
22 26 3 2
(method B): t = 1.68 min.
Example 205
(S)((3-(difluoromethyl)(7-methylquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
A mixture of 2N sodium carbonate solution (0.146 mL, 0.291 mmol), (S)
((5-(7-chloroquinolinyl)(difluoromethyl)pyridinyl)oxy)-2,4-dimethylpentan-
2-amine (0.0611 g, 0.146 mmol) (Example 197) ,2,4,6-trimethyl-1,3,5,2,4,6-
trioxatriborinane (0.018 g, 0.146 mmol) and 1,1'- bis(diphenylphosphine)ferrocene-
palladium(II)dichloride dichoromethane complex (5.94 mg, 7.28 µmol) in dioxane (1
mL) (degassed) was heated at 110 °C for 3 h. The reaction was diluted with ethyl
acetate and washed with water three times. The ethyl acetate layer was separated,
dried (Na SO ), filtered and concentrated under reduced pressure. The product was
purified by reverse phase Prep HPLC to afford (S)((3-(difluoromethyl)(7-
methylquinolinyl)pyridinyl)oxy)-2,4-dimethylpentanamine (1.1 mg, 2.5
mol, 2% yield). H NMR (500MHz, DMSO-d ) δ 8.93 (d, J=4.4 Hz, 1H), 8.51 (s,
1H), 8.13 (s, 1H), 7.93 (s, 1H), 7.73 (d, J=8.8 Hz, 1H), 7.53 - 7.47 (m, 2H), 7.32 (t,
J=55.0 Hz, 1H), 2.56 (s, 3H), 1.87 - 1.79 (m, 1H), 1.54 - 1.41 (m, 2H), 1.20 (s, 3H),
0.95 (m, 6H). (NMR water suppression also suppressed OCH ether signal); LCMS
(ESI) m/e 400.2 [(M+H) , calcd C H N F O, 400.2]; LC/MS retention time
23 28 3 2
(method B): t = 1.72 min.
Example 206
(S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)methoxy-[2,4'-bipyridin]-2'-
yl)carbamate
Part A: 6-Iodomethoxypyridinol
n- BuLi (0.319 mL, 0.797 mmol) was added to the THF (4 mL) solution of
2,6-diiodomethoxypyridinyl diethylcarbamate (0.316 g, 0.664 mmol) (Ref:
J.Org. Chem. 2002, 67, 3272-3276) at -78 °C. After stirring at -78 °C for 20 min, the
reaction was quenched by addition of NH Cl (sat.). The reaction was warmed to
room temperature and stirred for another 30 min. The volatiles were removed under
reduced pressure and the crude material was partitioned between ethyl acetate and
water. The ethyl acetate layer was separated, dried (Na SO ), filtered and
concentrated under reduced pressure. The residue was purified via silica gel
chromatography (eluted with 0-25% ethyl acetate in hexanes) to give 6-iodo
methoxypyridinol (0.033 g, 0.131 mmol, 20% yield). H NMR (400MHz,
CHLOROFORM-d) δ 7.95 (s, 1H), 7.14 (s, 1H), 3.92 (s, 3H), one exchangeable
proton was not observed; LCMS (ESI) m/e 251.9 [(M+H) , calcd C H INO , 252.0];
6 7 2
LC/MS retention time (method B): t = 0.85 min.
Part B: (S)-tert-butyl (1-((6-iodomethoxypyridinyl)oxy)-2,4-dimethylpentan
yl)carbamate
Preparation was described as Example 53, Part A. The crude material was
carried on without further purification. LCMS (ESI) m/e 465.0 [(M+H) , calcd
C H IN O , 465.1]; LC/MS retention time (method B): t = 2.24 min.
18 30 2 4 R
Part C: Boc protected (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)methoxy-
[2,4'-bipyridin]-2'-yl)carbamate
Suzuki reaction was performed as described in Example 193. Obtained Boc
protected (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)methoxy-[2,4'-
bipyridin]-2'-yl)carbamate (2.3 mg, 4.71 μmol, 22% yield for two steps). LCMS
(ESI) m/e 489.3 [(M+H) , calcd C H N O , 489.2]; LC/MS retention time (method
37 4 6
B): t = 2.14 min.
Part D: (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)methoxy-[2,4'-bipyridin]-
2'-yl)carbamate
TFA deprotection was performed as described in Example 32. Obtained (S)-
methyl (5-((2-amino-2,4-dimethylpentyl)oxy)methoxy-[2,4'-bipyridin]-2'-
yl)carbamate (1.2 mg, 3.09 μmol, 66% yield). H NMR (500MHz, DMSO-d ) δ
8.51 (s, 1H), 8.34 (d, J=5.1 Hz, 1H), 8.31 (s, 1H), 7.69 (d, J=5.1 Hz, 1H), 7.59 (s,
1H), 3.99 (s, 3H), 3.83 (s, 2H), 3.70 (s, 3H), 3.41 (br. s., 2H), 1.85 - 1.75 (m, 1H),
1.39 (dd, J=9.0, 5.7 Hz, 2H), 1.12 (s, 3H), 0.93 (m, 6H), one exchangeable proton
not observed. LCMS (ESI) m/e 389.3 [(M+H) , calcd C20H29N4O4, 389.2]; LC/MS
retention time (method B): t = 1.56 min.
Example 207
(S)((2'-(difluoromethyl)methoxy-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan-
2-amine
Part A: (S)-tert-butyl (1-((2'-(difluoromethyl)methoxy-[2,4'-bipyridin]yl)oxy)-
2,4-dimethylpentanyl)carbamate
Suzuki reaction was performed as described in Example 193 to afford (S)-
tert-butyl (1-((2'-(difluoromethyl)methoxy-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanyl)carbamate (12.9 mg, 0.028 mmol, 13% yield). LCMS (ESI) m/e
466.2 [(M+H) , calcd C H F N O , 466.2]; LC/MS retention time (method B): t =
24 34 2 3 4 R
2.65 min.
Part B: (S)((2'-(difluoromethyl)methoxy-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine
TFA deprotection was performed as described in Example 32. Obtained (S)
((2'-(difluoromethyl)methoxy-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
amine (5.0 mg, 0.014 mmol, 53% yield). H NMR (500MHz, DMSO-d ) δ 8.78 (d,
J=4.8 Hz, 1H), 8.38 (s, 2H), 8.26 (d, J=4.8 Hz, 1H), 7.84 (s, 1H), 7.03 (t, J=1.0 Hz,
1H), 4.03 (s, 3H), 3.96 (s, 2H), 1.85 - 1.75 (m, 1H), 1.56 - 1.42 (m, 2H), 1.21 (s, 3H),
0.94 (m, 6H), two exchangeable protons not observed. LCMS (ESI) m/e 366.2
[(M+H) , calcd C H F N O , 366.2]; LC/MS retention time (method B): t = 1.70
19 26 2 3 2 R
min.
Example 208
(S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)naphthalenyl)pyridin
yl)carbamate
Part A: (S)-tert-butyl (1-((4-bromonaphthalenyl)oxy)-2,4-dimethylpentan
yl)carbamate
Prepared as described in Example 53, Part A. Obtained (S)-tert-butyl (1-((4-
bromonaphthalenyl)oxy)-2,4-dimethylpentanyl)carbamate (37 mg, 0.085 mmol,
19% yield). H NMR (400MHz, CHLOROFORM-d) δ 8.29 (dd, J=7.8, 0.8 Hz, 1H),
8.18 (d, J=8.0 Hz, 1H), 7.67 - 7.35 (m, 3H), 6.73 (d, J=8.3 Hz, 1H), 4.28 (d, J=9.0
Hz, 1H), 4.13 (d, J=9.0 Hz, 1H), 1.86 (d, J=6.5 Hz, 2H), 1.69 (dd, J=13.9, 5.1 Hz,
1H), 1.51 (s, 3H), 1.42 - 1.38 (m, 9H), 1.01 (m, 6H); LCMS (ESI) m/e 458.1, 460.1
Br pattern [(M+Na) , calcd C H BrNNaO , 458.1]; LC/MS retention time (method
22 30 3
B): t = 2.60 min.
Part B: Boc protected (S)-methyl (4-(4-((2-amino-2,4-
dimethylpentyl)oxy)naphthalenyl)pyridinyl)carbamate
Prepared as described in Example 77, Part D. Obtained Boc protected (S)-
methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)naphthalenyl)pyridin
yl)carbamate (12.0 mg, 0.024 mmol, 69% yield). H NMR (400MHz,
CHLOROFORM-d) δ 8.37 (d, J=5.8 Hz, 2H), 8.16 (s, 1H), 7.94 - 7.90 (m, 1H), 7.58
- 7.49 (m, 2H), 7.38 (d, J=8.0 Hz, 1H), 7.15 (dd, J=5.1, 1.4 Hz, 1H), 6.91 (d, J=8.0
Hz, 1H), 4.33 (d, J=9.0 Hz, 1H), 4.22 - 4.17 (m, 1H), 3.82 (s, 3H), 1.94 - 1.83 (m,
1H), 1.73 (br. s., 2H), 1.42 (s, 9H), 1.52 (s, 3H), 1.03 (m, 6H), two exchangeable
protons not observed. LCMS (ESI) m/e 508.2 [(M+H) , calcd C29H38N3O5, 508.3];
LC/MS retention time (method B): t = 2.30 min.
Part C: (S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)naphthalenyl)pyridin-
2-yl)carbamate
TFA deprotection was performed as described in Example 32. Obtained (S)-
methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)naphthalenyl)pyridin
yl)carbamate (9.2 mg, 0.022 mmol, 95% yield). H NMR (500MHz, DMSO-d ) δ
8.40 (d, J=7.7 Hz, 1H), 8.37 (d, J=4.8 Hz, 1H), 7.95 (s, 1H), 7.85 (d, J=8.4 Hz, 1H),
7.59 (t, J=8.4 Hz, 2H), 7.42 (d, J=7.7 Hz, 1H), 7.16 (d, J=5.1 Hz, 1H), 7.06 (d,
J=8.1 Hz, 1H), 3.94 (s, 2H), 3.67 (s, 3H), 1.86 (d, J=6.6 Hz, 1H), 1.54 (dd, J=9.7,
.7 Hz, 2H), 1.25 (s, 3H), 0.94 (m, 6H), three exchangeable protons not observed.
LCMS (ESI) m/e 408.2 [(M+H) , calcd C H N O , 408.2]; LC/MS retention time
24 30 3 3
(method B): t = 1.78 min.
Example 209
(S)-2,4-dimethyl((4-(quinolinyl)naphthalenyl)oxy)pentanamine
Part A: (S)-tert-butyl (2,4-dimethyl((4-(quinolinyl)naphthalenyl)oxy)pentan-
2-yl)carbamate
Prepared as described in Example 77, Part D. Obtained (S)-tert-butyl (2,4-
dimethyl((4-(quinolinyl)naphthalenyl)oxy)pentanyl)carbamate (8.0 mg,
0.014 mmol, 40% yield). H NMR (400MHz, CHLOROFORM-d) δ 9.03 (d, J=4.3
Hz, 1H), 8.41 (d, J=8.5 Hz, 1H), 8.23 (d, J=8.5 Hz, 1H), 7.73 (ddd, J=8.4, 6.9, 1.5
Hz, 1H), 7.56 - 7.48 (m, 2H), 7.43 (d, J=4.3 Hz, 1H), 7.41 - 7.33 (m, 4H), 6.99 (d,
J=7.8 Hz, 1H), 4.39 (dd, J=8.4, 4.6 Hz, 1H), 4.25 (d, J=6.5 Hz, 1H), 1.97 - 1.88 (m,
1H), 1.81 - 1.72 (m, 2H), 1.57 (s, 3H), 1.43 (s, 9H), 1.08 - 1.03 (m, 6H), one
exchangeable proton not observed; LCMS (ESI) m/e 485.2 [(M+H) , calcd
C H N O , 485.3]; LC/MS retention time (method B): t = 2.26 min.
31 37 2 3 R
Part B: (S)-2,4-dimethyl((4-(quinolinyl)naphthalenyl)oxy)pentanamine
TFA deprotection was performed as described in Example 32. Obtained (S)-
2,4-dimethyl((4-(quinolinyl)naphthalenyl)oxy)pentanamine (6.3 mg,
0.016 mmol, 98% yield). H NMR (500MHz, DMSO-d ) δ 9.03 (d, J=4.4 Hz, 1H),
8.44 (d, J=6.2 Hz, 1H), 8.15 (d, J=8.4 Hz, 1H), 7.78 (t, J=7.5 Hz, 1H), 7.58 (t, J=7.5
Hz, 1H), 7.52 (d, J=4.0 Hz, 1H), 7.48 - 7.43 (m, 2H), 7.43 - 7.39 (m, 1H), 7.35 (d,
J=8.4 Hz, 1H), 7.20 (d, J=8.4 Hz, 1H), 7.13 (d, J=7.7 Hz, 1H), 4.00 (s, 2H), 1.90 -
1.85 (m, 1H), 1.65 - 1.50 (m, 2H), 1.29 (s, 3H), 1.01 - 0.94 (m, 6H) , two
exchangeable protons not observed; LCMS (ESI) m/e 385.2 [(M+H) , calcd
C H N O, 385.2]; LC/MS retention time (method B): t = 1.70 min.
26 29 2 R
Example 210
(S)-methyl (4-(5-((2-amino-2,4-dimethylpentyl)oxy)pyrimidinyl)pyridin
yl)carbamate
Part A: (S)-tert-butyl (1-((2-chloropyrimidinyl)oxy)-2,4-dimethylpentan
yl)carbamate
Prepared as described in Example 53, Part A. Obtained (S)-tert-butyl (1-((2-
chloropyrimidinyl)oxy)-2,4-dimethylpentanyl)carbamate (25.0 mg, 0.073
mmol, 49% yield). H NMR (400MHz, CHLOROFORM-d) δ 8.32 (s, 2H), 4.50 (s,
1H), 4.30 (d, J=8.5 Hz, 1H), 4.06 (d, J=8.8 Hz, 1H), 1.93 - 1.74 (m, 2H), 1.44 (dd,
J=13.9, 4.9 Hz, 1H), 1.39 (s, 9H), 1.36 (s, 3H), 0.99 (dd, J=6.5, 4.5 Hz, 6H).
Part B: (S)-methyl (4-(5-((2-amino-2,4-dimethylpentyl)oxy)pyrimidinyl)pyridin
yl)carbamate
A mixture of 2N sodium carbonate solution (0.073 mL, 0.145 mmol), 1,1'-
bis(diphenylphosphine)ferrocene-palladium(II)dichloride dichloromethane complex
(2.97 mg, 3.64 µmol) , (S)-tert-butyl (1-((2-chloropyrimidinyl)oxy)-2,4-
dimethylpentanyl)carbamate and (2-((methoxycarbonyl)amino)pyridin
yl)boronic acid (0.025 g, 0.128 mmol) in dioxane (1 mL) (degassed) was heated at
120 °C for 4 h. The reaction was diluted with ethyl acetate and washed with water
three times. The ethyl acetate layer was dried (Na SO ), filtered and concentrated
under reduced pressure. The crude material was diluted with DCM (3 mL) and TFA
(2 mL, 26.0 mmol) was added at room temperature. The mixture was stirred for 0.5
h at room temperature. The solvent was removed under reduced pressure and the
crude was purified by reverse phase Prep HPLC. Obtained (S)-methyl (4-(5-((2-
amino-2,4-dimethylpentyl)oxy)pyrimidinyl)pyridinyl)carbamate (1.9 mg, 5.07
mol, 7% yield). H NMR (500MHz, DMSO-d ) δ 8.76 (s, 1H), 8.73 (s, 2H), 8.39
(d, J=5.5 Hz, 1H), 7.86 (d, J=5.1 Hz, 1H), 3.96 (s, 2H), 3.71 (s, 3H), 1.86 - 1.78 (m,
1H), 1.46 - 1.36 (m, 2H), 1.15 (s, 3H), 0.94 (m, 6H), three exchangeable protons not
observed. LCMS (ESI) m/e 360.1 [(M+H) , calcd C H N O , 360.4]; LC/MS
18 26 5 3
retention time (method B): t = 1.55 min.
Example 211
(S)-methyl (4-(2-((2-amino-2,4-dimethylpentyl)oxy)pyrimidinyl)pyridin
yl)carbamate
Part A: (S)((5-bromopyrimidinyl)oxy)-2,4-dimethylpentanamine
Potassium tert-butoxide (0.242 mL, 0.242 mmol) was added to a solution of
(S)amino-2,4-dimethylpentanol (0.0265 g, 0.202 mmol) in THF (0.8 mL) at
room temperature. After 5 min, 5-bromochloropyrimidine (0.047 g, 0.242 mmol)
was added to the reaction mixture. The reaction was stirred at room temperature
overnight. The reaction was quenched by adding water. The volatiles were removed
under reduced pressure. The residue was diluted with ethyl acetate and water. The
ethyl acetate layer was separated and the aqueous layer was extracted with ethyl
acetate. The ethyl acetate layers were combined, dried (Na SO ), filtered and
concentrated under reduced pressure. The residue was purified via silica gel
chromatography (eluted with methanol in DCM from 0 to 10%). Obtained (S)((5-
bromopyrimidinyl)oxy)-2,4-dimethylpentanamine (0.014 g, 0.050 mmol, 25%
yield). H NMR (400MHz, CHLOROFORM-d) δ 8.53 (s, 2H), 4.11 (d, J=2.8 Hz,
2H), 1.87 - 1.75 (m, 1H), 1.66 - 1.56 (m, 2H), 1.48 (dd, J=5.6, 3.9 Hz, 2H), 1.22 (s,
3H), 0.98 (m, 6H). LCMS (ESI) m/e 310.1 [(M+Na) , calcd C H BrN ONa,
11 18 3
310.1]; LC/MS retention time (method B): t = 1.67 min.
Part B: (S)-methyl (4-(2-((2-amino-2,4-dimethylpentyl)oxy)pyrimidinyl)pyridin
yl)carbamate
Suzuki reaction was performed as described in Example 193. Obtained (S)-
methyl (4-(2-((2-amino-2,4-dimethylpentyl)oxy)pyrimidinyl)pyridin
yl)carbamate (8.4 mg, 0.023 mmol, 47% yield). H NMR (400MHz,
CHLOROFORM-d) δ 8.60 (s, 2H), 8.49 (s, 1H), 8.31 (dd, J=5.3, 0.5 Hz, 1H), 8.18
(s, 1H), 7.11 (dd, J=5.4, 1.6 Hz, 1H), 3.85 (s, 3H), 3.84 - 3.69 (m, 2H), 2.00 - 1.92
(m, 1H), 1.91 - 1.78 (m, 1H), 1.56 (dd, J=14.3, 5.0 Hz, 1H), 1.36 (s, 3H), 1.02 (d,
J=6.5 Hz, 3H), 0.92 (d, J=6.5 Hz, 3H), two exchangeable protons not observed;
LCMS (ESI) m/e 359.9 [(M+H) , calcd C18H26N5O3, 360.2]; LC/MS retention time
(method B): t = 1.76 min.
Example 212
(S)-2,4-dimethyl((2',4,6-trimethyl-[2,4'-bipyridin]yl)oxy)pentanamine
Suzuki reaction was performed as described in Example 193. Obtained (S)-
2,4-dimethyl((2',4,6-trimethyl-[2,4'-bipyridin]yl)oxy)pentanamine (10.3 mg,
0.031 mmol, 57% yield). H NMR (400MHz, CHLOROFORM-d) δ 8.57 (d, J=5.3
Hz, 1H), 7.75 (s, 1H), 7.62 (dd, J=5.1, 1.4 Hz, 1H), 7.46 (s, 1H), 3.66 - 3.55 (m, 2H),
2.64 (s, 3H), 2.60 (s, 3H), 2.39 (s, 3H), 2.08 (br. S, 2H); 1.88 (tt, J=12.7, 6.4 Hz, 1H),
1.54 (d, J=5.8 Hz, 2H), 1.34 (s, 3H), 1.04 (d, J=6.5 Hz, 3H), 1.02 (d, J=6.8 Hz, 3H);
LCMS (ESI) m/e 328.1 [(M+H) , calcd C H N O, 328.2]; LC/MS retention time
30 3
(method B): t = 1.44 min.
Example 213
(S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-4,6-dimethyl-[2,4'-bipyridin]-2'-
yl)carbamate
Suzuki reaction was performed as described in Example 193. Obtained (S)-
methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-4,6-dimethyl-[2,4'-bipyridin]-2'-
yl)carbamate (8.0 mg, 0.021 mmol, 38% yield). H NMR (400MHz,
CHLOROFORM-d) δ 8.52 (br. s, 2H), 8.33 - 8.17 (m, 1H), 7.68 (dd, J=5.3, 1.5 Hz,
1H), 7.53 (s, 1H), 3.85 (s, 3H), 3.65 - 3.52 (m, 2H), 2.60 (s, 3H), 2.56 (br.s, 2H), 2.38
(s, 3H), 1.88 (dquin, J=12.7, 6.4 Hz, 1H), 1.54 (d, J=5.3 Hz, 2H), 1.34 (s, 3H), 1.04
(d, J=6.8 Hz, 3H), 1.02 (d, J=6.5 Hz, 3H); LCMS (ESI) m/e 387.1 [(M+H) , calcd
C H N O , 387.2]; LC/MS retention time (method B): t = 1.54 min.
21 31 4 3 R
Example 214
(S)-2,4-dimethyl(4-(quinazolinyl)(trifluoromethyl)phenoxy)pentanamine
Prepared as described in Example 19. Obtained (S)-2,4-dimethyl(4-
(quinazolinyl)(trifluoromethyl)phenoxy)pentanamine (8.5 mg, 0.020 mmol,
19% yield). H NMR (500MHz, DMSO-d ) δ 9.34 (s, 1H), 8.17 - 8.03 (m, 5H), 7.79
(t, J=7.5 Hz, 1H), 7.47 (d, J=8.4 Hz, 1H), 3.94 (d, J=7.3 Hz, 2H), 1.85 - 1.76 (m,
1H), 1.43 (m, 2H), 1.16 (s, 3H), 0.97 - 0.89 (m, 6H), two exchangeable protons not
observed; LCMS (ESI) m/e 404.2 [(M+H) , calcd C H F N O, 404.4]; LC/MS
22 25 3 3
retention time (method B): t = 2.01 min.
Example 215
(S)(4-(3,6-dihydro-2H-pyranyl)(trifluoromethyl)phenoxy)-2,4-
dimethylpentanamine
Part A: 3,6-Dihydro-2H-pyranyl trifluoromethanesulfonate
KHMDS (6.66 mL, 3.33 mmol) was added to the THF (7 mL) solution of
dihydro-2H-pyran-4(3H)-one (0.2224 g, 2.221 mmol) and 1,1,1-trifluoro-N-phenyl-
N-((trifluoromethyl)sulfonyl)methanesulfonamide (0.952 g, 2.67 mmol) at -78 °C.
The reaction was stirred for 30 min. The reaction was diluted with diethyl ether and
washed with water (3x). The diethyl ether layer was separated, dried (Na SO ),
filtered and concentrated. The crude material was carried on without further
purification.
Part B: (S)-tert-butyl (2,4-dimethyl(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan
yl)(trifluoromethyl)phenoxy)pentanyl)carbamate
Prepared as described in Example 77, Part C. The crude material was carried
on without further purification. LCMS (ESI) m/e 523.2 [(M+Na) , calcd
C H BF NO Na, 524.3]; LC/MS retention time (method B): t = 2.61 min.
39 3 5 R
Part C: (S)(4-(3,6-dihydro-2H-pyranyl)(trifluoromethyl)phenoxy)-2,4-
dimethylpentanamine
A mixture of 2N sodium carbonate solution (0.106 mL, 0.212 mmol), 1,1'-
bis(diphenylphosphine)ferrocene-palladium(II)dichloride dichloromethane complex
(6.06 mg, 7.42 µmol), 3,6-dihydro-2H-pyranyl trifluoromethanesulfonate (98 mg,
0.424 mmol) and (S)-tert-butyl (2,4-dimethyl(4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolanyl)(trifluoromethyl)phenoxy)pentanyl)carbamate (53.1 mg,
0.106 mmol) in dioxane (2 mL) (degassed) was heated at 120 °C for 5 h. The
reaction was diluted with ethyl acetate and washed with water three times. The ethyl
acetate layer was dried (Na SO ), filtered and concentrated under reduced pressure.
The residue was diluted with DCM (3 mL) and TFA (2 mL, 26.0 mmol) was added at
room temperature. The reaction was stirred at room temperature for 0.5 h. The
solvent was removed under reduced pressure and the residue was purified by reverse
phase Prep HPLC to give (S)(4-(3,6-dihydro-2H-pyranyl)
(trifluoromethyl)phenoxy)-2,4-dimethylpentanamine (2.7 mg, 0.213 mmol, 7%
yield over three steps). H NMR (500MHz, DMSO-d ) δ 7.69 (d, J=8.4 Hz, 1H),
7.61 (s, 1H), 7.20 (d, J=8.4 Hz, 1H), 6.24 (m, 1H), 4.21 (d, J=2.6 Hz, 2H), 3.83 -
3.79 (m, 4H), 2.42 (br. s., 2H), 1.80 - 1.72 (m, 1H), 1.42 - 1.37 (m, 2H), 1.12 (s, 3H),
0.89 (m, 6H), two exchangeable protons not observed; LCMS (ESI) m/e 358.3
[(M+H) , calcd C H F NO , 358.2]; LC/MS retention time (method B): t = 1.99
19 27 3 2 R
min.
Example 216
(S)-2,4-dimethyl(4-(2-methylquinolinyl)(trifluoromethyl)phenoxy)pentan
amine
A mixture of 2N sodium carbonate solution (0.157 mL, 0.314 mmol), 1,1'-
bis(diphenylphosphine)ferrocene-palladium(II)dichloride dichloromethane complex
(8.97 mg, 10.99 µmol), (S)-tert-butyl (2,4-dimethyl(4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolanyl)(trifluoromethyl)phenoxy)pentanyl)carbamate
(0.079 g, 0.157mmol) (prepared in Example 215, Part B) and 4-chloro
methylquinoline (0.05 ml, 0.248 mmol) in dioxane (1 mL) (degassed) was heated at
120 °C for 5 h. The reaction was diluted with ethyl acetate and washed with water
three times. The ethyl acetate layer was dried (Na SO ), filtered and concentrated
under reduced pressure. The residue was diluted with DCM (3 mL) and was added
TFA (2 mL, 26.0 mmol) at room temperature. The reaction was stirred at room
temperature for 0.5 h. The solvent was removed under reduced pressure and the
material was purified by reverse phase HPLC/MS to afford (S)-2,4-dimethyl(4-(2-
methylquinolinyl)(trifluoromethyl)phenoxy)pentanamine (14.8 mg, 0.035
mmol, 22% yield). H NMR (500MHz, DMSO-d ) δ 8.02 (d, J=8.4 Hz, 1H), 7.83 -
7.73 (m, 4H), 7.55 (t, J=7.5 Hz, 1H), 7.44 - 7.41 (m, 2H), 3.94 - 3.87 (m, 2H), 3.47
(br. s., 2H), 2.70 (s, 3H), 1.87 - 1.79 (m, 1H), 1.42 (d, J=5.5 Hz, 2H), 1.15 (s, 3H),
0.95 (d, J=2.9 Hz, 3H), 0.93 (d, J=2.9 Hz, 3H); LCMS (ESI) m/e 417.3 [(M+H) ,
calcd C H F N O, 417.2]; LC/MS retention time (method B): t = 2.26 min.
24 28 3 2 R
Example 217
(S)(4-(6-chloroquinolinyl)(trifluoromethyl)phenoxy)-2,4-dimethylpentan
amine
Preparation was described as Example 19. Intermediate 6-chloro(4,4,5,5-
tetramethyl-1,3,2-dioxaborolanyl)quinoline was prepared as described in Example
77, Part B and Part C. Obtained (S)(4-(6-chloroquinolinyl)
(trifluoromethyl)phenoxy)-2,4-dimethylpentanamine (3.9 mg, 8.66 μmol, 7%
yield). H NMR (500MHz, DMSO-d ) δ 8.98 (d, J=4.4 Hz, 1H), 8.16 (d, J=8.8 Hz,
1H), 7.85 (dd, J=9.0, 2.4 Hz, 2H), 7.79 (d, J=2.6 Hz, 2H), 7.59 (d, J=4.4 Hz, 1H),
7.45 (d, J=8.8 Hz, 1H), 3.97 - 3.89 (m, 2H), 1.83 (dt, J=12.7, 6.1 Hz, 1H), 1.43 (d,
J=4.8 Hz, 2H), 1.16 (s, 3H), 0.94 (m, 6H); LCMS (ESI) m/e 419.9 [(M-NH ) , calcd
C H ClF NO, 420.1]; LC/MS retention time (method B): t = 2.07 min.
23 22 3 R
Example 218
(S)((5-(5,7-difluoroquinolinyl)(trifluoromethyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Part A: 5-Bromo(trifluoromethyl)pyridinol
NBS (2.334 g, 13.11 mmol) was added portionwise to a solution of 3-
(trifluoromethyl)pyridinol (1.6449 g, 10.09 mmol) in THF (15 mL) at room
temperature. The reaction was stirred at room temperature over the weekend. The
reaction was diluted with ethyl acetate and washed with water three times. The ethyl
acetate layer was separated, dried (Na SO ), filtered and concentrated under reduced
pressure to give crude 5-bromo(trifluoromethyl)pyridinol (2.12 g, 6.57 mmol,
65% yield) as a yellow solid. The material was carried on without further
purification. LCMS (ESI) m/e 241.8 [(M+H) , calcd C H BrF NO, 241.9]; LC/MS
6 4 3
retention time (method B): t = 1.57 min.
Part B: (S)-tert-butyl (1-((5-bromo(trifluoromethyl)pyridinyl)oxy)-2,4-
dimethylpentanyl)carbamate
A mixture of potassium carbonate (0.113 g, 0.814 mmol), (S)-tert-butyl 4-
isobutylmethyl-1,2,3-oxathiazolidinecarboxylate 2,2-dioxide (0.1593 g, 0.543
mmol) and 5-bromo(trifluoromethyl)pyridinol (0.197 g, 0.814 mmol) in DMF
(2 mL) was heated at 80 °C overnight. The reaction was diluted with ethyl acetate
and washed with water three times. The ethyl acetate layer was separated, dried
(Na SO ), filtered and concentrated under reduced pressure. The residue was
purified by silica gel chromatography (eluted with ethyl acetate in hexane from 0 to
%) to give (S)-tert-butyl (1-((5-bromo(trifluoromethyl)pyridinyl)oxy)-2,4-
dimethylpentanyl)carbamate (0.059 g, 0.111 mmol, 20% yield). H NMR
(400MHz, CHLOROFORM-d) δ 8.34 (d, J=2.5 Hz, 1H), 7.95 (d, J=2.5 Hz, 1H),
4.59 - 4.52 (m, 2H), 4.39 (d, J=10.3 Hz, 1H), 1.89 - 1.72 (m, 2H), 1.54 (d, J=8.8 Hz,
1H), 1.39 (s, 9H), 1.37 (s, 3H), 0.97 (m, 6H); F NMR (376MHz, CHLOROFORM-
d) δ -64.11 (s, 3F). LCMS (ESI) m/e 476.9 [(M+Na) , calcd C H BrF N O Na,
18 26 3 2 3
477.1]; LC/MS retention time (method B): t = 2.54 min.
Part C: (S)-tert-butyl (1-((5-(5,7-difluoroquinolinyl)(trifluoromethyl)pyridin
yl)oxy)-2,4-dimethylpentanyl)carbamate
Prepared as described in Example 193. Obtained (S)-tert-butyl (1-((5-(5,7-
difluoroquinolinyl)(trifluoromethyl)pyridinyl)oxy)-2,4-dimethylpentan
yl)carbamate (26.0 mg, 0.048 mmol, 80% yield). LCMS (ESI) m/e 540.2 [(M+H) ,
calcd C H F N O , 540.2]; LC/MS retention time (method B): t = 2.53 min.
27 31 5 3 3 R
Part D: (S)((5-(5,7-difluoroquinolinyl)(trifluoromethyl)pyridinyl)oxy)-
2,4-dimethylpentanamine
TFA deprotection was performed as described in Example 32. Obtained (S)
((5-(5,7-difluoroquinolinyl)(trifluoromethyl)pyridinyl)oxy)-2,4-
dimethylpentanamine (12.5 mg, 0.025 mmol, 56% yield). H NMR (500MHz,
DMSO-d ) δ 9.34 (s, 1H), 8.17 - 8.03 (m, 5H), 7.79 (t, J=7.5 Hz, 1H), 7.47 (d, J=8.4
Hz, 1H), 3.94 (d, J=7.3 Hz, 2H), 1.85 - 1.76 (m, 1H), 1.43 (m, 2H), 1.16 (s, 3H), 0.97
- 0.89 (m, 6H). LCMS (ESI) m/e 440.1 [(M+H) , calcd C H F N O, 440.2];
22 23 5 3
LC/MS retention time (method B): t = 2.04 min.
Example 219
(S)-2,4-dimethyl((5-(quinolinyl)(trifluoromethyl)pyridinyl)oxy)pentan
amine
Prepared as described in Example 218. Obtained (S)-2,4-dimethyl((5-
(quinolinyl)(trifluoromethyl)pyridinyl)oxy)pentanamine (6.1 mg, 0.015
mmol, 60% yield) as an off-white solid. H NMR (500MHz, DMSO-d ) δ 8.99 (d,
J=4.4 Hz, 1H), 8.63 (s, 1H), 8.31 (s, 1H), 8.14 (d, J=8.4 Hz, 1H), 7.88 - 7.82 (m,
2H), 7.66 (t, J=7.5 Hz, 1H), 7.60 (d, J=4.4 Hz, 1H), 4.25 - 4.18 (m, 2H), 1.84 (dt,
J=12.7, 6.1 Hz, 1H), 1.42 (d, J=5.5 Hz, 2H), 1.15 (s, 3H), 0.94 (m, 6H), two
exchangeable protons not observed; LCMS (ESI) m/e 404.0 [(M+H) , calcd
C H F N O, 404.4]; LC/MS retention time (method B): t = 1.77 min.
22 25 3 3 R
Example 220
(S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)(trifluoromethyl)-[3,4'-
bipyridin]-2'-yl)carbamate
Prepared as described in Example 218. Obtained (S)-methyl (6-((2-amino-
2,4-dimethylpentyl)oxy)(trifluoromethyl)-[3,4'-bipyridin]-2'-yl)carbamate (13.8
mg, 0.032 mmol, 96% yield) as an off-white solid. H NMR (500MHz, DMSO-d ) δ
.35 (br. s., 1H), 8.79 (s, 1H), 8.38 - 8.32 (m, 2H), 8.11 (s, 1H), 7.48 (d, J=5.1 Hz,
1H), 4.17 (q, J=10.3 Hz, 2H), 3.38 (br. s., 3H), 1.85 - 1.74 (m, 1H), 1.38 (d, J=5.5
Hz, 2H), 1.11 (s, 3H), 0.91 (m, 6H), two exchangeable protons not observed; LCMS
(ESI) m/e 427.0 [(M+H) , calcd C H F N O , 427.2]; LC/MS retention time
26 3 4 3
(method B): t = 1.84 min.
Example 221
(S)-2,4-dimethyl((2'-methyl(trifluoromethyl)-[3,4'-bipyridin]yl)oxy)pentan-
2-amine
Prepared as described in Example 218. Obtained (S)-2,4-dimethyl((2'-
methyl(trifluoromethyl)-[3,4'-bipyridin]yl)oxy)pentanamine (4.6 mg, 0.012
mmol, 68% yield). H NMR (500MHz, DMSO-d ) δ 8.87 (s, 1H), 8.52 (d, J=5.1 Hz,
1H), 8.46 (s, 1H), 7.72 (s, 1H), 7.62 (d, J=4.0 Hz, 1H), 4.16 (q, J=10.1 Hz, 2H), 2.54
(s, 3H), 1.84 - 1.75 (m, 1H), 1.37 (d, J=5.5 Hz, 2H), 1.10 (s, 3H), 0.91 (m, 6H), two
exchangeable protons not observed; LCMS (ESI) m/e 368.0 [(M+H) , calcd
C H F N O, 368.2]; LC/MS retention time (method B): t = 1.57 min.
19 25 3 3 R
Example 222
(S)((5-(6-chloroquinolinyl)methylpyridinyl)oxy)-2,4-dimethylpentan
amine
Part A: 4-Bromochloroquinoline
Prepared as described in Example 77, Part B. Obtained 4-Bromo
chloroquinoline (0.322 g, 1.33 mmol, 76% yield). H NMR (400MHz,
CHLOROFORM-d) δ 8.68 (d, J=4.8 Hz, 1H), 8.21 (d, J=2.3 Hz, 1H), 8.07 (d,
J=8.8 Hz, 1H), 7.76 - 7.70 (m, 2H). LCMS (ESI) m/e 243.7 [(M+H) , calcd
C H BrNCl,243.5]; LC/MS retention time (method B): t = 2.07 min.
9 5 R
Part B: 7-Chloro(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)quinoline
Prepared as described in Example 77, Part C. Carried on without further
purification. LCMS (ESI) m/e 207.9 [(M-NH ) , calcd C H BNClO , 207.0]; LC/MS
2 9 7 2
retention time (method B): t = 1.21 min.
Part C: (S)((5-(6-chloroquinolinyl)methylpyridinyl)oxy)-2,4-
dimethylpentanamine
Intermediate (S)((5-bromomethylpyridinyl)oxy)-2,4-dimethylpentan-
2-amine prepared as in Example 52, Part A. Suzuki reaction was performed as
described in Example 193. Obtained (S)((5-(6-chloroquinolinyl)
methylpyridinyl)oxy)-2,4-dimethylpentanamine (56.7 mg, 0.143 mmol, 26%
yield over two steps). H NMR (400MHz, CHLOROFORM-d) δ 8.94 (d, J=4.5 Hz,
1H), 8.14 (d, J=9.0 Hz, 1H), 8.08 (d, J=1.8 Hz, 1H), 7.82 (d, J=2.3 Hz, 1H), 7.69 (dd,
J=8.8, 2.3 Hz, 1H), 7.57 - 7.54 (m, 1H), 7.32 (d, J=4.5 Hz, 1H), 4.64 - 4.42 (m, 2H),
1.93 - 1.75 (m, 3H), 1.54 (s, 3H), 1.03 (d, J=6.3 Hz, 3H), 1.01 (d, J=6.3 Hz, 3H), two
exchangeable protons not observed; LCMS (ESI) m/e 366.9 [(M-NH ) , calcd
C H N ClO, 367.2]; LC/MS retention time (method B): t = 1.88 min.
22 24 2 R
Example 223
(S)((5-(6-fluoroquinolinyl)methylpyridinyl)oxy)-2,4-dimethylpentan
amine
Intermediate (S)((5-bromomethylpyridinyl)oxy)-2,4-dimethylpentan-
2-amine prepared as described in Example 52, Part A. The corresponding borolate
was prepared as described in Example 77, Part C. Suzuki reaction was performed as
described in Example 193. Obtained (S)((5-(6-fluoroquinolinyl)
methylpyridinyl)oxy)-2,4-dimethylpentanamine (9.7 mg, 0.026 mmol, 14%
yield). H NMR (400MHz, CHLOROFORM-d) δ 8.92 (d, J=4.5 Hz, 1H), 8.31 -
8.16 (m, 1H), 8.12 (d, J=2.0 Hz, 1H), 7.61 - 7.49 (m, 3H), 7.34 (d, J=4.3 Hz, 1H),
4.27 - 4.18 (m, 2H), 2.35 (s, 3H), 1.93 - 1.78 (m, 1H), 1.63 - 1.49 (m, 2H), 1.29 (s,
3H), 1.03 (d, J=6.8 Hz, 3H), 1.01 (d, J=6.8 Hz, 3H), two exchangeable protons not
observed; LCMS (ESI) m/e 368.2 [(M+H) , calcd C22H27N3FO, 368.2]; LC/MS
retention time (method B): t = 1.78 min.
Example 224
(S)((5-(5,7-difluoroquinolinyl)methylpyridinyl)oxy)-2,4-dimethylpentan-
2-amine
Part A: (S)-tert-butyl (1-((5-bromomethylpyridinyl)oxy)-2,4-dimethylpentan
yl)carbamate
Prepared as described in Example 53, Part A. obtained (S)((5-(5,7-
difluoroquinolinyl)methylpyridinyl)oxy)-2,4-dimethylpentanamine (3.06
g, 7.32 mmol, 86% yield). LCMS (ESI) m/e 422.9 [(M+Na) , calcd
C H BrN O Na, 423.1]; LC/MS retention time (method B): t = 2.48 min.
18 29 2 3 R
Part B: (S)-tert-butyl (1-((5-(5,7-difluoroquinolinyl)methylpyridinyl)oxy)-
2,4-dimethylpentanyl)carbamate
Suzuki reaction was performed as described in Example 193. Obtained (S)-
tert-butyl (1-((5-(5,7-difluoroquinolinyl)methylpyridinyl)oxy)-2,4-
dimethylpentanyl)carbamate (43.8 mg, 0.090 mmol, 59% yield). LCMS (ESI) m/e
486.1 [(M+H) , calcd C H N F O , 486.3]; LC/MS retention time (method B): t =
27 34 3 2 3 R
2.44 min.
Part C: (S)((5-(5,7-difluoroquinolinyl)methylpyridinyl)oxy)-2,4-
dimethylpentanamine
TFA deprotection was performed as described in Example 32. Obtained (S)-
1-((5-(5,7-difluoroquinolinyl)methylpyridinyl)oxy)-2,4-dimethylpentan
amine (33.9 mg, 0.088 mmol, 98% yield). H NMR (500MHz, DMSO-d ) δ 9.00 (d,
J=4.4 Hz, 1H), 8.10 (s, 1H), 7.79 (d, J=9.5 Hz, 1H), 7.75 (br. s., 1H), 7.61 - 7.52 (m,
1H), 7.45 (d, J=4.4 Hz, 1H), 4.45 - 4.31 (m, 2H), 2.33 (s, 3H), 1.89 - 1.74 (m, 2H),
1.66 (dd, J=14.1, 5.3 Hz, 1H), 1.42 (s, 3H), 0.98 (d, J=6.6 Hz, 3H), 0.94 (d, J=6.6
Hz, 3H), two exchangeable protons not observed; LCMS (ESI) m/e 386.3 [(M+H) ,
calcd C H N F O, 386.2]; LC/MS retention time (method B): t = 1.84 min.
22 26 3 2 R
Example 225
(S)((5-(7-chloroquinolinyl)methylpyridinyl)oxy)-2,4-dimethylpentan
amine
Intermediate (S)((5-bromomethylpyridinyl)oxy)-2,4-dimethylpentan-
2-amine was prepared as described in Example 52, Part A. The corresponding
borolate was prepared as described in Example 77, Part C. Suzuki reaction was
performed as described in Example 193. Obtained (S)((5-(7-chloroquinolinyl)-
3-methylpyridinyl)oxy)-2,4-dimethylpentanamine (22.5 mg, 0.058 mmol, 51%
yield). H NMR (500MHz, DMSO-d ) δ 8.98 (d, J=4.4 Hz, 1H), 8.17 (s, 2H), 7.96 -
7.91 (m, 1H), 7.81 (s, 1H), 7.66 (dd, J=9.0, 2.0 Hz, 1H), 7.53 (d, J=4.4 Hz, 1H), 4.15
- 4.07 (m, 2H), 2.30 (s, 3H), 1.87 - 1.79 (m, 1H), 1.45 (t, J=6.4 Hz, 2H), 1.17 (s, 3H),
0.95 (m, 6H), two exchangeable protons not observed; LCMS (ESI) m/e 384.3
[(M+H) , calcd C H N ClO, 384.2]; LC/MS retention time (method B): t = 1.98
22 27 3 R
min.
Example 226
(S)((6-(5,7-difluoroquinolinyl)methylpyridinyl)oxy)-2,4-dimethylpentan-
2-amine
Part A: (S)((6-chloromethylpyridinyl)oxy)-2,4-dimethylpentanamine
A mixture of TFA (0.4 mL, 5.19 mmol) and (S)-tert-butyl (1-((6-chloro
methylpyridinyl)oxy)-2,4-dimethylpentanyl)carbamate (0.064 g, 0.179 mmol,
0.179 mmol) in CH Cl (4 mL) was stirred at room temperature for 4 h. LCMS
showed complete conversion to (S)((6-chloromethylpyridinyl)oxy)-2,4-
dimethylpentanamine. The solvent was removed via vacuum and the material was
used without further purification. LCMS (ESI) m/e 257.1 [(M+H) , calcd
C13H ClN O, 257.1]; LC/MS retention time (method B): t = 1.64 min.
22 2 R
Part B: (S)((6-(5,7-difluoroquinolinyl)methylpyridinyl)oxy)-2,4-
dimethylpentanamine
Suzuki coupling was performed as described in Example 77, Part D.
Obtained (S)((6-(5,7-difluoroquinolinyl)methylpyridinyl)oxy)-2,4-
dimethylpentanamine (12.2 mg, 0.031 mmol, 43% yield). H NMR (500MHz,
DMSO-d6) δ 9.01 (d, J=4.4 Hz, 1H), 8.30 (s, 1H), 7.78 (d, J=8.8 Hz, 1H), 7.53 (br.
s., 1H), 7.49 (d, J=4.4 Hz, 1H), 7.47 (s, 1H), 3.94 (s, 2H), 2.31 (s, 3H), 1.88 - 1.80
(m, 1H), 1.48 (dd, J=13.0, 5.3 Hz, 2H), 1.20 (s, 3H), 0.95 (m, 6H), two exchangeable
protons not observed; LCMS (ESI) m/e 386.0 [(M+H) , calcd C H F N O, 386.2];
22 26 2 3
LC/MS retention time (method B): t = 1.79 min.
Example 227
(S)((6-(7-fluoroquinolinyl)methylpyridinyl)oxy)-2,4-dimethylpentan
amine
Prepared as described in Example 226. Obtained (S)((6-(7-fluoroquinolin-
4-yl)methylpyridinyl)oxy)-2,4-dimethylpentanamine (6.0 mg, 0.016 mmol,
63% yield). H NMR (400MHz, DMSO-d ) δ 8.98 (d, J=4.5 Hz, 1H), 8.47 (s, 1H),
8.34 (dd, J=9.3, 6.3 Hz, 1H), 7.82 (dd, J=10.3, 2.8 Hz, 1H), 7.67 (s, 1H), 7.59 (d,
J=4.5 Hz, 1H), 7.55 (td, J=8.9, 2.8 Hz, 1H), 4.10 (s, 2H), 2.37 (s, 3H), 1.86 - 1.78 (m,
1H), 1.63 (br. s., 1H), 1.57 - 1.50 (m, 1H), 1.30 (s, 3H), 0.95 (dd, J=11.7, 6.7 Hz,
6H), two exchangeable protons not observed; LCMS (ESI) m/e 368.0 [(M+H) ,
calcd C H FN O, 368.2]; LC/MS retention time (method B): t = 1.67 min.
22 27 3 R
Example 228
(S)((2',4-dimethyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine
Part A: (S)-tert-butyl (1-((2',4-dimethyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanyl)carbamate
Suzuki coupling was performed as described in Example 77, Part D. The
crude was used in the next reaction without purification. LCMS (ESI) m/e 414.0
[(M+H) , calcd C H N O , 414.3]; LC/MS retention time (method B): t = 2.02
24 36 3 3 R
min.
Part B: (S)((2',4-dimethyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine
TFA deprotection as described in Example 32. Obtained (S)((2',4-
dimethyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine (2.2 mg, 6.95 μmol,
17% yield over two steps). H NMR (600MHz, DMSO-d ) δ 8.50 (d, J=5.1 Hz,
1H), 8.34 (s, 1H), 7.96 (s, 1H), 7.86 (s, 1H), 7.78 (d, J=5.1 Hz, 1H), 3.88 (br. s., 2H),
2.54 (s, 3H), 2.31 (s, 3H), 1.82 (br. s., 1H), 1.45 - 1.38 (m, 2H), 1.15 (s, 3H), 0.93 (m,
6H), two exchangeable protons not observed; LCMS (ESI) m/e 314.1 [(M+H) ,
calcd C H N O, 314.2]; LC/MS retention time (method B): t = 1.50 min.
19 28 3 R
Example 229
(S)((6-(6-chloroquinolinyl)methylpyridinyl)oxy)-2,4-dimethylpentan
amine
Part A: (S)-tert-butyl (1-((6-(6-chloroquinolinyl)methylpyridinyl)oxy)-2,4-
dimethylpentanyl)carbamate
Suzuki coupling was performed as described in Example 77, Part D. The
crude was used in the next reaction without purification. LCMS (ESI) m/e 483.9
[(M+H) , calcd C H ClN O , 484.2]; LC/MS retention time (method B): t = 2.24
27 35 3 3 R
min.
Part B: (S)((6-(6-chloroquinolinyl)methylpyridinyl)oxy)-2,4-
dimethylpentanamine
TFA deprotection as described in Example 32. Obtained (S)((6-(6-
chloroquinolinyl)methylpyridinyl)oxy)-2,4-dimethylpentanamine (6.8
mg, 0.017 mmol, 16% yield over two steps). H NMR (500MHz, DMSO-d ) δ 9.00
(d, J=4.4 Hz, 1H), 8.48 (s, 1H), 8.40 (d, J=2.2 Hz, 1H), 8.12 (d, J=9.2 Hz, 1H), 7.82
(dd, J=8.8, 2.2 Hz, 1H), 7.71 (s, 1H), 7.69 (d, J=4.8 Hz, 1H), 3.95 (s, 2H), 2.35 (s,
3H), 1.84 (d, J=6.2 Hz, 1H), 1.45 (t, J=6.6 Hz, 2H), 1.18 (s, 3H), 0.95 (m, 6H), two
exchangeable protons not observed; LCMS (ESI) m/e 383.9 [(M+H) , calcd
C H ClN O, 384.2]; LC/MS retention time (method B): t = 1.81 min.
22 27 3 R
Example 230
(S)((6-(6-fluoroquinolinyl)methylpyridinyl)oxy)-2,4-dimethylpentan
amine
Part A: (S)-tert-butyl (1-((6-(6-fluoroquinolinyl)methylpyridinyl)oxy)-2,4-
dimethylpentanyl)carbamate
Suzuki coupling was performed as described in Example 77, Part D.
Obtained (S)-tert-butyl (1-((6-(6-fluoroquinolinyl)methylpyridinyl)oxy)-2,4-
dimethylpentanyl)carbamate (33.2 mg, 0.035 mmol, 35% yield). LCMS (ESI) m/e
468.2 [(M+H) , calcd C H FN O , 468.3]; LC/MS retention time (method B): t =
27 35 3 3 R
2.22 min.
Part B: (S)((6-(6-fluoroquinolinyl)methylpyridinyl)oxy)-2,4-
dimethylpentanamine
TFA deprotection as described in Example 32. Obtained (S)((6-(6-
fluoroquinolinyl)methylpyridinyl)oxy)-2,4-dimethylpentanamine (21.7
mg, 0.058 mmol, 82% yield). H NMR (500MHz, DMSO-d ) δ 8.98 (d, J=4.4 Hz,
1H), 8.53 (s, 1H), 8.18 (dd, J=9.2, 5.5 Hz, 1H), 8.07 (dd, J=11.0, 2.9 Hz, 1H), 7.73
(s, 2H), 7.69 (d, J=4.4 Hz, 1H), 4.15 (d, J=4.4 Hz, 2H), 2.39 (s, 3H), 1.89 - 1.81 (m,
1H), 1.66 (d, J=5.1 Hz, 1H), 1.56 (dd, J=14.1, 5.3 Hz, 1H), 1.33 (s, 3H), 0.99 (d,
J=6.6 Hz, 3H), 0.96 (d, J=6.6 Hz, 3H), two exchangeable protons not observed;
LCMS (ESI) m/e 368.2 [(M+H) , calcd C H FN O, 368.2]; LC/MS retention time
22 27 3
(method B): t = 1.67 min.
Example 231
(S)((6-(7-chloroquinolinyl)methylpyridinyl)oxy)-2,4-dimethylpentan
amine
Part A: (S)-tert-butyl (1-((6-(7-chloroquinolinyl)methylpyridinyl)oxy)-2,4-
dimethylpentanyl)carbamate
Suzuki coupling was performed as described in Example 77, Part D. The
crude was used in the next reaction without purification. LCMS (ESI) m/e 484.2
[(M+H) , calcd C H ClN O , 484.2]; LC/MS retention time (method B): t = 2.32
27 35 3 3 R
min.
Part B: (S)((6-(7-chloroquinolinyl)methylpyridinyl)oxy)-2,4-
dimethylpentanamine
TFA deprotection as described in Example 32. Obtained (S)-tert-butyl (1-((6-
(7-chloroquinolinyl)methylpyridinyl)oxy)-2,4-dimethylpentan
yl)carbamate (15.5 mg, 0.039 mmol, 34% yield over two steps). H NMR (500MHz,
DMSO-d ) δ 8.98 (d, J=4.4 Hz, 1H), 8.53 (s, 1H), 8.18 (dd, J=9.2, 5.5 Hz, 1H), 8.07
(dd, J=11.0, 2.9 Hz, 1H), 7.73 (s, 2H), 7.69 (d, J=4.4 Hz, 1H), 4.15 (d, J=4.4 Hz,
2H), 2.39 (s, 3H), 1.89 - 1.81 (m, 1H), 1.66 (d, J=5.1 Hz, 1H), 1.56 (dd, J=14.1, 5.3
Hz, 1H), 1.33 (s, 3H), 0.99 (d, J=6.6 Hz, 3H), 0.96 (d, J=6.6 Hz, 3H), two
exchangeable protons not observed; LCMS (ESI) m/e 384.1 [(M+H) , calcd
C H ClN O, 384.2]; LC/MS retention time (method B): t = 1.84 min.
22 27 3 R
Example 232
(S)((6-(7-fluoroquinolinyl)methylpyridinyl)oxy)-2,4-dimethylpentan
amine
Part A: (S)-tert-butyl (1-((6-(7-fluoroquinolinyl)methylpyridinyl)oxy)-2,4-
dimethylpentanyl)carbamate
Suzuki coupling was performed as described in Example 77, Part D.
Obtained (S)-tert-butyl (1-((6-(7-fluoroquinolinyl)methylpyridinyl)oxy)-2,4-
dimethylpentanyl)carbamate (56 mg, 0.055 mmol, 27% yield). LCMS (ESI) m/e
468.0 [(M+H) , calcd C H FN O , 468.3]; LC/MS retention time (method B): t =
27 35 3 3 R
2.24 min.
Part B: (S)((6-(7-fluoroquinolinyl)methylpyridinyl)oxy)-2,4-
dimethylpentanamine
TFA deprotection as described in Example 32. Obtained (S)((6-(7-
fluoroquinolinyl)methylpyridinyl)oxy)-2,4-dimethylpentanamine (36.4
mg, 0.095 mmol, 89% yield). H NMR (400MHz, DMSO-d ) δ 8.98 (d, J=4.5 Hz,
1H), 8.47 (s, 1H), 8.34 (dd, J=9.3, 6.3 Hz, 1H), 7.82 (dd, J=10.3, 2.8 Hz, 1H), 7.67
(s, 1H), 7.59 (d, J=4.5 Hz, 1H), 7.55 (td, J=8.9, 2.8 Hz, 1H), 4.10 (s, 2H), 2.37 (s,
3H), 1.86 - 1.78 (m, 1H), 1.63 (br. s., 1H), 1.57 - 1.50 (m, 1H), 1.30 (s, 3H), 0.95 (m,
6H), two exchangeable protons not observed; LCMS (ESI) m/e 368.0 [(M+H) ,
calcd C H FN O, 368.2]; LC/MS retention time (method B): t = 1.67 min.
22 27 3 R
Example 233
(S)((4-chloro(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentan-
2-amine
Part A: (S)-tert-butyl (1-((4-chloro(5,7-difluoroquinolinyl)pyridinyl)oxy)-
2,4-dimethylpentanyl)carbamate
Suzuki coupling was performed as described in Example 77, Part D.
Obtained (S)-tert-butyl (1-((4-chloro(5,7-difluoroquinolinyl)pyridinyl)oxy)-
2,4-dimethylpentanyl)carbamate (50.6 mg, 0.062 mmol, 62% yield). LCMS (ESI)
m/e 506.2 [(M+H) , calcd C H ClF N O , 506.2]; LC/MS retention time (method
26 31 2 3 3
B): t = 2.43 min.
Part B: (S)((4-chloro(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
TFA deprotection as described in Example 32. Obtained (S)((4-chloro
(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentanamine (16.2 mg,
0.040 mmol, 40% yield). H NMR (500MHz, DMSO-d ) δ 9.04 (d, J=4.4 Hz, 1H),
8.55 (s, 1H), 7.88 (s, 1H), 7.81 (d, J=9.5 Hz, 1H), 7.61 - 7.53 (m, 2H), 4.04 (s, 2H),
1.88 - 1.77 (m, 1H), 1.52 - 1.40 (m, 2H), 1.20 (s, 3H), 0.95 (m, 6H), two
exchangeable protons not observed; LCMS (ESI) m/e 406.1 [(M+H) , calcd
C H ClF N O, 406.1]; LC/MS retention time (method A): t = 1.82 min.
21 23 2 3 R
Example 234
(S)((4-chloro-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine
Part A: (S)-tert-butyl (1-((4-chloro-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
yl)carbamate
Suzuki coupling was performed as described in Example 77, Part D.
Obtained (S)-tert-butyl (1-((4-chloro-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan-
2-yl)carbamate (24.6 mg, 0.059 mmol, 25% yield). H NMR (400MHz,
CHLOROFORM-d) δ 8.72 (br. s., 2H), 8.41 (s, 1H), 7.83 (s, 3H), 4.59 (s, 1H), 4.41
(d, J=8.8 Hz, 1H), 4.21 (d, J=8.8 Hz, 1H), 1.95 - 1.80 (m, 2H), 1.56 (dd, J=13.9, 4.9
Hz, 1H), 1.44 (s, 3H), 1.40 (s, 9H), 1.01 (m, 6H). LCMS (ESI) m/e 420.2 [(M+H) ,
calcd C H ClN O , 420.2]; LC/MS retention time (method A): t = 2.07 min.
22 31 3 3 R
Part B: (S)((4-chloro-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine
TFA deprotection as described in Example 32. Obtained (S)((4-chloro-
[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine (7.2 mg, 0.022 mmol, 96%
yield). H NMR (500MHz, DMSO-d ) δ 8.68 (d, J=5.9 Hz, 2H), 8.64 (s, 1H), 8.35
(s, 1H), 8.04 (d, J=5.9 Hz, 2H), 4.18 (s, 2H), 1.85 - 1.77 (m, 1H), 1.66 - 1.60 (m,
1H), 1.52 (dd, J=14.1, 5.3 Hz, 1H), 1.29 (s, 3H), 0.95 (d, J=6.6 Hz, 3H), 0.93 (d,
J=6.6 Hz, 3H); LCMS (ESI) m/e 303.1 [(M-NH ) , calcd C H ClN O, 303.1];
2 17 20 2
LC/MS retention time (method B): t = 1.44 min.
Example 235
(S)((4-chloro(6-fluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentan
amine
Part A: (S)-tert-butyl (1-((4-chloro(6-fluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanyl)carbamate
Suzuki coupling was performed as described in Example 77, Part D.
Obtained (S)-tert-butyl (1-((4-chloro(6-fluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanyl)carbamate (62.0 mg, 0.109 mmol, 45% yield). LCMS (ESI) m/e
488.2 [(M+H) , calcd C H ClFN O , 488.2]; LC/MS retention time (method B): t
26 32 3 3 R
= 2.37 min.
Part B: (S)((4-chloro(6-fluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
TFA deprotection as described in Example 32. Obtained (S)((4-chloro
(6-fluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentanamine (42.3 mg,
0.109 mmol, 86% yield). H NMR (500MHz, DMSO-d ) δ 8.99 (d, J=4.4 Hz, 1H),
8.76 (s, 1H), 8.19 (dd, J=9.2, 5.9 Hz, 1H), 8.07 (s, 1H), 8.03 (dd, J=11.0, 2.9 Hz,
1H), 7.77 - 7.71 (m, 2H), 4.30 (s, 2H), 1.86 (dt, J=12.5, 6.2 Hz, 1H), 1.77 - 1.69 (m,
1H), 1.60 (dd, J=14.1, 5.7 Hz, 1H), 1.37 (s, 3H), 0.97 (m, 6H), two exchangeable
protons not observed; LCMS (ESI) m/e 388.1 [(M+H) , calcd C H ClFN O,
21 24 3
388.2]; LC/MS retention time (method B): t = 1.75 min.
Example 236
(S)((4-chloro(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentanamine
Prepared as described in Example 233. Obtained (S)((4-chloro
(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentanamine (2.6 mg, 6.82 mol,
16% yield). H NMR (500MHz, DMSO-d ) δ 9.00 (d, J=4.4 Hz, 1H), 8.70 (s, 1H),
8.21 (d, J=8.4 Hz, 1H), 8.12 (d, J=8.4 Hz, 1H), 8.00 (s, 1H), 7.82 (t, J=7.3 Hz, 1H),
7.69 - 7.56 (m, 2H), 4.09 (s, 2H), 1.86 (dt, J=13.0, 6.3 Hz, 1H), 1.49 (qd, J=13.9, 5.5
Hz, 2H), 1.22 (s, 3H), 0.96 (t, J=6.8 Hz, 6H), two exchangeable protons not
observed; LCMS (ESI) m/e 370.0 [(M+H) , calcd C H ClN O, 370.2]; LC/MS
21 25 3
retention time (method B): t = 1.75 min.
Example 237
(S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)chloro-[2,4'-bipyridin]-2'-
yl)carbamate
Suzuki coupling was performed as described in Example 77, Part D.
Obtained (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)chloro-[2,4'-bipyridin]-
2'-yl)carbamate (8.1 mg, 0.020 mmol, 35% yield). H NMR (600MHz, DMSO-d6) δ
8.59 (s, 1H), 8.52 (s, 1H), 8.34 (d, J=5.5 Hz, 1H), 8.19 (s, 1H), 7.67 (d, J=5.5 Hz,
1H), 4.01 - 3.96 (m, 2H), 3.71 (s, 3H), 1.85 - 1.77 (m, 1H), 1.45 - 1.36 (m, 2H), 1.17
- 1.12 (m, 3H), 0.95 - 0.89 (m, 6H), three exchangeable protons not observed; LCMS
(ESI) m/e 393.0 [(M+H) , calcd C H ClN O , 393.2]; LC/MS retention time
19 26 4 3
(method B): t = 1.63 min.
Example 238
(S)((4-chloro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine
Part A: (S)-tert-butyl (1-((4-chloro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanyl)carbamate
Suzuki coupling was performed as described in Example 77, Part D.
Obtained (S)-tert-butyl (1-((4-chloro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanyl)carbamate (107.4 mg, 0.247 mmol, 49% yield). H NMR
(400MHz, CHLOROFORM-d) δ 8.57 (d, J=5.0 Hz, 1H), 8.38 (s, 1H), 7.80 (s, 1H),
7.70 (d, J=0.5 Hz, 1H), 7.59 (dd, J=5.3, 1.3 Hz, 1H), 4.39 (d, J=8.5 Hz, 1H), 4.19 (d,
J=8.8 Hz, 1H), 2.64 (s, 3H), 1.95 - 1.77 (m, 2H), 1.55 (dd, J=13.9, 4.9 Hz, 1H), 1.43
(s, 3H), 1.39 (s, 9H), 1.00 (m, 6H), one exchangeable proton not observed; LCMS
(ESI) m/e 434.2 [(M+H) , calcd C H ClN O , 433.2]; LC/MS retention time
23 33 3 3
(method B): tR = 2.07 min.
Part B: (S)((4-chloro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
amine
TFA deprotection as described in Example 32. Obtained (S)((4-chloro-2'-
methyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine (271.7 mg, 0.806
mmol, 81% yield). H NMR (400MHz, CHLOROFORM-d) δ 8.59 (d, J=5.3 Hz,
1H), 8.35 (s, 1H), 7.82 (s, 1H), 7.72 - 7.69 (m, 1H), 7.60 (dd, J=5.3, 1.3 Hz, 1H),
3.97 - 3.90 (m, 2H), 2.64 (s, 3H), 1.83 (dt, J=12.7, 6.1 Hz, 1H), 1.53 (t, J=5.5 Hz,
2H), 1.28 (s, 3H), 1.04 - 0.96 (m, 6H), two exchangeable protons not observed;
LCMS (ESI) m/e 334.3 [(M+H) , calcd C H ClN O, 334.2]; LC/MS retention time
18 25 3
(method B): t = 1.49 min.
Example 239
(S)((4-chloro(6-chloroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentan
amine
Part A: (S)((4,6-dichloropyridinyl)oxy)-2,4-dimethylpentanamine bis(2,2,2-
trifluoroacetate)
TFA (2 mL, 26.0 mmol) was added a solution of (S)-tert-butyl (1-((4,6-
dichloropyridinyl)oxy)-2,4-dimethylpentanyl)carbamate (0.146 g, 0.387 mmol)
in DCM (4 mL) at room temperature. The reaction was stirred for 1.5 h at room
temperature. The solvent was removed under reduced pressure and the crude
material was carried on without further purification. LCMS (ESI) m/e 259.9 [(M-
NH ) , calcd C H C NO, 260.1]; LC/MS retention time (method B): t = 1.73 min.
2 12 16 l2 R
Part B: (S)((4-chloro(6-chloroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Suzuki coupling was performed as described in Example 77, Part D.
Obtained (S)((4-chloro(6-chloroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine (8.4 (S)((4-chloro(6-chloroquinolinyl)pyridin
yl)oxy)-2,4-dimethylpentanamine (mg, 0.020 mmol, 22% yield over two steps).
H NMR (500MHz, DMSO-d ) δ 9.01 (d, J=4.4 Hz, 1H), 8.71 (s, 1H), 8.35 (d, J=2.2
Hz, 1H), 8.14 (d, J=9.2 Hz, 1H), 8.04 (s, 1H), 7.83 (dd, J=8.8, 2.2 Hz, 1H), 7.74 (d,
J=4.4 Hz, 1H), 4.06 (s, 2H), 1.89 - 1.80 (m, 1H), 1.52 - 1.40 (m, 2H), 1.18 (s, 3H),
0.95 (m, 6H), two exchangeable protons not observed; LCMS (ESI) m/e 403.8
[(M+H) , calcd C H Cl N O, 404.1]; LC/MS retention time (method B): t = 1.91
21 24 2 3 R
min.
Example 240
(S)((2',4-dichloro-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine
Part A: (S)-tert-butyl (1-((2',4-dichloro-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanyl)carbamate
Suzuki coupling was performed as described in Example 77, Part D.
Obtained (S)-tert-butyl (1-((2',4-dichloro-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanyl)carbamate (12.6 mg, 0.014 mmol, 7% yield). LCMS (ESI) m/e
476.1 [(M+Na) , calcd C H Cl N O Na, 476.2]; LC/MS retention time (method
22 29 2 3 3
A): t = 2.52 min.
Part B: (S)((2',4-dichloro-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine
TFA deprotection as described in Example 32. Obtained (S)((2',4-
dichloro-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine (4.9 mg, 0.014
mmol, 100% yield). H NMR (500MHz, DMSO-d ) δ 8.60 (s, 1H), 8.51 (d, J=5.5
Hz, 1H), 8.44 (s, 1H), 8.15 (s, 1H), 8.08 (dd, J=5.1, 1.5 Hz, 1H), 1.82 (dquin,
J=12.8, 6.4 Hz, 1H), 1.41 (t, J=5.3 Hz, 2H), 1.14 (s, 3H), 0.93 (m, 6H), two
exchangeable protons not observed; LCMS (ESI) m/e 337.0 [(M-NH ) , calcd
C H Cl N O, 337.1]; LC/MS retention time (method B): t = 1.98 min.
17 19 2 2 R
Example 241
(S)((4-chloro(7-fluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentan
amine
Part A: (S)-tert-butyl (1-((4-chloro(7-fluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanyl)carbamate
Suzuki coupling was performed as described in Example 77, Part D.
Obtained (S)-tert-butyl (1-((4-chloro(7-fluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanyl)carbamate (30.5 mg, 0.021 mmol, 20% yield). LCMS (ESI) m/e
488.2 [(M+H) , calcd C H ClFN O , 488.2]; LC/MS retention time (method B): t
26 32 3 3 R
= 2.37 min.
Part B: (S)((4-chloro(7-fluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
TFA deprotection as described in Example 32. Obtained (S)((4-chloro
(7-fluoroquinolinyl)pyridinyl)oxy)-2,4-dimethylpentanamine (4.4 mg, 0.011
mmol, 18% yield). H NMR (500MHz, DMSO-d ) δ 9.01 (d, J=4.4 Hz, 1H), 8.68 (s,
1H), 8.33 (dd, J=9.4, 6.4 Hz, 1H), 8.01 (s, 1H), 7.85 (dd, J=10.5, 2.4 Hz, 1H), 7.66
(d, J=4.4 Hz, 1H), 7.60 - 7.53 (m, 1H), 4.04 (s, 2H), 1.85 (dt, J=12.7, 6.5 Hz, 1H),
1.45 (t, J=6.4 Hz, 2H), 1.18 (s, 3H), 0.96 (m, 6H), two exchangeable protons not
observed; LCMS (ESI) m/e 388.1 [(M+H) , calcd C H ClFN O, 388.2]; LC/MS
21 24 3
retention time (method B): t = 1.82 min.
Example 242
(S)((4-chloro(7-(trifluoromethyl)quinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Part A: (S)-tert-butyl (1-((4,6-dichloropyridinyl)oxy)-2,4-dimethylpentan
yl)carbamate
Prepared as described in Example 53,Part A. Obtained (S)-tert-butyl (1-((4,6-
dichloropyridinyl)oxy)-2,4-dimethylpentanyl)carbamate (765.6 mg, 2.03 mmol,
74% yield). H NMR (400MHz, CHLOROFORM-d) δ 8.05 - 8.02 (m, 1H), 7.35 (s,
1H), 4.55 (s, 1H), 4.30 (d, J=8.8 Hz, 1H), 4.11 (d, J=8.8 Hz, 1H), 1.91 - 1.75 (m,
2H), 1.58 - 1.48 (m, 1H), 1.41 - 1.38 (m, 12H), 0.98 (m, 6H). LCMS (ESI) m/e 399.0
[(M+Na) , calcd C H Cl NaN O , 399.1]; LC/MS retention time (method B): t =
17 26 2 2 3 R
2.41 min.
Part B: (S)-tert-butyl (1-((6-(7-fluoroquinolinyl)methylpyridinyl)oxy)-2,4-
dimethylpentanyl)carbamate
Suzuki coupling was performed as described in Example 77, Part D.
Obtained (S)-tert-butyl (1-((6-(7-fluoroquinolinyl)methylpyridinyl)oxy)-2,4-
dimethylpentanyl)carbamate (26.3 mg, 0.049 mmol, 33% yield). LCMS (ESI) m/e
538.1 [(M+H) , calcd C H ClF N O , 538.2]; LC/MS retention time (method B): t
27 32 3 3 3 R
= 2.51 min.
Part C: (S)((4-chloro(7-(trifluoromethyl)quinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
TFA deprotection as described in Example 32. Obtained (S)((4-chloro
(7-(trifluoromethyl)quinolinyl)pyridinyl)oxy)-2,4-dimethylpentanamine
(17.7 mg, 0.040 mmol, 83% yield). H NMR (500MHz, DMSO-d ) δ 9.14 (d, J=4.3
Hz, 1H), 8.69 (s, 1H), 8.49 (d, J=8.5 Hz, 1H), 8.45 (s, 1H), 8.06 (s, 1H), 7.90 (d,
J=8.9 Hz, 1H), 7.85 (d, J=4.6 Hz, 1H), 4.04 (s, 2H), 1.85 (dt, J=12.5, 6.3 Hz, 1H),
1.45 (t, J=5.8 Hz, 2H), 1.18 (s, 3H), 0.95 (m, 6H), two exchangeable protons not
observed; LCMS (ESI) m/e 438.3 [(M+H) , calcd C H ClF N O, 438.1]; LC/MS
22 24 3 3
retention time (method A): t = 1.66 min.
Example 243
(S)((4-chloro-2',3'-dimethyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
amine
Part A: (S)-tert-butyl (1-((4-chloro-2',3'-dimethyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanyl)carbamate
Suzuki coupling was performed as described in Example 77, Part D.
Obtained (S)-tert-butyl (1-((4-chloro-2',3'-dimethyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanyl)carbamate (23 mg, 0.014 mmol, 7% yield). LCMS (ESI) m/e
448.2 [(M+H) , calcd C H ClN O , 448.2]; LC/MS retention time (method B): t =
24 35 3 3 R
2.14 min.
Part B: (S)((4-chloro-2',3'-dimethyl-[2,4'-bipyridin]yl)oxy)-2,4-
dimethylpentanamine
TFA deprotection as described in Example 32. Obtained (S)((4-chloro-
2',3'-dimethyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine (1.5 mg, 4.14
mol, 8% yield). H NMR (500MHz, DMSO-d ) δ 8.46 (d, J=5.1 Hz, 1H), 8.42 (s,
1H), 7.46 (s, 1H), 7.28 (br. s., 1H), 4.08 (br. s., 2H), 2.57 (s, 3H), 2.07 (s, 3H), 1.61
(br. s., 1H), 1.43 - 1.25 (m, 2H), 1.15 (br. s., 3H), 0.91 - 0.66 (m, 6H), two
exchangeable protons not observed; LCMS (ESI) m/e 348.2 [(M+H) , calcd
C H ClN O, 348.2]; LC/MS retention time (method B): t = 1.34 min.
19 27 3 R
Example 244
(S)((5-(difluoromethyl)-2'-methyl-[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentan-
2-amine
Suzuki reaction was performed as described in Example 193. Obtained (S)
((5-(difluoromethyl)-2'-methyl-[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentan
amine (9.8 mg, 0.028 mmol, 49% yield). H NMR (500MHz, DMSO-d ) δ 8.76 (s,
1H), 8.50 (d, J=5.2 Hz, 1H), 8.33 (s, 1H), 7.66 (s, 1H), 7.57 (d, J=4.9 Hz, 1H), 7.28
(t, J=1.0 Hz, 1H), 4.19 (s, 2H), 1.85 (s, 3H), 1.82 - 1.73 (m, 1H), 1.44 (qd, J=13.9,
.5 Hz, 2H), 1.16 (s, 3H), 0.92 (d, J=6.7 Hz, 3H), 0.89 (d, J=6.4 Hz, 3H); LCMS
(ESI) m/e 333.2 [(M-NH ) , calcd C H N F O, 333.2]; LC/MS retention time
2 19 23 2 2
(method B): t = 1.46 min.
Example 245
(R)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)(difluoromethyl)-[3,4'-
bipyridin]-2'-yl)carbamate
Suzuki coupling was performed as described in Example 77, Part D.
Obtained (R)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)(difluoromethyl)-[3,4'-
bipyridin]-2'-yl)carbamate (13.3 mg, 0.032 mmol, 54% yield). H NMR (500MHz,
DMSO-d ) δ 8.69 (s, 1H), 8.35 (d, J=5.1 Hz, 1H), 8.22 (s, 1H), 8.11 (s, 1H), 7.44 (d,
J=3.7 Hz, 1H), 7.39 - 7.14 (t, J=44.0Hz, 1H), 4.15 (d, J=2.6 Hz, 2H), 3.71 (s, 3H),
1.84 - 1.73 (m, 1H), 1.40 (t, J=6.1 Hz, 2H), 1.13 (s, 3H), 0.92 (m, 6H); LCMS (ESI)
m/e 392.2 [(M-NH ) , calcd C H F N O , 392.2]; LC/MS retention time (method
2 20 24 2 3 3
B): t = 1.70 min.
Example 246
(R)((3-(difluoromethyl)(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentan
amine
Part A: (R)((5-bromo(difluoromethyl)pyridinyl)oxy)-2,4-dimethylpentan
amine
Prepared as described in Example 193. Obtained (R)((5-bromo
(difluoromethyl)pyridinyl)oxy)-2,4-dimethylpentanamine (275 mg, 0.465
mmol, 55% yield). LCMS (ESI) m/e 320.1 [(M-NH ) , calcd C H BrF NO, 320.1];
2 13 17 2
LC/MS retention time (method B): t = 1.95 min.
Part B: (R)((3-(difluoromethyl)(quinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Suzuki coupling was performed as described in Example 77, Part D.
Obtained (R)((3-(difluoromethyl)(quinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine (6.3 mg, 0.016 mmol, 24% yield). H NMR (500MHz,
DMSO-d ) δ 8.98 (d, J=4.4 Hz, 1H), 8.52 (s, 1H), 8.16 - 8.12 (m, 2H), 7.87 - 7.80
(m, 2H), 7.69 - 7.62 (m, 1H), 7.56 (d, J=4.4 Hz, 1H), 7.29 (t, J=1.0 Hz, 1H), 4.19 (s,
2H), 1.87 - 1.78 (m, 1H), 1.49 - 1.38 (m, 2H), 1.16 (s, 3H), 0.94 (m, 6H), two
exchangeable protons not observed; LCMS (ESI) m/e 386.2 [(M+H) , calcd
C H F N O, 386.2]; LC/MS retention time (method B): t = 1.65 min.
22 26 2 3 R
Example 247
(R)((3-(difluoromethyl)(2-methylpyrimidinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Suzuki coupling was performed as described in Example 77, Part D.
Obtained (R)((3-(difluoromethyl)(2-methylpyrimidinyl)pyridinyl)oxy)-
2,4-dimethylpentanamine (7.7 mg, 0.022 mmol, 37% yield). H NMR (500MHz,
DMSO-d ) δ 9.12 (s, 1H), 8.77 (d, J=5.1 Hz, 1H), 8.68 (s, 1H), 7.98 (d, J=5.5 Hz,
1H), 7.42 - 7.16 (t, J=55.0 Hz, 1H), 4.18 (s, 2H), 2.69 (s, 3H), 1.85 - 1.75 (m, 1H),
1.41 (dd, J=9.0, 5.7 Hz, 2H), 1.14 (s, 3H), 0.92 (m, 6H); LCMS (ESI) m/e 334.1
[(M-NH ) , calcd C H F N O, 334.2]; LC/MS retention time (method B): t = 1.81
2 18 22 2 3 R
min.
Example 248
(R)((3-(difluoromethyl)(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Suzuki coupling was performed as described in Example 77, Part D. Obtained (R)
((3-(difluoromethyl)(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4-
dimethylpentanamine (8.4 mg, 0.020 mmol, 21% yield). H NMR (500MHz,
DMSO-d ) δ 9.02 (d, J=4.4 Hz, 1H), 8.44 (s, 1H), 8.12 (br. s., 1H), 7.81 (d, J=9.2
Hz, 1H), 7.61 (ddd, J=12.3, 9.5, 2.4 Hz, 1H), 7.52 (d, J=4.8 Hz, 1H), 7.40 - 7.14 (t,
J=55.0 Hz, 1H), 4.16 (s, 2H), 1.86 - 1.77 (m, 1H), 1.42 (dd, J=7.9, 5.7 Hz, 2H), 1.15
(s, 3H), 0.94 (m, 6H); LCMS (ESI) m/e 405.1 [(M-NH ) , calcd C H F N O,
2 22 21 4 2
405.2]; LC/MS retention time (method B): t = 2.01 min.
Example 249
(R)((5-(7-chloroquinolinyl)(difluoromethyl)pyridinyl)oxy)-2,4-
dimethylpentanamine
Suzuki coupling was performed as described in Example 77, Part D.
Obtained (R)((5-(7-chloroquinolinyl)(difluoromethyl)pyridinyl)oxy)-2,4-
dimethylpentanamine (16.9 mg, 0.039 mmol, 34% yield). H NMR (500MHz,
DMSO-d ) δ 9.01 (d, J=4.4 Hz, 1H), 8.52 (s, 1H), 8.19 (d, J=2.2 Hz, 1H), 8.16 (s,
1H), 7.87 (d, J=9.2 Hz, 1H), 7.69 (dd, J=9.2, 2.2 Hz, 1H), 7.60 (d, J=4.4 Hz, 1H),
7.42 - 7.16 (t, J=55.0Hz, 1H), 4.19 (s, 2H), 1.85 - 1.77 (m, 1H), 1.49 - 1.37 (m, 2H),
1.16 (s, 3H), 0.94 (m, 6H); LCMS (ESI) m/e 403.1 [(M-NH ) , calcd
C H ClF N O, 403.1]; LC/MS retention time (method B): t = 1.97 min.
22 22 2 2 R
Example 250
N-(4'-((2-amino-2,4-dimethylpentyl)oxy)-3'-methyl-[1,1'-biphenyl]yl)acetamide
Part A: Benzyl (1-(4-bromomethylphenoxy)-2,4-dimethylpentanyl)carbamate
Prepared as described in Example 29, Part A. Obtained benzyl (1-(4-bromo-
2-methylphenoxy)-2,4-dimethylpentanyl)carbamate (33 mg, 0.076 mmol, 27%
yield). LCMS (ESI) m/e 456.1 [(M+Na) , calcd C H BrNO Na, 456.1]; LC/MS
22 28 3
retention time (method B): t = 2.55 min.
Part B: Benzyl (1-((3'-aminomethyl-[1,1'-biphenyl]yl)oxy)-2,4-dimethylpentan-
2-yl)carbamate
Suzuki reaction was performed as described in Example 193. Obtained
benzyl (1-((3'-aminomethyl-[1,1'-biphenyl]yl)oxy)-2,4-dimethylpentan
yl)carbamate (21.1 mg, 0.047 mmol, 62% yield). H NMR (400MHz,
CHLOROFORM-d) δ 7.38 - 7.29 (m, 7H), 7.21 (t, J=7.8 Hz, 1H), 6.99 - 6.94 (m,
1H), 6.88 (t, J=1.9 Hz, 2H), 6.65 (ddd, J=7.9, 2.3, 0.9 Hz, 1H), 5.06 (s, 2H), 4.93 (s,
1H), 4.13 (d, J=8.8 Hz, 1H), 3.99 (d, J=8.8 Hz, 1H), 3.73 (br. s., 2H), 2.28 (s, 3H),
1.92 - 1.77 (m, 2H), 1.72 - 1.65 (m, 1H), 1.48 (s, 3H), 0.98 (m, 6H); LCMS (ESI)
m/e 447.5 [(M+H) , calcd C H N O , 447.6]; LC/MS retention time (method A): t
28 35 2 3 R
= 2.38 min.
Part C: Benzyl (1-((3'-acetamidomethyl-[1,1'-biphenyl]yl)oxy)-2,4-
dimethylpentanyl)carbamate
Acetyl chloride (1 drop) was added to a solution of benzyl (1-((3'-amino
methyl-[1,1'-biphenyl]yl)oxy)-2,4-dimethylpentanyl)carbamate (0.0221 g,
0.049 mmol) in CH Cl (2 mL) at room temperature. The reaction was stirred for 10
min at room temperature before addition of triethylamine (1 drop). The reaction was
stirred for 2 h the concentrated under reduced pressure. The residue was carried on
without further purification. LCMS (ESI) m/e 489.5 [(M+H) , calcd C H N O ,
37 2 4
489.3]; LC/MS retention time (method A): t = 2.39 min.
Part D: N-(4'-((2-amino-2,4-dimethylpentyl)oxy)-3'-methyl-[1,1'-biphenyl]
yl)acetamide
A mixture of Pd/C (3 mg, 2.82 µmol) and benzyl (1-((3'-acetamidomethyl-
[1,1'-biphenyl]yl)oxy)-2,4-dimethylpentanyl)carbamate (23.94 mg, 0.049
mmol) in ethanol (3 mL) was hydrogenated via a H balloon at room temperature
overnight. The reaction was filtered through a celite pad and washed with DCM.
The filtrate was concentrated and the residue was purified by reverse phase Prep
HPLC. Obtained N-(4'-((2-amino-2,4-dimethylpentyl)oxy)-3'-methyl-[1,1'-
biphenyl]yl)acetamide (11.4 mg, 0.031 mmol, 64% yield) as an off-white solid.
H NMR (500MHz, DMSO-d ) δ 9.99 (s, 1H), 7.82 (s, 1H), 7.51 (d, J=7.9 Hz, 1H),
7.41 - 7.24 (m, 4H), 6.98 (d, J=8.5 Hz, 1H), 3.72 (d, J=3.1 Hz, 2H), 2.26 (s, 3H),
2.07 (s, 3H), 1.85 - 1.78 (m, 1H), 1.46 - 1.41 (m, 2H), 1.16 (s, 3H), 0.93 (t, J=6.3 Hz,
6H); LCMS (ESI) m/e 338.4 [(M-NH ) , calcd C H NO , 338.2]; LC/MS retention
2 22 28 2
time (method A): t = 2.03 min.
BIOLOGICAL DATA
Methods
AAK1 Kinase Assay
The assays were performed in U-bottom 384-well plates. The final assay
volume was 30 μl prepared from 15 μl additions of enzyme and substrates
(fluoresceinated peptide (5-FAM)-Aha-KEEQSQITSQVTGQIGWR-NH2 and ATP)
and test compounds in assay buffer (10 mM Tris-HCL pH 7.4, 10 mM MgCl 0.01%
Tween-20 and 1.0 mM DTT). The reactions were initiated by the combination of
bacterially expressed, GST-Xa-hAAK1 with substrates and test compounds. The
reactions were incubated at room temperature for 3 hours and terminated by adding
60 μl of 35 mM EDTA buffer to each sample. The reactions were analyzed on the
Caliper LabChip 3000 (Caliper, Hopkinton, MA) by electrophoretic separation of the
fluorescent substrate and phosphorylated product. Inhibition data were calculated by
comparison to EDTA quenched control reactions for 100% inhibition and vehicle-
only reactions for 0% inhibition. The final concentration of reagents in the assays are
ATP, 22 μM; (5-FAM)-Aha-KEEQSQITSQVTGQIGWR-NH2, 1.5 μM; GST-Xa-
hAAK1, 3.5 nM; and DMSO, 1.6%. Dose response curves were generated to
determine the concentration required inhibiting 50% of kinase activity (IC ).
Compounds were dissolved at 10 mM in dimethylsulfoxide (DMSO) and evaluated at
eleven concentrations. IC values were derived by non-linear regression analysis.
Results are shown in Table 1.
Table 1
AAK1 IC
Example
(nM)
1 2.7
2 3.0
3 0.30
4 2.8
0.50
6 0.47
7 0.42
8 0.53
10
11 3.3
12 1.6
13 1.1
14 0.87
0.81
16 6.6
17 24
18 5.0
19 0.36
0.34
21 0.74
22 0.65
23 0.76
24 0.63
1.0
26 0.69
27 1.0
28 1.2
29 0.67
1.4
31 4.5
32 4.5
33 0.32
34 15
0.77
36 0.89
37 0.51
38 0.79
39 3.2
40 8.7
41 3.8
42 3.3
43 0.64
44 2.8
45 1.2
46 0.86
47 0.77
48 4.6
49 2.6
50 0.38
63 24
64 1.1
65 42
66 0.65
67 4.7
68 2.6
69 0.76
70 2.3
71 0.55
72 0.53
73 0.51
74 0.07
75 34
76 1.7
77 0.92
78 0.49
79 16
80 19
81 7.8
82 0.85
83 1.8
84 2.2
85 0.32
86 1.2
87 0.87
0.46
0.66
12.1
0.68
0.83
0.72
0.62
109 340
110 3.5
111 650
112 970
113 43
114 1400
115 13
116 0.93
117 1.0
118 0.85
119 3.2
120 0.51
121 0.30
122 0.51
123 2.2
124 1.2
125 1.6
126 0.80
127 6.2
128 3.5
129 1.4
130 1.4
131 0.82
132 1.5
133 0.92
134 4.4
135 3.5
136 4.8
137 27
138 35
139 0.77
140 470
141 1.8
142 4.1
143 0.45
144 1.3
145 0.24
146 0.19
147 0.56
148 0.34
149 1.5
150 24
152 0.68
153 1.9
154 6.8
155 57
156 110
157 19
158 5.4
159 1.5
160 0.8
161 1.7
162 530
163 1100
164 254
165 21
166 20
167 1040
168 58
169 101
170 285
171 48
172 1295
173 42
174 54
175 17
176 53
177 8.7
178 150
179 2.0
180 24
181 1.9
182 8.7
183 8.8
184 3.3
185 66
186 18
187 2.2
188 92
189 0.49
190 1.2
191 0.99
192 9.6
193 2.9
194 1.5
195 0.25
196 0.20
197 0.31
198 2.2
199 1.0
200 1.2
201 0.64
202 3.1
203 21
204 0.23
205 0.70
206 4.3
207 19
208 4.6
209 21
210 79
211 491
212 1024
213 22
214 0.86
215 197
216 25
217 0.56
218 1.0
219 0.59
220 0.38
221 4.1
222 1.2
223 0.88
224 1.1
225 0.74
226 0.93
227 0.93
228 22
229 1.0
230 1.1
231 0.47
232 0.41
233 0.73
234 3.2
235 0.36
236 0.98
237 1.4
238 2.1
239 0.39
240 2.2
241 0.86
242 1.9
243 1071
244 262
245 11
246 26
247 234
248 74
249 27
250 659
251 1098
AAK1 Knockout Mice
Mice homozygous (-/-) for the disruption of the AAK1 gene were prepared by
two methods; gene trapping and homologous recombination.
Gene trapping is a method of random insertional mutagenesis that uses a
fragment of DNA coding for a reporter or selectable marker gene as a mutagen.
Gene trap vectors have been designed to integrate into introns or genes in a manner
that allows the cellular splicing machinery to splice vector encoded exons to cellular
mRNAs. Commonly, gene trap vectors contain selectable marker sequences that are
preceded by strong splice acceptor sequences and are not preceded by a promoter.
Thus, when such vectors integrate into a gene, the cellular splicing machinery splices
exons from the trapped gene onto the 5' end of the selectable marker sequence.
Typically, such selectable marker genes can only be expressed if the vector encoding
the gene has integrated into an intron. The resulting gene trap events are
subsequently identified by selecting for cells that can survive selective culture.
Embryonic stem cells (Lex-1 cells from derived murine strain A129), were
mutated by a process involving the insertion of at least a portion of a genetically
engineered vector sequence into the gene of interest, the mutated embryonic stem
cells were microinjected into blastocysts which were subsequently introduced into
pseudopregnant female hosts and carried to term using established methods. See,
e.g., “Mouse Mutagenesis”, 1998, Zambrowicz et al., eds., Lexicon Press, The
Woodlands, TX. The resulting chimeric animals were subsequently bred to produce
offspring capable of germline transmission of an allele containing the engineered
mutation in the gene of interest.
AAK1-gene disrupted mice were also made by homologous recombination.
In this case, the second coding exon of the murine AAK1 gene (see GenBank
Accession Number NM_177762) was removed by methods known in the art. See,
e.g., U.S. Patent Nos. 5,487,992, 5,627,059, and 5,789,215.
Mice homozygous (-/-) for the disruption of the AAK1 gene were studied in
conjunction with mice heterozygous (+/-) for the disruption of the AAK1 gene, and
wild-type (+/+) litter mates. During this analysis, the mice were subject to a medical
work-up using an integrated suite of medical diagnostic procedures designed to
assess the function of the major organ systems in a mammalian subject.
Homozygous (-/-) “knockout” mice were studied in conjunction with their
heterozygous (+/-) and wild-type (+/+) litter mates. Disruption of the AAK1 gene
was confirmed by Southern analysis. Expression of the murine homolog of AAK1
was detected by RT-PCR in murine brain; spinal cord; eye; thymus; spleen; lung;
kidney; liver; skeletal muscle; bone; stomach, small intestine and colon; heart;
adipose; asthmatic lung; LPS liver; blood; banded heart; aortic tree; prostate; and
mammary gland (5 week virgin, mature virgin, 12 DPC, 3 day post-partum
(lactating), 3 day post-weaning (early involution), and 7 day post-weaning (late
involution)).
AAK1 homozygous (-/-) and their wild-type (+/+) littermates were tested
using the formalin paw test in order to assess their acute and tonic nociceptive
responses. For these tests, Automatic Nociception Analyzers (purchased from the
Ozaki lab at University of California, San Diego) were used. A metal band was
placed around the left hind paw of each mouse 30 minutes prior to testing. After the
-minute acclimation period, 20 µl of 5% formalin is subcutaneously injected in the
dorsal surface of the left hind paw. Mice were individually housed in cylindrical
chambers for 45 minutes. Fresh 5 % formalin solution was prepared by diluting
formaldehyde (Formalde-fresh 20%, Fisher Scientific, Fair Lawn, NJ) with distilled
water. Investigatory compounds were administered 30 minutes prior to formalin
injection.
A computer recorded flinches per minute, total flinches for phase I (acute
phase = first 8 minutes), and total flinches for phase II (tonic phase = time between
minutes 20 - 40) through an electromagnetic field. See Yaksh TL, Ozaki G,
McCumber D, Rathbun M, Svensson C, Malkmus S, Yaksh MC. An automated
flinch detecting system for use in the formalin nociceptive bioassay. J Appl Physiol.,
2001; 90:2386-402. As shown in Figure 1, phase 1 and phase 2 data were obtained
using homozygous (-/-) mice females (n = 16), wild-type females (n = 15),
homozygous (-/-) mice males (n = 9), and wild-type males (n = 18). In all groups and
in both phases, the AAK1 homozygous (-/-) mice exhibited significantly less
recorded paw flinching than their wild-type (+/+) littermates.
It will be evident to one skilled in the art that the present disclosure is not
limited to the foregoing illustrative examples, and that it can be embodied in other
specific forms without departing from the essential attributes thereof. It is therefore
desired that the examples be considered in all respects as illustrative and not
restrictive, reference being made to the appended claims, rather than to the foregoing
examples, and all changes which come within the meaning and range of equivalency
of the claims are therefore intended to be embraced therein.
Claims (24)
1. A compound of formula (I) (I), 5 or a pharmaceutically acceptable salt thereof, wherein: A is selected from , , , , , , and ; wherein “ ” denotes the point of attachment to B; B is selected from 10 , , , , , and ; wherein “*” indicates the point of attachment to R5 and “**” indicates the point of attachment to ring A; R is selected from hydrogen, amino, -CO2H, difluoromethyl, ethyl, halo, hydroxymethyl, methoxy, methyl, –NHC(O)CH , -NHCO CH , trifluoromethoxy, 3 2 3 15 and trifluoromethyl; R is selected from hydrogen, cyano, -CH OH, halo, and methyl; R is selected from hydrogen, cyano, cyclopropyl, difluoromethyl, halo, hydroxymethyl, methoxy, methyl, methylsulfonyl, trifluoromethoxy, trifluoromethyl, -CH N(CH ) , and a five-membered aromatic ring containing one, two, or three 2 3 2 20 heteroatoms selected from nitrogen, oxygen, and sulfur; R is selected from hydrogen, halo, and methyl; R is selected from , , and ; R is selected from hydrogen, ethyl, fluoromethyl, difluoromethyl, methyl, 25 and trifluoromethyl; and R is methyl.
2. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein A is selected from 30 , , and .
3. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein B is selected from and .
4. A compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein B is 40
5. A compound of claim 1 wherein R is
6. A compound of claim 1 selected from (S)-N-(4-(4-((2-aminomethylpentyl)oxy)fluorophenyl)pyridin 45 yl)acetamide; (S)-N-(4-(4-((2-aminomethylpentyl)oxy)methoxyphenyl)pyridin yl)acetamide; (S)-N-(4-(4-((2-aminomethylpentyl)oxy)cyanophenyl)pyridin yl)acetamide; 50 (S)((2-aminomethylpentyl)oxy)(2-aminopyridinyl)benzonitrile; (S)-N-(4-(4-((2-aminomethylpentyl)oxy) (trifluoromethyl)phenyl)pyridinyl)acetamide; (S)-N-(4-(4-((2-aminomethylpentyl)oxy) (trifluoromethoxy)phenyl)pyridinyl)acetamide; 55 (S)-N-(4-(4-((2-aminomethylpentyl)oxy)methylphenyl)pyridin yl)acetamide; (S)-N-(4-(4-((2-aminomethylpentyl)oxy)chlorophenyl)pyridin yl)acetamide; (S)-N-(4-(4-((2-aminomethylpentyl)oxy)-3,5-difluorophenyl)pyridin 60 yl)acetamide; (S)-N-(4-(4-((2-aminomethylpentyl)oxy)chlorofluorophenyl)pyridin- 2-yl)acetamide; (S)-N-(4-(4-((2-aminomethylpentyl)oxy)fluoro (trifluoromethyl)phenyl)pyridinyl)acetamide; 65 (S)-N-(4-(4-((2-aminomethylpentyl)oxy)-2,5-difluorophenyl)pyridin yl)acetamide; (S)-methyl (4-(4-((2-aminomethylpentyl)oxy)fluorophenyl)pyridin yl)carbamate; (S)-methyl (4-(4-((2-aminomethylpentyl)oxy)(isoxazol 70 yl)phenyl)pyridinyl)carbamate; (S)((2-aminomethylpentyl)oxy)(2-methylpyridinyl)benzonitrile; (S)((2-aminomethylpentyl)oxy)(2-methoxypyridinyl)benzonitrile; (S)((2-aminomethylpentyl)oxy)(2-(trifluoromethyl)pyridin yl)benzonitrile; 75 (S)(2-(isoxazolyl)(2-methylpyridinyl)phenoxy)methylpentan amine; (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy) (trifluoromethyl)phenyl)pyridinyl)acetamide; (S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy) 80 (trifluoromethyl)phenyl)pyridinyl)carbamate; (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)cyanophenyl)pyridin yl)acetamide; (S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)cyanophenyl)pyridin- 2-yl)carbamate; 85 (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy) (difluoromethyl)phenyl)pyridinyl)acetamide; (S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy) (difluoromethyl)phenyl)pyridinyl)carbamate; (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy) 90 (trifluoromethoxy)phenyl)pyridinyl)acetamide; (S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy) (trifluoromethoxy)phenyl)pyridinyl)carbamate; (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)fluorophenyl)pyridin yl)acetamide; 95 (S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)fluorophenyl)pyridin- 2-yl)carbamate; methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)chlorophenyl)pyridin yl)carbamate; methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)methylphenyl)pyridin 100 yl)carbamate; methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)-2,3-dimethylphenyl)pyridin- 2-yl)carbamate; (S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy) (hydroxymethyl)phenyl)pyridinyl)carbamate; 105 (S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy) cyclopropylphenyl)pyridinyl)carbamate; (S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)(trifluoromethyl)phenyl) (hydroxymethyl)pyridinyl)acetamide; (S)(4-(2-(difluoromethyl)pyridinyl)(trifluoromethyl)phenoxy)-2,4- 110 dimethylpentanamine; (S)((2-amino-2,4-dimethylpentyl)oxy)(2-(difluoromethyl)pyridin yl)benzonitrile; (S)(2-(difluoromethyl)(2-(difluoromethyl)pyridinyl)phenoxy)-2,4- dimethylpentanamine; 115 (S)(4-(2-(difluoromethyl)pyridinyl)(trifluoromethoxy)phenoxy)-2,4- dimethylpentanamine; (S)(4-(3-chlorofluoropyridinyl)(trifluoromethyl)phenoxy)-2,4- dimethylpentanamine; (S)(4-(5-chlorofluoropyridinyl)(trifluoromethyl)phenoxy)-2,4- 120 dimethylpentanamine; (S)(4-(2-fluoromethylpyridinyl)(trifluoromethyl)phenoxy)-2,4- dimethylpentanamine; (S)(4-(2,3-difluoropyridinyl)(trifluoromethyl)phenoxy)-2,4- dimethylpentanamine; 125 (S)-2,4-dimethyl(4-(pyridinyl)(trifluoromethyl)phenoxy)pentan amine; (S)(4-(2-fluoropyridinyl)(trifluoromethyl)phenoxy)-2,4- dimethylpentanamine; (S)-2,4-dimethyl(4-(2-methylpyridinyl) 130 (trifluoromethyl)phenoxy)pentanamine; (S)(4-(3-methoxypyridinyl)(trifluoromethyl)phenoxy)-2,4- dimethylpentanamine; (S)(4-(3-fluoropyridinyl)(trifluoromethyl)phenoxy)-2,4- dimethylpentanamine; 135 (S)((2-amino-2,4-dimethylpentyl)oxy)(2-methylpyridin yl)benzonitrile; (S)(2-cyclopropyl(2-methylpyridinyl)phenoxy)-2,4-dimethylpentan- 2-amine; (S)(2-(difluoromethyl)(2-methylpyridinyl)phenoxy)-2,4- 140 dimethylpentanamine; methyl (6-((2-amino-2,4-dimethylpentyl)oxy)-[3,4'-bipyridin]-2'- yl)carbamate; (S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)methyl-[3,4'-bipyridin]- 2'-yl)carbamate; 145 (S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)cyano-[3,4'-bipyridin]-2'- yl)carbamate; (S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)methyl-[3,4'-bipyridin]- 2'-yl)carbamate; (S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)chloro-[3,4'-bipyridin]-2'- 150 yl)carbamate; (S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)methoxy-[3,4'-bipyridin]- 2'-yl)carbamate; (S)((2'-chloromethyl-[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentan amine; 155 (S)((2'-(difluoromethyl)methyl-[3,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (S)((2-amino-2,4-dimethylpentyl)oxy)-2'-(difluoromethyl)-[3,4'- bipyridine]carbonitrile; (S)((5-chloro-2'-methyl-[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentan 160 amine; (S)((2',5-dimethyl-[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine; (S)((5-methoxy-2'-methyl-[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentan amine; methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-[2,4'-bipyridin]-2'- 165 yl)carbamate; (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)methyl-[2,4'-bipyridin]- 2'-yl)carbamate; (S)((2',6-dimethyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine; (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)chloro-[2,4'-bipyridin]-2'- 170 yl)carbamate; (S)((6-chloro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan amine; (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)methyl-[2,4'-bipyridin]- 2'-yl)carbamate; 175 (S)-2,4-dimethyl(4-(quinolinyl)(trifluoromethyl)phenoxy)pentan amine; (S)-2,4-dimethyl(2-(trifluoromethyl)(7-(trifluoromethyl)quinolin yl)phenoxy)pentanamine; (S)(4-(7-fluoroquinolinyl)(trifluoromethyl)phenoxy)-2,4- 180 dimethylpentanamine; (S)(4-(5,7-difluoroquinolinyl)(trifluoromethyl)phenoxy)-2,4- dimethylpentanamine; (S)(4-(6-fluoroquinolinyl)(trifluoromethyl)phenoxy)-2,4- dimethylpentanamine; 185 (S)(2-cyclopropyl(quinolinyl)phenoxy)-2,4-dimethylpentanamine; 1-(2-chlorofluoro(quinolinyl)phenoxy)-2,4-dimethylpentanamine; (S)((5-(7-fluoroquinolinyl)methylpyridinyl)oxy)-2,4- dimethylpentanamine; (S)((2-amino-2,4-dimethylpentyl)oxy)(5,7-difluoroquinolin 190 yl)nicotinonitrile; (S)((3-chloro(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentan amine; (S)((3-methoxy(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentan amine; 195 (S)((2-amino-2,4-dimethylpentyl)oxy)(1,6-naphthyridin yl)nicotinonitrile; (S)-2,4-dimethyl((2-methyl(quinolinyl)pyridinyl)oxy)pentan amine; (S)-2,4-dimethyl((4-methyl(quinolinyl)pyridinyl)oxy)pentan 200 amine; (S)((2-chloro(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentan amine; (S)(4-(1H-pyrrolo[2,3-b]pyridinyl)(trifluoromethyl)phenoxy)-2,4- dimethylpentanamine; 205 (S)(4-(1,6-naphthyridinyl)(trifluoromethyl)phenoxy)-2,4- dimethylpentanamine; (S)((2-amino-2,4-dimethylpentyl)oxy)(1,6-naphthyridin yl)benzonitrile; (S)((2-amino-2,4-dimethylpentyl)oxy)(1,5-naphthyridin 210 yl)benzonitrile; (S)(4-(7-chloroquinolinyl)(trifluoromethyl)phenoxy)-2,4- dimethylpentanamine; (S)(4-((2-amino-2,4-dimethylpentyl)oxy) (trifluoromethyl)phenyl)quinolinecarbonitrile; 215 (S)-2,4-dimethyl(2-methyl(2-methylpyridinyl)phenoxy)pentan amine; (S)(2-fluoro(2-methylpyridinyl)phenoxy)-2,4-dimethylpentan amine; (S)(4-(2-fluoropyridinyl)methylphenoxy)-2,4-dimethylpentan 220 amine; (S)(2-fluoro(2-fluoropyridinyl)phenoxy)-2,4-dimethylpentan amine; (S)((2-amino-2,4-dimethylpentyl)oxy)(2-fluoropyridin yl)benzonitrile; 225 (S)((2'-fluoromethyl-[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentan amine; (S)(6-((2-amino-2,4-dimethylpentyl)oxy)methylpyridinyl)quinoline- 7-carbonitrile; (S)((5-fluoro-2'-methyl-[3,4'-bipyridin]yl)oxy)-2,4-dimethylpentan 230 amine; (S)((3-fluoro(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentan amine; (S)(6-((2-amino-2,4-dimethylpentyl)oxy)fluoropyridinyl)quinoline carbonitrile; 235 (S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)cyanophenyl) fluoropyridinyl)carbamate; (S)((2-amino-2,4-dimethylpentyl)oxy)-2'-methyl-[3,4'-bipyridine] carbonitrile; (S)((2-amino-2,4-dimethylpentyl)oxy)(7-methylquinolin 240 yl)benzonitrile; (S)((2-amino-2,4-dimethylpentyl)oxy)(3-fluoromethylpyridin yl)benzonitrile; (S)((2-amino-2,4-dimethylpentyl)oxy)(quinolinyl)benzonitrile; (S)((2-amino-2,4-dimethylpentyl)oxy)(5-fluoromethylpyridin 245 yl)benzonitrile; (S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)cyanophenyl) fluoropyridinyl)carbamate; (S)((6-fluoro-2',4-dimethyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan- 2-amine; 250 methyl (5-((3-isobutylazetidinyl)methoxy)methyl-[2,4'-bipyridin]-2'- yl)carbamate; (S)((2-aminomethylpentyl)oxy)(6-methylpyridazinyl)benzonitrile; (S)(2-(isoxazolyl)(quinolinyl)phenoxy)methylpentanamine; (S)(4-((2-amino-2,4-dimethylpentyl)oxy)(trifluoromethyl)phenyl) 255 methylnicotinic acid; (S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy) ((dimethylamino)methyl)phenyl)pyridinyl)carbamate; (S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy) (methylsulfonyl)phenyl)pyridinyl)carbamate; 260 (S)-2,4-dimethyl(4-(2-methylpyridinyl) (methylsulfonyl)phenoxy)pentanamine; (S)-2,4-dimethyl(2-(methylsulfonyl)(quinolinyl)phenoxy)pentan amine; (S)(2-(difluoromethyl)(6-fluoroquinolinyl)phenoxy)-2,4- 265 dimethylpentanamine; (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)(difluoromethyl)-[2,4'- bipyridin]-2'-yl)carbamate; (S)((2-(difluoromethyl)(quinolinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; 270 (S)((6-(difluoromethyl)-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)(difluoromethyl)-[2,4'- bipyridin]-2'-yl)carbamate; (S)((4-(difluoromethyl)(quinolinyl)pyridinyl)oxy)-2,4- 275 dimethylpentanamine; (S)((4-(difluoromethyl)-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (S)((2',6-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; 280 (S)((2',4-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (S)((2'-(difluoromethyl)methyl-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (S)(2-cyclopropyl(2-(difluoromethyl)pyridinyl)phenoxy)-2,4- 285 dimethylpentanamine; (S)((2-(difluoromethyl)(6-fluoroquinolinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; (S)((2-(difluoromethyl)(7-fluoroquinolinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; 290 (S)((2-(difluoromethyl)(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; (S)((4-(difluoromethyl)(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; (S)((4-(difluoromethyl)(7-fluoroquinolinyl)pyridinyl)oxy)-2,4- 295 dimethylpentanamine; (S)((4-(difluoromethyl)(6-fluoroquinolinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; ((S)((4-(difluoromethyl)(6-(trifluoromethyl)quinolinyl)pyridin yl)oxy)-2,4-dimethylpentanamine; 300 (S)((4-(difluoromethyl)(6-(trifluoromethoxy)quinolinyl)pyridin yl)oxy)-2,4-dimethylpentanamine; (S)((2-chloro(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; (S)((2-chloro(7-fluoroquinolinyl)pyridinyl)oxy)-2,4- 305 dimethylpentanamine; (S)((6-(7-fluoroquinolinyl)methylpyridinyl)oxy)-2,4- dimethylpentanamine; (S)((6-(6-fluoroquinolinyl)methylpyridinyl)oxy)-2,4- dimethylpentanamine; 310 (S)((2-(difluoromethyl)(2-methylpyrimidinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; (S)((2-(difluoromethyl)(6-methylpyrimidinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; (S)((4-(difluoromethyl)-2'-ethyl-[2,4'-bipyridin]yl)oxy)-2,4- 315 dimethylpentanamine; (S)((2'-chloro(difluoromethyl)-3'-fluoro-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (S)((2'-chloro(difluoromethyl)-5'-fluoro-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; 320 (S)-2,4-dimethyl((2'-methyl(trifluoromethyl)-[2,4'-bipyridin] yl)oxy)pentanamine; (S)-2,4-dimethyl((6-(quinolinyl)(trifluoromethyl)pyridin yl)oxy)pentanamine; (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)(trifluoromethyl)-[2,4'- 325 bipyridin]-2'-yl)carbamate; (S)((2'-chloro(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (S)((4-(difluoromethyl)-5'-fluoro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; 330 (S)((4-(difluoromethyl)-3'-fluoro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (S)((4-(difluoromethyl)(2-methylpyrimidinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; (S)(2-(difluoromethyl)(2-methylpyrimidinyl)phenoxy)-2,4- 335 dimethylpentanamine; (S)((2-amino-2,4-dimethylpentyl)oxy)-3'-fluoromethyl-[2,4'-bipyridin]- 2'-amine ; (S)((2'-chloro-3'-fluoromethyl-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; 340 (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-5'-fluoromethyl-[2,4'- bipyridin]-2'-yl)carbamate; (S)((2'-chloro-5'-fluoromethyl-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-3'-fluoromethyl-[2,4'- 345 bipyridin]-2'-yl)carbamate; (S)((2'-chloro(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (S)((2'-chloro(difluoromethyl)-3'-fluoro-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; 350 (S)((6-(difluoromethyl)-3'-fluoro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; ((S)((6-chloro-2'-(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (S)((4-(difluoromethyl)(6-methylpyridazinyl)pyridinyl)oxy)-2,4- 355 dimethylpentanamine; (S)((2-(difluoromethyl)(6-methylpyridazinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; (R)-2,4-dimethyl((2'-methyl(trifluoromethyl)-[2,4'-bipyridin] yl)oxy)pentanamine; 360 (R)-2,4-dimethyl((6-(quinolinyl)(trifluoromethyl)pyridin yl)oxy)pentanamine; (R)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)(trifluoromethyl)-[2,4'- bipyridin]-2'-yl)carbamate; (R)((2'-chloro(difluoromethyl)-3'-fluoro-[2,4'-bipyridin]yl)oxy)-2,4- 365 dimethylpentanamine; (R)((2'-chloro(difluoromethyl)-5'-fluoro-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (R)((2'-chloro(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; 370 (R)((4-(difluoromethyl)-2'-ethyl-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (R)((4-(difluoromethyl)-5'-fluoro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (R)((4-(difluoromethyl)-3'-fluoro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4- 375 dimethylpentanamine; (R)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)methyl-[2,4'-bipyridin]- 2'-yl)carbamate; (R)((2',6-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; 380 (R)((2',4-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (S)-methyl (4-(difluoromethyl)((2-hydroxy-2,4-dimethylpentyl)oxy)-[2,4'- bipyridin]-2'-yl)carbamate; (S)((4-(difluoromethyl)-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4- 385 dimethylpentanol; (S)-methyl (5-((2-amino(fluoromethyl)methylpentyl)oxy) (difluoromethyl)-[2,4'-bipyridin]-2'-yl)carbamate; (R)-methyl (5-((2-amino(fluoromethyl)methylpentyl)oxy) (difluoromethyl)-[2,4'-bipyridin]-2'-yl)carbamate; 390 (S)-methyl (5-((2-amino(fluoromethyl)methylpentyl)oxy) (difluoromethyl)-[2,4'-bipyridin]-2'-yl)carbamate; (R)-methyl (5-((2-amino(fluoromethyl)methylpentyl)oxy) (difluoromethyl)-[2,4'-bipyridin]-2'-yl)carbamate; (S)((2',6-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)(fluoromethyl) 395 methylpentanamine; (S)((2',4-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)(fluoromethyl) methylpentanamine; (R)((2',6-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)(fluoromethyl)- 4-methylpentanamine; 400 (R)((2',4-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)(fluoromethyl)- 4-methylpentanamine; (S)((4-(difluoromethyl)-2'-methyl-[2,4'-bipyridin]yl)oxy) (fluoromethyl)methylpentanamine; (R)((4-(difluoromethyl)-2'-methyl-[2,4'-bipyridin]yl)oxy) 405 (fluoromethyl)methylpentanamine; (S)-N-(4-(4-((2-aminomethylpentyl)oxy)fluorophenyl)pyridin yl)acetamide; (S)((3-chloro(7-fluoroquinolinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; 410 (S)((3-chloro(6-fluoroquinolinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; (S)((3-chloro(2-methylpyrimidinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; (S)((2'-chloro(difluoromethyl)-[3,4'-bipyridin]yl)oxy)-2,4- 415 dimethylpentanamine; (S)((5-(difluoromethyl)-2'-methyl-[3,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (S)((3-(difluoromethyl)(7-fluoroquinolinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; 420 (S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)(difluoromethyl)-[3,4'- bipyridin]-2'-yl)carbamate; (S)((5-(7-chloroquinolinyl)(difluoromethyl)pyridinyl)oxy)-2,4- dimethylpentanamine; (S)((3-(difluoromethyl)(2-methylpyrimidinyl)pyridinyl)oxy)-2,4- 425 dimethylpentanamine; (S)((2',5-bis(difluoromethyl)-[3,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (S)((3-(difluoromethyl)(6-fluoroquinolinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; 430 (S)((3-(difluoromethyl)(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; (S)((3-(difluoromethyl)(7-(trifluoromethyl)quinolinyl)pyridin yl)oxy)-2,4-dimethylpentanamine; (S)((5-(difluoromethyl)-2',3'-dimethyl-[3,4'-bipyridin]yl)oxy)-2,4- 435 dimethylpentanamine; (S)((3-(difluoromethyl)(quinolinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; (S)((3-(difluoromethyl)(7-methylquinolinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; 440 (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)methoxy-[2,4'-bipyridin]- 2'-yl)carbamate; (S)((2'-(difluoromethyl)methoxy-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)naphthalenyl)pyridin- 445 2-yl)carbamate; (S)-2,4-dimethyl((4-(quinolinyl)naphthalenyl)oxy)pentanamine; (S)-methyl (4-(5-((2-amino-2,4-dimethylpentyl)oxy)pyrimidinyl)pyridin yl)carbamate; (S)-methyl (4-(2-((2-amino-2,4-dimethylpentyl)oxy)pyrimidinyl)pyridin 450 yl)carbamate; (S)-2,4-dimethyl((2',4,6-trimethyl-[2,4'-bipyridin]yl)oxy)pentan amine; (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-4,6-dimethyl-[2,4'- bipyridin]-2'-yl)carbamate; 455 (S)-2,4-dimethyl(4-(quinazolinyl)(trifluoromethyl)phenoxy)pentan amine; (S)(4-(3,6-dihydro-2H-pyranyl)(trifluoromethyl)phenoxy)-2,4- dimethylpentanamine; (S)-2,4-dimethyl(4-(2-methylquinolinyl) 460 (trifluoromethyl)phenoxy)pentanamine; (S)(4-(6-chloroquinolinyl)(trifluoromethyl)phenoxy)-2,4- dimethylpentanamine; (S)((5-(5,7-difluoroquinolinyl)(trifluoromethyl)pyridinyl)oxy)- 2,4-dimethylpentanamine; 465 (S)-2,4-dimethyl((5-(quinolinyl)(trifluoromethyl)pyridin yl)oxy)pentanamine; (S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)(trifluoromethyl)-[3,4'- bipyridin]-2'-yl)carbamate; (S)-2,4-dimethyl((2'-methyl(trifluoromethyl)-[3,4'-bipyridin] 470 yl)oxy)pentanamine; (S)((5-(6-chloroquinolinyl)methylpyridinyl)oxy)-2,4- dimethylpentanamine; (S)((5-(6-fluoroquinolinyl)methylpyridinyl)oxy)-2,4- dimethylpentanamine; 475 (S)((5-(5,7-difluoroquinolinyl)methylpyridinyl)oxy)-2,4- dimethylpentanamine; (S)((5-(7-chloroquinolinyl)methylpyridinyl)oxy)-2,4- dimethylpentanamine; (S)((6-(5,7-difluoroquinolinyl)methylpyridinyl)oxy)-2,4- 480 dimethylpentanamine; (S)((6-(7-fluoroquinolinyl)methylpyridinyl)oxy)-2,4- dimethylpentanamine; (S)((2',4-dimethyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine; (S)((6-(6-chloroquinolinyl)methylpyridinyl)oxy)-2,4- 485 dimethylpentanamine; (S)((6-(6-fluoroquinolinyl)methylpyridinyl)oxy)-2,4- dimethylpentanamine; (S)((6-(7-chloroquinolinyl)methylpyridinyl)oxy)-2,4- dimethylpentanamine; 490 (S)((6-(7-fluoroquinolinyl)methylpyridinyl)oxy)-2,4- dimethylpentanamine; (S)((4-chloro(5,7-difluoroquinolinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; (S)((4-chloro-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine; 495 (S)((4-chloro(6-fluoroquinolinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; (S)((4-chloro(quinolinyl)pyridinyl)oxy)-2,4-dimethylpentan amine; (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)chloro-[2,4'-bipyridin]-2'- 500 yl)carbamate; (S)((4-chloro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan amine; (S)((4-chloro(6-chloroquinolinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; 505 (S)((2',4-dichloro-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentanamine; (S)((4-chloro(7-fluoroquinolinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; (S)((4-chloro(7-(trifluoromethyl)quinolinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; 510 (S)((4-chloro-2',3'-dimethyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan- 2-amine; (S)((5-(difluoromethyl)-2'-methyl-[3,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (R)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)(difluoromethyl)-[3,4'- 515 bipyridin]-2'-yl)carbamate; (R)((3-(difluoromethyl)(quinolinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; (R)((3-(difluoromethyl)(2-methylpyrimidinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; 520 (R)((3-(difluoromethyl)(5,7-difluoroquinolinyl)pyridinyl)oxy)- 2,4-dimethylpentanamine; (R)((5-(7-chloroquinolinyl)(difluoromethyl)pyridinyl)oxy)-2,4- dimethylpentanamine; and N-(4'-((2-amino-2,4-dimethylpentyl)oxy)-3'-methyl-[1,1'-biphenyl] 525 yl)acetamide; or a pharmaceutically acceptable salt thereof.
7. A compound of claim 1 selected from (S)(4-(2-(difluoromethyl)pyridinyl)(trifluoromethyl)phenoxy)-2,4- 530 dimethylpentanamine; (S)-2,4-dimethyl(4-(2-methylpyridinyl) (trifluoromethyl)phenoxy)pentanamine; (S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)methyl-[2,4'-bipyridin]- 2'-yl)carbamate; 535 (S)((4-(difluoromethyl)-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (S)((2',6-bis(difluoromethyl)-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (S)-2,4-dimethyl((2'-methyl(trifluoromethyl)-[2,4'-bipyridin] 540 yl)oxy)pentanamine; (S)((4-(difluoromethyl)-3'-fluoro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; (S)((6-(difluoromethyl)-3'-fluoro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4- dimethylpentanamine; 545 (S)((3-(difluoromethyl)(2-methylpyrimidinyl)pyridinyl)oxy)-2,4- dimethylpentanamine; and (S)((4-chloro-2'-methyl-[2,4'-bipyridin]yl)oxy)-2,4-dimethylpentan amine; or a pharmaceutically acceptable salt thereof.
8. A compound of claim 1 of formula (II) (II), or a pharmaceutically acceptable salt thereof, wherein: 555 A is selected from , , , , , and ; wherein “ ” denotes the point of attachment to B; B is selected from phenyl and pyridinyl; R is selected from hydrogen, difluoromethyl, halo, methoxy, methyl, – 560 NHC(O)CH , -NHCO CH , and trifluoromethyl; R is selected from hydrogen, -CH OH, and halo; R is selected from hydrogen, cyano, cyclopropyl, difluoromethyl, halo, hydroxymethyl, methoxy, methyl, trifluoromethoxy, trifluoromethyl, and a five- 565 membered aromatic ring containing one, two, or three heteroatoms selected from nitrogen, oxygen, and sulfur; R is selected from hydrogen, halo, and methyl; and R is selected from hydrogen, ethyl, fluoromethyl, difluoromethyl, methyl, and trifluoromethyl.
9. A compound of claim 1 which is (S)((2',6-bis(difluoromethyl)-[2,4'- bipyridin]yl)oxy)-2,4-dimethylpentanamine; or a pharmaceutically acceptable salt thereof. 575
10. A composition comprising a pharmaceutically acceptable amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
11. Use of a compound of claim 1, or a pharmaceutically acceptable salt thereof 580 in the manufacture of a medicament for inhibiting adaptor associated kinase 1 (AAK1) activity.
12. Use of a compound of claim 1, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or managing a disease or a disorder 585 mediated by AAK1 activity.
13. The use of claim 12, wherein the disease or disorder is selected from Alzheimer’s disease, bipolar disorder, pain, Parkinson’s disease, and schizophrenia. 590
14. The use of claim 13 wherein the pain is neuropathic pain.
15. The use of claim 14 wherein the neuropathic pain is fibromyalgia or peripheral neuropathy. 595
16. A composition comprising a pharmaceutically acceptable amount of a compound of claim 9, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
17. Use of a compound of claim 9, or a pharmaceutically acceptable salt thereof 600 in the manufacture of a medicament for inhibiting adaptor associated kinase 1 (AAK1) activity.
18. Use of a compound of claim 9, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for for treating or managing a disease or a 605 disorder mediated by AAK1 activity.
19. The use of claim 18, wherein the disease or disorder is selected from Alzheimer’s disease, bipolar disorder, pain, Parkinson’s disease, and schizophrenia. 610
20. The use of claim 19 wherein the pain is neuropathic pain.
21. The use of claim 20 wherein the neuropathic pain is fibromyalgia or peripheral neuropathy.
22. A compound of any one of claims 1, 6, 7, 8 or 9 substantially as described herein with reference to any example thereof and with or without reference to the accompanying figures. 620
23. A composition of claim 10 or 16 substantially as described herein with reference to any example thereof and with or without reference to the accompanying figures.
24. A use of claim 11, 12, 17 or 18 substantially as described herein with 625 reference to any example thereof and with or without reference to the accompanying figures.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461973942P | 2014-04-02 | 2014-04-02 | |
US61/973,942 | 2014-04-02 | ||
US201462061591P | 2014-10-08 | 2014-10-08 | |
US62/061,591 | 2014-10-08 | ||
PCT/US2015/023805 WO2015153720A1 (en) | 2014-04-02 | 2015-04-01 | Biaryl kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ725814A NZ725814A (en) | 2021-06-25 |
NZ725814B2 true NZ725814B2 (en) | 2021-09-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10981910B2 (en) | Biaryl kinase inhibitors | |
US8969564B2 (en) | Aryl ether-base kinase inhibitors | |
US10544120B2 (en) | Biaryl kinase inhibitors | |
EP3044226B1 (en) | Aryl ether-base kinase inhibitors | |
US10174044B2 (en) | Fused pyridines as kinase inhibitors | |
NZ725814B2 (en) | Biaryl kinase inhibitors |